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Abstract 
 
Discrepancies between research evidence and clinical practice remain one of 
the most persistent problems in the provision of high-quality health care. 
Clinical practice guidelines aim to inform clinical decision-making by providing 
summaries of recent, credible research evidence with recommendations for 
clinical practice.  However, timely and effective implementation of guidelines 
into practice is inconsistent.  
Prostate cancer is the most common cancer registered in Australia and is the 
second most common cause of cancer death in males. Radical prostatectomy 
is the most frequent procedure for locally advanced prostate cancer, however 
following surgery it is estimated that between 20% and 50% of men are at 
“high risk” of experiencing progression or recurrence (defined as pT3 disease 
or having positive surgical margins). Three randomised controlled trials have 
demonstrated survival, recurrence and disease progression benefits from 
post-operative adjuvant radiotherapy for these patients.   Consistent with 
other international guidelines, the Australian Cancer Network Clinical Practice 
Guideline for the Management of Locally Advanced and Metastatic Prostate 
Cancer (2010) recommends "patients with extracapsular extension, seminal 
vesicle involvement or positive surgical margins receive post-operative 
external beam radiation therapy within four months of surgery” (p37). With 
less than 10% of men with high-risk prostate cancer receiving care in 
accordance with this guideline, the development of effective strategies to 
rectify this situation holds potential to improve care processes and outcomes 
for this group of patients. 
This thesis explores whether a multifaceted intervention implemented 
through a urological clinical network can improve the rates of referral of men 
for consideration for adjuvant radiotherapy. It comprises seven iterative 
  xix 
studies that address urologists’ knowledge, attitudes and equipoise for the 
use of adjuvant radiotherapy for high-risk prostate cancer, the development 
of a clinical network embedded intervention and the evaluation of this 
intervention within a step-wedge cluster randomised trial ‘Clinician-Led 
Improvement in Cancer Care (CLICC)’.  The National Health and Medical 
Research Council (NHMRC) co-funded the CLICC implementation trial in 
partnership with the Prostate Cancer Foundation of Australia (PCFA), with in-
kind support provided by the NSW Agency for Clinical Innovation (ACI). The 
thesis is presented as a series of journal articles. 
Chapter one first provides an epidemiological perspective of prostate cancer 
including prevalence, tumour staging and grading, treatment modalities and 
their rates of utilisation, rates and predictors of disease recurrence after 
primary treatment, and current post-operative patterns of care in Australia 
and elsewhere. Evidence to support guideline recommended post-operative 
adjuvant radiotherapy for men with adverse features post-prostatectomy is 
critically appriased. The remainder of Chapter One introduces the landscape 
of intervention strategies to promote clinician behaviour change, including 
evidence specific to the cancer context. Chapter One concludes with a 
description of the organisation of healthcare and cancer services in New South 
Wales (NSW), Australia to introduce the setting for the CLICC implementation 
trial.  
Chapter two (paper published) is a systematic review of evidence of the 
effectiveness of clinical networks as an organisational vehicle to improve 
quality of care and patient outcomes. A systematic search was undertaken in 
accordance with the PRISMA approach in Medline, Embase, CINAHL and 
PubMed for relevant papers between 1 January 1996 and 30 September 2014. 
Established protocols were used to separately examine and assess the 
evidence from quantitative and qualitative primary studies and then integrate 
  xx 
findings to draw conclusions. A total of 23 eligible studies (10 quantitative; 13 
qualitative) were included. Of the quantitative studies, eight focused on 
improving quality of care and two focused on improving patient outcomes. 
Studies were limited by a lack of rigorous experimental design. The current 
best available empirical evidence indicates that clinical networks can be 
effective vehicles for quality improvement in service delivery and patient 
outcomes across a range of clinical disciplines. However, the ability to draw 
conclusions is limited somewhat by relatively low quality quantitative 
research. 
Chapter three (paper published) presents the results of a nationwide survey of 
157 Australian-based urologist members of the Urological Society of Australia 
and New Zealand (USANZ) (45% response rate) two years after the publication 
of the Australian Cancer Network Clinical Practice Guidelines for the 
Management of Locally Advanced and Metastatic Prostate Cancer. Just over 
half of respondents (54%) were aware of the guidelines. Just over half agreed 
the recommendation for adjuvant radiotherapy is based on a valid 
interpretation of the underpinning evidence (54.1%, 95% CI [46%, 62.2%]) but 
less than one third agreed adjuvant radiotherapy will lead to improved patient 
outcomes (30.2%, 95% CI [22.8%, 37.6%]).  Treatment preferences were 
varied.  A positive attitude towards the clinical practice recommendation was 
significantly associated with treatment preference for adjuvant radiotherapy 
(rho = 0.520, p < 0.0001). There was stronger preference for adjuvant 
radiotherapy in more recently trained urologists (registrars) while preference 
for watchful waiting was greater in more experienced urologists (consultants) 
(b= 0.156, p= 0.034; 95% CI [.048, 1.24]). The results of the survey indicate 
that there remains clinical equipoise among Australian urologists in relation to 
adjuvant radiotherapy for men with adverse pathologic features following 
radical prostatectomy. 
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Chapter four provides an overview of the PRECEDE-PROCEED model of 
behaviour change and how it was used to develop the CLICC conceptual 
program logic framework. The chapter then presents the findings of a needs 
and barriers analysis and outlines how intervention elements were mapped to 
barriers and facilitators using the CLICC conceptual program logic framework. 
The needs and barriers analysis included: iterative workshops; results from 
the national survey of urologists (detailed in Chapter Three); consumer 
feedback; semi-structured interviews with urologists, radiation oncologists 
and clinical nurse coordinators at CLICC sites; and consultation with the 
Cancer Care Action Advisory Group established for the CLICC implementation 
trial.  Barriers were identified at the clinician, patient and hospital system 
levels and the chapter concludes with a description of how these were 
addressed through physician- and context-focused intervention elements. 
Chapter five (paper published) comprises the study protocol for the CLICC 
implementation trial; a stepped wedge cluster randomised controlled trial 
involving urological multidisciplinary teams (MDTs) from nine NSW hospitals 
linked to the NSW Agency for Clinical Innovation (ACI) Urology Clinical 
Network. The primary outcome was increased referral to radiation oncology 
for discussion of adjuvant radiotherapy in line with guideline recommended 
care or referral to a clinical trial of adjuvant versus salvage radiotherapy 
(RAVES - Radiotherapy Adjuvant Vs Early Salvage; TROG.08.03). Secondary 
outcomes were: increased discussion of the patient at a MDT meeting within 
four months after surgery; initial patient consultation with a radiation 
oncologist; and commencement of radiotherapy.  
Chapter six provides the rationale for the process evaluation conducted in 
parallel with the CLICC implementation trial. This used mixed methods to 
identify mechanisms of provider and organisational change, which were 
assessed using three domains  (i) whether the intervention was implemented 
  xxii 
as intended with fidelity (implementation); (ii) why the intervention did or did 
not result in evidence-based care (participation and response); and (iii) why 
the intervention was or was not implemented or sustained across 
implementation sites (context). Quantitative measures were included to 
assess implementation, participation and response, combined with qualitative 
exploration of participants’ experience of, and response to, the intervention 
and the contextual characteristics of the participating CLICC sites. Results of 
the process evaluation demonstrate that CLICC intervention elements were 
implemented with fidelity across the nine participating sites with all Clinical 
Leaders and participating urologists meeting the minimum requirement for 
exposure. Participation was high across eight of nine CLICC sites; all eligible 
urologists participated from five MDTs and more than three quarters (37 of 
55; 76%) of eligible urologists participated overall. One site was an outlier with 
only 2 of 11 eligible urologists (18%) consenting to participate. Through the 
process evaluation it emerged that non-participation was considered to be 
due to lack of willingness to change practice and reluctance to provide access 
to medical records for review of current practice. Response to the CLICC trial 
was varied both within and across study sites and a number of contextual 
factors emerged that impacted on implementation and participation.  
Chapter seven presents results of the CLICC implementation trial based on 
data from independent medical record review to determine whether the 
CLICC intervention resulted in change in primary and secondary outcomes. 
After adjustment for potential confounders, there was no significant effect of 
the intervention on the primary outcome of referral to radiotherapy or the 
RAVES trial within 4 months after prostatectomy (32% post-intervention 
versus 30% pre-intervention) (adjusted RR=1.05; 95% CI [0.74, 1.49]; p = 
0.892). The effect of the intervention on referral was significantly modified by 
site (p < 0.001) with evidence that the intervention worked better in some 
sites than others. Specifically, the intervention appeared to work best in four 
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sites, each with similar increases in referral rates: Site 1 (RR=1.37; 95% CI 
[0.42-4.46]); Site 4 (RR=1.27; 95% CI [0.75-2.17]); Site 7 (RR=1.60; 95% CI 
[0.80-3.19]) and Site 8 (RR=1.57; 95% CI [1.01-2.43]). There was a significant 
effect of the intervention on the secondary outcome of discussion of the 
patient at a MDT meeting within 4 months after prostatectomy (adjusted 
RR=4.31; 95% CI [2.40, 7.75]; p < 0.001). Fifty-nine per cent of intervention 
patients (240 of 407) were discussed at a MDT meeting within 4 months after 
prostatectomy compared with 17% of control patients (88 of 505). Amongst 
those discussed patients with a MDT recommendation for referral to 
radiotherapy or the RAVES trial, however, less than half (62 of 140; 44%) were 
subsequently referred to radiation oncology within 4 months after 
prostatectomy.  
To determine whether persisting clinician knowledge or attitudinal barriers 
were the underlying reason for the lack of a significant effect on the primary 
outcome of referral to radiotherapy or RAVES within 4 months after 
prostatectomy Chapter eight presents results from baseline and post-
intervention participant surveys to measure change in knowledge, attitudes 
and beliefs. Twenty-nine of 37 participants (78%) completed the baseline 
survey and 24 of 37 (65%) completed the post-intervention survey; more than 
half (20 of 37; 54%) completed both surveys. There was no change in CLICC 
participants’ treatment preferences between baseline and post-intervention 
surveys. When asked to indicate their preferred management approach for 
three hypothetical scenarios, there was an increase in the proportion who 
indicated a preference for adjuvant radiotherapy post-intervention for a 
hypothetical patient with a 19% 10-year risk of biochemical relapse. However, 
this change was not significant; urologists were on average 0.2 points more 
favourable towards this patient receiving adjuvant radiotherapy post-
intervention than they were at baseline with mean scores of 6.8 and 7.0 
respectively (mean difference 0.2; 95% CI [-0.8, 1.2]; p = 0.666). There were no 
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significant changes in participants’ understanding of the current literature and 
evidence for the treatment of prostate cancer between baseline and post-
intervention surveys and this was supported by open text survey responses in 
which a number of participants noted that they had prior knowledge of the 
evidence from these trials but continued to challenge its veracity. Overall 
there was no change in agreement with the clinical practice recommendation 
for adjuvant radiotherapy for locally advanced disease between baseline and 
post-intervention (mean difference -0.1; 95% CI [-0.3, 0.1]; p = 0.490) 
reflecting lack of significant change across the majority of underlying attitudes 
within this domain. The only significant change in attitudes was less 
agreement post-intervention that the recommendation is consistent with the 
opinions of respected clinical colleagues (mean difference -0.4; 95% CI [-0.7, 
0.0]; p = 0.027). This suggests that within the wider urological community 
there is potentially less agreement with the recommendation for adjuvant 
radiotherapy for men with adverse pathological features post prostatectomy 
than was considered to be the case at baseline. 
Chapter nine (paper published) presents the results of a follow-up nationwide 
survey of urologist members of the Urological Society of Australia and New 
Zealand (USANZ) conducted to determine whether knowledge, attitudes and 
self-reported practice have shifted nationally among the wider urological 
community independently of the CLICC implementation trial. Ninety-six 
respondents completed the 2015 survey (30% response rate) compared with 
157 (45% response rate) in 2012. Urologists were significantly less favourable 
towards adjuvant radiotherapy in 2015 than in 2012 for the hypothetical 
clinical case with a 19% 10-year risk of biochemical relapse; urologists were on 
average 1.8 points less favourable towards Case 1 receiving adjuvant 
radiotherapy in 2015 than they were in 2012 with mean scores of 2.9 and 4.7 
respectively (mean difference -1.8; 95% CI [-2.6, -1.0]; p < 0.001. Overall, 
urologists’ were less positive towards the recommendation for post-operative 
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adjuvant radiotherapy for men with locally advanced prostate cancer in 2015 
than in 2012, reflecting a significant change across a number of attitudes and 
beliefs. Consistent with CLICC participant surveys, urologist members of 
USANZ were less likely to agree in 2015 than 2012 that the recommendation is 
consistent with the opinions of respected clinical colleagues (mean difference 
-0.5; 95% CI [-0.8, -0.3]; p < 0.001). Of note, urologists also felt other 
urologists would more likely be critical if they routinely referred the target 
patient group for radiotherapy in 2015 compared with 2012 (p = 0.007). These 
results show that while CLICC participant attitudes remained largely 
unchanged between baseline and the post-intervention survey conducted in 
2015, with a slight but non-significant tendency towards being more 
favourable towards adjuvant radiotherapy for a hypothetical clinical case with 
19% 10-year risk of biochemical relapse, the wider urological community was 
significantly less favourable towards adjuvant radiotherapy for the same 
hypothetical clinical case in the follow-up survey conducted in the same year.   
Chapter ten provides an overview of the studies included in this thesis and 
discusses the implications of results for clinical practice, and clinical practice 
guideline implementation more generally.  
Due to the inclusion of published and submitted papers, each chapter in this 
thesis is written to be able to standalone. Therefore, there is some replication 
in reference lists as some references apply to multiple chapters. 
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Chapter 1: Introduction and scope of thesis 
 
1.1 Introduction 
1.1.1 Prevalence of prostate cancer 
Prostate cancer is the most common cancer registered in Australia and the 
second highest cause of cancer death in Australian males.(1, 2) The most 
recently available incidence data from the Australia Institute of Health and 
Welfare documented 19,993 new cases of prostate cancer in 2011 and in the 
five years from 2007 to 2011 there were on average more than 20,000 
diagnoses per year. This equates to a 1 in 7 risk of diagnosis before 75 years 
and a 1 in 5 risk before 85 years of age for Australian men, with the peak age 
for diagnosis being between 65 and 69 years.(2) The most recently available 
statistics for New South Wales (NSW), Australia from Cancer Institute NSW 
indicate that there were 7,277 new cases of prostate cancer diagnosed in 
2009, accounting for a third of all new cancers in males in that year.(3) 
According to figures published by GLOBOCAN, the World Health Organisation 
International Agency for Research on Cancer, globally, more than 1.1 million 
new cases of prostate cancer were recorded in 2012, accounting for around 8 
per cent of all new cancer cases and 15 per cent in men.(4) Incidence is higher 
in more rather than less developed countries with age-standardised incidence 
rates highest in Australia and New Zealand (111.6 per 100,000), North 
America (97.2 per 100,000), Western Europe (94.9 per 100,000) and Northern 
Europe (85 per 100,000). This is presumed due to greater detection through 
widespread prostate specific antigen (PSA) testing and subsequent biopsy in 
these regions.(5) 
1.1.2 Prostate cancer staging and grading 
The integration of clinical stage, Prostate-Specific Antigen (PSA) level and 
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histologic tumour grade can be used to determine the extent or spread of 
prostate cancer and predict outcomes after treatment. The most widely used 
staging system for prostate cancer is the American Joint Committee on Cancer 
(AJCC) TNM system,(6) which is based on 3 key prognostic markers: 1. the 
extent of the primary tumor (T category); 2. whether the cancer has spread to 
nearby lymph nodes (N category); and 3. the absence or presence of distant 
metastasis (M category).  
The TNM staging system 
In the TNM system for prostate cancer, a simplified summary of staging is as 
follows: 
T1 Tumour so small that it cannot be detected by feeling the prostate or 
 on ultrasound 
T2 Tumour can be felt but is still confined within prostate 
T3 Tumour extends through the prostatic capsule and may have 
 spread into  seminal vesicles 
T4 Tumour invades adjacent structures other than seminal vesicles, 
 such as bladder, rectum or pelvic wall 
N1 Tumour is found in lymph nodes 
M1 Tumour has distant metastases 
 
Within each stage, subgroupings a–d indicate the extent of spread within that 
stage (Figure 1.1). The PSA level at the time of diagnosis and/or the Gleason 
score, based on the prostate biopsy or surgery (histologic tumour grade) is 
used in conjunction with the TNM stage to stratify patients into prognostic 
groups.   
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Figure 1.1: American Joint Committee on Cancer (AJCC) TNM system 
subgroups 
 
Used with permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original 
and primary source for this information is the AJCC Cancer Staging Manual, Seventh Edition (2010) 
published by Springer Science+Business Media. 
 
This thesis is concerned with the management of men with high-risk prostate 
cancer post prostatectomy. This is defined as anyone with T3 disease (one or 
7t h  EDITION
Primary Tumor (T)   
CLINICAL
 TX  Primary tumor cannot be assessed
 T0  No evidence of primary tumor
 T1  Clinically inapparent tumor neither 
palpable nor visible by imaging
 T1a  Tumor incidental histologic fnding 
in 5% or less of tissue resected
 T1b  Tumor incidental histologic fnding 
in more than 5% of tissue resected
 T1c  Tumor identifed by needle 
biopsy (for example, because 
of elevated PSA)
 T2  Tumor confned within prostate1
 T2a  Tumor involves one-half 
of one lobe or less
 T2b  Tumor involves more than one-half 
of one lobe but not both lobes
 T2c  Tumor involves both lobes
 T3  Tumor extends through 
the prostate capsule2
 T3a  Extracapsular extension 
(unilateral or bilateral)
 T3b  Tumor invades seminal vesicle(s)
 T4  Tumor is fxed or invades adjacent 
structures other than seminal 
vesicles, such as external sphincter, 
rectum, bladder, levator muscles, 
and/or pelvic wall (Figure A)
ANATOMIC STAGE/PROGNOSTIC GROUPS6
Group T N M PSA Gleason
I T1a–c N0 M0 PSA <10 Gleason ≤6
T2a N0 M0 PSA <10 Gleason ≤6
T1–2a N0 M0 PSA X Gleason X
IIA T1a–c N0 M0 PSA <20 Gleason 7
T1a–c N0 M0 PSA ≥10<20 Gleason ≤6
T2a N0 M0 PSA ≥10<20 Gleason ≤6
T2a N0 M0 PSA <20 Gleason 7
T2b N0 M0 PSA <20 Gleason ≤7
T2b N0 M0 PSA X Gleason X
IIB T2c N0 M0 Any PSA Any Gleason
T1–2 N0 M0 PSA ≥20 Any Gleason
T1–2 N0 M0 Any PSA Gleason ≥8
III T3a–b N0 M0 Any PSA Any Gleason
IV T4 N0 M0 Any PSA Any Gleason
Any T N1 M0 Any PSA Any Gleason
Any T Any N M1 Any PSA Any Gleason
Notes
1 Tumor found in one or both lobes by needle biopsy, but not palpable or reliably visible by imaging, is classifed as T1c.
2 Invasion into the prostatic apex or into (but not beyond) the prostatic capsule is classifed not as T3 but as T2.
3 There is no pathologic T1 classifcation.
4 Positive surgical margin should be indicated by an R1 
descriptor (residual microscopic disease).
5 When more than one site of metastasis is present, the 
most advanced category is used. pM1c is most advanced.
6 When either PSA or Gleason is not available, grouping should be determined 
by T stage and/or either PSA or Gleason as available.
Definitions
Pathologic (pT)3
 pT2  Organ confned
 pT2a  Unilateral, one-half of 
one side or less
 pT2b  Unilateral, involving more than 
one-half of side but not both sides
 pT2c  Bilateral disease
 pT3  Extraprostatic extension
 pT3a  Extraprostatic extension 
or microscopic invasion 
of bladder neck4
 pT3b  Seminal vesicle invasion
 pT4  Invasion of rectum, levator 
muscles, and/or pelvic wall
Regional Lymph Nodes (N)
CLINICAL
 NX  Regional lymph nodes 
were not assessed
 N0  No regional lymph node metastasis
 N1  Metastasis in regional 
lymph node(s) 
PATHOLOGIC
 pNX  Regional nodes not sampled
 pN0  No positive regional nodes
 pN1  Metastases in regional node(s)
Distant Metastasis (M)5
 M0  No distant metastasis
 M1  Distant metastasis
 M1a  Nonregional lymph node(s)
 M1b  Bone(s)
 M1c  Other site(s) with or 
without bone disease
Figure A. T4 tumor invading adjacent structures other 
than seminal vesicles, such as bladder, rectum, levator 
muscles, and/or pelvic wall.
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more of extracapsular extension, seminal vesicle invasion, positive surgical 
margins). Patients with metastatic disease were not included. 
The Prostate Specific Antigen (PSA) level at time of diagnosis 
The percentage of free PSA in blood serum at the time of diagnosis can be 
used for risk stratification, providing an estimate of the likelihood of having 
biopsy-detectable prostate cancer as well as the extent and biological 
potential of the cancer. While the range of normal PSA values varies with age 
(Table 1.1), for the average man aged over 50 years, with no suspicious Digital 
Rectal Examination, the likelihood of having biopsy-detectable prostate cancer 
with a serum PSA level between 0.0 and 2.0 ng/ml is approximately 10%. This 
risk increases to 15% to 25% if the PSA level is 2.0 to 4.0 ng/ml; 17% to 32% if 
the PSA level is 4.0 to 10.0 ng/ml; and 43% to 65% if the PSA level is above 
10.0 ng/ml.(7, 8) In addition, the proportion of men with higher volume 
cancers, extraprostatic disease, higher grade disease, and biochemical failure 
after treatment all increase as the PSA level increases.(9) When the PSA level 
at diagnosis is less than or equal to 4.0 ng/ml, 80% of men will have organ-
confined disease. This proportion decreases at higher PSA levels to about 70% 
when the PSA level is between 4.0 and 10.0 ng/ml and about 50% when the 
PSA level is greater than 10.0 ng/ml.(10) At PSA levels higher than 10.0 ng/ml 
at diagnosis a significant proportion of men will have incurable, metastatic 
disease.(11) The PSA level at diagnosis is also significantly associated with the 
risk of biochemical recurrence after treatment.(12)  
 
Table 1.1: Age specific reference ranges for serum PSA 
Age (years) Normal total PSA range (ng/ml) 
40 - 49 0.0 – 2.5  
50 – 59 0.0 – 3.5  
60 – 69 0.0 – 4.5  
70 and older 0.0 – 6.5 
Adapted from: Stricker P. (2001) Prostate cancer. Part 1 Issues in screening and 
diagnosis.(11)  
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The Gleason score 
The Gleason Grading System (13), the most widely used grading system 
worldwide, is a score of the tumour grade of adenocarcinoma of the prostate 
i.e. how abnormal, or poorly differentiated, biopsy tissue looks in comparison 
with well-differentiated normal tissue. Upon pathological examination, the 
cancer is assigned two Gleason grades based on the histologic pattern of 
arrangement of carcinoma cells. The primary grade is the most common 
Gleason pattern while the secondary grade is the next most common Gleason 
pattern. The primary and secondary grades are added together to derive the 
Gleason score from two to a maximum ten (for example, 3+4=7). Increasing 
Gleason grade is directly related to a number of histopathologic end points, 
including tumour size, margin status, and pathologic stage. Gleason grade has 
also been linked to a number of clinical end points, including clinical stage, 
progression to metastatic disease, and survival.(14) Therefore, the higher the 
Gleason score, the more aggressive the cancer, and the more likely it will grow 
and spread (Table 1.2). While patients with a Gleason score ranging from 2-6 
are considered to have low risk disease, patients with a Gleason score ≥ 7 are 
at greater risk for extraprostatic extension and biochemical recurrence.(15) 
For example, in a series of 2404 men who underwent radical prostatectomy at 
Johns Hopkins Medical Institutions between 1982 and 1999, the biochemical 
failure rate overall was 17%. For the Gleason 8-10 patients, 10-year disease 
free survival was 29%, which dropped to 15% by 15 years.(16) In another 
study of 547 consecutive patients in the Cancer of the Prostate Strategic 
Urological Research Endeavor (CaPSURE) database who underwent radical 
prostatectomy between June 1988 and September 2000, the 5-year disease-
free survival rate for men with a biopsy Gleason score of 8-10 was 38%.(17) 
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Table 1.2: Gleason score descriptive summary 
Adapted from National Comprehensive Cancer Network (NCCN) Guidelines for patients. 
Prostate Cancer, Version 1. 2015.(18) 
 
1.1.3 Treatment modalities and rates of utilisation 
United States National Comprehensive Cancer Network (NCCN) guidelines 
suggest that many men with very low-risk clinically localised disease should be 
managed with active surveillance. Men with low- and intermediate-risk 
disease should be managed with active surveillance or with external beam 
radiation therapy, radical prostatectomy, brachytherapy, or a combination of 
these treatments. Men with high-risk disease should be managed with 
external beam radiotherapy plus androgen deprivation therapy with or 
without high dose rate brachytherapy. Alternatively high-risk disease should 
be managed with radical prostatectomy and pelvic node dissection.(19) 
In Australia, radical prostatectomy is the most frequent procedure for 
clinically localised and intermediate-risk prostate cancer. NSW Central Cancer 
Registry data were analysed in the Prostate Cancer Care Outcomes Study 
(PCOS)(20) for more than 1600 men under the age of 70 years diagnosed with 
histopathologically confirmed localised prostate cancer (clinical stage T1a to 
T2c with no evidence of lymph node involvement or distant metastases) 
between October 2000 and October 2002. Sixty percent (981/1636) had 
radical prostatectomy as primary treatment. The remainder predominantly 
had external beam radiation therapy (18% [289/1636]) with or without 
Gleason Score Risk Description 
2-6 Low Low grade well differentiated tumour.  
The cancer is likely to grow and spread very slowly. 
Treatment may never be needed.  
7 Intermediate Intermediate grade, moderately differentiated 
tumour. 
The cancer is likely to grow and spread at a modest 
pace. Treatment is needed to prevent future 
problems. 
8-10 High High grade, poorly differentiated tumour. 
The cancer is likely to grow and spread quickly.  
Treatment is needed at diagnosis. 
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androgen deprivation therapy, which was more common in older men with 
later stage disease, or were kept under active surveillance (12% [280/1636]). 
More extensive NSW Central Cancer Registry data including 51,341 men 
diagnosed between 2001 and 2009 showed the frequency of radical 
prostatectomy in NSW increased progressively each year.(21) Victorian 
Prostate Cancer Registry data for men diagnosed with prostate cancer from 
2008 to 2011 report, overall, 71.0% (1933/2724) received surgery, 
radiotherapy and/or brachytherapy. Nearly half of men with clinically localised 
disease (46.1% [1168/2531]) and more than half of those with intermediate-
risk of disease progression (54.5% [655/1201]) underwent radical 
prostatectomy. Just over a quarter (25.6% [698/2724]) had external beam 
radiotherapy. In total, 558 men (20.5% of those for whom treatment data 
were collected) were recorded as having received androgen deprivation 
therapy either alone or in combination with other primary or salvage 
treatment. Twelve percent (72/594) of those with high-risk localised disease 
and 40.6% (299/736) of those with low risk of progression received no active 
treatment.(19) This is consistent with unpublished combined data from 
clinical registries in South Australia and Victoria for 13,598 men diagnosed 
with prostate cancer between 2008 and 2013. Sixty percent received radical 
treatment within 12 months of diagnosis with radical prostatectomy more 
common than radiotherapy as the curative approach (67% versus 33%). One 
quarter (25%) were managed using an observational approach with or without 
androgen deprivation therapy.(22)  
These Australian figures reflect those reported in a population-based analysis 
of contemporary patterns of care in the US. Data from the Surveillance, 
Epidemiology, and End Results (SEER) database including 12,732 men under 
60 years old diagnosed with localised prostate cancer between 2010 and 2011 
show that 61.0% (3693/6058) with low-risk and 67.4% (3335/4947) with 
intermediate-risk had radical prostatectomy while 20.7% (1254/6058) with 
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low-risk and 21.6% (1071/4947) with intermediate-risk had radiotherapy. 
16.8% (1018/6058) with low-risk and 6.4% with intermediate-risk (318/4947) 
had no active treatment.(23)    
1.1.4 Rates and predictors of recurrence after primary treatment 
Following radical prostatectomy as the primary curative treatment, it is 
estimated that 20% to 50% of men are at ‘high risk’ of experiencing 
progression or recurrence.(24-27) Rates of recurrence are 40-60% higher 
among patients with adverse pathological risk factors, namely extracapsular 
extension, seminal vesicle invasion or positive surgical margins.(28) All three 
risk factors are independently predictive and in combination yield a worse 
prognosis.  
With regard to extracapsular extension, in a cohort study of 112 patients who 
underwent radical prostatectomy between 1969 and 1993, with a minimum of 
10 years follow up (29), the overall 10-year clinical progression and/or 
biochemical failure free survival was 63%. For patients with no capsular 
involvement (n=62) disease free survival was 69%. For men with invasion into, 
but not through the capsule (n=24), the rate was similar at 67%, while for 
those men with invasion through the capsule (n=26) the rate dropped to 39% 
(p=0.017). This statistic is identical to that of another large long-term cohort 
study of 16,782 patients in the Johns Hopkins database who underwent 
radical prostatectomy between 1982 and 2008 (30) in which patients with 
extraprostatic extension (n=5316) had a 39% biochemical failure rate and 11% 
cancer specific death rate by 12 years. Other studies reporting on the 
prognosis of extraprostatic positive disease have documented 5-year failure 
free survival between 48% and 68%.(31, 32) In a study of 2518 Mayo Clinic 
radical prostatectomy patients with pT2N0M0 or pT3N0M0 prostate cancer, 
men with extracapsular extension (n=847) had a 5-year progression free 
survival rate (progression was defined as a PSA level > 0.4ng/ml on at least 
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one occasion) of 68% compared with 82% in those without extracapsular 
extension (n=1671), (p < 0.001).(31) A further study of 438 patients treated 
with radical prostatectomy alone between 1987 and 1993 reported 5 year 
biochemical relapse-free survival rate (relapse was defined as a PSA level > 
0.2ng/ml) of 48% in patients with extracapsular extension (n=206) compared 
with 85% for patients without (n=131), (p < 0.0001).(33) It is likely that the 
higher PSA level for the determination of relapse in the Mayo Clinical study is 
a factor in the smaller proportion of patients who were considered to have 
recurrent disease in that cohort.  
Multiple studies have demonstrated that extracapsular extension in 
conjunction with positive surgical margins results in lower disease free 
survival rates; 5-year failure free survival reported from 33-55% and 10-year 
failure free survival reported from 20%-53% depending on the definition of 
failure, median length of follow up and patient selection criteria.(32, 34-36)  
Surgical margin status has also been found to be an independent predictor of 
recurrence. A comprehensive summary of literature by Swanson and Basler 
(32) concluded that patients with positive margins had double the overall 
death rate (60%) as those with organ or specimen confined disease (30%) and 
that margin positive disease had a reported 19-64% recurrence rate, a 5-year 
failure free survival of 36%-86% and 10-year failure free survival of 26%-61%. 
The large variation in reported biochemical recurrence and failure-free 
survival rates across the 17 primary studies was due to a number of 
methodological differences including variable PSA levels for the determination 
of biochemical recurrence (range, > undetectable to > 0.4ng/ml) and median 
follow-up time (range, 25 months to 121 months). For example, the lowest 
recurrence rate (19%) was defined as PSA >0.3ng/ml at a mean follow-up of 
46 months (n=350) (37) and the highest (64%) was defined as PSA ≥0.2ng/ml 
at median 62 months follow-up (n=60).(38) Furthermore, there were marked 
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differences in samples sizes that affected the precision of these estimates 
(range, n=60 to n=1501). Differences in sample size, PSA levels and median 
follow-up were also evident in the studies reporting the highest and lowest 5- 
and 10-year survival rates. Of note, the largest study (n=1501, PSA ≥ 0.2 ng/ml 
on two occasions, median follow-up 38 months) reported 7-year disease free 
survival in 60% of patients with positive surgical margins.(39) An Australian 
study that sought to establish predictors of biochemical recurrence by 
analyzing the pathological characteristics of positive surgical margins found 
that a higher Gleason grade carcinoma (grade 4 or 5) at a positive surgical 
margin is significantly associated with biochemical failure after radical 
prostatectomy.(40) In the study with the lowest reported failure rate of 19% 
(37), rates of recurrence increased to 20% in the margin positive group with 
Gleason grade 7 (n=153) and 52% in the margin positive group with Gleason 
grade 8-10 (n=50). 
Seminal vesicle involvement has similarly been linked with increased risk of 
biochemical failure, and death, in a number of studies. For seminal vesicle 
positive patients in one study (16), 5-year disease free survival was 48%, 
dropping to 30% by 10 years and 17% by 15 years. These statistics are similar 
to those reported for the study of 2518 Mayo Clinic patients; for 5-year 
progression free survival was 81% for 2183 patients without seminal vesicle 
involvement compared with 52% for the 335 patients with seminal vesicle 
involvement (p < 0.001). Other studies have shown seminal vesicle positive 
patients had a 73-75% biochemical failure rate and 23-28% death rate at 10-
12 years.(30, 41) For example, of 673 patients in the Johns Hopkins radical 
prostatectomy database with seminal vesicle involvement, 75% had 
experienced biochemical recurrence at 12 years follow up.(30) These rates 
increased if patients also had extraprostatic disease.(41) 
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1.1.5 Recommendations for post-operative care for men with adverse 
features post-prostatectomy 
Data from three large prospective randomized controlled trials (Table 1.3) 
involving more than 1800 men have shown the use of adjuvant radiotherapy 
within 4 months of resection significantly reduces the risk of biochemical 
recurrence and improves local recurrence and clinical progression free 
survival compared with surgery alone among patients with adverse 
pathological risk factors.(42-46) Overall survival was also improved after 
longer-term follow-up of patients in one trial (47). These trials include the: 
EORTC Trial 22911 (42, 45); SWOG S8794 (43, 47, 48); and ARO Trial 96–
02/AUP AP 09/95 (44, 46).  
European Organisation for Research and Treatment of Cancer (EORTC) Trial 
22911 
EORTC 22911 (42), a multicentre, phase III randomised controlled trial, 
involved 1005 patients, treated across 37 institutions throughout Europe. 
Eligible patients were those aged less than 76 years with histopathologically 
confirmed stage pT2-3 N0M0 prostate cancer with at least one risk factor post 
radical prostatectomy: tumour growth beyond the capsule (extracapsular 
extension); positive surgical margins; or invasion of the seminal vesicles. 
Following surgery as the primary curative treatment, patients were randomly 
assigned to one of two arms: 1. wait-and-see (n=503); or 2. immediate post-
operative radiotherapy (60Gy conventional irradiation delivered over 6 
weeks), within 16 weeks of surgery (n=502). The primary endpoint was 
biochemical progression-free survival. Clinical progression-free survival was 
defined as survival with no evidence of clinical, sonographic, radiographic or 
scintigraphic recurrence. Biochemical progression was defined as an increase 
of more than 0.2 μg/L over the nadir (lowest post-operative PSA value) 
measured on three occasions at least two weeks apart. Biochemical 
progression-free survival was counted from the day of randomisation to the 
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day of first clinical or biochemical progression or start of treatment in absence 
of progression, if any. Median follow-up was 5 years for both groups. The 
cumulative rate of locoregional failure was significantly lower in the post-
irradiation group (5.4%; 98% CI [2.7% – 8.0%] versus 15.4%; 98% CI [11.2% - 
19.6%]; p<0.0001).  Clinical progression-free survival was significantly higher 
in the irradiated group (hazard ratio [HR] 0.61; 98% CI [0.43 – 0.87]; 
p=0.0009), as was biochemical progression-free survival (hazard ratio [HR] 
0.48; 98% CI [0.37 – 0.62]; p<0.0001). At 5 year follow-up there was no 
significant difference in overall survival for the wait-and-see versus irradiation 
groups (93.1%; 98% CI [90.1% - 96.2%] versus 92.3%; 98% CI [89.1% - 95.5%; 
p=0.6796). Any grade and grade 2 (moderate) or grade 3 (severe) late adverse 
effects, including nausea or vomiting, diarrhea, frequency passage of urine, 
dysuria, skin and haematuria, were more common in the irradiated group 
(p=0.0045 and p=0.0005, respectively). Events of grade 3 toxicity were rare 
and incidence did not differ between groups at five years (2.6%; 98% CI [0.8% 
– 4.4%] wait-and-see versus 4.2%; 98% CI [3.4% - 5.0%]; p=0.0726). 
At longer term follow-up(45) (median 10.6 years; range 2 months – 16.6 
years) biochemical progression-free survival was significantly improved in the 
irradiated group (60.6%; 95% CI [55.7% – 65.2%] over the wait-and see-group 
(41.1%; 95% CI [36.4% – 45.8%]) (hazard ratio [HR] 0.49; 95% CI [0.41 – 0.59]; 
p<0.0001). Improvements in clinical progression-free survival, however, were 
not maintained (70.3%; 95% CI [65.5% – 74.6%] in the postoperative 
irradiation group versus 64.8%; 95% CI [59.8% – 69.3%] in the wait-and-see 
group; hazard ratio [HR] for clinical progression or death 0.81; 95% CI [0.65 – 
1.01]; p=0.0539). There was no significant difference in overall survival at 10 
years (total number of deaths 130 out of 502 patients in irradiated group 
versus 115 out of 503 patients in the wait-and-see group; hazard ratio [HR] 
1.18; 95% CI [0.91 – 1.53]; p=0.20). Late adverse effects (any type, any grade) 
were more frequent in the postoperative irradiation group than in the wait-
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and-see group at 10 years follow-up (cumulative incidence 70·8%; 95% CI 
[66·6% – 75·0%] versus 59·7%; 95% CI [55·3% – 64·1%]; p=0.001). 
Southwest Oncology Group (SWOG) Trial S8794 
SWOG S8794 (43, 47, 48) a multi-institutional, randomised controlled trial 
conducted in the United States, included men diagnosed with T3N0M0 
prostate cancer with pathologically determined extracapsular extension, 
positive margins and/or seminal vesicle involvement between 1988 and 1995. 
A total of 425 eligible men who had undergone radical prostatectomy within 
the prior 16 weeks were randomised to: 1. adjuvant radiotherapy (60 to 64 Gy 
in 30 to 32 fractions), initiated within 10 working days of randomisation 
(n=214); or 2. observation (n=211). The primary endpoint was metastasis-free 
survival, defined as the time from randomisation to first evidence of 
metastasis or death due to any cause. Secondary outcomes included prostate-
specific antigen (PSA) relapse, recurrence-free survival, overall survival, 
freedom from hormonal therapy, and postoperative complications. A post-
operative PSA level at enrolment ≤0.2 ng/mL was considered undetectable. 
Biochemical relapse was defined as a PSA level exceeding 0.4 ng/mL after 
enrollment for those with a postsurgical PSA level of 0.4 ng/mL or lower. At 
first publication of results (48), median follow-up was 10.6 years (range 9.2 to 
12.7 years). There was no statistically significant difference in metastasis-free 
survival or overall survival. Seventy-six out of 214 (35.5%) men in the adjuvant 
radiotherapy group were diagnosed with metastatic disease or died of any 
cause (median metastasis-free estimate, 14.7 years), compared with 91 out of 
211 (43.1%) in the observation group (median metastasis-free estimate, 13.2 
years) (hazard ratio [HR] 0.75; 95% CI [0.55 - 1.02]; p=0.06). Neither were 
there significant between-group differences for overall survival (71 deaths, 
median survival of 14.7 years for radiotherapy versus 83 deaths, median 
survival of 13.8 years for observation; hazard ratio [HR] 0.80; 95% CI [0.58 - 
1.09]; p=0.16).  There were, however, significant reductions in PSA relapse 
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(median PSA relapse–free survival, 10.3 years for radiotherapy versus 3.1 
years for observation; hazard ratio [HR] 0.43; 95% CI [0.31 - 0.58]; p<0.001) 
and disease recurrence (defined as any evidence of measurable or evaluable 
disease e.g. bone lesions) in the adjuvant radiotherapy group (median 
recurrence-free survival, 13.8 years for radiotherapy versus 9.9 years for 
observation; hazard ratio [HR] 0.62; 95% CI [0.46 - 0.82]; p=0.001). Ten per 
cent of patients in the radiotherapy group had received hormonal therapy by 
five years compared with 21% in the observation group (hazard ratio [HR] 
0.45; 95% CI [0.29 – 0.68’ p<0.001). Post-operative complications were more 
common in the adjuvant radiotherapy group than the observation group 
(23.8% versus 11.9%; relative risk, 2.0; 95% CI [1.3 – 3.1]; p=0.002), including 
rectal complications (3.3% versus 0%; p=0.02), urethral strictures (17.8% 
versus 9.5%; relative risk, 1.9; 95% CI [1.1 – 3.1]; p=0.02), and total urinary 
incontinence (6.5% versus 2.8%; relative risk, 2.3; 95% CI [0.9 – 5.9]; p=0.11). 
Longer-term results were subsequently published (47), with median follow-up 
12.7 years for the radiation arm (range 11.4 to 15.1 years) and 12.5 years for 
the observation arm (range 11.1 to 14.0 years). At 12 years follow-up 114/211 
observation patients (54%) (median metastasis-free survival 12.9 years) had 
died or had metastatic disease compared with 93/214 irradiated patients 
(43%) (median metastasis-free survival 14.7 years). The hazard ratio [HR] for 
metastasis-free survival with adjuvant radiotherapy was 0.71 (95% CI [0.54 - 
0.94; p=0.016). At 12 year follow-up overall survival was also significantly 
improved in the adjuvant radiotherapy arm (hazard radio [HR] 0.72; 95% CI 
[0.55 - 0.96]; p=0.023). Longer-term rates of post-operative complications 
were not reported. 
Arbeitsgemeinschaft Radiologische Onkologie (ARO) und Urologische 
Onkologie of the German Cancer Society (ARO 96-02/AUO AP 09/95) Trial 
ARO 96-02/AUO AP 09/95 (44) was a German multi-centre phase III 
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randomised controlled trial conducted between 1997 and 2004 across 22 
institutions. Eligible men, aged less than 76 years, with histologically proven 
adenocarcinoma of the prostate, with a pathological stage pT3-4 N0 and 
positive or negative surgical margins were randomly assigned to: 1. immediate 
post-operative radiotherapy (three-dimensional conformal radiotherapy with 
60 Gy delivered in 30 fractions) within six to 12 weeks following surgery 
(n=194); or 2. wait-and-see (n=194). An undetectable post-operative PSA was 
defined as less than 0.1 ng/ml. PSA progression for patients with previously 
undetectable PSA was stated after two consecutive determinations with 
increasing PSA values. The primary end point was biochemical progression-
free survival. After exclusion of patients with progressive disease (those who 
did not achieve an undetectable PSA or who commenced hormonal 
treatment), 114 patients had adjuvant radiotherapy and 159 patients were 
observed under a wait-and-see policy. The overall median follow-up period 
was 53.7 months (radiotherapy group, range, 5.3 to 108.8 months; wait-and-
see group, range, 1.3 to 102.5 months). At 5 years follow-up, there was 
significant improvement in biochemical progression-free survival in patients 
with undetectable PSA after radical prostatectomy in the adjuvant 
radiotherapy group (72%; 95% CI [65% - 81%] versus 54%; 95% CI [45% - 63%]; 
hazard ratio [HR] 0.53; 95% CI [0.37 - 0.79]; p=0.0015). The cumulative rate of 
grade 1 adverse effects for bladder and rectum was 21.9% in the radiotherapy 
group and 3.7% in the wait-and-see group (p<0.0001). There were three 
events for grade 2 genitourinary adverse effects (2%) and two grade 2 
gastrointestinal adverse effects in the radiotherapy group compared with 
none in the wait-and-see group. There was only one event of grade 3 bladder 
toxicity in the radiotherapy group (0.3%) and no grade 4 events were 
recorded.  
Subsequent analyses were conducted to determine the efficacy of adjuvant 
radiotherapy at 10-year follow-up with the primary end point of progression-
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free survival. (46) Progression was defined as biochemical recurrence, clinical 
recurrence or death. Median follow-up was 111.3 months for the 
radiotherapy group (range, 2.3 – 167.8 months) and 112.2 months for the 
wait-and-see group (range, 1.3 – 161.4 months). Progression-free survival was 
significantly better in the irradiated group; Kaplan-Meier estimates were 56% 
in the radiotherapy group versus 35% in the wait-and-see group (hazard ratio 
[HR] 0.51; 95% CI [0.37 – 0.70]; P<0.0001). The study was underpowered to 
assess metastasis-free survival or overall survival as end points. 
Table 1.3: Evidence from randomised controlled trials for the efficacy of 
adjuvant radiotherapy (ART) post radical prostatectomy (RP) 
 
 
There has been some criticism of these trials, most notably the lack of a well-
defined salvage radiotherapy arm which meant many patients in the wait-and-
see groups did not ever receive salvage radiotherapy or if given it was 
delivered with PSA values >1.2ng/ml rather than at low PSA recurrence such 
as 0.2ng/ml which is the current trigger for salvage radiotherapy. 
Consequently, in about 40% of cases there was clinically palpable, biopsy-
proven, or radiographically evident local failure increasing the risk of 
concurrent micrometastatic disease and making further local therapy 
potentially futile.(49) This means it is not possible, from the results of these 
trials, to make a direct comparison between the efficacies of immediate 
adjuvant radiotherapy over early salvage radiotherapy at the first sign of a PSA 
recurrence. It has also been argued that ARO 96-02/AUO AP 09/95, which 
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exclusively included patients who achieved an undetectable PSA after radical 
prostatectomy, to prospectively test whether they also benefit from 
immediate post-surgical radiotherapy, is the only truly adjuvant trial among 
the three.(46) 
Nonetheless, on the basis of the cumulative evidence from these trials, 
several international clinical practice guidelines (50-54) were published 
between 2010 and 2013 with a recommendation that men with extracapsular 
extension, seminal vesicle invasion or positive surgical margins should be 
offered adjuvant radiotherapy after radical prostatectomy. 
Specifically, this thesis is related to a Grade B recommendation in the 2010 
Clinical Practice Guidelines for the Management of Locally Advanced and 
Metastatic Prostate Cancer produced by the Australian Cancer Network (52) 
that ‘patients with extracapsular extension, seminal vesicle involvement or 
positive surgical margins receive post-operative external beam radiation 
therapy within four months of surgery’ (p37). This recommendation is echoed 
in the more recently published 2013 American Urological Association 
Guideline, Adjuvant and Salvage Radiotherapy after Prostatectomy, which 
states ‘Physicians should offer adjuvant radiotherapy to patients with adverse 
pathologic findings at prostatectomy (Standard; Evidence Strength: Grade A)’ 
(p1).(51)  
1.1.6 Current post-operative patterns of care  
A number of patterns of care studies demonstrate historically low rates of 
utilisation of adjuvant radiation in patients with adverse pathological features 
post-prostatectomy. These studies consistently report only approximately 10-
20% of eligible patients receive treatment in Australia (19, 20, 55, 56), Canada 
(57, 58) and the United States (59-62) and rates of adjuvant radiotherapy did 
not increase following publication of randomised controlled trial data. For 
example, in NSW, Australia’s most populous state with 7.4 million inhabitants, 
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less than 10% of men diagnosed with locally advanced prostate cancer 
between 2000 and 2002 received adjuvant radiotherapy within the 
recommended timeframe.(20) This figure is consistent with more recent 
Victorian Cancer Registry Data including men diagnosed with prostate cancer 
between August 2008 and February 2011 of whom only 8% with high-risk 
clinically localised disease received external beam radiotherapy following 
radical prostatectomy.(19) Other analyses of the same Registry data (56) 
found that 9.4% of men with at least one adverse pathologic feature (any of 
positive surgical margin, extracapsular extension, or seminal vesicle invasion) 
and no evidence of lymph node metastases received adjuvant radiotherapy. 
Further, a retrospective analysis of data from the US National Cancer Data 
Base indicates declining use of radiotherapy for adverse features after radical 
prostatectomy. That study, including 97,270 patients diagnosed with prostate 
cancer between 2005 and 2011, found receipt of postoperative radiotherapy 
significantly decreased from 9.1% to 7.3% (p < 0.001).(63) These figures 
identify a significant gap between evidence-based guideline recommended 
care and actual clinical practice.  
1.1.7 How to address the evidence-practice gap?  
This type of disconnect between research evidence and clinical practice is not 
unique (64), and remains one of the most persistent problems in providing 
high-quality healthcare.(65) Clinical practice guidelines such as the one that is 
the focus of this thesis have been extensively developed as a means to 
disseminate best practice and ensure clinical decision-making is informed by 
recent, credible research evidence, thereby improving healthcare processes 
and outcomes. However, timely and effective uptake of evidence-based 
guideline recommendations into clinical practice is haphazard (66), and it is 
often difficult to make changes across the health system even when there is 
compelling evidence.(67) The difficulty in achieving large scale adoption of 
proven innovations and recommended care (as well as discontinuing 
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ineffective or harmful practices) has been characterised as a ‘translation 
block’.(68-71)  
A number of steps are necessary to translate innovations from basic research 
into routine health service delivery. Cancer Institute NSW classifies the stages 
of translational research as follows:  
• T1 ‐ Translation to humans: developing treatments and interventions from 
basic research through observational studies, case studies, and Phase 1 
and II clinical trials 
• T2 ‐ Translation to patients: testing the efficacy and effectiveness of 
treatments and interventions and translation of new clinical science 
and knowledge into routine clinical practice and health decision making 
through observational studies, evidence synthesis and guidelines 
development and Phase III clinical trials 
• T3 ‐ Translation to practice: dissemination and implementation for system‐
wide change by embedding evidence‐based guidelines into health 
practice through dissemination research, implementation research, 
diffusion research, and Phase IV clinical trials 
 
This thesis relates to a National Health and Medical Research Council 
(NHMRC) Partnership Project co-funded by the Prostate Cancer Foundation of 
Australia (PCFA) titled ‘Improving evidence-based care for locally advanced 
prostate cancer: A randomised phased trial of clinical guideline 
implementation through a clinical network’ (working title Clinician-Led 
Improvement in Cancer Care (CLICC)) an implementation research study that 
sits within the T3 phase of the translation spectrum.   
Established research indicates that successful implementation of evidence-
based care depends critically on the extent to which strategies address 
prospectively identified barriers, through theoretical frameworks of behaviour 
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change.(72, 73)  Therefore, a conceptual program logic model was developed 
to underpin the design of a multi-faceted guideline implementation strategy 
based on the PRECEDE-PROCEED model, which comprises eight steps for the 
planning, implementation and evaluation of behaviour change 
interventions.(74, 75) The four phases of PRECEDE represent the pre-
intervention diagnostic planning process, encompassing Predisposing, 
Reinforcing, and Enabling Constructs in Educational/Environmental Diagnosis 
and Evaluation. The additional four phases of PROCEED guide the 
implementation and evaluation of intervention programs designed through 
the PRECEDE process through Policy, Regulatory, and Organizational 
Constructs in Educational and Environmental Development. Taken as a whole, 
PRECEDE-PROCEED relates interpersonal factors and system characteristics 
into one model to inform change in practice and enables the integration of 
context-specific barriers into ‘predisposing factors’ (e.g. knowledge and 
attitudes of the target group); ‘reinforcing factors’ (e.g. opinions and 
behaviour of peers); and ‘enabling factors’ (e.g. capacity of the system and 
hospital processes). PRECEDE-PROCEED was the most widely used theory in a 
systematic review of the use of theory in the design of guideline dissemination 
and implementation strategies, and interpretation of the results of rigorous 
evaluations.(76) Further systematic reviews have shown that trials that 
intervene to alter these three factors are the most successful.(77) Details of 
how PRECEDE-PROCEED was used to develop the conceptual program logic 
model for this study and the intervention mapping process are provided in 
Chapter 4. 
1.1.8 The landscape of intervention strategies for clinician behavioural 
change  
Recommendations from clinical guidelines are more likely to become 
embedded within practice when they: are initiated and led by local clinical 
leaders; are tailored to the local context; and engage clinicians in the design of 
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the implementation strategy.(64, 66, 77-79) Richard Grol (80) argues that to 
effectively implement evidence-based practice, research has to change so that 
it develops through collaborations between clinicians, researchers, patients, 
policy makers, and quality improvement experts. 
Specifically, the growing body of evidence suggests several core 
implementation strategies are effective in bringing about system-wide and 
sustained change (64, 76, 79, 81): 
1. Local clinical champions/opinion leaders supporting change within their 
practices and settings 
2. Systems, structural, and organisational support for system-wide 
changes to enable implementation strategies to be rolled out and 
scaled up (e.g. legislation, resources, mechanisms for communication 
and collaboration between health sectors) 
3. Ongoing monitoring, evaluation, and feedback of changes as they are 
implemented 
There is further evidence from a number of Cochrane reviews and overviews 
or syntheses of systematic reviews supporting these intervention strategies as 
the most effective in terms of impact on professional practice and healthcare 
outcomes: 
Local clinical champions/opinion leaders supporting change within their 
practices and settings 
A review of 18 randomised controlled trials investigating the effectiveness of 
opinion leaders (either as a single intervention or as part of multiple 
interventions) to disseminate evidence-based practice using objective 
measures of professional performance and/or health outcomes reported a 
12% absolute increase in compliance with best evidence overall. Further, 
when local opinion leaders were utilised within the context of a 
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multidisciplinary team, thereby improving collaboration between health 
sectors, compliance increased by 18%.(82)  
A synthesis of 33 systematic reviews, reporting 714 primary studies, examined 
the effectiveness of several clinical guideline implementation strategies. The 
authors concluded that there was variable evidence of moderate quality, for 
the effectiveness of local opinion leaders in the promotion of behaviour 
change and guideline adherence. Improvements of up to 39% were reported, 
with a median adjusted risk difference of 0.10, representing 10% greater 
compliance in intervention groups. (83) 
Systems, structural, and organisational support for system-wide changes to 
enable implementation strategies to be rolled out and scaled up 
A number of systems, structural or organisational interventions have been the 
subject of systematic review including: point of care reminders (84) and 
decision support systems (83); and interactive educational meetings (85) or 
educational outreach as mechanisms for improved communication.(83)  
The effects of on-screen, point of care computer reminders were assessed in a 
review of 28 randomised or quasi-randomised studies reporting at least one 
outcome involving a clinical endpoint or adherence to a recommended 
process of care.(84) Point of care computer reminders generally achieved 
small to modest improvements in provider behaviour: median improvement 
in process adherence of 4.2% (interquartile range (IQR): 0.8% to 18.8%) across 
all reported process outcomes; 3.3% (IQR: 0.5% to 10.6%) for medication 
ordering; 3.8% (IQR: 0.5% to 6.6%) for vaccinations; and 3.8% (IQR: 0.4% to 
16.3%) for test ordering.  
In the synthesis of systematic reviews mentioned previously (83), the use of 
reminder and clinical support systems consistently resulted in significant 
practice improvements in process or compliance of up to 71.8%. Interactive 
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educational sessions (effects ranging from 1% to 39%), and educational 
outreach or academic detailing (up to 68% relative improvement in process or 
compliance), which actively engaged clinicians, were generally effective while 
didactic education and passive dissemination strategies were largely 
ineffective.  
The effects of continuing medical education meetings and workshops on 
professional practice and health care outcomes were further evaluated in a 
review of 81 trials involving more than 11,000 health professionals.(85) 
Educational meetings alone or combined with other interventions resulted in 
a 6% median adjusted improvement in compliance (interquartile range 2.9% 
to 15.3%). Univariate meta-regression indicated didactic (risk difference 6.9) 
or interactive (risk difference 3.0) meetings alone were less effective than 
mixed interactive and didactic meetings (median adjusted risk difference 
13.6). Educational meetings were less effective for more complex compared 
with less complex behaviours (adjusted risk difference -0.3). Conversely, they 
appeared to be more effective for more versus less serious outcomes (risk 
difference 2.9).  
Ongoing monitoring, evaluation, and feedback of changes as they are 
implemented 
The provision of performance feedback as a strategy to improve professional 
practice was assessed in a review of 140 primary studies.(86) Across 49 
included studies featuring dichotomous outcomes, the weighted median 
adjusted risk difference was a 4.3% (interquartile range (IQR) 0.5% to 16%) 
absolute increase in healthcare professionals’ compliance with desired 
practice. Multivariable meta-regression suggested that feedback may be more 
effective when baseline performance is low, the source is a supervisor or 
colleague, it is provided more than once, it is delivered in both verbal and 
written formats, and when it includes both explicit targets and an action plan.  
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The synthesis of systematic reviews reported moderate evidence for the 
effectiveness of audit and feedback on process or compliance measures with 
effect sizes ranging from a 17% decline, through no effect, to a 63% 
improvement. More consistent effects were seen for cost outcomes with 
decreases of up to 37% following guideline implementation coupled with 
audit and feedback, typically achieved through a reduction in the number of 
diagnostic tests being performed, with no reported detrimental patient 
outcomes.(83) 
Multifaceted versus single intervention strategies 
The synthesis of systematic review findings additionally reported that 
multifaceted intervention strategies had greater evidence of effects than 
single intervention strategies with significant improvements in guideline 
compliance and behavioural change (reported effects up to 60%).(83) This is 
consistent with an earlier overview of systematic reviews of interventions to 
change provider behaviour which concluded that while single interventions 
are of variable effectiveness, with none clearly more effective than another, 
multifaceted interventions based on assessment of potential barriers to 
change are more likely to be effective.(87) Another overview of systematic 
reviews of implementation of research into practice similarly concluded that 
while opinion leaders, systems, structural and organisational support, and 
audit and feedback can achieve small to moderate impacts in isolation, they 
are far more effective when combined in more complex interventions that 
include multiple strategies, which consider both context and process.(88)  
It should be noted however, that the most recent overview of 25 systematic 
reviews of moderate or strong methodological quality directly comparing the 
effectiveness of multifaceted interventions with single interventions in 
changing health care professionals behaviour (89) reported mixed results and 
concluded that, based on three levels of analyses, there was no compelling 
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evidence multicomponent interventions were more effective.  Direct 
statistical analyses of effect size/dose-response in three reviews found no 
significant association between the number of intervention components and 
the effect size. Four out of eight reviews reporting direct (non-statistical) 
comparisons of the effectiveness of multifaceted compared with single 
interventions found multifaceted interventions to be generally effective 
compared with single interventions, while the remaining four found that 
multifaceted interventions had either mixed effects or were generally 
ineffective compared with single interventions. Twenty-three reviews 
indirectly compared the effectiveness of multifaceted compared to single 
interventions (by comparing multifaceted interventions to controls versus 
single interventions to controls). Fifteen of these showed similar effectiveness 
for multifaceted and single interventions when compared to controls. Of the 
remaining eight reviews, six found multifaceted interventions had mixed 
effectiveness while single interventions were reported to be generally 
effective. The authors conclude that ‘a single or less complex multifaceted 
intervention that is tailored to overcome the barriers and enhance the 
enablers of the behaviour that needs to be changed may be appropriate’. 
Intervention strategies for clinician behavioural change in the cancer context 
It is widely accepted that context is fundamental in the design and 
implementation of quality improvement behavioural change 
interventions.(90, 91) It is therefore, necessary to consider whether cancer 
specialists are a discrete clinical group that might require a different approach 
given that there are some evidence-based practices, such as post-
prostatectomy referral to radiation oncology for consideration of adjuvant 
radiotherapy, over which they solely have control.  
A review of 34 systematic reviews, published between 2005 and 2010, 
considered the evidence for interventions tested in cancer-specific 
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environments.(92) Clinician focused interventions included: education; audit 
and feedback; information technology/information management/informatics; 
clinical decisions support systems, computerised order entry and reminders; 
local opinion leaders; tailored interventions; clinical pathways; guidelines; and 
discharge planning. The reviewers concluded that evidence of effectiveness 
for improvement in professional practice and clinical outcomes was most 
promising for educational outreach (5% median improvement on 
dichotomous outcomes, IQR 1% to 20%; 23% median improvement on 
continuous outcomes, IQR 0% to 617%); and, audit and feedback 
interventions (4% median improvement on dichotomous outcomes, IQR -16% 
to 70%; 11.9% median improvement on continuous outcomes, IQR 10.3% to 
67.5%). Local opinion leaders were most effective for reduction in clinician 
non-compliance (median decrease in rates of non-compliance 7%; IQR -6% to 
12%). Tailored interventions also improved some clinical outcomes with 8/14 
studies demonstrating a benefit of tailoring (pooled odds ratio 1.54; 95% CI 
[1.16, 2.01]). Educational outreach and audit and feedback were both more 
effective as part of multifaceted interventions than when used as single 
interventions. Further audit and feedback was more effective when baseline 
compliance was low and when delivered more frequently.  
Another systematic review of quality improvement interventions directed at 
cancer specialists (93) included 12 studies, including three randomised 
controlled trials (RCTs) conducted in response to concerns about quality of 
care in common cancers including breast, colon, rectum, ovarian and prostate. 
The majority of interventions included more than one quality improvement 
strategy, most commonly utilising a combination local opinion leaders, 
education and an audit and feedback component that varied between 
feedback at the clinician level and at the group level. None of the three RCTs 
demonstrated a consistent benefit of the intervention strategies tested. A 
combination of local opinion leaders, educational meetings, 
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observational/learning practice and individual level audit and feedback had no 
effect on outcomes for patients with rectal cancer. Similarly academic 
detailing led by local opinion leaders, coupled with educational meetings and 
printed materials had no impact on outcomes for stage II colon cancer. One 
RCT did, however, report that an educational outreach program involving a 
meeting with an expert was more effective than group level feedback for 
adherence to antiemetic guidelines across some but not all chemotherapy 
categories. Uncontrolled before and after studies tended to report more 
benefits of the tested intervention strategies. Across all types of study process 
measures were more commonly reported, with larger effect sizes (mean risk 
difference 17.3%; -1.7% to 48.6%), than outcome measures (mean risk 
difference 4.5%; 1.4% to 9%). 
Variability in quality, reporting and outcomes of the primary evidence was 
common across systematic reviews, with limited descriptions of different 
intervention components that would enable replication by other cancer 
specialists. The few randomised controlled trials are outweighed by studies of 
lower quality observational design resulting in the potential for uncontrolled 
confounding, such that it is not possible to draw definitive conclusions about 
the most effective clinician-focused interventions. Further most interventions 
included multiple components but few assessed their effectiveness 
separately. Therefore, there is a need for more rigorous study design, 
execution and reporting of quality improvement intervention studies to 
increase knowledge about the most effective strategies for the uptake of 
evidence-based practice in the cancer context. 
1.1.9 Organisation of health care services in New South Wales (NSW), 
Australia 
Given the importance of context, in order to determine which of the 
multitude of potential behaviour change intervention strategies might be the 
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most effective for the current purpose, it is necessary to consider the 
organisation of health- and cancer-care services in NSW.  
Overall coordination of the public health system within Australia is the 
responsibility of the Commonwealth in combination with the state and 
territory governments. The Commonwealth focuses on public health, research 
and national information management while the states and territories are 
largely responsible for the delivery of public sector health services and the 
regulation of health workers in the public and private sectors.(94) 
NSW Health 
NSW Health is comprised of the Ministry of Health (the Ministry), statutory 
health corporations (the Pillars), Local Health Districts (LHDs), and affiliated 
health organisations.(95)  
The Ministry focuses on policy, funding and performance across the health 
system and has regulatory functions, public health functions (disease 
surveillance, control and prevention) and system management functions 
(state-wide planning, purchasing and performance monitoring of hospitals 
and health services).  
 
The five pillars, namely, the: Agency for Clinical Innovation (ACI); Bureau of 
Health Information (BHI); Cancer Institute NSW; Clinical Excellence 
Commission (CEC); and Health Education and Training Institute (HETI) provide 
support to the LHDs. The five pillars cover the following functions: 
 Agency for Clinical Innovation (ACI) - responsibility for state-wide 
clinician engagement through clinical service networks with 
responsibility for clinical redesign, and development and 
implementation models of care to make the public health system more 
efficient, better performing and sustainable over the longer term.  
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 Bureau of Health Information (BHI) - responsibility for reporting of 
health care quality information to the community, healthcare 
professionals and policymakers.  
 Cancer Institute NSW – responsibility for cancer control, including 
reducing the incidence of cancer, increasing survival from cancer and 
improving the quality of life for people with cancer and their carers.  
 Clinical Excellence Commission (CEC) - responsibility for system quality 
and safety, including critical response management for adverse clinical 
incidents and clinical risk management, and providing leadership in 
clinical governance with LHDs.  
 Health Education and Training Institute (HETI) – responsibility for 
development and training for clinicians and health administrators.  
There are 15 LHDs in NSW with responsibility and accountability for governing 
hospital and health service delivery for their local population. These LHDs 
cover a wide range of settings, from primary care posts in the remote outback 
to metropolitan tertiary health centres. There are also two specialist networks 
focusing on children's and paediatric services, justice health and forensic 
mental health. A third specialist network covers public health services 
provided by St Vincent's Health, a Catholic not-for-profit health and aged care 
provider.  
1.1.10 Cancer care in NSW  
Multidisciplinary care, involving a team of surgeons, radiation oncologists, 
medical oncologists, nurses, pathologists, radiologists and allied health 
professionals, is widely accepted as best practice in cancer care. A 
multidisciplinary approach can help to refine treatment recommendations, 
coordinate care and achieve optimal cancer outcomes for people with cancer. 
The establishment of multidisciplinary teams (MDTs) has been advocated for 
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widely internationally (96) and in Australia (97, 98), including the introduction 
of two Australian Commonwealth Government Medical Benefit Scheme (MBS) 
payment items in 2006 (99) enabling Medicare rebate claims to encourage 
and support clinicians participating in cancer case conferences. In a review of 
published literature, (100) MDT discussion was demonstrated to have a 
signiﬁcant impact on clinical decision-making for various cancer types.  
The NSW government cancer control agency, the Cancer Institute NSW, works 
with LHDs within the NSW Health system to assist them in providing cancer 
services. As part of this role the Cancer Institute NSW has supported the 
development MDTs across NSW through a number of different grant, project 
and evaluation activities.(101) 
1.1.11 A clinical networks approach to implementation  
Networks of clinical experts are increasingly being implemented as a strategy 
to improve health care processes and outcomes and achieve change in the 
health system. Formalised managed clinical networks have been established 
in the United States, United Kingdom and other parts of Europe, Australia and 
Canada with significant financial investment.(102-111) These clinical networks 
of volunteer health professionals provide a framework for doctors, nurses, 
allied health professionals, managers, and consumers to collaborate across 
regional and service boundaries to drive improvements in service delivery and 
care outcomes through innovation in clinical practice.  
While there are numerous different models of clinical network from fully 
integrated service delivery systems, such as Kaiser Permanente or the 
Veterans Health Administration in the United States, to informal communities 
of practice, all have the shared aim of engaging clinicians in the 
implementation of quality improvement initiatives.(103, 104, 106, 109, 112) 
These clinical networks can uniquely provide ‘bottom up’ views on the best 
ways of tackling complex healthcare problems within the local context 
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coupled with the strategic and operational ‘top down’ support necessary to 
facilitate and champion changes in practice at the clinical interface.(113, 114) 
Clinical networks embody, or have the potential to enable, the core features 
of successful implementation strategies and therefore are a mechanism for 
health system change and increasing the uptake of evidence-based care for 
three reasons: 
1. Clinical networks include clinical leaders who can design and champion 
change to improve care within their practices and influence wider 
culture change within their healthcare settings 
2. Clinical networks are a ‘ready-made’ organisational structure through 
which innovations may be promulgated and accelerated by clinicians 
3. Clinical networks provide a structure to monitor and evaluate changes 
as they are implemented to answer questions about effectiveness and 
the success of implementation strategies 
There are data suggestive of networks being effective in improving the quality 
of patient care (103, 106, 108, 115) and there is evidence from ‘before and 
after’ controlled studies that when clinical practice guidelines are 
implemented through clinical networks there are improvements in 
compliance with guideline recommendations.(116, 117) However, much of 
the evidence for the effectiveness of clinical networks is anecdotal and the 
relatively few quantitative studies are limited by lack of a rigorous 
experimental design (a systematic review of the clinical networks literature is 
provided in Chapter 2). Subsequently there remains a need to more formally 
test the efficacy of a network approach to health care quality improvement. 
The Agency for Clinical Innovation (ACI) in their capacity as the agency 
responsible for clinician engagement has established a coordinated program 
of 30 managed clinical networks, institutes and taskforces in NSW. The 
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networks are formed around a diverse range of specialty health service areas 
and serve a population of 7.5 million people.(118) State-funded, they have a 
system-wide focus where members identify and advocate for models of 
service delivery (e.g. outreach services, new equipment, using technology to 
improve diagnosis) and quality improvement initiatives (e.g. guideline 
development and dissemination, training and education for health 
professionals).(119-122) 
The implementation trial that is the focus of this thesis was funded to test a 
range of strategies to increase the uptake of a clinical practice guideline 
recommendation into routine care for patients with prostate cancer in 
hospitals within the ACI Urology Network, with in-kind support provided by 
the Network. The Urology Network was established to improve equity of 
access, promote high quality care and improve outcomes for NSW patients 
with urological conditions. Led by an executive committee, which includes 
doctors, nurses, academics, allied health staff and consumers, the network 
has more than 80 members and includes representatives from the NSW 
Ministry of Health, local health districts (LHDs), specialty network governed 
health corporations, Clinical Excellence Commission (CEC) and the Cancer 
Institute NSW. 
Specifically, the study involves nine urological MDTs, linked to the ACI Urology 
Network, responsible for the treatment of patients with prostate cancer in 
hospitals spread across eight LHDs.  Full details of hospital and patient 
eligibility criteria are provided in the published study protocol (Chapter 5). 
 
1.2 Scope of thesis 
This thesis presents a series of studies conducted within the overarching 
framework of a stepped-wedge prospective phased randomised controlled 
trial ‘Clinician-Led Improvement in Cancer Care (CLICC)’ funded by the 
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National Health and Medical Research Council (NHMRC) in partnership with 
the Prostate Cancer Foundation of Australia (PCFA), with in-kind support 
provided by the NSW Agency for Clinical Innovation (ACI).    
This thesis includes those components for which I have had primary 
conceptual, methodological, analytical and interpretative responsibility, 
except where explicitly acknowledged in the text, and I am the first author of 
all publications arising from this work. 
 
1.3 Thesis statement 
This thesis addresses the following aims:  
 
(a) To develop and trial a locally tailored, multifaceted implementation 
strategy that harnesses the NSW Agency for Clinical Innovation (ACI) 
Urology Clinical Network to increase evidence-based care for men with 
high-risk prostate cancer following radical prostatectomy in selected 
NSW hospitals. 
(b) To identify reasons why changes in behaviour and outcomes occurred 
or did not occur in CLICC hospitals and why the implementation 
strategy did or did not result in increased compliance with guideline 
recommended care. 
(c) To consider how findings could be translated to the implementation of 
other clinical practice guideline recommendations. 
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Chapter 2: The effectiveness of clinical networks in improving 
quality of care and patient outcomes:  a systematic review of 
quantitative and qualitative studies 
 
Publication arising from this chapter 
Brown B, Patel C, McInnes E, Mays N, Young J & Haines M. The effectiveness 
of clinical networks in improving quality of care and patient outcomes: A 
systematic review of quantitative and qualitative studies. BMC Health Services 
Research. 2016; 16:360. DOI: 10.1186/s12913-016-1615-z     
 
2.1 Abstract 
Background: Reorganisation of healthcare services into networks of clinical 
experts is increasing as a strategy to promote the uptake of evidence-based 
practice and to improve patient care.  This is reflected in significant financial 
investment in clinical networks. However, there is still some question as to 
whether clinical networks are effective vehicles for quality improvement. The 
aim of this review was to ascertain the effectiveness of clinical networks and 
identify how successful networks improve quality of care and patient 
outcomes. 
Methods: A systematic search was undertaken in accordance with the PRISMA 
approach in Medline, Embase, CINAHL and PubMed for relevant papers 
between 1 January 1996 and 30 September 2014. Articles were included if the 
primary focus was on clinical networks as defined in Table 2.1. Both 
quantitative and qualitative studies were included. Established protocols were 
used separately to examine and assess the evidence from quantitative and 
qualitative primary studies, including risk of bias, then synthesise and 
integrate findings.  
Results: A total of 22 eligible studies (9 quantitative; 13 qualitative) were 
included. Of the quantitative studies, seven focused on improving quality of 
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care and two focused on improving patient outcomes. Quantitative studies 
were limited by a lack of rigorous experimental design. The existing evidence 
indicates that clinical networks may be effective vehicles for quality 
improvement in service delivery and patient outcomes across a range of 
clinical disciplines. However, there was variability in the networks’ ability to 
make meaningful network- or system-wide change across more complex 
measures for processes that required intensive professional education or 
more comprehensive redesign of the care pathway. Findings from quantitative 
studies were supplemented with insights from qualitative studies to explain 
why some networks were more successful than others. Specifically, networks 
that had a positive impact on quality of care and patients outcomes had 
adequate resources, credible leadership and efficient management coupled 
with effective communication strategies and collaborative trusting 
relationships.  
Conclusions: There is evidence that clinical networks may improve the 
delivery of healthcare though there are few high quality quantitative studies 
of their effectiveness. Our findings can provide policymakers with some 
insight into how to successfully plan and implement clinical networks by 
ensuring strong clinical leadership, an inclusive organisational culture, 
adequate resourcing and localised decision-making authority. 
 
2.2 Background 
Networks of clinical experts are increasingly being established as a strategy to 
promote the uptake of evidence-based practice and drive improvements in 
standards of patient care.  These clinical networks are argued to represent a 
shift away from hierarchical, bureaucratic organisation of healthcare services 
to one which engages clinicians more in the development of improved models 
of care, integration of services and multidisciplinary collaboration.[1, 2] 
Broadly, clinical networks provide a structure for clinicians to work more 
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closely across institutional and professional boundaries, and allow for 
continuous working relationships and flow of knowledge about best practice 
between individuals and organisations, thereby improving the quality of and 
access to care for patients, including those who require coordination of care 
across a range of settings. With this shared aim, clinical networks have been 
established in the United Kingdom (UK) [3-5], other parts of Europe [6, 7], 
Australia [1, 8-10], Canada [11], and the United States (US).[12]  
The use of networks to reduce fragmentation, and increase efficient and 
seamless integration of service delivery is well established in other public 
services.[13, 14] There has already been significant financial investment. For 
example, in the UK the NHS England allocated £42 million in the 2013/2014 
financial year (approximately $27.7m USD) to the establishment of strategic 
clinical networks to strengthen the existing less formalised clinical 
networks.[15, 16] In Australia, $58 million AUD (approximately $48.7m USD) 
was allocated in the 2010/11 Budget for the establishment of Lead Clinicians’ 
Groups in Local Hospital Networks.[17] However, the question remains: does 
the planning and delivery of services through clinical networks improve 
quality of care?   
The term “clinical network” has been used to describe many variants of 
networks [2, 18] (see Table 2.1). For this review, we excluded studies of fully 
integrated service delivery systems because they are very contextually specific 
with overarching administrative structures through which networked services 
are delivered (e.g. Kaiser Permanente or the Veterans’ Health Administration 
in the US). We also excluded ‘communities of practice’ because there has 
been a systematic review published which assessed the evidence of whether 
they improved the uptake of best practices and mentoring of new 
practitioners in the health sector.[19] That review identified 13 primary 
studies, none of which met the eligibility criteria for quantitative analysis to 
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evaluate effectiveness. Consequently, the effectiveness of communities of 
practice in the healthcare sector remains unknown.   
Previous systematic reviews [2, 19] of other models of clinical networks were 
not able to draw conclusions because of limited and poor quality research. 
This is a fairly common conclusion for reviews of newly established, innovative 
healthcare structures, processes and systems.[20-22] A large-scale systematic 
review of clinical networks published in 2004 described models and functions 
of networks across multiple public service sectors.[2] That review had a broad 
focus in order to derive implications for management, governance, leadership 
and policy of networks in health and social care.  In relation to healthcare, this 
review concluded that there was no evidence of how effective networks were 
in improving patient care.  A more recent review focused on the structure of 
social networks of health professionals concluded, “cohesive and collaborative 
health professional networks can facilitate the coordination of care and 
contribute to improving quality and safety of care”.[23] As defined in that 
review, social networks could be considered to share the characteristics of 
communities of practice, typified by natural structural network features and 
fluid interactions, rather than the more hierarchical structure of clinical 
networks and their associated governance arrangements. 
The current review focuses on managed and non-managed clinical networks, 
defined as voluntary clinician groupings that aim to improve clinical care and 
service delivery using a collegial approach to identify and implement a range 
of quality improvement strategies [8] (see Table 2.1 for further definitions).  
The primary aim was to investigate the effectiveness of these clinical networks 
to improve: a) quality of care (defined as increased uptake of evidence-based 
practice); and b) patient outcomes (based on objective outcome measures). 
Sub-aims of the review were to: i) assess the quality of the methods used in 
each of the studies; and ii) identify how clinical networks achieved their 
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Table 2.1: Typology of clinical networks 
 
 Community of practice  Information network Clinical network  
(non-managed)  
Clinical network  
(managed) 
Integrated service 
delivery  
Definition  Groups of people who 
share a concern or 
passion for something 
they do and learn how 
to do it better as they 
interact regularly.  
Communities of practice 
are characterised by 
voluntary and transitory 
memberships without a 
hierarchical structure. 
Soft networks are largely 
referral systems whereby 
members list themselves 
in an electronic directory 
to receive information 
and resources. 
Groups of voluntary 
experts who work together 
on common concerns to 
develop solutions that 
involve transcending 
traditional boundaries.  
These networks are 
characterised by a 
hierarchical structure with 
governance arrangements.    
These tend to be organised 
by clinical discipline. 
Groups of clinicians 
who deliver services 
across boundaries 
between healthcare 
professions and the 
different sectors of the 
health system. These 
tend to be organised by 
clinical discipline. 
Networks made up of 
healthcare organisations 
as well as individuals 
within them with an 
overarching administrative 
structure with a focus on 
integration and 
coordination of clinical 
services. These tend to be 
organised by geographical 
region. 
Membership  Individuals  
 
 
Flexible and 
unrestricted  
Individuals  
 
 
Flexible and unrestricted  
Individuals  
 
 
Flexible and voluntary  
Individuals and  
healthcare 
organisations  
Formal  
Healthcare organisations  
 
Contractual arrangements 
about service delivery  
Governance and 
management  
Non-hierarchical and 
informal  
 
“Bottom up”  
 
Non-hierarchical and 
informal 
   
“Bottom up”  
 
Semi-hierarchical 
 
 
“Bottom up”  
 
Hierarchical 
 
 
“Mix of bottom up and 
top down”  
Hierarchical 
  
 
“Top down”  
 
Overlap with other 
typology  
 
 
Enclave*  Enclave  Individualistic  Individualistic Hierarchical  
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 Community of practice  Information network Clinical network  
(non-managed)  
Clinical network  
(managed) 
Integrated service 
delivery  
Example  Canadian Health 
Services Research 
Foundation - The 
Executive Training for 
Research Application 
(EXTRA) program alumni 
community of practice, 
Canada 
http://www.cfhi-
fcass.ca/sf-
docs/default-
source/extra/cfhi-
extra_brochure-2015-
e.pdf 
NHS UK – CHAIN: Contact, 
Help, Advice and 
Information Network, UK  
 
 
 
 
 
 
 
 
http://chain.ulcc.ac.uk/ch
ain/index.html 
NSW Agency for Clinical 
Innovation’s networks, 
Australia  
 
 
 
 
 
 
 
 
 
http://www.aci.health.nsw
.gov.au/ 
NHS National Services 
Division Scotland 
Managed Clinical 
Networks, UK  
 
 
 
 
 
 
http://www.nsd.scot.n
hs.uk/%5C%5C/services
/nmcn/index.html 
Veterans Integrated 
Service Networks, 
Veterans' Health 
Administration, US   
 
 
 
 
 
 
 
http://www2.va.gov/direc
tory/guide/division_flsh.as
p?dnum=1 
Included in this 
review  
NOT INCLUDED NOT INCLUDED INCLUDED INCLUDED NOT INCLUDED 
 
*Enclave is defined where members are individuals rather than organisations whose participation is voluntary and often transient 
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impacts.  Evidence of impact on quality of care and patient outcomes from 
quantitative studies was supplemented with findings of qualitative research to 
aid interpretation of results and facilitate understanding of the process of 
network implementation, network structure, the ways in which networks have 
been used to improve knowledge sharing and coordination of services, and 
key features necessary for success. This is the first systematic review that has 
explicitly focused on the effectiveness of clinical networks to improve quality 
of care and patient outcomes. 
 
2.3 Methods 
The review was conducted in accordance with the Preferred Reporting Items 
for Systematic Reviews and Meta-Analyses (PRISMA) approach to ensure the 
transparent and complete reporting of the searching, systematic screening 
and independent quality assessment.[24] The concepts and overarching 
methods for systematic reviews [25] have been adapted for a mixed methods 
systematic review using the framework outlined by Thomas and colleagues 
[26, 27] which allows independent syntheses of quantitative and qualitative 
studies followed by integration of findings. Given the lack of high quality 
evidence from randomised controlled trials, we adopted a pragmatic 
approach examining all available evidence, from primary observational 
studies, and assessing study quality within this lower level of the evidence 
hierarchy using established protocols. A detailed description of the search can 
be found in Appendix I. Articles were eligible for inclusion in this review if:  
i) The primary focus of the paper was on clinical networks in any 
healthcare setting (e.g. acute, primary, community, vertical 
integration)  
ii) The networks corresponded with the category of network that 
would be included - that is a managed or non-managed clinical 
network  
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iii) The paper reported an outcome related to improvement of quality 
of care or patient outcomes (based on objective measures) 
Excluded were:  
i) Abstracts and titles with the term ‘clinical network’ that were not 
referring to actual clinical networks (e.g. clinical network guidelines, 
simulation studies for proposed networks, protocol papers detailing 
study plans of networks, information technology or infrastructure 
networks) 
ii) Research networks  
iii) Clinical trial networks 
iv) Clinical guideline networks   
v) Integrated service delivery networks (sometimes called regional 
networks or networked hospitals, Health Management 
Organisations and managed care organisations in the United States) 
vi) Articles that used clinical networks as vehicles for samples for 
studies 
vii) Articles that were not published in peer review journals (e.g. 
conference proceedings)  
 
2.4 Search Strategy 
Papers were identified in two stages and selected for inclusion using the 
PRISMA steps (see Figures 2.1 and 2.2). Two researchers (BB, MH) initially 
searched Medline, Embase and CINAHL for relevant papers between 1996 and 
2010. In the second stage of the literature search, two researchers (BB, CP) 
performed an updated literature search in PubMed and CINAHL for the period 
covering 1 January 2011 to 30 September 2014. Details on search terms can 
be found in Appendix I. Full text publications identified through reference lists 
were screened for eligibility using the screening criteria. The reviewers 
independently reviewed abstracts and selected full text articles to confirm 
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whether the publication should be included in the analysis. Discrepancies 
were resolved through discussion and consensus. After discussion, there was 
100% agreement on which articles met the eligibility criteria for inclusion. 
With 17 articles from the initial search and 5 from the updated search, a total 
of 9 quantitative and 13 qualitative eligible studies were identified from the 
search period 1 January 1996 to 30 September 2014.  
 
Figure 2.1: PRISMA Flow Diagram – Initial search 1996-2010 
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Figure 2.2: PRISMA Flow Diagram – Updated search 2011-September 2014 
 
 
 
 
 
 
2.5 Quality and assessment of risk bias 
The quality assessments of quantitative and qualitative studies were 
conducted separately.[25, 28]  
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Quantitative Studies 
The quantitative study designs were assessed on the basis of whether they 
would meet the study design acceptable for a Cochrane Effective Practice and 
Organisation of Care Group (EPOC) review with those being: a) patient or 
cluster randomised control trials; b) non-randomised cluster control trials; c) 
controlled before and after studies; and d) interrupted time series [29, 30]. 
Given the lack of high quality study designs found in the included articles, 
study designs were coded into the followed grades of evidence used 
previously for a communities of practice review [19]: 
1. Experimental  
2. Quasi-experimental studies (controlled trials, time series, controlled 
before and after designs)  
3. Observational designs (before and after studies, cross-sectional studies).   
 
The assessment of the quality of the methods and reporting drew on elements 
of EPOC and the Agency for Healthcare Research and Quality [29, 31]: 
 Was the study free from selective outcome reporting? (yes/no/unclear) 
 For comparative studies, was the control/comparison group used 
equivalent to the intervention group? (yes/no) (where appropriate)  
 For non-comparative studies, were the cases representative (i.e. all 
eligible cases over a defined period of time, all cases in a defined 
catchment area, all cases in a defined hospital, clinic or group, or an 
appropriate sample of those cases)? [32] (yes/no) (where appropriate)  
 Was there a clear description of the exposure or intervention? (yes/no) 
 Was the study adequately protected against contamination? 
(yes/no/unclear) (where appropriate) 
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 Statistical analysis – were the methods appropriate and was reporting 
adequate? (yes/no) 
 Was there a declaration of funding or sponsorship? (yes/no) 
 Was the study free from other risks of bias? (yes/no) 
 
The studies were grouped into three categories on the basis of quality of 
methods and reporting [33]: 
 High quality – design and conduct of study address risk of bias, 
appropriate measurement of outcomes, appropriate statistical and 
analytical methods, low drop-out rates, adequate reporting; 
 Moderate quality – do not meet all criteria for a rating of good quality 
but no flaw is likely to cause major bias, some missing information; 
 Low quality – significant biases including inappropriate design, conduct, 
analysis or reporting, large amounts of missing information, 
discrepancies in reporting. 
 
Qualitative Studies  
There is lack of consensus about how to assess risk of bias for qualitative 
studies [9]. For this review we considered that assessing the validity of the 
methods and quality of the reporting was the most appropriate approach to 
take [10, 11]. To do this, we used nine criteria to assess the quality of 
qualitative studies recently developed by Harden and colleagues [12] and two 
criteria on the extent to which the ‘participant voice’ [13] was elucidated 
using a definition suggested by Mays and Pope [10] (see Box 2).  
 
Arbitrary cut offs were selected as:   
 High quality – those meeting 8 or more criteria 
 Medium quality – those meeting between 5 and 7 criteria 
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 Low quality – those meeting fewer than five criteria 
 
Box 2 - Criteria used to assess the quality of the qualitative studies. 
 
Quality of reporting [26] 
1. Were the aims and objectives clearly reported? 
2. Was there an adequate description of the context in which the research 
was carried out? 
3. Was there an adequate description of the network and the methods by 
which the sample was identified and recruited? 
4. Was there an adequate description of the methods used to collect 
data? 
5. Was there an adequate description of the methods used to analyse 
data? 
 
Use of strategies to increase reliability and validity [26] 
6. Were there attempts to establish the reliability of the data collection 
tools (for example, by use of interview topic guides)? 
7. Were there attempts to establish the validity of the data collection 
tools (for example, with pilot interviews)? 
8. Were there attempts to establish the reliability of the data analysis 
methods (for example, by use of independent coders)? 
9. Were there attempts to establish the validity of data analysis methods 
(for example, by searching for negative cases)? 
 
Quality of the application of the methods [35] 
10. The extent to which qualitative studies are grounded in and reflect 
study participants’ perspective and experiences (as evidenced by the 
use of supporting quotes) 
11. Whether the studies produce also rich or ‘thick’ descriptions of the 
investigation and explanatory insights rather than ‘thin’ descriptions or 
flat summaries of the findings. 
 
Two review authors (BB, CP) independently assessed the risk of bias of each 
study; discrepancies were resolved by consensus with a third author (MH) as 
needed. Studies were grouped into three categories (high, medium and low). 
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For the quantitative studies, the reviewers agreed that observational articles 
would not be given a “high” quality rating even when bias was minimised in 
the study due to the difficulty in controlling confounding and attributing 
causality when using an observational design for effectiveness studies. 
Following discussion, there was 100% agreement on the quality assessment 
rating of the included articles between the three researchers (see Table 2.2). 
Quality ratings were used descriptively to assess the strength of evidence. 
 
2.6 Data extraction and synthesis 
Data relating to each eligible study were extracted in a standard way directly 
into a data extraction table (see Appendix II). Studies were first categorised as 
either qualitative or quantitative. Quantitative papers were then further 
categorised independently by two reviewers (BB, CP) according to the focus of 
the study: 1. improving quality of care; or 2. improving patient outcomes (see 
Table 2.2). The two reviewers independently used content analysis to identify 
and categorise the qualitative papers into four agreed themes: 1. features and 
outcomes of effective networks; 2. network implementation; 3. organisational 
structure; or 4. organisational learning and knowledge (see Table 2.3). The 
main findings of the quantitative and qualitative studies were first examined 
separately. Due to the heterogeneity of the included quantitative studies and 
their outcomes, results were reported in narrative form. Qualitative methods 
were used to thematically analyse and synthesise textual data extracted from 
the qualitative studies. Results from the quantitative narrative analysis were 
then integrated with the qualitative synthesis in the discussion to identify 
recurrent themes and explain how successful networks achieved their 
outcomes.  
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2.7 Results  
Appendix II presents an overview of the 22 studies including details of context, 
sample, research aim, study design, methods, outcomes, and main results. 
Synthesis of quantitative studies 
Table 2.2 summarises study characteristics and quality ratings. With the 
exception of one study published in 1999, the remainder (eight) were 
published after 2000, with four published since 2011.  Four were undertaken 
in the UK, two in France, two in Australia and one in the US. The studies 
involved networks covering diverse clinical specialties including: cancer 
(three); cardiac services (two); diabetes (one); end stage renal disease (one); 
and neonatal services (two).  
Of the nine included quantitative studies, seven focused on improving quality 
of care and two focused on improving patient outcomes (see Appendix II for 
measures used in each study). Based on our quality assessment criteria, six 
studies (67%) were of moderate quality and three studies (33%) were of low 
quality (Table 2.2). Studies were limited by the use of observational rather 
than experimental designs (7 of 9). 
Four studies (3, 4, 39, 43) described the impact of the establishment and 
reorganisation of healthcare into clinical networks, while five studies (6, 7, 40-
41) described the impact of network initiatives. Network initiatives included 
development and dissemination of clinical practice guidelines and protocols, 
educational activities (e.g. workshops), clinical audit and provision of 
feedback, care pathway redesign, facilitation of multidisciplinary team care, 
patient education, and other interventions to improve clinical care (such as 
point-of-care reminders and availability of new technology). 
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Table 2.2: Summary of included quantitative articles 
Authors Country Type of Network Theme Study Design Quality Rating* 
Gale et al 2012 (3) UK Managed clinical network 
for neonatal services 
Improving quality of care Observational – before and 
after 
Moderate 
Greene et al 2009 (40) UK Tayside Diabetes Managed 
Clinical Network 
Improving quality of care Observational – cross-
sectional 
Moderate 
Hamilton et al 2005 (4) Scotland Managed clinical network 
for cardiac services 
Improving quality of care Quasi-experimental – 
interrupted time series 
Moderate 
McClellan et al 1999 (42) USA End Stage Renal Disease 
Networks 
Improving patient outcomes Observational – before and 
after 
Low 
McCullough et al 2014 (39) Scotland Scottish Sarcoma Managed 
Clinical Network 
Improving quality of care Observational – 
retrospective before and 
after 
Low 
Ray-Coquard et al 2002 (6) France Regional cancer network of 
hospitals 
Improving quality of care Quasi-experimental – 
controlled before and after 
Moderate 
Ray-Coquard et al 2005 (7) France Regional cancer network of 
hospitals 
Improving quality of care Observational – before and 
after 
Moderate 
Spence & Henderson-
Smart 2010 (41) 
Australia Australian and New Zealand 
Neonatal Network 
Improving quality of care Observational – before and 
after 
Low 
Tideman et al 2014 (43) Australia Integrated cardiac support 
network 
Improving patient outcomes Observational – 
retrospective before and 
after 
Moderate 
*Quality rating definitions: 
 High quality – design and conduct of study address risk of bias, appropriate measurement of outcomes, appropriate statistical and analytical 
methods, low drop-out rates, adequate reporting 
 Moderate quality – do not meet all criteria for a rating of good quality but no flaw is likely to cause major bias, some missing information 
 Low quality – significant biases including inappropriate design, conduct, analysis or reporting, large amounts of missing information, discrepancies 
in reporting
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Effectiveness of clinical networks to improve quality of care  
A total of seven studies examined quality of care indicators, all of which 
achieved significant improvements on some or all indicators. Studies are listed 
by clinical specialty.   
 Cancer 
Three observational studies (two moderate and one low quality) reported 
improvements on quality of care indicators related to previous provision of 
cancer services. In a controlled before and after study, Ray-Cocquard et al [6] 
reported an increase in the observed compliance rate for overall treatment 
sequences post-implementation of clinical practice guidelines established and 
disseminated by a regional cancer network for hospitals in the network; 36% 
(126 out of 346) vs 12% (34 out of 282) and 46% (56 out of 123) vs 14% (14 
out of 103) (p<0.001) for breast and colon cancer, respectively. In the control 
group of non-network hospitals, there was no difference in the observed 
compliance rate pre-and post-implementation. In a three-year follow up 
repeated controlled before and after study, Ray-Cocquard et al [7] observed 
that compliance of medical decisions with clinical practice guidelines was 
higher at follow up for colon cancer (73%; 95% CI [67%, 79%] v 56%; 95% CI 
[49%, 63%], respectively; p=0.003) and similar for the two periods for breast 
cancer (36%; 95% CI [31%, 41%] v 40%; 95% CI [35%, 44%], respectively; 
p=0.24). In the control group, compliance was higher at three-year follow up 
for colon cancer (67%; 95% CI [58%, 76%] v 38%; 95% CI [29%, 47%], 
respectively; p=0.001) and identical for the two periods for breast cancer (4%; 
95% CI [1%, 7%] v 7%; 95% CI [3%, 11%], respectively; p=0.19).  These findings 
indicate that clinical network-led improvements can be sustained over time. 
While there was improvement in compliance for colon cancer in both 
networked and non-networked hospitals at three-year follow-up, behaviour 
change was more rapid in the region within the cancer network suggesting 
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that valid evidence-based information was disseminated more expeditiously 
through the network.  
In a retrospective observational study, McCullough et al [39] conducted a 
cohort analysis of patient records and administrative datasets before and 
after establishment of the Scottish Sarcoma Managed Clinical Network. More 
patients were seen by more specialties after establishment of the network 
and the time interval from receipt of referral to initial assessment by the 
service improved from a median of 19.5 days to 10 days. However the interval 
between initial GP consultation and initial assessment by the service increased 
from 35 to 41 days (p=0.57). Patients undergoing investigation with a 
magnetic resonance imaging (MRI) scan prior to excision of the sarcoma 
increased from 67% to 86% after the establishment of the network 
(p=0.0009). The proportion of patients undergoing appropriate biopsy 
increased from 57% to 79% (p=0.006), while complete resection margins 
increased from 48% to 81% (p<0.001). 
 Cardiac services 
In one quasi-experimental interrupted time series study (moderate quality), 
Hamilton et al [4] reported statistically significant improvement in two out of 
16 clinical care indicators (pain to needle time <90min; p=0.05 and 70% on 
beta-blockade at 6 months post myocardial infarction; p=0.05) and non-
significant improvement in nine others following the set-up of a managed care 
network for cardiac services in Scotland. Five indicators showed no 
improvement and there was no impact on resource costs.  
 Diabetes 
One study (moderate quality) [40] retrospectively evaluated the impact of 
quality improvement initiatives undertaken by the Tayside Diabetes Managed 
Clinical Network in the UK using data extracted from the regional diabetes 
register. Simple process indicators such as measuring glycated haemoglobin, 
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blood pressure and cholesterol rapidly improved, while there was slow 
continuous improvement on others such as recording of smoking status, 
measurement of creatinine, assessment of foot vascular and neurological 
status and retinal screening (all significance levels p<0.001). Improvements 
were greater for type 2 than type 1 diabetes for which three indicators did not 
change significantly. Significant shifts of care for type 2 diabetes into primary 
care were achieved. Network organisation and leadership with a clear vision 
for best care were important facilitators in implementing quality improvement 
initiatives and achieving widespread clinical engagement, with information 
technology playing a supportive role.  
 Neonatal Care 
Two observational before and after studies, one in Australia (low quality) [41] 
and one in the UK (moderate quality) [3] reported neonatal care outcomes of 
neonatal care networks. The previously established Australian and New 
Zealand Neonatal Network [41] drove the implementation of multiple 
intervention strategies to increase evidence-based practice for the treatment 
of newborn pain, resulting in improvements across three outcomes. Increased 
use of a pain assessment tool for ventilated neonates, an increase in the 
percentage of infants receiving sucrose for procedural pain (41% to 61%; 
p<0.005) and increased staff awareness of a clinical practice guideline for the 
management of newborn pain (61% to 86%; chi square =73.8, d.f. 1, p=0.000) 
were reported. Family awareness of infant pain and strategies to manage the 
pain also increased from 19% to 48% (chi square =52.3, d.f. 1, p=0.000).  
In the UK, the impact of reorganisation of neonatal specialist care services for 
high-risk pre-term babies into managed clinical networks for neonatal services 
achieved improvements [3]. The proportion of babies born at 27-28 weeks 
gestation at hospitals providing the highest volume of specialist care increased 
from 18% to 49% (risk difference 31%, 95% CI [28, 33]; OR: 4.30, 95% CI [3.83, 
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4.82]; p<0.001). The proportion of babies undergoing acute and late postnatal 
transfer in England increased (7% v 12% and 18% v 22%, respectively; 
p<0.001). There was no reduction in the number of infants from multiple 
births separated by transfer.  
Effectiveness of clinical networks to improve patient outcomes  
Two observational (one prospective and one retrospective before and after) 
studies (one moderate and one low quality) assessed patient outcome 
measures, both reporting improvements on primary indicators. A study in the 
US [42] assessed the effects of a quality improvement intervention on 
network-specific Urea Reduction Ratios (URRs) driven by the End Stage Renal 
Disease Network. URRs improved during the intervention period (63% to 67%; 
p<0.001) and the proportion of under-dialysed patients in the networks 
decreased from 56.6% to 31.7% (chi-squared for trend, p<0.0001).  Successful 
intervention strategies included audit and feedback coupled with educational 
interventions, involvement of a diversity of physicians and clinical leaders, and 
persistence over several years. 
In Australia, the regionalised Cardiovascular Clinical Network (ICCNet) was 
established to improve outcomes of patients with myocardial infarction (MI) 
in rural settings.[43] Among rural hospitals, 30-day mortality decreased 
among patients presenting to hospitals integrated into the clinical network 
(13.93% before ICCNet vs 8.92% after ICCNet; p<0.001). After adjustment for 
temporal improvement in MI outcome, baseline comorbidities and MI 
characteristics, availability of immediate cardiac support (i.e. presentation to 
an ICCNet hospital) was associated with a 22% relative odds reduction in 30-
day mortality compared with patients presenting to rural centres outside the 
clinical network (OR, 0.78; 95% CI [0.65, 0.93]; p=0.007). A strong association 
between network support and increased rate of transfer of patients to 
metropolitan hospitals was observed (before ICCNet, 1102/2419 [45.56%] vs 
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after ICCNet, 2100/3211 [65.4%]; p<0.001). Increased transfers were 
associated with a lower total length of stay compared with admissions before 
implementation of the network. Rates of angiography increased among rural 
patients, but remained lower than in metropolitan patients.  
Synthesis of qualitative studies 
Table 2.3 summarises key study characteristics and quality ratings. All of the 
13 studies were published in 2005 or later. Eight were undertaken in the UK, 
two in Australia, two in Canada, and one in Sweden. The majority of studies 
used a case study or comparative case study approach to examine clinical 
networks. A summary of findings is available in Appendix II. According to our 
criteria, nine of the 13 studies were given a high quality rating while four were 
given a moderate quality rating. Although none were rated low quality, 
studies were limited by their lack of use of sufficient strategies to establish 
reliability (e.g. independent coding) or validity of data analysis (e.g. reporting 
of negative cases).  
While five articles (44-48) specifically addressed the features and outcomes of 
effective networks, articles that fell in the other three subcategories similarly 
identified leadership, interpersonal relationships, organisational structure and 
resourcing as factors that contribute to the network effectiveness.  
Features and outcomes of effective networks 
Five papers (one high and four moderate quality) [44-48] identified the 
following characteristics as enabling a network to be successful: 
 Supportive policy environments and links with government agencies; 
 Sufficient resources – in particular, having a project/network leader or 
coordinator provided a clear advantage, as did the availability of 
information and communication technologies;
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Table 2.3: Summary of included qualitative articles 
Authors Country Type of Network Theme Study Design Quality Rating* 
Addicott 2008 (50) UK Managed clinical network 
for cancer services 
Organisational structure Comparative case study High 
Addicott & Ferlie 2007 (51) UK Managed clinical network 
for cancer services 
Organisational structure Comparative case study High 
Addicott et al 2007 (52) UK Managed clinical network 
for cancer services 
Organisational structure Comparative case study High 
Addicott et al 2006 (53) UK Managed clinical network 
for cancer services 
Organisational learning and 
knowledge 
Observational, cross-
sectional organisational 
process study 
High 
Ahgren & Axelsson 2007 
(44) 
Sweden ‘Chains of care’ (managed 
clinical networks) for 
patients having the same 
illness or symptom 
Features and outcomes of 
effective networks 
Cross-sectional embedded 
multiple-case study 
High 
Baker & Wright 2006 (45) UK Managed clinical network 
for paediatric liver services 
Features and outcomes of 
effective networks 
Appreciative Inquiry 
methodology (case study) 
Moderate 
Burnett et al 2005 (54) UK Various managed clinical 
networks (cancer, coronary 
heart disease, stroke, 
mental health) 
Organisational learning and 
knowledge 
Qualitative information and 
knowledge needs analysis 
(comparative case study) 
Moderate 
Cunningham et al 2012 
(46) 
Australia Advisory clinical networks – 
two networks for 
musculoskeletal health 
(NSW and WA) 
Features and outcomes of 
effective networks 
Longitudinal comparative 
case study 
High 
Fleury et al 2002 (49) Canada Mental health integrated 
service network 
Network implementation Case study and multi-
dimensional analytic model 
Moderate 
Hogard & Ellis 2010 (47) UK Managed clinical network 
for personality disorder  
Features and outcomes of 
effective networks 
Evaluation Trident 
methodology (case study) 
Moderate 
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Authors Country Type of Network Theme Study Design Quality Rating* 
McInnes et al 2012 (48) Australia Voluntary collegial clinical 
networks in NSW 
established by the NSW 
Agency for Clinical 
Innovation 
Features and outcomes of 
effective networks 
Comparative case study High 
Tolson et al 2007 (5) Scotland Managed clinical network 
(Palliative Care), linking 
primary, secondary and 
tertiary care 
Network implementation Realistic Evaluation 
methodology (qualitative 
pilot case study) 
High 
Touati et al 2006 (13) Canada Managed clinical network 
(cancer) 
Network implementation Longitudinal qualitative case 
study 
High 
*Quality rating definitions: 
 High quality – those meeting 8 or more criteria 
 Medium quality – those meeting between 5 and 7 criteria 
 Low quality – those meeting fewer than five criteria 
 
The full list of 11 criteria can be found in Appendix I.
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 A bottom-up, locally-initiated and driven approach to network 
implementation, with subsequent formalisation to increase the adoption 
of new processes; 
 A positive, trusting culture where networks are seen as desirable and 
perceived to be necessary to sharing knowledge, and where there is open 
and inclusive communication, clinician engagement and widespread 
stakeholder participation; 
 The norms and values of the network are compatible with those of the 
organisations involved; 
 Strong leadership, particularly by clinical leaders and network managers; 
 Inclusive membership in the network, including representation of patients 
and other stakeholders; 
 Evidence-based work plans and projects that address issues identified by 
network members, particularly gaps in current practice, with goals that are 
feasible and can be objectively measured. 
The studies noted that success was dependent on a combination of these 
factors being present rather than just a few isolated features. In particular, 
commitment to a set of shared values and objectives was necessary but 
insufficient for clinical effectiveness in the absence of other factors.[47]  
The following characteristics of ineffective clinical networks were identified as 
hindering their success: 
 Lack of funding and resources; 
 Tension, distrust and competition (particularly over resources) between 
network members; 
 Poor communication and unwillingness to collaborate; 
 Lack of confidence in the ability of network leaders and managers; 
 67 
 Lack of representation of key stakeholders in certain contexts (e.g. rural 
and indigenous interests); 
 Poor record keeping and documentation, which made it difficult to 
measure the impact of network initiatives and track progress. 
Outcomes of effective networks included the development or reorganisation 
of service delivery into clear clinical pathways, provision of holistic services, 
improved working relationships and collaboration within the network, and 
improved clinical knowledge and skills of network members.  
Network Implementation 
Three articles (two high and one moderate quality) described the process of 
implementing a clinical network and the key lessons learned from the 
implementation process [5, 13, 49]. Two of the studies described positive 
steps towards the implementation of clinical networks [5, 13], while one study 
described a negative experience.[49] The overarching lesson was that the 
implementation of a network is extremely complex and requires 
“considerable time, resources and initiatives at different levels of the 
healthcare system”.[13] Successful implementation required strong 
leadership, coordination and a sense of shared values and trust between 
network members. While vital, clinical leadership alone was insufficient.[13] 
Trust between network members, whether inter-organisational or inter-
professional, was regarded as being vital to the implementation process. 
Members had to be receptive to the concept of the network. For this, the 
values of the network must match the values of the organisation and the 
individual’s practice. Power imbalances between institutions in a network 
were observed to hinder the implementation process, as larger institutions 
were viewed as “hoarding resources” leaving smaller practices at a 
disadvantage, resulting in their disengagement.[49] 
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The availability of adequate resources for the network was also essential. This 
included funding, administration and human resources. The formalisation of 
processes was seen as a positive step, but only when done under the direction 
of the clinical teams. Inexperience in change management and unfamiliarity 
with leading development projects were cited as barriers to 
implementation.[5] It was essential for network members to have confidence 
in the expertise and ability of the people leading the changes to the system; 
where leaders lacked legitimacy and were perceived to lack the required 
knowledge and expertise, implementation was slow. Having clinical leaders 
who championed change was essential for buy-in from other clinical staff.[5, 
13] Implementation of the network was also unsuccessful when a top down 
approach was used, where the network was mandated and led by external 
organisations rather than having clinicians set priorities and driving the 
implementation process. Without genuine participation of the physicians 
involved, implementation was difficult and did not appear to affect 
practice.[49] 
One study reported briefly on some of the outcomes of the implementation 
process which were generally viewed as positive.[5] There were better 
working relationships between teams, enhanced knowledge, and a greater 
commitment to the practice of evidence-based care. There also appeared to 
be improved patient outcomes – interviewed patients reported better 
management of their symptoms and had greater knowledge about how to 
manage their condition.  
Organisational Structure 
Three articles (all high quality) looked at how networks were structured and 
how network structure affected the ability to function in the local context.[50-
52] All three articles referred to a single study of five managed clinical 
networks for cancer in the UK. Due to the top down approach used to set up 
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these networks by the government, the networks achieved limited success in 
organising and working together effectively, with only one network emerging 
as a successful anomaly. Despite attempting to delegate authority to the local 
level, the organisational structure of the networks maintained decision-
making power at a centralised level. Boards had limited strategic influence, 
with decision making power and budgetary responsibilities ultimately ascribed 
to the Strategic Health Authorities and Primary Care Trusts; only one board 
was able to have a noteworthy impact due to the seniority of its 
members.[50] At all levels, network members in positions of less influence 
struggled to make an impact. Network Management Teams relied on 
interpersonal skills to influence members to cooperate, and were unsuccessful 
in all but one network.[51] Medical staff overwhelmingly dominated decision-
making in all networks, often with the intention of acquiring resources and/or 
accreditation status for their own institutions.[51] An imbalance of power 
between medical staff meant that those with less power (typically those 
clinicians with smaller district hospital units as opposed to those working at a 
major cancer centre) frequently resisted decisions and implementing changes 
due to a perception that their interests were not taken into consideration.[51]  
The organisation of the networks also limited their ability to implement 
knowledge sharing and educational activities.[52] Because power and 
influence remained centralised and there was strong resistance to any 
changes being implemented, there was little impact on organisational 
processes. Only one network, where the Network Management Team was 
viewed positively and had an open and facilitative approach to implementing 
changes, was able to implement some education and training activities. The 
Team was able to successfully leverage pre-existing relationships to build 
support for and engagement in the network, and adapt interventions to the 
local context.  
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Organisational learning and knowledge 
Two papers (one high and one moderate quality) [53, 54] focused on 
organisational learning and the transfer of knowledge within networks. 
Members of clinical networks identified organisational learning as a desirable 
outcome that could increase individual knowledge and improve patient 
outcomes. They recognised that easy access to timely information would 
enable them to work more efficiently.[54] However not all networks were 
able to successfully implement educational measures. Those that were 
successful had adequate resources, good network management, appropriate 
organisational structure that facilitated inclusive and open participation, 
enthusiastic network members and a positive learning environment. Networks 
where educational initiatives were unsuccessful were characterised by 
organisational structures that impeded knowledge sharing, poor relationships 
between network members, weak management and the perception of 
increasing competition among members. Due to the uneven distribution of 
resources, individuals competed over resources, which fostered distrust and a 
lack of willingness to collaborate. Several respondents believed education 
would become more of a priority when structural issues were addressed.[53]  
 
2.8 Discussion   
Testing the effectiveness of clinical networks 
There is an emerging, albeit limited, body of empirical quantitative research 
into the effectiveness of clinical networks. Amongst the nine studies included, 
the majority (seven) focused on improvement in service delivery. Only two 
reported on clinical networks’ impacts on patient outcomes. None of the 
quantitative studies were of high quality, and several (3 of 9) were of low 
quality. All except two used observational study designs; none used a 
randomised controlled trial. The lack of studies with a rigorous design limits 
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the conclusions that can be drawn. Although the vast majority (9 of 13) of the 
qualitative studies were rated “high quality” and their findings complement 
those of the empirical studies, they are not designed to determine whether 
clinical networks can successfully improve health service delivery and patient 
outcomes. 
The best available empirical evidence indicates that clinical networks may be 
effective vehicles for quality improvement. Among the studies reviewed, 
networks were judged to improve quality based on several endpoints relating 
to both service delivery (such as adherence to clinical guidelines and 
protocols, development of clear patient pathways, and use of clinical tools) 
and patient outcomes (such as reduced mortality, improvement in 
biomarkers, and improved time to treatment). Desirable intermediate 
outcomes were also reported in both the quantitative and qualitative studies, 
such as improved knowledge amongst clinical staff and patients, greater 
clinical collaboration and greater availability of resources. There is some 
evidence that clinical networks may be effective in engaging clinicians in 
service redesign and reform [55], and developing and implementing protocols 
and clinical practice guidelines.[56] Quality improvement programs 
undertaken by networks largely report significant improvements across 
several quality of care indicators for a range of clinical disciplines including 
cancer [6, 7, 39], diabetes [40], and neonatal care.[3, 41] The two studies 
reporting patient outcome measures similarly demonstrated positive effects 
of network-specific interventions for end stage renal disease [42] and 
reorganisation of cardiac services.[43] There is some evidence to demonstrate 
that improvements may be sustained over time.[7, 42] 
Although these findings generally indicate that clinician-led networks may 
improve care, other studies have not reported such consistent results. One 
study examining the impact of a managed clinical network for cardiac services 
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on patient care found that only two out of sixteen clinical care indicators 
significantly improved.[4] The authors note that changes were not noticeable 
until two years after network start up, which was an intensive process. This 
resonates with the findings of other studies [40, 57], which found simple 
process measures rapidly improved but that there was slower improvement 
across more complex measures that required intensive professional education 
or comprehensive redesign of the care pathway. There was also variability in 
the ability of networks to make meaningful network- or system-wide change. 
A qualitative comparative case study of five cancer networks in the UK 
conducted by Addicott et al [53] highlighted a great degree of variability in the 
extent to which networks successfully implemented planned activities and the 
consequent success of the network. This would suggest that some quality 
improvements are likely to be incremental and that complex changes may 
take longer to be successfully embedded into routine care. Therefore, while 
clinical networks can be effective in improving care, this is not always the 
case.  
Features of effective networks 
Variability in networks’ success in improving healthcare is multifactorial and 
dependent on the local context. Implementation of a clinical network and its 
initiatives is a time- and resource-consuming process.[4] Critical factors for 
success identified across the quantitative and qualitative studies were strong 
leadership by clinical leaders and managers, availability of sufficient resources, 
and involvement of a broad range of people from different healthcare 
professions to patients and other stakeholders. Successful networks and their 
initiatives were typically driven by a few individual clinical leaders and 
dedicated managers who were widely respected by their colleagues and 
deeply committed to the purpose and values of the networks. Furthermore, 
networks without adequate administrative, human and technological 
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resources were less effective. Several qualitative studies reported that lack of 
a network manager or project coordinator and insufficient administrative and 
technological support to improve communication, collect relevant data and 
share educational tools reduced the effectiveness of networks.  
Network structure was also perceived to impact upon success. Networks 
where decision-making power was decentralised to the local level were more 
successful.[44, 48, 50-52, 58] Several participants in the qualitative studies 
noted that without an appropriate organisational structure, the networks 
were unlikely to be able to change organisational processes and implement 
quality improvement measures. This could partially explain why some 
networks were able to change simple process measures like ordering 
additional laboratory tests, but were unsuccessful at changing more complex 
processes and systems, like clinical pathways, that may have required the 
support of a strong network structure.  
These findings are in agreement with those of two reports that included an 
examination of what makes an effective managed clinical network. The first of 
these by Guthrie et al [59] in the UK identified the following key factors: 
inclusiveness to ensure that all relevant stakeholders are actively engaged 
with the network; strong credible leadership and effective management based 
on negotiation, facilitation and influence; adequate resourcing for network 
coordination; strong two-way communication strategies within the network; 
and collaborative relationships with wider organisational context to ensure 
network priorities are aligned with those of individual network members as 
well as local, regional and national organisations and agencies. Respondents in 
that study additionally agreed that ‘networks should start with relatively 
small, non-contentious issues to achieve some “early wins” in order to 
demonstrate the benefits of networks and secure broader engagement and 
ownership’. The current review identified the same. The second report by 
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Cancer Australia [60] similarly identified the need for clear and structured 
management arrangements with one person acting as the overall lead 
coupled with inclusive multidisciplinary representation. Emphasis was also 
placed on patient involvement to ensure alignment of network priorities with 
the wider context and the need for formalised reporting requirements to 
evaluate network quality improvement initiatives. This report further stressed 
the role of clinical networks in the dissemination of evidence-based practice 
and promotion of continuing professional development, similar to our 
category of organisational learning and knowledge.   
Strengths and limitations of the review  
This is the first systematic review that has explicitly focused on the 
effectiveness of clinical networks to improve quality of care and patient 
outcomes. Like all systematic reviews, the conclusions of this review are 
limited by its scope and the range and quality of the research we have been 
able to uncover. Clinical networks are a relatively new phenomenon and it is 
difficult to identify relevant papers in any emerging field. This is especially true 
of research relating to clinical networks, which is often classified by clinical 
discipline. There is a lack of consistent terminology used to describe clinical 
networks, which was particularly evident in the earlier studies. To facilitate 
accurate identification of eligible studies, the researchers worked closely with 
a librarian to develop an iterative inclusive search strategy. It should be noted 
that 29 potentially relevant full-text articles were not available and, therefore, 
not screened for inclusion.  This could have resulted in exclusion of potentially 
eligible articles. Furthermore, it is possible that other relevant articles have 
been published since the date of the last search. 
Clinical networks have many forms, are hard to define and operate in 
different contexts. Further, the reasons for setting up networks vary, as do 
their goals. This is reflected in the diverse aims of the studies included in this 
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review, which made it challenging to draw together the lessons to be learned. 
We have strengthened the utility of this review by supplementing the 
relatively few quantitative empirical papers with qualitative research so as to 
be able to draw conclusions about the features necessary to enable clinical 
networks to be effectively used as implementation vehicles. To the best of our 
knowledge, this is the first time quantitative and qualitative results have been 
synthesised to evaluate clinical networks as an innovative way to organise 
healthcare delivery and what makes them successful.  
Future research questions and methods  
This review highlights the gaps in the literature relating to the effectiveness of 
clinical networks in improving quality of care and patient outcomes, 
particularly a lack of empirical studies with rigorous study designs. The 
absence of randomised controlled trials and the few observational studies 
limits the ability to draw robust conclusions about whether clinical networks 
are more effective at improving health service delivery and patient outcomes 
than other approaches.  
While results so far have been mostly positive, more studies are necessary to 
determine whether improvements in service delivery are translating into 
improved patient outcomes. Of note, only two studies were identified that 
explicitly measured change in patient outcome indicators. There is a need to 
strengthen the existing body of knowledge through higher level evidence from 
rigorously designed randomised controlled trials to test the impact of clinical 
network-led initiatives on both quality of care and patient outcome indicators. 
Where it is not possible to conduct internally and externally valid 
experimental studies within a real-world setting, observational studies with 
stronger methodological designs, like controlled before-and-after or 
interrupted time series studies, would improve upon the learning from the 
descriptive studies that are currently most prevalent in the literature. 
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Empirical studies are also needed to quantify what makes a network more or 
less successful and determine the features necessary to strengthen existing 
and effectively implement new clinical networks. While the qualitative articles 
provided significant narrative on what was perceived to make a network 
effective, this was rarely quantified or examined in any depth in the 
quantitative studies. Furthermore, data on whether clinical networks are cost-
effective vehicles to bring about change in a complex system is lacking. Only 
one study reported on the economic impact of the implementation of a 
clinical network [4] and found no difference in the average cost per patient. 
More comprehensive economic analyses are required to evaluate whether 
clinical networks are a cost-effective way to improve quality and outcomes 
through coordinated integration of services and better flow of knowledge 
about best practice. 
2.9 Conclusions 
There is some evidence that clinical networks may be vehicles to implement 
quality improvement initiatives.  Given that clinical networks are being widely 
established, particularly in the UK and Australia, it is important to develop 
rigorous evidence to underpin future developments. Unfortunately, the 
generally low quality of quantitative effectiveness studies limits the ability to 
draw conclusions as to whether clinical networks can effectively improve the 
provision of healthcare and patient outcomes and whether these 
improvements can be maintained. Put simply, the research needs to ‘catch up’ 
with the operational developments in clinical networks. Our findings can, 
however, provide policymakers with some insight into the planning and 
implementation of a clinical network, specifically in regards to organisational 
structure, resourcing and interpersonal relationships, in order to increase the 
likelihood of success. Policymakers, clinicians and researchers need to work 
together in the implementation of clinical networks and their initiatives to 
design rigorous evaluations from the outset.  
 77 
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2.11 Research reporting checklist 
The PRISMA Checklist for systematic reviews was used. A copy of the checklist 
is included in Appendix III.  
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Chapter 3: Knowledge, attitudes and beliefs towards 
management of men with locally advanced prostate cancer 
following radical prostatectomy: an Australian survey of 
urologists 
 
Publication arising from this chapter 
Brown B, Young J, Kneebone AB, Brooks AJ, Dominello A & Haines M. 
Knowledge, Attitudes and Beliefs Towards Management of Men with 
Locally Advanced Prostate Cancer Following Radical Prostatectomy: An 
Australian Survey of Urologists. BJU Int. 2016; 117 (Supp 4): 35-44. doi: 
10.1111/bju.13037. 
 
 
3.1 Abstract 
Objective: To investigate Australian urologists’ knowledge, attitudes and 
beliefs, and the association of these with treatment preferences relating to 
guideline-recommended adjuvant radiotherapy for men with adverse 
pathologic features following radical prostatectomy.  
Subjects and methods: A nationwide mailed and web-based survey of 
Australian urologist members of the Urological Society of Australia and New 
Zealand (USANZ). 
Results: 157 surveys were included in the analysis (45% response rate). Just 
over half of respondents (54%) were aware of national clinical practice 
guidelines for the management of prostate cancer. Urologists’ attitudes and 
beliefs towards the specific recommendation for post-operative adjuvant 
radiotherapy for men with locally advanced prostate cancer were mixed. Just 
over half agreed the recommendation is based on a valid interpretation of the 
underpinning evidence (54.1%, 95% CI [46%, 62.2%]) but less than one third 
agreed adjuvant radiotherapy will lead to improved patient outcomes (30.2%, 
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95% CI [22.8%, 37.6%]).  Treatment preferences were varied, demonstrating 
clinical equipoise.  A positive attitude towards the clinical practice 
recommendation was significantly associated with treatment preference for 
adjuvant radiotherapy (rho =0.520, p<0.0001). There was stronger preference 
for adjuvant radiotherapy in more recently trained urologists (registrars) while 
preference for watchful waiting was greater in more experienced urologists 
(consultants) (b=0.156, p=0.034; 95% CI [.048, 1.24]). Urologists’ attitudes 
towards clinical practice guidelines in general were positive. 
Conclusion: There remains clinical equipoise among Australian urologists in 
relation to adjuvant radiotherapy for men with adverse pathologic features 
following radical prostatectomy. 
 
3.2 Introduction 
As in other industrialised countries, prostate cancer is the most commonly 
registered cancer in Australia and the second most prevalent cause of cancer 
death in men.(1) Radical prostatectomy is the standard treatment for localised 
prostate cancer. Following surgery, however, it is estimated that between 20% 
and 50% of men are at “high risk” of experiencing progression or 
recurrence.(2) Rates of recurrence are 40-60% higher among patients with 
adverse pathological risk factors.(3) Three prospective randomized trials 
(RCTs) have shown the use of adjuvant therapy within 4 months of resection 
improves biochemical progression-free survival compared with surgery alone 
among patients with adverse pathological risk factors.(4-6) Furthermore, 
overall survival was improved after longer-term follow-up of patients in one 
trial.(7) On the basis of this evidence, Australian Cancer Network, (8) 
American Urological Association, (9) European Society for Medical Oncology, 
(10) and Canadian (11, 12) clinical practice guidelines recommend that men 
with extracapsular extension, seminal vesicle invasion or positive surgical 
margins should be offered adjuvant radiotherapy after radical prostatectomy. 
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However, a statewide patterns of care study found that in New South Wales 
(NSW), Australia’s most populous state with 7.4 million inhabitants, less than 
10% of men with locally advanced prostate cancer receive adjuvant 
radiotherapy within the recommended timeframe.(13) These figures are 
consistent with data from other regions of Australia (14, 15) and the United 
States where recent analyses indicate only 10 - 20% of qualifying patients 
receive adjuvant radiotherapy.(16-19)  
The discrepancy between recommended care and clinical practice is indicative 
of the controversy surrounding adjuvant radiotherapy. In a recent American 
survey, urologists were less confident in the benefit of adjuvant radiotherapy 
in terms of overall survival or durable biochemical control and predicted 
higher rates of erectile dysfunction due to radiotherapy than radiation 
oncologists.(20) Furthermore, lack of access to radiotherapy services, 
concerns about overtreatment and toxicities, patient preferences and co-
morbidities may all impact on referral patterns.  
In more general terms, low rates of compliance with clinical practice guideline 
recommendations may be due to a number of factors, including lack of 
knowledge, negative attitudes, concerns about risks and benefits and 
underpinning evidence, or clinical inertia.(21, 22) Furthermore, when there is 
dissonance between clinical experience and clinical practice guideline 
recommendations, compliance is variable.(23) Thus it is has been 
demonstrated that less experienced physicians are more likely to follow new 
guideline recommendations.(24)  
We do not know which of this multitude of potential barriers are the most 
important in the current context. To evaluate Australian urologists’ 
knowledge, attitudes and beliefs and their association with treatment 
preferences relating to adjuvant radiotherapy for men with locally advanced 
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prostate cancer following radical prostatectomy we conducted a national 
survey of urologists. We hypothesised that: 
1. A negative attitude towards the recommendation that ‘patients with 
extracapsular extension, seminal vesicle involvement or positive surgical 
margins receive post-operative external beam radiation therapy within 
four months of surgery’ will be associated with a preference to not refer 
for adjuvant radiotherapy but rather ‘watch and wait’ and refer for 
salvage radiotherapy if the Prostate Specific Antigen (PSA) level rises. 
2. In clinical scenarios where there is equipoise, guideline concordant 
practice i.e. preference for adjuvant radiotherapy will be more common in 
more recently trained urologists (registrars) and those working in teaching 
hospitals where there is a multidisciplinary approach to care. 
 
The survey provided baseline data to inform the development of the 
“Clinician-Led Improvement in Cancer Care (CLICC)” study (NHMRC 
Partnership Grant APP1011474).(25) CLICC is an implementation trial working 
with urologists to test strategies to support change in practice to increase fully 
informed decision making in patients with locally advanced prostate cancer 
following radical prostatectomy.  
 
3.3 Subjects and Methods 
Study sample 
Australian based urologists and trainees of the Urological Society of Australia 
and New Zealand (USANZ), identified through the USANZ member 
communications database. 
Questionnaire development 
Survey questions were developed following literature review in addition to 
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workshops with urologists, radiation oncologists and nurses. The survey 
comprised 6 sections (see Appendix IV for the full survey). Section 1 included 
three clinical scenarios (see Box 3.1) to investigate levels of clinical equipoise.  
Urologists were asked to indicate the strength of their preference for watchful 
waiting or adjuvant radiotherapy on a linear analog scale with one treatment 
option anchored at each end of the scale. The scale was centered on zero to 
represent ‘‘undecided’’ and marked from ‘‘1’’ to ‘‘5’’ toward each end to 
represent increasing certainty in the treatment approach.(26) Additional 
questions explored clinical uncertainty. Section 2 asked questions about the 
use of, and attitudes towards, clinical practice guidelines. This section also 
asked questions about acceptable levels of evidence, survival effects and side 
effects, in addition to providing an open response option to provide 
comments about adjuvant radiotherapy following radical prostatectomy. 
Section 3 asked questions relating to innovation and current clinical practice. 
Section 4 included questions relating to other barriers to adherence to the 
clinical practice recommendation including patient preferences, financial 
disincentives and administrative constraints. Section 5 assessed perceptions of 
organisational readiness for change. Section 6 collected demographic 
information. Where appropriate, questions were derived from previously 
validated (21, 27, 28) and non-validated tools (29-36) used to assess attitudes 
and barriers to the implementation of clinical practice guidelines (CPGs). The 
survey used a five-point Likert scale (“strongly disagree” to “strongly agree” 
with an additional “don’t know” option) and was formatted in both web-
based and hard copy versions. 
Pilot testing 
The survey was pilot-tested on a purposive sample of senior urologists who 
are the clinical leaders at the hospitals involved in the CLICC implementation 
trial.(25)  
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Box 3.1: Clinical Case Scenarios 
 
Survey administration 
An initial letter of invitation was mailed together with a hard copy of the 
survey. This written invitation was followed by an email invitation with a link 
to the web-based version. Two reminder emails and a final mailed postcard 
reminder with a further hard copy of the survey followed up initial contact. All 
correspondence was initiated centrally by USANZ Communications to 
maintain integrity of their member list. Respondents who completed the 
survey were eligible to enter a competition to win an iPad.  
Statistical analyses 
Data were analysed using IBM SPSS Statistics Version 22.0. Only surveys that 
provided responses beyond the three clinical scenarios were included in the 
analyses.  
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Likert scale response categories were collated for analysis such that strongly 
disagree/disagree are reported as a single disagree category and 
agree/strongly agree are reported as agree. 
A summary score was calculated from respondents’ total scores on questions 
within each domain by summing the values for all non-missing items and 
dividing by the total number of items completed to assess overall attitudes 
and beliefs relating to clinical practice guidelines. These summary scores were 
used in subsequent analyses.  
Spearman correlation coefficients were used to examine associations between 
attitudes and beliefs, and treatment preference. T-tests were used to explore 
relationships between knowledge and treatment preference. Multiple 
regression modeling was conducted to identify independent predictors of CPG 
concordant treatment preference. Statistical significance was defined as 
p<0.05.  
Qualitative textual data were explored inductively using content analysis to 
identify barriers to the implementation of the clinical practice 
recommendation that ‘patients with extracapsular extension, seminal vesicle 
involvement or positive surgical margins receive post-operative external beam 
radiation therapy within four months of surgery’.  
Clinical Equipoise 
Three clinical scenarios were given to urologists as outlined in Box 3.1. Each 
reflected a different risk of recurrence but all fell under the “high-risk” 
category as outlined in the Australian Cancer Network Guidelines.(8) Cases 1, 
2 and 3 had a 19%, 10% and 89% 10-year risk of biochemical relapse 
respectively according to Memorial Sloan Kettering Cancer Center nomograms 
(37) highlighting the heterogeneity of patients in the “high-risk” cohort.  
Responses to clinical scenarios were transposed to a continuous 0 to 10 point 
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scale for analysis. Treatment preferences were categorised as follows: 0 – 3 = 
watchful waiting is preferable; 4 – 6 = undecided; 7 – 10 = adjuvant 
radiotherapy is preferable.  
Clinical equipoise is defined as “genuine uncertainty within the expert medical 
community” about which treatment would be most beneficial for 
patients.(38) A recent US survey of Institutional Review Board committee 
expert members found that conduct of a clinical trial enrolling humans was 
perceived as unethical when the equipoise level was beyond 80% (80:20 
distribution of uncertainty).(39) In line with this finding, and previous 
equipoise studies,(26) we define clinical equipoise as a situation in which less 
than 80% of clinicians are in agreement about the most appropriate treatment 
for a given scenario.  
 
3.4 Results 
Response Rate 
Of 370 urologists invited to participate, 20 were considered ineligible for this 
study (Paediatrics n=1, Retired n=15, Deceased n=1, Insufficient address n=3) 
resulting in a final sample of 350. Surveys were included if they were 
completed up to the end of Clinical Scenario 3. All 157 returned surveys (79 
hard copy, 78 online) were included in the final sample (45% response rate).  
Respondent characteristics are summarized in Table 3.1.  
Knowledge – awareness of the Australia Cancer Network Clinical Practice 
Guidelines  
54% of respondents reported that they were aware of the Guidelines. Of 
these, 45% found out about it from USANZ, the peak professional body for 
urological surgeons in Australia and New Zealand. A colleague referred 22% to 
the Guidelines. 
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Post-operative treatment decisions  
Following radical prostatectomy 57% of urologists believed the 
multidisciplinary team is best placed to decide upon the most appropriate 
treatment option. 28% believed the urological surgeon is best placed to 
decide, 13% the patient, 1% the medical oncologist, and 1% the radiation 
oncologist.   
Attitudes and beliefs related to the recommendation for adjuvant radiotherapy 
for locally advanced disease   
There was variability in urologists’ attitudes and beliefs towards this clinical 
practice recommendation. 54.1%; 95% CI [46%, 62.2%] agreed it is based on a 
valid interpretation of underpinning evidence. Less than one third agreed that 
following the recommendation would lead to improved patient outcomes 
(30.2%; 95% CI [22.8%, 37.6%]). Two thirds agreed that patients may 
experience unnecessary discomfort if they follow this recommendation 
(65.7%; 95% CI [58%, 73.4%]. 91.8%; 95% CI [87.3%, 96.3%] agreed this 
recommendation should only be followed within fully informed decision 
making by the patient. See Table 3.2 for full details. 
Evidence from randomised controlled trials 
More than half of urologists (54.8%) considered two to three randomised 
controlled trials provide an acceptable level of evidence to support a 
recommendation in favour of adjuvant radiotherapy. The majority of 
urologists (70%) considered that nine to 10 years or more follow up are 
necessary to convince them of the benefits of adjuvant radiotherapy.  
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Table 3.1: Baseline Characteristics of Respondents (n=157) 
Demographic n (%) 
Sex  
Female 14 (8.9) 
Male 126 (80.3) 
Missing 17 (10.8) 
Age Group  
20-30 1 (0.6) 
31-40 38 (24.2) 
41-50 48 (30.6) 
51-60 27 (17.2) 
>60 26 (16.6) 
Missing 17 (10.8) 
Level of experience  
Consultant 117 (74.5) 
Salaried University Academic 5 (3.2) 
Staff Specialist 11 (7.0) 
Registrar 5 (3.2) 
Other 2 (1.3) 
Missing 17 (10.8) 
Number of years in practice  
0-5 28 (24.2) 
6-10 24 (15.3) 
11-15 19 (12.1) 
16-20 17 (10.8) 
21-25 15 (9.6) 
26-30 12 (7.6) 
>30 15 (9.6) 
Missing 17 (10.8) 
Performs Radical Prostatectomy  
Yes 113 (72.0) 
No 26 (16.6) 
Missing 18 (11.4) 
Location of Practice  
Capital City 91 (58.0) 
Other major urban area 27 (17.2) 
Rural 19 (12.1) 
Remote 1 (0.6) 
Other 1 (0.6) 
Missing 18 (11.5) 
Clinical setting in which MAJORITY of 
prostate cancer patients are treated 
 
Teaching hospital 51 (32.5) 
Public non-teaching hospital 8 (5.1) 
Private hospital 78 (49.7) 
Missing 20 (12.7) 
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Attitudes and beliefs related to clinical practice guidelines in general 
Overall, attitudes towards CPGs in general were positive with 78.4%; 95% CI 
[71.8%, 85%] of urologists reporting they use CPGs in their practice. Urologists 
agreed that CPGs are: good educational tools (89.3%; 95% CI [84.3%, 94.3%]); 
a convenient source of advice (89.2%; 95% CI [84.2%, 94.2%]); and intended to 
improve quality by standardising care (88.6%; 95% CI [83.5%, 93.7%]). There 
was less agreement that CPGs improve patient outcomes (52.4%; 95% CI 
[44.4%, 60.4%]. See Table 3.3 for full details. 
Univariate analysis revealed a significant correlation between summary scores 
for attitudes towards CPGs in general and attitudes towards the clinical 
practice recommendation for adjuvant radiotherapy for locally advanced 
disease (rho=0.226; p<0.01). 
Barriers to implementation  
Thematic analysis of open text responses indicated that barriers to the 
implementation of the Australian Cancer Network Guidelines 
recommendation for adjuvant radiotherapy for locally advanced disease fall 
into three main categories: 
1. Need for individualised care - 40% (32/80) of respondents expressed 
concerns about lack of applicability for some patients resulting in a 
preference to watch and wait. Particular concerns related to patients 
with incontinence “return of continence without bladder neck stenosis 
is my major decision maker” and those with concerns about impotence 
“Those men who wish to maximize erectile function with PSA <.01 I am 
happy to keep under surveillance after fully informed discussion”.  
2. Perceived lack of evidence / lack of confidence in trial data – 30% 
(24/80) of respondents reported concerns about the evidence base 
underlying the recommendation. “My impression is the controversy lies 
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with adjuvant versus salvage XRT when PSA becomes detectable. I 
understand there is no evidence to favour adjuvant yet”.  
3. Concerns about side effects / overtreatment – 25% (20/80) of 
respondents noted that toxicities related to radiotherapy and potential 
unnecessary treatment are a barrier to the implementation of this 
recommendation. “Significant under-representing of urinary toxicity - 
incontinence & intractable strictures caused by RT [radiotherapy] post 
prostatectomy, therefore why expose 50% of men unnecessarily to 
potentially harmful treatment when with ultrasensitive PSA we can wait 
& select those men who really will benefit from it?” 
 
Treatment preference 
Treatment preferences for the three clinical scenarios are detailed in Figure 
3.1 and Table 3.4. 
Figure 3.1: Current level of certainty about which treatment option is better 
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Table 3.2: Attitudes towards the Australia Cancer Network Guidelines recommendation that ‘patients with extracapsular 
extension, seminal vesicle involvement or positive surgical margins receive post-operative external beam radiation therapy 
within four months of surgery’ 
 Disagree Neither agree nor 
disagree 
Agree Don’t know 
 n % n % n % n % 
This recommendation should only be followed within fully informed decision making 
by the patient 
1 0.6 9 6.2 134 91.8 2 1.4 
If I follow this recommendation my patients may experience unnecessary discomfort 21 14.4 28 19.2 96 65.7 1 0.7 
The recommendation is based on a valid interpretation of the underpinning evidence 30 20.6 30 20.5 79 54.1 7 4.8 
This recommendation is consistent with the opinions of my respected clinical 
colleagues 
36 24.7 44 30.1 64 43.8 2 1.4 
There are other recommendations for the appropriate management of this patient 
population that conflict with this one 
26 17.8 51 34.9 63 43.1 6 4.1 
This recommendation is consistent with my clinical experience with this patient group 42 28.8 42 28.8 62 42.4 - - 
I support post-operative external beam radiation therapy for patients but not within 
four months of surgery 
44 30.2 48 32.9 52 35.6 2 1.3 
Following this recommendation will lead to improved patient outcomes 24 16.5 64 43.8 44 30.1 14 9.6 
This recommendation does not reflect evidence that is emerging on this topic 53 39 46 33.8 30 22.1 7 5.1 
The side-effects of adjuvant radiotherapy for patients with locally advanced cancer 
outweigh the benefits  
68 46.5 48 32.9 29 19.9 1 0.7 
If I don’t follow this recommendation I may be liable for malpractice 
103 70.5 25 17.1 9 6.2 9 6.2 
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Table 3.3: Attitudes towards clinical practice guidelines in general 
 Disagree Neither agree nor 
disagree 
Agree Don’t know 
In general, clinical guidelines: n % n % n % n % 
 
Are good educational tools 
 
4 2.7 12 8.1 133 89.3 - - 
Are a convenient source of advice 
 
4 2.7 12 8.1 132 89.2 - - 
Are intended to improve quality by standardising care 
 
3 2.0 14 9.4 132 88.6 - - 
Improve patient outcomes 
 
4 2.7 60 40.3 78 52.3 7 4.7 
Are based on an unbiased synthesis of robust scientific evidence 
 
32 21.5 39 26.2 72 48.3 6 4.0 
Are too rigid to apply and adapt to individual patients 
 
68 45.9 33 22.3 46 31.1 1 0.7 
Are oversimplified cookbook medicine 
 
67 45.3 39 26.3 41 27.7 1 0.7 
Are not readily accessible when I want to refer to them 
 
69 46.6 46 31.1 32 21.6 1 0.7 
Limit my ability to apply clinical judgment 
 
98 66.2 24 16.2 26 17.6 - - 
Provide contradictory advice 
 
74 49.7 47 31.5 24 16.1 4 2.7 
Interfere with my professional autonomy 
 
84 56.8 42 28.4 22 14.8 - - 
Are intended to cut costs 
 
59 39.6 60 40.3 18 12 12 8.1 
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There was clinical equipoise for Case 1: 45% indicated that watchful waiting is 
preferable; 12% were undecided; 43% indicated that adjuvant radiotherapy is 
preferable. The preferred treatment option for Case 2 was watchful waiting in 
86% of urologists. For Case 3 adjuvant radiotherapy was considered 
preferable by 89%.  
There was no significant difference in treatment preferences between those 
who were aware of the Guidelines (M=5.28, SD=3.63) and those who were not 
(M=6.03, SD=3.66); t(147)=-1.244, p=0.215.  
Univariate analysis revealed a significant positive correlation between attitude 
towards the clinical practice recommendation and concordant treatment 
preference (rho=0.520, p<0.0001).  
 
Table 3.4: Current level of certainty about which treatment option is better 
 Watchful waiting is 
preferable 
Undecided Adjuvant radiotherapy is 
preferable 
 N % 95% CI (%) N % 95% CI (%) N % 95% CI (%) 
    
Case 1 71 45 37.22, 52.78 18 12 6.92, 17.08 68 43 35.26, 50.74 
    
Case 2 135 86 80.57, 91.43 11 7 3.01, 10.99 11 7 3.01, 10.99 
    
Case 3 14 9 4.52, 13.48 3 2 0, 4.19 140 89 84.11, 93.89 
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Adjusted multivariable analysis demonstrated that a positive attitude towards 
the recommendation for adjuvant radiotherapy was the most significant 
predictor of concordant treatment preference (b=0.527, p<0.0001; 95% CI 
[.273, .473]). Preference for adjuvant radiotherapy decreased by urologist age 
group (b=-0.165, p=0.025; 95% CI [-1.055, -0.071]). Preference for adjuvant 
radiotherapy was greater in more recently trained urologists (registrars) while 
preference for watchful waiting was more common in experienced urologists 
(consultants) (b=0.156, p=0.034; 95% CI [0.048, 1.24]). There were no other 
signiﬁcant associations with demographic or practice characteristics of 
respondents. 
Other factors 
Less than one fifth agreed (17.8%; 95% CI [11.46%, 24.17%]) that the 
Australian Cancer Network Guidelines recommendation takes into account 
patient needs and preferences. More than 60% (61.4%; 95% CI [53.34%, 
69.46%]) believe routinely referring patients to radiation oncology will 
increase costs.  
Innovation and readiness for change 
There was some variation in regard to urologists’ willingness to try new 
procedures in their practice; however, no urologists reported that they only 
try new procedures when regulations require them.  
Urologists generally believed there is organisational readiness for change in 
their organisation. See table 3.5 for further details. 
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Table 3.5: Innovation and organisational readiness for change 
 N % 95% CI (%) 
Innovation    
I experiment with new procedures 20 14.2 8.42, 19.98 
I prefer to wait until other have tried new 
procedures  
43 30.5 22.87, 38.13 
I prefer to wait until new procedures have 
been established for a while 
78 55.3 47.06, 63.54 
I only try new procedures when regulations 
require them 
0 0 N/A 
Organisational readiness for change    
Urology leaders in my organisation believe 
current practice patterns can be improved 
113 81 74.5, 87.5 
Urology leaders in my organisation encourage 
and support changes in practice to improve 
care 
130 93 91.39, 98.61 
Urology leaders in my organisation are willing 
to try new protocols 
114 83 76.78, 89.22 
Urology leaders in my organisation work 
cooperatively with senior 
leadership/management to make appropriate 
changes 
118 84 77.93, 90.07 
 
3.5 Discussion 
We conducted a survey of urologists throughout Australia. Just over half were 
aware of the Australia Cancer Network Clinical Practice Guidelines for the 
Management of Men with Locally Advanced and Metastatic Prostate Cancer 
(8) suggesting dissemination strategies could be improved.  
Urologists varied in their attitudes and beliefs regarding adjuvant 
radiotherapy after radical prostatectomy for men with adverse pathologic 
features. Less than one third agreed following the recommendation for 
adjuvant radiotherapy would lead to improved patients outcomes.  The lack of 
confidence in the efficacy of adjuvant radiotherapy is evident in the level of 
clinical uncertainty for a clinical scenario describing a patient with adverse 
pathologic features that would indicate its use.  This may be a reflection of the 
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lack of confidence in the randomised controlled trials that form the evidence 
base for this recommendation.(4-7) These trials have been criticised for the 
absence of a well-defined salvage radiotherapy arm; many patients in the 
surgery alone control arm never received salvage radiotherapy and, when 
given, treatment was often delivered with PSA values >1.2ng/ml rather than 
at low PSA recurrence such as 0.2ng/ml which is the current trigger for salvage 
radiotherapy. The result is a perceived lack of evidence to support the benefit 
of adjuvant radiotherapy over selective early salvage radiotherapy. This direct 
comparison is the focus of two ongoing clinical trials (RAVES (40) and 
RADICALs (41)). Urologists also expressed concern about possible 
overtreatment for a significant proportion of patients whose cancer may 
never recur.(42) Clinical practice guidelines define “high-risk” as patients with 
positive surgical margins, seminal vesicle involvement or extra-capsular 
extension.(8-12) However, established post-prostatectomy nomograms 
indicate that not all adverse pathologic features are equal in terms of risk of 
relapse.(37) For example, a patient with a pre-operative PSA of 5, Gleason 7 
disease with some extracapsular extension and clear margins has a less than 
10% risk of relapse (our case 2 clinical scenario).  We can see that urologists 
are using information other than the presence of adverse pathologic features 
in clinical decision-making through their reluctance to recommend adjuvant 
radiotherapy for this case.  
There was also concern about the potential side effects and toxicities 
associated with radiotherapy treatment.  These concerns may be abated by 
longer term follow up data from randomised controlled trials given that 70% 
considered 9 to 10 years or more follow up are necessary to convince them of 
the benefits of adjuvant radiotherapy. Longer-term follow-up for the 
Southwest Oncology Group (SWOG) trial reported improvements in 
biochemical and clinical progression-free survival and local control at 10 years 
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and increased overall survival at 12 years.(7) Results at median follow-up of 
10.6 years for the European Organisation for Research and Treatment of 
Cancer (EORTC) trial (43) support results at 5 year follow up for improved 
biochemical progression-free survival and local control. While improvements 
in clinical progression-free survival were not maintained, exploratory analyses 
suggest that adjuvant radiotherapy may improve clinical progression-free 
survival in patients with positive surgical margins. A recent Australian study 
that sought to establish predictors of biochemical recurrence by analysing the 
pathological characteristics of positive surgical margins, found that the 
presence of Gleason grade 4 or 5 at the margin was significantly associated 
with biochemical recurrence.(44) These results concur with the updated 
report of the SWOG trial (7) which indicates patients with higher Gleason 
score tumours may receive a larger metastasis-free survival benefit from 
adjuvant radiotherapy than those with lower Gleason scores so the former 
group may be the most appropriate for referral to radiation oncology.  
There was a perception that the clinical practice recommendation is not 
applicable, or does not take into account treatment preference, for some 
patients, especially those with ongoing incontinence or who wish to maximize 
erectile function. Overwhelmingly, urologists agreed that the 
recommendation for adjuvant radiotherapy should only be followed within 
fully informed patient decision-making, suggesting a propensity for shared-
decision making.  
It is of note that attitudes towards clinical practice guidelines in general were 
positive with the majority of urologists reporting that they routinely use them 
in practice, implying that the conflicting opinions around this particular clinical 
practice recommendation are due to some underlying factor rather than more 
general reticence.  
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Following radical prostatectomy, just over half of urologists believed the 
multidisciplinary team is best placed to decide upon the most appropriate 
treatment option. However, nearly one third believed the urological surgeon 
is best placed suggesting there may be some inconsistency in engagement 
with a multidisciplinary approach to cancer care despite evidence that it leads 
to improved survival, adherence to guidelines (45), reduced time to diagnosis 
and treatment and increased enrolment in clinical trials, in addition to 
improved patient satisfaction.(46) A recent single-centre Australian study (47) 
found that discussion of patients at a uro-oncology multidisciplinary meeting 
resulted in substantial changes to the clinician’s original treatment plan in 
more that one quarter of cases presented. That study additionally reported 
that where there was no original plan, multidisciplinary discussion increased 
cross-referral between clinical disciplines, a significant finding given that only 
one per cent of urologists in our survey sample agreed a radiation oncologist 
is best placed to decide upon the most appropriate post-operative treatment. 
This reluctance to refer patients for a radiation oncology opinion (8, 9) could 
potentially explain the low uptake of adjuvant radiotherapy.(13-18) It could 
additionally signify a more general need to promote multimodality as the 
standard of care for high-risk disease.(48) Wider adoption of a collaborative 
multidisciplinary approach to treatment planning would enhance cross-
discipline communication and understanding of the relative risks and benefits 
associated with multimodal and adjuvant treatment strategies.    
Concordant treatment preference was not associated with awareness of the 
Guidelines suggesting that knowledge may be necessary but insufficient to 
bring about change in practice.  However, a positive attitude toward the 
clinical practice recommendation for adjuvant radiotherapy was significantly 
associated with concordant treatment preference. This implies that change 
efforts seeking to increase guideline adherence would be better focused on 
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changing clinician attitudes and beliefs rather than seeking to simply increase 
knowledge.  Guidelines concordant treatment preference was greater in 
registrars suggesting that continuing medical education or professional 
development maybe a successful vehicle to improve attitudes towards clinical 
practice guidelines and promulgate new research evidence.  Targeting 
clinicians to embed a culture of evidence-based practice at an early stage in 
their career may also increase the likelihood of life long practice improvement 
and more timely adoption of new innovations in care. 
The design of the CLICC study (25) was informed by the results of this survey, 
which highlight the need to increase engagement with a multidisciplinary 
approach to care. Specifically, CLICC elements include: 1. National and local 
urological clinical leaders to promote key messages including the potential 
need for multimodal care and referral to radiation oncology for discussion of 
adjuvant radiotherapy if adverse pathological features are present post-
prostatectomy. 2. A quick reference guide to supporting evidence, 
information on current radiotherapy techniques, potential side effects and 
toxicity, together with key points to aid discussion with patients before and 
after surgery to support fully informed decision-making. 3. Regular audit and 
feedback reports detailing the number of patients referred to radiation 
oncology and information on the number of patients at high risk who are 
discussed at multidisciplinary team meetings. 4. Automatic case flagging 
whereby all patients of participating urologists who have had a 
histopathological examination of a radical prostatectomy specimen and who 
have extracapsular extension, positive surgical margins or seminal vesicle 
invasion are submitted automatically through the pathology provider to the 
hospital urology multidisciplinary team meeting for discussion. Full details of 
CLICC elements are detailed in the study protocol.(25) 
The response rate (45%) is higher than the average response rate for online 
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surveys reported at 33% (49) and that of a similar US survey of urologists and 
radiation oncologists (20% overall).(20) This study is, limited by the reliance on 
self-reported physician treatment preferences, which may not directly reflect 
real-world utilisation of adjuvant radiotherapy. However, the results are in 
line with Australian and US analyses that report low levels of post-surgery 
radiotherapy treatment for high-risk prostate cancer (13-18) and the self 
reported practice of American urologists.(20) The CLICC implementation trial 
(25) will provide further data on current referral patterns in participating NSW 
hospitals.  
 
3.6 Conclusion  
This national survey of urologists highlights remaining clinical equipoise 
among Australian urologists in relation to adjuvant radiotherapy for men with 
adverse pathologic features following radical prostatectomy.  
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Chapter 4: The CLICC conceptual program logic model and 
intervention mapping 
 
4.1 Overview of the PRECEDE-PROCEED model of behaviour change 
The PRECEDE-PROCEED model (Figure 4.1) (1-3) was originally developed in 
the 1970s by Lawrence Green and colleagues from a number of US academic 
institutions and public and private health service providers as a model for 
preventive public health. The model has been updated and refined over the 
subsequent four decades to allow more intrinsic strategic mapping of 
interventions to contextual educational and environmental needs, and is a 
widely utilised tool for designing, implementing and evaluating health 
behaviour change programs. A fundamental premise behind the model is that 
any change process should focus initially on the desired outcome rather than 
the activities that may give rise to that outcome. The four formative phases of 
PRECEDE, therefore, move logically backward from: social (Phase 1) and 
epidemiological (Phase 2) assessment of the desired outcome; to where and 
how one might intervene to bring about that outcome through educational 
and environmental assessment (Phase 3); to administrative and policy 
assessment and intervention alignment (Phase 4). The subsequent four phases 
of PROCEED cover the actual implementation of the intervention (Phase 5); 
process evaluation (Phase 6) to determine whether the intervention is being 
delivered as intended; impact evaluation (Phase 7) to determine if the 
program is having the intended impact on the target population and if there 
are any unintended consequences be they positive or negative; and outcome 
evaluation (Phase 8) to assess whether the intervention is resulting in the 
desired outcome that was envisioned in Phase 1.  
The PRECEDE-PROCEED model stresses that since health-related behaviours 
are caused by multiple factors, efforts to effect change should also be 
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multidimensional. Further, given that most health-related behaviours are 
voluntary, including those of treating clinicians, change interventions should 
be participatory and, from the outset, involve all stakeholders whose 
behaviour needs to change.  
 
Figure 4.1: Phases of the PRECEDE-PROCEED model  
 
Adapted from Green L. http://www.lgreen.net/precede.htm [accessed October 2015] 
 
4.2 Phases of the PRECEDE-PROCEED model in relation to this thesis 
In the context of this thesis, Phase 1 was predetermined by an Australian 
national strategy to improve prostate cancer services and thereby improve 
patients’ quality of life and survival, which identified the provision of 
evidence-based care for these men as a high priority (4) (Phase 1: social 
assessment). Evidence from a number of randomised controlled trials (5-9) 
indicates that the desired outcome of improved quality of life and survival can 
be achieved by altering clinical practice to increase referral to radiation 
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oncology for consideration of adjuvant radiotherapy for men with adverse 
disease features following surgery, in line with the clinical practice 
recommendation in published guidelines (10-14) (Phase 2: epidemiological 
assessment). The remainder of this chapter outlines how educational and 
ecological assessment (Phase 3) and administrative and policy assessment 
(Phase 4) were used to conceptualise the design of the CLICC implementation 
trial, which aimed to increase the uptake of this clinical practice 
recommendation. The planned implementation (Phase 5) of the CLICC 
intervention is outlined in the published study protocol (Chapter 5). The 
process evaluation (Phase 6) is presented in Chapter 6. The impact evaluation 
(Phase 7) and outcome evaluation (Phase 8) are presented in Chapters 7 and 
8. 
 
4.3 Needs and barriers analysis to inform the development of the CLICC 
implementation trial 
In keeping with the participatory emphasis of the PRECEDE-PROCEED model, a 
needs and barriers analysis (Figure 4.2) was conducted by the author, as 
outlined under Phase 3: Educational and ecological assessment and Phase 4: 
Administrative and policy assessment below. The needs and barriers analysis 
involved consultation with multiple clinical stakeholders, consumers and 
representatives of cancer policy agencies through workshops, interviews and 
surveys to maximise engagement and ensure that intervention elements were 
aligned with the local context. Barriers were considered at three levels: (i) 
individual clinician; (ii) patient; and (iii) hospital systems and processes, 
including the urological multidisciplinary team. A summary of identified 
barriers at each level is provided in Figure 4.3.   
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Phase 3: Educational and ecological assessment 
Iterative workshops 
A convenience sample of twenty-five Urology Network members participated 
in two workshops. Prior to submission of a research grant funding application, 
an initial workshop was undertaken during a routinely scheduled Network 
meeting attended by the Network Co-Chairs, Network Manager, urologist 
members and consumer representatives. This workshop aimed to determine 
whether the scope of the proposed study was viable within the Network 
context. Following award of funding, interviews were conducted with a 
purposive sample of nursing and radiation oncology staff, from three hospitals 
within the Network to identify perceived barriers to the implementation of 
the clinical practice recommendation at the local level. Barriers identified 
through these interviews were fed back during a second workshop, conducted 
during a subsequent routinely scheduled Network meeting, to determine 
whether there was consensus and to assess the relative importance of each 
barrier from the perspective of Network members. In priority order barriers 
agreed by Network members were as follows:  
Clinician level barriers 
Perceived clinician level barriers predominantly related to divergent 
interpretation of the evidence to support the clinical practice 
recommendation.  
Patient level barriers 
Treatment preference and cost of care were proposed as patient level 
barriers.  
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Systems and process level barriers 
Waiting times for pathology results and post-surgical appointments with the 
consulting urologist and radiation oncologist were cited as the most likely 
hospital systems and process barriers. 
 
Figure 4.2: Needs and barriers analysis to inform CLICC intervention design 
 
National survey of urologists   
To determine the extent to which barriers identified at the local level by 
Network members were representative of those evident in the wider 
urological population, a survey was administered to all urologist members of 
the Urological Society of Australia and New Zealand. Completed by more than 
half of all practicing urologists in Australia (n=157), and detailed fully in 
Chapter 3 previously, this survey identified a poor level of awareness of the 
Australian version of this clinical practice guideline. Other barriers were 
identified through the survey as follows: 
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Clinician level barriers 
In addition to some lack of knowledge, other clinician level barriers related to 
concerns about the quality of evidence from the randomised controlled trials 
that underpin the clinical practice recommendation. This was coupled with 
concerns about the potential for overtreatment in some patients whose 
cancer may not recur and subsequent unnecessary discomfort and/or 
radiotherapy associated toxicity or side effects such as impotence, urinary or 
fecal incontinence and urethral stricture.  
Patient level barriers 
Perceived patient level barriers were similar to those cited by Network 
members, these being individual treatment preferences and financial cost.  
Systems and process level barriers 
Survey participants indicated no hospital system or process barriers. 
Consumer feedback 
During the development phase of the CLICC study, the Urology Network 
conducted a focus group with 15 consumer representatives to develop a guide 
for clinicians on the patient experience of prostate cancer.(15) The results of 
this consultation demonstrated that the majority of patients want to be fully 
informed about all potential treatment options, and their associated 
outcomes and side effects. Of significance to Phase 3: Educational and 
ecological needs assessment, patients indicated that their preference was for 
the urologist to initiate discussion and provide sufficient information to 
support fully informed patient decision-making. Key information priorities, in 
addition to considerations for psychosocial support, were: 
 Curative treatment versus active surveillance and the likely associated 
outcomes 
 Available treatment options, including surgery and/or radiation therapy 
and the types of each 
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 Treatment side effects including short- and long-term risks of 
incontinence and impotence and options for rectification if these occur  
 Risk of short- or long-term recurrence after initial treatment and 
management should this occurs  
 Experience in treating prostate cancer including patient outcomes 
 Recommended treatment for the individual patient and the reasoning 
for this recommendation  
 Other health professionals that may be involved in treatment such as 
radiation oncologists, physiotherapists and continence nurses  
 An estimate of treatment timings and costs and explanation of issues 
around public versus private treatment 
Semi-structured interviews 
To further elucidate local educational and ecological needs, and to inform the 
design of intervention components to address these context specific needs, 
semi-structured telephone interviews were undertaken with a purposive 
sample of urologists (n=9), clinical nurse consultants (n=7) and radiation 
oncologists (n=10) at the nine participating CLICC study sites (see Chapter 5 
for further details of hospital eligibility and urologist inclusion/exclusion 
criteria). Interviews asked questions about the membership and structure of 
the urological multidisciplinary team, perceived current practice in relation to 
post-radical prostatectomy referrals to radiation oncology, and barriers to the 
implementation of the clinical practice recommendation. Interviews were 
transcribed verbatim and textual data were analysed against the three barrier 
levels identified previously, namely: (i) individual clinician; (ii) patient; and (iii) 
hospital systems and processes, including the urological multidisciplinary 
team. Barriers identified by urologists were consistent with those highlighted 
in the workshops and survey. 
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Clinician level barriers 
Clinician level barriers related to concerns about evidence, potential 
overtreatment and radiotherapy associated toxicity/side effects. In addition, 
two ongoing clinical trials (RAVES (16) and RADICALS (17)) comparing the 
efficacy of adjuvant radiotherapy with early salvage radiotherapy at the time 
of a confirmed PSA recurrence, the former being conducted within Australia, 
also raised doubt about routine referral for  adjuvant radiotherapy.  
Patient level barriers 
Treatment cost was not considered to be a barrier within CLICC study 
hospitals as radiotherapy services tend to sit within the public system and are 
therefore not billed to patients. Clinical nurse consultants and radiation 
oncologists perceived that patient treatment preferences were highly 
influenced by the opinion of the urological surgeon and this was frequently 
cited as a barrier to attending a radiation oncology consultation. Radiation 
oncologists further noted that urologists did not have sufficient specialist 
knowledge to enable fully informed discussion with patients about 
radiotherapy treatment options, their associated outcomes and potential side 
effects or toxicity.  
Systems and process level barriers 
Waiting times for pathology results or post-surgical appointments and timely 
access to radiotherapy services were not considered to affect capacity to 
change clinical practice in CLICC study sites. Reportedly there was, however, 
considerable cultural variation in engagement with the urological 
multidisciplinary team (MDT) both between urologists within CLICC study 
hospitals and across CLICC study hospitals more generally. This was 
exemplified by variable attendance at MDT meetings and selective 
presentation of patients for discussion. Variable engagement with the MDT in 
CLICC hospitals was suggested to be indicative of urologists’ reticence towards 
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collaborative multidisciplinary treatment planning. This view is supported 
somewhat by the results of the national urologist survey (Chapter 3) in which 
just over half (57%) believed the multidisciplinary team is best placed to 
decide upon the most appropriate post-operative treatment option. Further, 
data for the period 2008 – 2011 from the Cancer Institute NSW demonstrate 
that while there was an increase in the proportion of new patients diagnosed 
with many cancers discussed at MDT meetings, the proportion decreased in 
urological MDTs.(18) The reduction in numbers of patients with urological 
cancers presented for discussion at MDT meetings is possibly due to selective 
presentation of cases, as noted in CLICC semi-structured interviews. Across all 
CLICC hospital study sites, presentation of cases to the MDT is at the 
discretion of the consulting urologist. There is no requirement for all cancer 
patients to be discussed by the MDT and no formal process to identify sub-
groups of patients with higher risk cancers that may benefit from 
multidisciplinary input or multimodal care.  
Figure 4.3: Summary of barriers to implementation 
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Phase 4: Administrative and policy assessment and intervention alignment 
Consultation with the Cancer Care Action Advisory Group 
As part of the CLICC study, a Cancer Care Action Advisory Group was 
established to provide advice about the policy positioning of the study, 
opportunities and barriers to impact cancer care, and how best to disseminate 
results into policy and practice. The group includes representatives from a 
number of Australian cancer policy agencies, professional societies including 
those representing urologists and radiation oncologists, urological clinical 
trials groups and consumer advocacy groups.  
Eighteen members of the Cancer Care Action Advisory Group attended a two-
hour meeting to evaluate the barriers identified in Phase 3 and the proposed 
intervention elements to address these barriers to ensure they were feasible, 
scalable and potentially translatable to other cancers. The group considered 
that the proposed intervention elements were feasible and that they had face 
validity.  
 
4.4 The CLICC conceptual program logic framework 
Intervention alignment 
Intervention elements were mapped to barriers identified in Phase 3 using the 
CLICC conceptual program logic framework (Chapter 5, Figure 5.2). Through 
this framework, clinician level barriers (knowledge, attitudes, perceptions, and 
norms) were mapped to physician-focused components (predisposing and 
reinforcing factors). Hospital level barriers (systems and processes, and 
culture) were mapped to context-focused components (enabling factors). 
Intervention elements were developed in consultation with members of the 
Urology Network to ensure they had face validity. 
Briefly, physician-focused intervention components included: 
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 Non-didactic, interactive provider education (predisposing factor) 
 Dissemination of printed materials (predisposing factor) 
 Opinion leaders (reinforcing factor) 
 Audit and feedback (reinforcing factor) 
The context-focused component comprised: 
 Implementation of a new system for automatic flagging of eligible cases 
for discussion at MDT meetings (enabling factor) 
 
A full description of intervention elements and how these relate to the 
PRECEDE-PROCEED model is provided in the study protocol (Chapter 5). 
It should be noted that the CLICC study was primarily conceptualised a 
physician-focused intervention with the specific aim of changing provider 
referral behaviour. Consequently, research governance and ethical approvals 
did not permit direct patient interaction. Patient level barriers (treatment 
preferences) were, therefore, outside the scope of the study. However, to the 
extent that the consulting urologist influences patient treatment preferences, 
CLICC attempted to address these barriers through provider education and 
printed materials. Health system and wider contextual barriers were also 
excluded. Policy and resource implications will be considered by the Cancer 
Care Action Advisory Group and the Urology Network at the conclusion of the 
study when results are determined, if it is deemed appropriate that any or all 
of the CLICC intervention elements should be scaled-up and spread beyond 
the participating study sites. 
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Chapter 5: Clinician-led improvement in cancer care (CLICC) - 
testing a multifaceted implementation strategy to increase 
evidence-based prostate cancer care: phased randomised 
controlled trial - study protocol 
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5.1 Abstract 
Background: Clinical practice guidelines have been widely developed and 
disseminated with the aim of improving healthcare processes and patient 
outcomes but the uptake of evidence-based practice remains haphazard. 
There is a need to develop effective implementation methods to achieve 
large-scale adoption of proven innovations and recommended care. Clinical 
networks are increasingly being viewed as a vehicle through which evidence-
based care can be embedded into healthcare systems using a collegial 
approach to agree on and implement a range of strategies within hospitals. In 
Australia, the provision of evidence-based care for men with prostate cancer 
has been identified as a high priority. Clinical audits have shown that fewer 
than 10% of patients in New South Wales (NSW) Australia at high risk of 
recurrence after radical prostatectomy receive guideline recommended 
radiation treatment following surgery. This trial will test a clinical network-
based intervention to improve uptake of guideline recommended care for 
men with high-risk prostate cancer. 
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Methods/Design: In Phase I, a phased randomised cluster trial will test a 
multifaceted intervention that harnesses the NSW Agency for Clinical 
Innovation (ACI) Urology Clinical Network to increase evidence-based care for 
men with high-risk prostate cancer following surgery. The intervention will be 
introduced in nine NSW hospitals over 10 months using a stepped wedge 
design. Outcome data (referral to radiation oncology for discussion of 
adjuvant radiotherapy in line with guideline recommended care or referral to 
a clinical trial of adjuvant versus salvage radiotherapy) will be collected 
through review of patient medical records. In Phase II, mixed methods will be 
used to identify mechanisms of provider and organisational change. Clinicians’ 
knowledge and attitudes will be assessed through surveys. Process outcome 
measures will be assessed through document review. Semi-structured 
interviews will be conducted to elucidate mechanisms of change.  
Discussion: The study will be one of the first randomised controlled trials to 
test the effectiveness of clinical networks to lead changes in clinical practice in 
hospitals treating patients with high-risk cancer. It will additionally provide 
direction regarding implementation strategies that can be effectively 
employed to encourage widespread adoption of clinical practice guidelines.  
Trial registration: Australian New Zealand Clinical Trials Registry (ANZCTR): 
ACTRN12611001251910. 
 
5.2 Background  
The evidence-practice gap 
The discrepancy between research evidence and clinical practice is well 
documented (1), and remains one of the most persistent problems in 
providing high-quality healthcare.(2) Clinical practice guidelines have been 
extensively developed as a means to disseminate best practice and ensure 
clinical decision-making is informed by recent, credible research evidence, 
thereby improving healthcare processes and outcomes. However, timely and 
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effective implementation of guidelines into clinical practice is inconsistent (3), 
and it remains surprisingly difficult to make changes across the health system 
even when there is compelling evidence.(4)  
The difficulty in achieving large scale adoption of proven innovations and 
recommended care (as well as discontinuing ineffective or harmful practices) 
has been characterised as a ‘translation block’.(5-8)  
Effective implementation 
Previous research indicates that successful implementation of evidence-based 
care depends critically on the extent to which strategies address prospectively 
identified barriers, through theoretical frameworks of behaviour change (9, 
10), and promote provider acceptance.(3) Recommendations from clinical 
guidelines are more likely to become embedded within practice when they: 
are initiated and led by local clinical leaders; are tailored to the local context; 
and engage clinicians in the design of the implementation strategy.(1,3, 11-13) 
Grol (14) argues that to effectively implement evidence-based practice, 
research urgently has to change so that it develops through collaborations 
between clinicians, researchers, patients, policy makers, and quality 
improvement experts.  
Specifically, the growing body of evidence suggests several core 
implementation strategies are effective in bringing about system-wide and 
sustained change (1, 11, 15, 16):  
1. Clinical champions/leaders supporting change within their practices and 
settings; 
2. System, structural, and organisational support for system-wide changes to 
enable implementation strategies to be rolled out and scaled up (e.g., 
legislation, resources, mechanisms for communication and collaboration 
between health sectors);  
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3. Ongoing monitoring, evaluation, and feedback of changes as they are 
implemented. 
Clinical networks—a medium for implementation 
In New South Wales (NSW), Australia, a coordinated program of 30 clinical 
networks, institutes and taskforces has been established by the NSW Agency 
for Clinical Innovation (ACI), a board-governed statutory organisation funded 
by the NSW Ministry of Health.  
These clinical networks of volunteer health professionals provide a framework 
for doctors, nurses, allied health professionals, managers, and consumers to 
collaborate across regional and service boundaries to drive improvements in 
service delivery and care outcomes through innovation in clinical practice.  
This type of non-mandatory clinical network is increasingly being viewed as a 
vehicle through which evidence-based care can be embedded into healthcare 
systems using a collegial approach to agree on and implement a range of 
strategies within hospitals. They provide ‘bottom up’ views on the best ways 
of tackling complex healthcare problems coupled with the strategic and 
operational ‘top down’ support necessary to facilitate and champion changes 
in practice at the clinical interface.(17, 18) There is evidence from ‘before and 
after’ controlled studies that when clinical practice guidelines are 
implemented through clinical networks there are improvements in 
compliance with guideline recommendations and the quality of care.(19, 20) 
Clinical networks embody, or have the potential to enable, the core features 
of successful implementation strategies and therefore are a mechanism for 
health system change and increasing the uptake of evidence-based care for 
three reasons: 
1. Clinical networks contain clinical leaders who can design and champion 
change to improve care within their practices and influence wider culture 
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change within their healthcare settings. 
2. Clinical networks are a ‘ready-made’ organisational structure through 
which innovations may be promulgated and accelerated by clinicians. 
3. Clinical networks provide a structure to monitor and evaluate changes as 
they are implemented to answer questions about effectiveness and the 
success of implementation strategies. 
Prostate cancer clinical practice guidelines—an opportunity to translate 
research into effective healthcare practice 
Prostate cancer is the most common cancer registered in Australia and is the 
second highest cause of cancer death in males.(21) Radical prostatectomy is 
the most frequent procedure for localised prostate cancer, however following 
surgery it is estimated that 20% to 50% of men are at ‘high risk’ of 
experiencing progression or recurrence.(22-25) A national strategy to improve 
prostate cancer services and thereby improve patients’ quality of life and 
survival identified the provision of evidence-based care for these men as a 
high priority.(26) Persuasive evidence from randomised controlled trials 
indicates the need to alter current practice by offering radiotherapy to men 
with adverse disease features following surgery as radiotherapy treatment 
halves the risk of recurrence [27-29] and improves biochemical disease-free 
survival.(30) A Grade B recommendation (denoting that the Clinical Practice 
Guideline expert working group considered that the body of evidence can be 
trusted to guide practice in most situations) in the Clinical Practice Guidelines 
for the Management of Locally Advanced and Metastatic Prostate Cancer 
produced by the Australian Cancer Network (31) recommends that ‘patients 
with extracapsular extension, seminal vesicle involvement or positive surgical 
margins receive post-operative external beam radiation therapy within four 
months of surgery.’ This recommendation is echoed in the more recently 
published American Urological Association Guideline, Adjuvant and Salvage 
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Radiotherapy after Prostatectomy, which states ‘Physicians should offer 
adjuvant radiotherapy to patients with adverse pathologic findings at 
prostatectomy (Standard; Evidence Strength: Grade A)’.(32) The most recently 
available data indicate less than 10% of patients with locally advanced 
prostate cancer in NSW Australia receive guideline recommended care.(33) 
Patterns of care for prostate cancer in NSW generally reflect practice in other 
Australian jurisdictions.(34, 35) These data are consistent with that from the 
United States where less than 20% of eligible patients receive adjuvant 
radiotherapy, indicating substantial room for improvement.(36) Current 
evidence about strategies to encourage the adoption of clinical practice 
guidelines is limited (1-3, 9, 37) and provides little clear direction about 
approaches that can be effectively employed in specific settings.  
 
5.3 Aims  
The aim of this study is to develop and trial a locally tailored, multifaceted 
implementation strategy that harnesses the NSW Agency for Clinical 
Innovation (ACI) Urology Clinical Network to increase evidence-based care for 
men with high-risk prostate cancer following prostatectomy in selected NSW 
hospitals.(31) Specifically, the aim is to increase referral to radiation oncology 
for a discussion about radiotherapy, and the associated risks and benefits of 
treatment, to support fully informed decision making. 
 
An additional aim is to identify reasons why changes in behaviour and 
outcomes occurred or did not occur in study hospitals and why the 
implementation strategy did or did not result in increased compliance with 
guideline recommended care.  
If the intervention is successful we will also assess the sustainability of 
increases in referral patterns within the hospitals through interviews with key 
stakeholders. 
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5.4 Approach to intervention design  
Any reason for resisting new practice is a barrier to change and the potential 
importance of such barriers and their influence on quality improvement 
activities has been highlighted in numerous studies(38-41) A recent systematic 
review indicates that tailored interventions are more effective when they are 
designed to address prospectively identified local barriers to change.(10) A 
key component of our method is to tailor our intervention so that it 
incorporates features that will facilitate changes in provider behaviour by 
addressing local level obstacles. 
Intervention elements have been informed by reviews of the clinical practice 
change literature (9, 11, 37, 38, 42-61), and refined and tailored to take 
account of the organisational context in which providers practice through a 
multi-component needs and barriers analysis, including: iterative workshops 
with members of the ACI Urology Clinical Network; a national baseline survey 
(offered in web-based and paper form) of all urologist members of the 
Urological Society of Australia and New Zealand, the peak professional body, 
to explore current knowledge, attitudes and practice in the wider context 
(results published elsewhere); semi-structured interviews with urology, 
radiation oncology, and nursing staff at target hospitals to explore site specific 
practice and barriers; consumer feedback on what information patients want 
from their urologist; and consultation with a cancer policy advisory group to 
ensure intervention elements are feasible, scalable and potentially 
translatable to other cancers (see Figure 5.1 for summary). 
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Figure 5.1: Approach to intervention design 
 
Results from these activities indicate that, in priority order, barriers can be 
grouped into three main clusters:  
1. Clinician: attitudes and beliefs held by individual clinicians about the 
validity of the evidence base supporting the guideline recommendation 
(54% of urologists surveyed agreed that the recommendation is based on a 
valid interpretation of the underlying evidence) - notably due to ongoing 
clinical trials, which raise doubts as to the treatment benefit of adjuvant 
radiotherapy versus early salvage radiotherapy; concerns about 
overtreatment and toxicity/side effects associated with radiotherapy and 
lack of familiarity with current radiotherapy techniques (two thirds of 
urologists surveyed agreed that patients may experience unnecessary 
discomfort if they follow the recommendation).  
2. Patient: treatment preferences (perceived to be influenced by interaction 
with urologists). 
Consulta on	with	Cancer	Care	Ac on	Advisory	Group	
Evaluate	feasibility	with	policy	agencies	–	3	June	2013		
Consumer	feedback	
ACI	Urology	Clinical	Network	Consumer	Representa ves:	What	pa ents	want	from	their	urologist	at	prostate	cancer	diagnosis	(N≈15)		
Semi-structured	interviews	to	iden fy	site	specific	needs	and	barriers		
Cancer	Care	Nurse	Coordinators	(N=7)	 Radia on	Oncologists	(N=10)	 Urologist	Clinical	Leaders	(N=9)	
Na onal	survey	of	urologists	to	explore	current	knowledge,	a tudes	and	prac ce	and	wider	context	
Urologist	members	of	the	Urological	Society	of	Australia	and	New	Zealand	(USANZ)	(N=157),	45%	response	rate	
Itera ve	workshops		
ACI	Urology	Clinical	Network	Members	(N=25)	 Interviews	with	nursing	and	radia on	oncology	staff	
Literature	review	
Components	of	interven ons	that	have	been	successfully	used	in	the	implementa on	of	clinical	prac ce	guidelines	
  
 
129 
3. Hospital system and processes: variation in urologists’ engagement with 
the multidisciplinary team (MDT) of specialist surgeons, medical 
oncologists, radiation oncologists, nurses and other allied health 
professionals providing specialist cancer care; and selective presentation 
of high-risk prostate cancer cases to the MDT resulting in inconsistent 
multidisciplinary discussion of all available treatment options and 
pathways.  
 
5.5 Conceptual model  
Intervention components are underpinned by the PRECEDE-PROCEED theory 
of behaviour change (62, 63) that relates interpersonal factors and system 
characteristics into one model to inform change in practice. This theory 
enables the integration of barriers identified through our mixed methods 
needs and barriers analysis into ‘predisposing factors’ (e.g., knowledge and 
attitudes of the target group); ‘reinforcing factors’ (e.g., opinions and 
behaviour of peers); and ‘enabling factors’ (e.g., capacity of the system and 
hospital processes). This is one of the most widely used theories to support 
rigorous trials of the implementation of guidelines (16) and systematic 
reviews have shown that trials that intervene to alter these three factors are 
the most successful.(13) Figure 5.2 illustrates how the identified barriers to 
change in prostate cancer care have been grouped into the factors of the 
PRECEDE-PROCEED theory. Additionally, Figure 5.2 illustrates the intervention 
components that have been designed to target each barrier. 
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Figure 5.2: Conceptual Model: adaptation of PRECEDE-PROCEED model of 
behaviour change 
 
 
5.6 Intervention components 
Physician-focused components 
1. Provider education (predisposing factor): The Urologist Clinical Leader at 
each hospital will be supported to facilitate an interactive education 
session at a routinely scheduled multidisciplinary team (MDT) meeting. 
This session will be moderated by members of the research team to 
ensure fidelity and will last approximately 10 to 15 minutes. Participants 
will be presented with an introduction to the study, including a summary 
of the evidence underlying the guideline recommendation through a video 
presentation to control for inconsistency across sites. The video includes 
the Co-Chair of the ACI Urology Clinical Network, a peer-identified national 
urologist opinion leader, and a consumer who introduce key messages 
through discussion of their practice and experience.  
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2. Dissemination of printed materials (predisposing factor): In the active 
implementation phase all urologists will be given a full copy of the Clinical 
Practice Guidelines for the Management of Locally Advanced and 
Metastatic Prostate Cancer and a summary card that allows quick 
reference to the evidence supporting the specific recommendation that is 
the focus of the study, together with information on potential side effects 
and toxicity. The reverse of this summary card provides information on 
current radiotherapy techniques and key points to guide impartial 
discussion with patients before and after surgery to support fully informed 
decision-making. This includes the potential need for multidisciplinary care 
and consultation with a radiation oncologist to obtain information about 
what radiotherapy would involve and the likely benefits and risks of 
treatment if high-risk features are found upon histopathological 
examination of the prostate specimen.  
3. Opinion leaders (reinforcing factor): A key aspect of the intervention will 
be the use of Urologist Clinical Leaders in each hospital, identified by peers 
as being educationally influential, to engage the target group. Clinical 
Leaders will reinforce key messages, persuade peers to participate in the 
study and will model targeted referral behaviours and promote practice 
change.(64) Following the education session, Clinical Leaders will provide 
ongoing peer support and engage in discussions with colleagues to seek 
and provide feedback on practice and any continuing barriers to change. 
The Clinical Leaders are members of the ACI Urology Clinical Network and 
were recruited by the Network Co-Chair, an expert opinion leader who is 
influential due to his authority and status amongst his peers.(65) The 
introduction of key messages by a national opinion leader in the video 
presented at the education session provides an additional level of peer-to-
peer influence. 
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4. Audit and feedback (reinforcing factor): Following commencement of the 
intervention, urologists will be provided with ongoing feedback reports 
detailing the number of patients referred to radiation oncology, at the 
individual, hospital and study level, obtained through data extraction from 
medical records. The feedback report will also include information on the 
number of patients at high risk who are discussed at MDT meetings. The 
initial feedback report will include baseline data. Feedback will be provided 
via email or SMS depending on the preferred method of communication of 
each participant. Aggregated quarterly feedback reports will additionally 
be presented verbally by the Clinical Leader at MDT meetings.  
Context-focused components 
Guideline dissemination and educational components will address gaps in 
provider knowledge. However, a number of reviews indicate that increased 
knowledge is necessary but insufficient to change individual or organisational 
behaviour.(41) It is also necessary to enable change by increasing means or 
reducing barriers.(66) Therefore, in conjunction with physician-focused 
components, utilising the leverage of the ACI Urology Clinical Network to 
address the systems barriers identified through the mixed methods needs and 
barriers analysis, context-focused components will include a new system for 
automatic case flagging at MDT meetings (enabling factor). Urologists 
practising at the nine target hospitals will be requested to provide consent for 
the names of all patients who have had a histopathological examination of a 
radical prostatectomy specimen and who have extracapsular extension, 
positive surgical margins or seminal vesicle involvement to be submitted 
automatically to the hospital urology MDT meeting for discussion. Pathology 
providers will provide a list of all eligible patients to the MDT coordinator. This 
will reduce variation in practice and selective presentation of cases to the 
MDT meeting with the intent to promote more collaborative decision-making 
and increased referral to radiation oncology for high-risk patients. 
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5.6 Methods 
Phase I: intervention rollout and implementation trial  
Hypotheses 
Compared with pre-intervention, a larger proportion of post-operative radical 
prostatectomy patients who are at high risk of recurrence (have extracapsular 
extension, seminal vesicle involvement or positive surgical margins) treated in 
hospitals after implementation of the intervention will receive a referral to 
radiation oncology for consideration of adjuvant radiotherapy or referral to 
the RAVES trial [Radiotherapy Adjuvant Vs Early Salvage (Protocol Number: 
TROG.08.03); see the “RAVES Trial” subsection for details].  
Design 
This will be a phased randomised cluster trial with phased introduction of a 
clinical network led organisational intervention in nine hospitals over 10 
months. The order in which hospitals will receive the intervention will be 
determined randomly using a stepped wedge study design (see Figure 3). This 
design, originally developed for community studies, has more recently been 
applied to health service interventions in hospitals (67) and has the following 
advantages: provides a control comparison where geographic controls are not 
possible; allows all hospitals in the clinical network with multidisciplinary 
teams to take part in the intervention; enables the intervention to be tested 
within the parameters of real-world allocation of clinical network resources 
with a phased roll out of the hospital-based intervention; and complies with 
the Cochrane Effective Practice and Organisation of Care Group’s consensus 
statement about study designs of sufficient quality to be included in 
systematic reviews. This study will be conducted and reported in accordance 
with the CONSORT statement for the reporting of pragmatic trials.(68, 69)  
The intervention will be rolled out across the nine hospitals in five steps of 
two-month blocks from November 2013 to September 2014. Throughout the 
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study, hospitals will either be in the active implementation (intervention) or 
passive (control) phase (see Figure 5.3). Eligibility criteria for inclusion are 
public hospitals: with a urology multidisciplinary team (MDT) comprising 
specialists, nurses, and allied health professionals; and that are members of 
the ACI Urology Clinical Network and have a urologist who will act as the 
Clinical Leader for that site. All urologists who are members of the urology 
multidisciplinary team at intervention hospitals will be eligible for inclusion 
(n4 – 10 urologists per hospital).  
 
Figure 5.3: Stepped Wedge Study Design: Staged rollout of intervention from 
December 2013 to September 2014 
 
The solid shaded blocks represent introduction of the intervention over 5 steps. The 
intervention will be rolled out across the nine hospitals in two-month blocks. Patient medical 
records will be reviewed for a period of 12 months following the interactive education 
session. Therefore data collection will not be completed until September 2015. *Control-only 
monitoring. 
Outcomes  
Primary outcomes are patient referral to radiation oncology for discussion of 
adjuvant radiotherapy in line with guideline recommended care or referral to 
the RAVES trial (see the ‘RAVES Trial’ subsection for details). Secondary 
outcomes include: an initial patient consultation with a radiation oncologist; 
enrolment in the RAVES trial; and commencement of radiotherapy. 
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RAVES Trial – an opportunity to demonstrate shift in equipoise 
RAVES [Radiotherapy Adjuvant Vs Early Salvage (Protocol Number: 
TROG.08.03)] is a multi-centre phase III clinical trial comparing survival and 
quality of life outcomes for patients at high-risk post prostatectomy who are 
randomised to have: i) radiotherapy deferred (salvage radiotherapy) until their 
prostate specific antigen (PSA) begins to rise (common current practice); OR ii) 
immediate radiotherapy (adjuvant radiotherapy) after surgery (regarded as 
evidence-based standard of care). This is seen as a very important local trial as, 
despite international evidence that adjuvant radiotherapy is effective, this 
practice has not been widely adopted due to Urologists’ concerns about side 
effects and overtreatment. The aim of the RAVES trial is to determine whether 
salvage radiotherapy is as effective as adjuvant radiotherapy and results in 
improved quality of life.  
Data collection—data extraction from patients’ medical records  
Outcome data to assess changes in healthcare practice will be collected 
through data extraction from urologists’ and radiotherapy patients’ medical 
records by independent, trained research assistants who are blind to the date 
that the intervention was commenced at the hospital. Baseline data will be 
collected retrospectively for patients undergoing a radical prostatectomy 
during January 2013 to November 2013. Pilot testing of the medical record 
review tools and processes will allow us to train the research assistants and 
establish and test data collection procedures.  
Information from medical records 
Treatment outcomes that will be collected through medical record review for 
cases with extracapsular extension, seminal vesicle involvement or positive 
surgical margins (confirmed by pathology reports) are: referral to 
radiotherapy, taken from the surgeon’s notes (including dates of surgery and 
referral) or in the case where there was no referral that radiotherapy was 
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discussed and the reason(s) for not referring to radiotherapy; uptake of 
radiotherapy or enrolment into the RAVES trial from the radiation oncology 
database; and time between surgery and commencement of radiotherapy. 
Individual case records will be reviewed for a minimum of six months after 
initial radical prostatectomy. 
Data will be abstracted from medical records at hospitals, cancer centres and 
urologists’ private consulting rooms using previously established methods.(33)  
Hospital level factors will be collected from centrally held records including 
specialist cancer centre and size. Patient level factors will be collected from 
the medical and hospital records including: month and year of birth, 
comorbidities, stage of cancer, Gleason score, PSA level at diagnosis, country 
of birth and private health insurance status. Remoteness of residence and 
socio-economic status (SES) of the cases will be assigned using their postcode 
of residence and the ARIA (70) and SEIFA (71), respectively. 
Hormone therapy, comorbidities, pre-diagnostic PSA levels, Gleason score, 
country of birth, and health insurance status are potential barriers to referral 
for radiotherapy.  
Study sample  
The unit of study will be the participating multidisciplinary teams (MDT). Nine 
public hospital-based MDTs in NSW will participate. The hospitals are located 
in both metropolitan and regional areas. Approximately four to ten urologists 
will be included at each site.  
Data analysis 
The primary analysis will be conducted at the individual patient level using a 
generalised estimating equations (GEE) approach to account for repeated 
outcome observations within clusters (urologists and MDTs). The dependent 
variable for this analysis will be referral to a radiation oncology service for 
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adjuvant radiotherapy or enrolment into the RAVES trial (versus no referral) 
for each prostate cancer case. The exposure variable will be the intervention 
status (pre versus post) of the hospital at the time of the post-prostatectomy 
consultation. Other independent variables will be added to the model if they 
are shown to be independently associated with radiotherapy referral and/or 
their inclusion in the model changes the linear coefficient of the intervention 
effect by more than 20% in absolute value. Analysis to determine the extent 
to which changes in urologists’ knowledge, attitudes and beliefs (Phase II) 
mediated any changes in referral patterns will be assessed by including 
clinicians’ change scores in the GEEs.  
Sample size and statistical power 
Based on estimates from the NSW Central Cancer Registry and Medicare 
claims data we estimate that 3,517 NSW men will have a radical 
prostatectomy in 2013. Approximately 1,618 (46%) of these will be performed 
in the nine hospitals with urological MDTs participating in the ACI Urology 
Clinical Network according to linked cancer registry and hospital data for all 
NSW men diagnosed with prostate cancer. Assuming no major change has 
occurred in this distribution, there will be 1,348 radical prostatectomies over 
the 10 months of this trial. Of these, 20 to 50% or 270 to 671 men will be at 
‘high risk’.(72-75) The stepped wedge design is relatively insensitive to 
variations in the intracluster correlation (ICC) as a consequence of its efficient 
use of within-cluster and between-cluster information and has little impact on 
the study's power. However, based on the best available information, we 
estimate that the ICC for use of radiotherapy will be between 0.09 and 
0.15.(76) 
The most recently available data indicate 10% of high-risk men receive 
radiotherapy after surgery in NSW.(33) With the release of the Australian 
Cancer Network Clinical Practice Guidelines and the commencement of the 
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RAVES trial we estimate that at the commencement of our trial, 
administration of radiotherapy following surgery will have increased to 15% to 
20% of high-risk patients. Our stepped wedge study design with nine clusters, 
six time intervals (including the pre-intervention control step) and ICCs of 0.09 
to 0.15 will have at least 80% power to detect an increase in referral to a 
radiation oncologist from 15% to 35%, or 20% to 40% if a minimum of 30% of 
patients are at high risk, and from 20% to 35% if at least 50% of prostate 
cancer cases are at high risk. 
Staff training and evaluation 
Primary and secondary outcomes can be measured reliably through clinical 
data collection and this method has been used previously.(33, 77, 78) 
Research assistants conducting the medical record review will be trained and 
we will conduct a 10% blinded re-review to assess inter-rater reliability.  
Phase II: identify mechanisms of provider and organisational change 
Design 
‘Before and after’ mixed methods study to measure knowledge, attitudes, 
process, and explanatory variables. 
 
Urologists’ knowledge and attitudinal outcomes 
Hypotheses 
Compared with pre-intervention measures, urologists post-intervention will 
have: increased knowledge about the evidence for appropriate adjuvant 
radiotherapy for high-risk prostate cancer patients after radical prostatectomy 
and the associated risks and benefits of treatment; and more positive 
attitudes towards the need for referral to radiation oncology as a means to 
support fully informed patient decision making.  
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Data Collection 
A quantitative study of urologists will be conducted using a questionnaire to 
assess knowledge, beliefs, social influences, attitudes and motivation at three 
time points: baseline (pre-intervention); six months after the roll-out of the 
intervention; and at the end of the study (n ≈ 4 – 10 urologists per hospital). 
The survey is tailored to the intervention, uses previously identified domains 
(knowledge, beliefs, motivation, social influences), constructs, and generic 
questions to investigate the implementation of evidence-based practice (48), 
and is modelled on questions developed for other clinical conditions.(79) The 
measures using Likert scales have been developed through pilot testing and 
their feasibility and reliability will be assessed as part of the data collection in 
accordance with best practice.(80) Questions are consistent with those used 
in the baseline nationwide survey of urologists to enable comparison between 
groups. These surveys produce continuous scores for knowledge, beliefs, 
social influences, attitudes, and motivation at the clinician level that will be 
averaged for each hospital at each time point. 
A follow up nationwide survey of urologist members of the Urological Society 
of Australia and New Zealand (USANZ) (n ≈ 370) will be conducted to 
determine whether urologists’ attitudes shifted locally/nationally without 
intervention.  
Process outcomes 
Research question  
Was the intervention implemented as intended? 
Data collection 
The date of commencement of the intervention will be noted as the day the 
Urologist Clinical Leader within each site facilitated the educational 
intervention session. Agendas and minutes of subsequent MDT meetings will 
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be reviewed using a method developed by members of the investigator team 
(81) to assess: numbers attending the meeting; frequency of mentioning the 
study; discussion of cases flagged by pathology; presentation of medical 
record review feedback; and changes in hospital practice as indicators of 
sustained interest in the intervention and organisational process changes.  
Research Questions  
1. Why did or did not the intervention result in evidence-based care?  
2. Why was or was not the intervention implemented or sustained in 
hospitals?  
Data Collection 
1. Qualitative semi-structured interviews with Clinical Leaders at the end of 
the study to feedback study results and explore the reasons for them 
(n=9).  
2. Qualitative semi-structured telephone interviews, informed by feedback 
from Clinical Leaders, with urologists in the nine intervention hospitals at 
the end of the study to feedback study results and further explore the 
reasons for them (n≈4 – 10 urologists per hospital).  
Data analysis 
Survey data will be analysed using bivariable methods (means, t-tests and 
ANOVA for normally distributed continuous data; medians and non-
parametric tests for non-normally distributed continuous data; and 
proportions and chi-squared tests for categorical data). 
Semi-structured interview data will be analysed thematically using a matrix-
based framework to organise data according to the theoretical framework 
used for the intervention design to identify why changes did or did not 
happen in the hospitals and why the intervention did or did not result in 
improved care.  
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5.7 Research governance 
The study has been approved by Royal Prince Alfred Research Ethics 
Committee (ID: X12-0388 & HREC/12/RPAH/584). Site-specific approval (SSAs) 
from the research governance office at each of the nine participating hospitals 
has been obtained. Site-specific approval from Cancer Council NSW ethics 
committee has been granted to cover data collection, storage and analysis at 
Cancer Council NSW.  
 
5.8 Trial status 
The intervention and data collection phase of the study commenced in 
November 2013. 
 
5.9 Discussion 
Clinical networks such as those established by the NSW Agency for Clinical 
Innovation are increasingly being viewed as an important strategy for 
increasing evidence-based practice in Australia and other countries. This 
interest in clinical networks is accompanied by significant investment in them 
but few studies have directly tested their effectiveness in driving 
implementation initiatives. To the authors’ knowledge, this study will be one 
of the first randomised controlled trials to test the effectiveness of clinical 
networks to lead changes in clinical practice in hospitals treating patients with 
high-risk cancer and improve evidence-based care. 
 
5.10 Limitations 
The aim of this study is to target referral patterns of practising clinicians using 
the leverage of a clinical network. Intervention components therefore focus 
on the attitudinal and systems barriers at the urologist and hospital level. 
While we have sought consumer input into the design of provider-focused 
materials to provide guidance on what information patients want from 
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consultation with their physician, ethics approval for the current study does 
not permit direct interaction with patients being treated by urologists in the 
study. The research team is developing a proposal for a sub-study focused on 
how patients can influence the treatment they receive, to be conducted at the 
end of Phase I.  
 
5.12 Authors’ contributions 
The authors are the investigators of the research grant funding this research 
activity. BB, in collaboration with all other authors, conceptualised the 
research project and developed the protocol presented in this paper. All 
authors provided input into various aspects of the study, provided ongoing 
critique, and approved the final version of the manuscript. 
 
5.13 Ethics approval 
Ethical approval to conduct the study has been obtained from Royal Prince 
Albert Hospital Human Research Ethics Committee, January 2013 (ID: X12-
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Chapter 6: Process evaluation  
 
6.1 Background 
In order to increase the utility of implementation research and aid interpretation of 
outcomes, it is necessary to conduct high quality process evaluation in parallel with 
trials of complex interventions.(1, 2) This is especially true for interventions that seek 
to change health care provider behaviours in complex settings, where there may not 
be a clear causal pathway.(3) Process evaluation can help understand issues of 
program implementation, explain discrepancies between expected and observed 
outcomes in relation to context, and provide insights into possible causal 
mechanisms and effect modifiers to aid subsequent translation from research into 
practice.(4) 
Process evaluations most commonly use qualitative methods to explore participants' 
perceptions of acceptability of interventions and whether they were implemented as 
planned, with fidelity. This type of evaluation provides context-specific insights that 
can help interpret the results of an individual trial, but is arguably less helpful in 
predicting the likely generalisability of findings.(3) Given that complex interventions 
may act at multiple levels including systems, organisations, professions or 
individuals, a theory-oriented approach to process evaluation, underpinned by 
behavioural constructs hypothesised a priori, may be more useful for exploring how 
interventions function across different settings and to identify causal mechanisms, 
and barriers and enablers to translation into routine clinical practice. 
 
6.2 Aims and objectives 
The primary aim of the CLICC process evaluation was to identify mechanisms of 
provider and organisational change (5), which were assessed using three domains 
adapted from the process evaluation of a complex intervention aiming to increase 
the use of research in health policy and programs(6): (i) whether the intervention 
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was implemented as intended (implementation); (ii) why the intervention did or did 
not result in more evidence-based care (participation and response); and (iii) why 
was or was not the intervention implemented or sustained across implementation 
sites (context). Specifically domains were assessed as follows: 
Participation 
Participation was considered in terms of recruitment and reach, specifically: the 
proportion of the target population that actually received the intervention, and their 
representativeness. 
Implementation 
Implementation was considered as the extent to which the intervention was 
implemented as planned with fidelity, the degree to which essential elements were 
delivered, the level of exposure, and local adaptation.  
Response 
Response was considered as the extent to which multidisciplinary teams integrated 
and adopted new knowledge, systems and processes into their routine practice. 
Unintended consequences and outcomes in response to the intervention were also 
evaluated. 
Context 
Context was documented to enable consideration of any setting characteristics that 
may have influenced the delivery of the intervention or impacted on its effectiveness 
or maintenance/sustainability across study sites. Contextual evaluation will facilitate 
interpretation of the outcomes of the CLICC trial and maximise the potential for scale 
up and spread.  
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6.3 Methods 
6.3.1 Evaluation framework 
The CLICC conceptual program logic model (5) (Chapter Four) informed the design of 
the process evaluation to explore how well the theory underpinning the intervention 
was realised in the design and delivered in the real world context of the study.(6) 
CLICC elements are summarised in Figure 6.1. A mixed methods approach was used 
to gather quantitative measures of intervention elements to assess implementation, 
participation and response, and context, combined with qualitative exploration of 
participants experience of, and response to, the intervention (predisposing, enabling 
and reinforcing factors) and the contextual characteristics of the nine participating 
study sites. 
 
Figure 6.1 CLICC intervention elements 
 
• Flagging of eligible cases 
by pathologist to the 
MDT coordinator for 
addition to MDT agenda 
for discussion  
• Quarterly individual, 
hospital and aggregate 
study level feedback on 
patient characteristics, 
MDT discussion and 
referral patterns 
• Local Clinical Leader at 
each site 
• Statewide opinion leader 
(ACI Urology Network 
co-chair) 
• National opinion leader 
(President, USANZ) 
• CLICC video 
• CLICC printed resource 
• Full copy of Australian 
Cancer Network Clinical 
Practice Guideline 
• Supporting randomised 
controlled trial 
publications 
Provider 
Education and 
Printed 
Materials 
(Predisposing 
factor) 
Opinion 
Leaders 
(Reinforcing 
factor) 
Automated 
Systems 
(Enabling 
factor) 
Audit & 
Feedback 
(Reinforcing 
factor) 
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6.3.2 Data collection 
Quantitative data 
Quantitative data were extracted into an intervention tracking data collection form 
(fidelity checklist) for each participant. This tracking form was completed by the 
study team, using the data sources outlined below, to record individual exposure to 
intervention elements including: opinion leaders; the CLICC introductory video; 
printed educational materials; audit feedback reports; and flagging of eligible 
patients by pathology for discussion at multidisciplinary team meetings, together 
with participation in evaluation activities. 
Participation  
Participant recruitment at each site was documented in a recruitment database, 
which included the overall number of urologist members of each of the nine 
participating multidisciplinary teams and the number who consented, declined, did 
not respond or withdrew from the study (including dates). The recruitment database 
was also used to track follow-up of non-attendees by Clinical Leaders and/or the 
research team to recruit them into the study according to predetermined protocols. 
Implementation 
The date of commencement of the intervention was recorded as the day the 
Urologist Clinical Leader at each site facilitated the educational intervention session 
during a routinely scheduled multidisciplinary team meeting. Attendance of 
urologists at the intervention session was recorded. The aggregate level of exposure 
to, and adaptation of, intervention elements at each site was also recorded in an 
intervention-tracking database. 
Response 
Where available, agendas and minutes of MDT meetings for the duration of the 
active intervention phase were reviewed to assess response to the intervention. 
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The extent to which participants integrated and adopted new knowledge was 
assessed through pre- and post-intervention surveys to measure knowledge, 
attitudes and beliefs. Results are presented in Chapter Eight.  
The extent to which multidisciplinary teams integrated the MDT flagging process into 
routine practice was recorded in an MDT tracking database, which included the date 
the patient was flagged by pathology, whether the patient was added to an MDT 
agenda, date of discussion, and the MDT recommendation (where known). Data 
were extracted from MDT administrative records and supplemented with data from 
patient medical records (data collection methods for patient medical record review 
are detailed in Chapter Seven). 
It was not possible to assess frequency of mentioning the study or changes in 
hospital practice through meeting minutes, as proposed in the published study 
protocol, due to inconsistencies in MDT recording keeping.(5) 
Context 
Setting characteristics such as frequency, organisation and record keeping of 
multidisciplinary team meetings were documented together with contact 
information for the MDT coordinator at each site, and for public and private 
pathology and radiation oncology service providers for each participating Clinical 
Leader and urologist. Patient volume, public/private case mix and other setting 
characteristics were collected through independent medical record review. Further 
analyses including potential effect modifiers are detailed in Chapter Seven. 
Qualitative data 
Qualitative semi-structured interviews were conducted with Clinical Leaders and 
urologist participants at the end of the active intervention phase of the study to 
explore participants’ experience of, and response to intervention elements 
(predisposing, reinforcing and enabling factors), together with contextual factors 
which may have hindered or facilitated their implementation and sustainability. 
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Interview themes are detailed in Table 6.1. Full interview guides can be found in 
Appendices V and VI. 
Analyses 
Generalised linear regression models with a Poisson distribution and log link, and 
generalised estimating equation (GEE) adjustment for the clustering of patients 
within urologists were used to estimate the relative proportions (RR) of patients 
who, within 4 months after prostatectomy, were: (1) flagged by pathology for 
discussion at the MDT; and (2) discussed by the MDT among those flagged. The 
dichotomous dependent variable in each regression model was outcome (1) or (2). 
Independent variables were site (1 through 9) and insurance status (public versus 
private patient). The categories within each independent variable correspond to 
groups for which the outcomes are compared. 
Interviews were transcribed verbatim to produce transcripts of narrative text for 
thematic analysis. The CLICC evaluation framework guided the initial categorisation 
of text, whereby each segment of interview text was conceptually linked to one of 
two qualitative evaluation domains: response to the intervention (predisposing, 
enabling and reinforcing factors); and the contextual characteristics of the nine 
participating study sites. The author conducted all interviews and analyses and two 
iterations of comparative coding were undertaken to ensure consistency. Negative 
cases are reported with supporting text where identified. The CLICC investigator 
team assessed applicability and face validity. 
 
6.4 Results 
6.4.1 Participation  
Eligibility criteria 
Eleven NSW hospitals met the CLICC implementation trial inclusion criteria of having: 
(i) a urological MDT; and (ii) a member(s) of the ACI Urology Network.  
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All urologist members of a participating urology MDT, who: (i) performed radical 
prostatectomy during the control or intervention phase; and (ii) reviewed their high-
risk prostate cancer cases (post-radical prostatectomy) at the participating MDT at 
the time the intervention commenced at that site, were eligible for inclusion. The 
latter two eligibility criteria were included after publication of the study protocol [5] 
to enable exclusion of urologists who: (i) did not perform any radical prostatectomies 
during the study period and, therefore, would not contribute any clinical data; and 
(ii) are members of a participating MDT for the purposes of other urological 
conditions but present radical prostatectomy patients for review at a different non-
participating MDT.  
Participation 
The urological MDTs at two eligible hospitals declined to participate. From the 
remaining nine eligible sites 55 urologists (inclusive of nine Clinical Leaders) were 
invited to participate in CLICC. Six were ineligible as they performed no radical 
prostatectomies during the specified study period, eight declined, and four withdrew 
consent, resulting in a total of 37 participants (nine Clinical Leaders and 28 
participating urologists). The proportion of participating eligible urologists across 
sites is shown in Table 6.2. Overall participation was 76% with 100% of eligible 
urologists participating at five out of nine sites (Sites 1, 4, 5, 6 and 8). The response 
rate at Site 2 was anomalously low (18%) with only two out of 11 eligible urologists 
participating. Of note, four urologists at that site initially provided consent but 
withdrew when contacted by the medical record review team to arrange access 
patient medical records. Sites 3, 7 and 9 each had one eligible urologist who declined 
to participate. A participant flow diagram is provided in Chapter Seven (Figure 7.2). 
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Table 6.1: Process evaluation interview themes 
Interviewee Process evaluation 
domain 
Interview theme 
Clinical Leader Participation and 
response 
- Understanding of role and work undertaken as 
Clinical Leader 
Context - Factors that hindered or facilitated role as Clinical 
Leader 
- Interaction with colleagues 
- Contextual factors that hindered or facilitated the 
implementation of the project 
 Sustainability - Continuation of CLICC elements 
Clinical Leader 
Participating urologist 
Participation and 
response 
 
- Adequacy of information about what the study 
was hoping to achieve 
- Perceptions of study success  
- Most helpful intervention components  
- Effect(s) of the intervention on MDT decision-
making 
- Effect(s) of the intervention on relationships with 
colleagues 
- Any concerns regarding the implementation of 
the intervention or unintended outcomes  
- Perceptions of the extent to which the 
intervention resulted in change in practice and any 
wider changes in patterns of care 
- Contributions of the project to patient care 
- Benefits of the project for participants 
Context - Conditions critical to the project’s success/lack of 
success 
Participating 
urologist 
Context - Perception of the supportiveness of, and 
interaction with, the Clinical Leader 
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Table 6.2: Proportion of participating eligible urologists by site (ranked) 
 Total number of 
eligible* urologists 
Number of participating 
urologists 
Proportion participating in 
CLICC % 
Site 6 5 5  100 
Site 5 5 5 100 
Site 4 4 4 100 
Site 8 4 4 100 
Site 1 4 4  100 
Site 3 6 5 83 
Site 7 5 4 80 
Site 9 5 4 80 
Site 2 11 2 18 
Total 49  37 76 
*Performed one or more radical prostatectomies during the baseline and/or study period and reviewed high-
risk prostate cancer cases (post-radical prostatectomy) at the participating MDT at the time the intervention 
commenced at that site 
 
6.4.2 Implementation 
The CLICC intervention was rolled out across the nine participating sites as per the 
stepped wedge design in the study protocol (Figure 6.1). The trial commenced at the 
first site in December 2013 and the final site in August 2014.  
The last RP recruited to the Intervention group occurred on 31 March 2015. The 
minimum period of exposure to CLICC intervention elements was 13 months (Site 9) 
and the maximum period of exposure was 21 months (Site 1). 
Attendance at the introductory CLICC intervention session 
Twenty-nine participating urologists attended the introductory CLICC intervention 
sessions across the nine sites. This included all nine Clinical Leaders and 20 of the 28 
other participating urologists.  
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Figure 6.1: Stepped Wedge Study Design: Staged rollout of CLICC intervention from 
December 2013 to September 2014 
 
 
 
Exposure to CLICC intervention elements 
Aggregate site level exposure to CLICC intervention elements is summarised in Table 
6.3. 
Opinion leaders 
The CLICC implementation trial incorporated three levels of opinion leader: (i) a local 
Clinical Leader for each site; (ii) a statewide opinion leader (Urology Network Co-
Chair); and (iii) a national opinion leader (President of USANZ).  
The Urology Network Co-Chair made the initial approach to the nine Clinical Leaders 
to recruit them to their role in the study. The Clinical Leader for each study site was 
briefed on the aims and elements of CLICC by the study team and was provided with 
a script to facilitate the introductory CLICC intervention session. All urologist 
participants attended at least one MDT meeting at which the Clinical Leader 
presented aggregate quarterly feedback reports for discussion, providing further 
exposure to the local opinion leader element. Thirty-two of the 37 participants (all 
nine clinical leaders and 23 participating urologists) (86%), were exposed to the 
Urology Network Chair and President of USANZ through the CLICC introductory 
video; 29 viewed the video at the introductory CLICC intervention sessions and three 
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viewed it subsequently as part of recruitment to the study. Four of the five 
participants who did not view the CLICC introductory video discussed the study 
directly with the Urology Network Chair. The Clinical Leader discussed the study with 
the remaining participating urologist.  
All participants met the minimum requirement of watching the CLICC introductory 
video or having a discussion with the Clinical Leader for their site and/or Urology 
Network Co-Chair. 
Provider education and printed materials 
In addition to the educational elements in the CLICC introductory video, participants 
were provided with an information pack at the CLICC intervention session containing: 
a full copy of the Australian Cancer Network Clinical Practice Guideline for the 
Management of Locally Advanced and Metastatic Prostate Cancer; peer review 
journal publications reporting the results and long-term follow up of the EORTC (7, 
8), SWOG (9-11) and ARO (12, 13) randomised controlled trials that form the 
evidence base for the clinical practice guideline recommendation; and the CLICC 
printed resource (Appendix VII) comprising a summary of the guideline 
recommendation and supporting evidence and a patient-urologist discussion guide. 
The information pack was emailed and mailed to participants who did not attend the 
CLICC intervention session.  
All participants met the minimum requirement of receiving the CLICC printed 
resource.  
Audit and feedback 
Individual quarterly feedback reports, based on data from independent patient 
medical record and MDT record review, were sent to participants by mail and email 
(see Appendix VIII for feedback report templates). Individual reports were received 
on the day of a routinely scheduled MDT meeting at which the Clinical Leader 
presented site and aggregate study level reports for discussion. Participants received 
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a maximum of four and a minimum of two feedback reports, as outlined in Table 6.2, 
depending on date of commencement of the intervention at their site. A total of 110 
individual feedback reports and 26 site and aggregate study level reports for 
presentation by the Clinical Leader to the MDT were distributed to participants.  
All participants attended at least one MDT meeting at which the Clinical Leader 
presented site and aggregate study level feedback. Inconsistencies in MDT record 
keeping across sites meant that it was not possible to accurately determine which 
participants were in attendance at all MDT meetings where feedback was presented. 
Nor were we able to confirm whether all feedback was presented for discussion at 
the MDT meetings as scheduled at two sites (Sites 3 and 5). 
All participants met the minimum requirement being mailed and emailed all 
scheduled individual feedback reports following consent to participate in the study.  
Automated systems 
Clinical Leaders and urologist participants provided consent for the names of all 
patients (public and private) who were subject to a histopathological examination of 
a radical prostatectomy specimen for prostate cancer and who had extracapsular 
extension, positive surgical margins or seminal vesicle invasion to be submitted to 
the urology MDT for discussion. Flagging commenced as soon as signed consent was 
forwarded to the pathology provider. There was an unanticipated gap in flagging 
from March 2014 to June 2014 for private patients serviced by one pathology 
provider, which affected Sites 1, 2 and 3. 
Flagging of eligible patients involved six private pathology providers. The largest 
private pathology provider serviced more than three quarters (78%; 29 out of 37) of 
the participating urologists across eight of the nine sites.  After an initial period of 
manual identification and flagging, this provider integrated software code into their 
database such that reports were generated every two weeks to capture eligible 
patients from the preceding fortnight. Email notifications were sent directly from the 
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pathologist to the nominated MDT coordinator (copying the Clinical Leader and 
participating urologist(s)) for each site with a list of patients to be added to the 
agenda for the subsequent MDT meeting. The remaining five private pathology 
providers and eight public pathology providers manually identified and flagged 
eligible patients as per locally agreed protocols. Calendar reminders were set up for 
the nominated contact at each pathology service to prompt notification prior to 
scheduled MDT meetings. The study team monitored pathology flagging and, where 
necessary, followed up with reminder telephone calls. One public pathology service 
provider (Site 7) declined to support patient flagging citing insufficient resources.  
All participants met the minimum requirement providing consent for eligible patients 
to be flagged by pathology to the MDT coordinator for discussion by the MDT from 
the time of consent or for a minimum of six months. 
The extent to which pathology providers within and across sites were able to 
implement the flagging process is detailed in Table 6.4. There was significant 
variation in the proportions of “all patients” flagged between sites (p<0.001) (p-value 
shown in Table 6.5, proportions shown in Table 6.4 and Table 6.5). Overall, 318 of 
407 eligible patients were flagged by pathology for discussion at the MDT (78%). 
Flagging of private patients was consistent across the sites that used the largest 
private pathology provider. One hundred percent of private patients were flagged for 
discussion during the study period at two of the eight sites that used this provider, 
these being the last two sites to enter the trial when the process was fully 
established (Sites 8 and 9). As noted, Sites 1, 2 and 3, the first to enter the CLICC trial 
prior to the establishment of an optimally efficient process, were adversely affected 
by a gap in MDT flagging that occurred while this pathology provider integrated 
software code with 68%, 67% and 84% of eligible private patients flagged 
respectively. Across all private pathology service providers, 85% (280 of 329) of 
eligible private patients were flagged for discussion.  The Clinical Leader and all 
participating urologists at Site 5 used alternate private pathology providers who 
combined flagged a little over a third (4 of 11; 36%) of eligible patients. 
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Table 6.3: Site level exposures to CLICC intervention elements  
 Opinion Leaders Provider Education and Printed Materials Audit & Feedback^ Automated Systems 
 Clinical 
Leader 
Urology 
Network 
Co-
Chair*  
President 
of 
USANZ* 
 
CLICC 
Video 
Full 
CPG** 
RCT*** 
papers 
CLICC 
printed 
resource 
Report 1 Report 2 Report 3 Report 4 Public 
pathology 
MDT 
flagging 
Private 
pathology 
MDT 
flagging 
Site 1 X X X X X X X X X X X X X 
Site 2 X X X X X X X X X X X X X 
Site 3 X X X X X X X X X X X X X 
Site 4 X X X X X X X X X X  X X 
Site 5 X X X X X X X X X X  X X 
Site 6 X X X X X X X X X   X X 
Site 7 X X X X X X X X X    X 
Site 8 X X X X X X X X X   X X 
Site 9 X X X X X X X X X   X X 
* CLICC video 
** CPG: Australian Cancer Network Clinical Practice Guideline for the Management of Locally Advanced and Metastatic Prostate Cancer(14) 
*** Randomised controlled trial 
^  Feedback report templates are included in Appendix VII 
Feedback Report 1: individual, site level and aggregate study level pre-CLICC (baseline) outcome data (1 January 2013 – end of month prior to CLICC intervention 
commencement) 
Feedback Report 2: site level and aggregate study level pre-CLICC (baseline) outcome data / individual and site level post-CLICC MDT discussion data 
Feedback Report 3: individual, site level and aggregate study level pre-CLICC (baseline) and post-CLICC outcome data / individual and site level post-CLICC MDT discussion 
data 
Feedback Report 4: individual, site level and aggregate study level post-CLICC MDT discussion data / aggregate study level pre-CLICC (baseline) outcome data
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Public patients were significantly less likely to be flagged by pathology for 
discussion than private patients (Relative Risk 0.56; 95% CI [0.42, 0.75; 
p<0.001) (data shown in Table 6.5). Overall, 38 of 78 (49%) of eligible public 
patients were flagged. The public pathology provider at Site 7 declined to 
support flagging. While agreement was received from the other public 
pathology providers, no eligible public patients were flagged at Site 6 (0 of 1 
eligible patients flagged; 0%) or Site 8 (0 of 4 eligible patients flagged; 0%). 
One public pathology provider (Site 9), with regular prompts from the study 
team, was able to achieve comparable results with the largest private 
pathology provider with 15 of 18 eligible patients flagged (83%).  
 
Integration of the MDT flagging process into routine practice by 
multidisciplinary teams is detailed in Table 6.5.  
 
Table 6.4: Proportion of eligible patients who were flagged by pathology 
(ranked by All patients) 
 
 All patients Private patients Public patients 
 Number 
of high- 
risk 
cases 
Number 
of cases 
flagged 
% 
flagged 
Number 
of high- 
risk 
cases 
Number 
of cases 
flagged 
% 
flagged 
Number 
of high- 
risk 
cases 
Number 
of cases 
flagged 
% 
flagged 
Site 6 36 34 94% 35 34 97% 1 0 0% 
Site 8 52 48 92% 48 48 100% 4 0 0% 
Site 9 32 29 91% 14 14 100% 18 15 83% 
Site 3 120 96 80% 106 89 84% 14 7 50% 
Site 4 54 40 74% 44 37 84% 10 3 30% 
Site 7 34 25 74% 28 25 89% 6 0 0% 
Site 1 48 32 67% 31 21 68% 17 11 65% 
Site 2 12 8 67% 12 8 67% 0 0 . 
Site 5 19 6 32% 11 4 36% 8 2 25% 
Total 407 318 78% 329 280 85% 78 38 49% 
 
6.4.3 Response 
The proportion of flagged patients who were added to an agenda and 
discussed by the MDT within four months of surgery is presented in Table 6.5 
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as a measure of integration of the MDT flagging process into routine clinical 
practice. There was significant variation between sites in the proportion of 
patients discussed among those flagged (p<0.001). While, as noted previously, 
public patients were significantly less likely to be flagged for discussion than 
private patients, there was no significant difference in the proportion 
discussed among those flagged (Relative Risk 1.15; 95% CI [0.89, 1.49]; 
p=0.282). Two sites discussed 100% of flagged patients (Site 5: 6 of 6; Site 6: 
34 of 34). Site 3, the site with the highest patient volume, discussed the 
lowest proportion flagged cases (30 of 96; 31%).  
 
Three sites (Sites 2, 3 and 8) adapted the process for adding patients to the 
MDT agenda after receiving notification of eligible patients from pathology. At 
Site 2 the MDT coordinator did not list eligible patients on the agenda for 
discussion unless a request was received from the participating urologist. At 
Site 3 and Site 8 discussion of patients was delayed until after receipt of the 
first post-operative PSA test result.  
Secondary outcome data reporting the proportion of patients discussed at the 
MDT before and after the implementation of the flagging process are 
presented in Chapter Seven (Table 7.2) to determine if there was a significant 
increase in discussion of patients after the intervention.  
Sensitivity analyses including potential effect modifiers of the effects of the 
intervention on likelihood of being discussed at the MDT are reported in 
Chapter Seven (Supplementary Table S7.2). 
Due to inconsistencies in MDT record keeping it was not possible to accurately 
record the MDT recommendation across all sites. Nonetheless, 
recommendations that were recorded were included in subgroup analyses 
exploring the relationship between MDT recommendation and referral to 
radiotherapy or RAVES in Chapter Seven (Table 7.4).  
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6.4.3 Context 
Eight of the nine MDTs held fortnightly meetings and one met monthly (Site 
4). All nine MDTs included both public and private patients. All but one site 
had a designated MDT coordinator (administrator or nurse) responsible for 
scheduling and agendas. At the remaining site (Site 3), organisation of the 
MDT was delegated to the incumbent urology Registrars. Record keeping was 
variable across sites ranging from a formal MDT database documenting 
discussion and recommendations maintained by a data manager (Sites 8 and 
9), MDT administration records maintained by the MDT coordinator (Sites 2, 
3, 4 and 6), letters of recommendation produced by the MDT coordinator 
(Sites 1 and 5), a MDT “flag” in the electronic patient medical record (Site 3), 
or ad hoc notes taken by the MDT coordinator, cancer care nurse coordinator 
or Registrar (Site 7). The level of detail, timeliness and completeness of MDT 
records was variable. 
 
6.4.4 Semi-structured interviews 
All nine Clinical Leaders [CL] (100%) and 20 out of 28 participating urologists 
[PU] (71%) participated in an end of study interview resulting in a total sample 
of 29 (overall response rate 78%). Two of the interviewees (one Clinical Leader 
and one participating urologist) did not complete all interview questions due 
to time constraints. Responses are grouped by process evaluation domain and 
interview theme.  
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Table 6.5: Integration of the MDT flagging process into routine care (ranked 
by Discussed among those flagged) 
 
    Flagged   
Discussed
1
 among those 
flagged 
Characteristic N1^ 
 
n1  
(% of N1) 
Adjusted # 
 RR (95%CI) N2^^ 
 
n2 
(% of N2) 
Adjusted # 
 RR (95%CI) 
All patients: 407 318 (78%)   318 220 (69%)   
Hospital 
      Site 6 36 34 (94%) 1.13 (1.03, 1.25) 34 34 (100%) 3.30 (2.70, 4.03) 
Site 5 19 6 (32%) 0.46 (0.16, 1.32) 6 6 (100%) 3.14 (2.50, 3.95) 
Site 1 48 32 (67%) 0.94 (0.81, 1.09) 32 30 (94%) 2.94 (2.29, 3.78) 
Site 4 54 40 (74%) 0.96 (0.78, 1.17) 40 36 (90%) 2.92 (2.29, 3.72) 
Site 8 52 48 (92%) 1.13 (1.07, 1.21) 48 40 (83%) 2.74 (2.23, 3.37) 
Site 2 12 8 (67%) 0.79 (0.75, 0.84) 8 6 (75%) 2.47 (2.03, 3.02) 
Site 7 34 25 (74%) 0.94 (0.67, 1.33) 25 18 (72%) 2.37 (1.59, 3.54) 
Site 9 32 29 (91%) 1.42 (1.24, 1.63) 29 20 (69%) 2.09 (1.29, 3.37) 
Site 3 120 96 (80%) ref. 96 30 (31%) ref. 
p-value 
  
<0.001 
  
<0.001 
Insurance 
      Private 329 280 (85%) ref. 280 190 (68%) ref. 
Public 78 38 (49%) 0.56 (0.42, 0.75) 38 30 (79%) 1.15 (0.89, 1.49) 
p-value     <0.001     0.282 
^ Intervention group patients 
^^ Intervention group patients who were flagged
 
1
Patient discussed at MDT meeting within 4 months after prostatectomy 
# Adjusted for hospital/MDT and insurance with urologist as the clustering variable 
 
Participation and response 
Understanding of role and work undertaken  
All nine Clinical Leaders reportedly understood their role as to encourage 
urologist participation and facilitate implementation of CLICC elements and 
felt adequately informed about what they were expected to do.  Only three of 
the nine (Sites 5, 6 and 7) additionally viewed their role as one of an opinion 
leader to actively influence and promote participating urologist behaviour 
change:   
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"To constantly remind the urologists that men with unfavourable 
histological results from surgery should at least have the discussion and 
be considered for radiotherapy and to keep that in focus." [CL – Site 7] 
 
Adequacy of information about what the study was hoping to achieve  
18 of 20 urologists reported that they felt adequately informed about what 
the study was hoping to achieve. The remaining two reported that they were 
informed but were unsure if there was an undisclosed purpose to the study: 
“I was informed but I’m not sure if what we were told is what it was really 
looking at … it’s almost like an audit thing.” {PU – Site 6] 
 
“Having [X] as the lead in this hospital, and I have the highest respect for 
him, but there seemed to be an element of not being able to discuss what 
the investigators were hoping to achieve on a theoretical basis.” [PU – Site 
4] 
 
Perceptions of study success 
There was variability in participants’ perceptions of whether the study was 
successful both within and across study sites.  
More than three quarters of interviewees (22 of 29; 76%) considered that 
CLICC was successful in their hospital. The most commonly cited reason for 
perceived success (n=15) was increased discussion of patients at the MDT 
ensuring no patient got missed or “slipped through the cracks”: 
“… every meeting there are generally CLICC patients that come up, there is 
always discussion about those patients and probably in more detail then 
would happen before. In the interest of time we wouldn’t have always 
discussed every patient - if they have low volume cancer then a couple of 
the urologists would just keep an eye on them. Patients are presented 
courtesy of [the pathology provider] and that has increased discussion.” 
[CL – Site 7] 
Several participants (n=7) viewed the study as successful in terms of general 
involvement of the MDT and contribution of patient data through medical 
record review but were unsure whether this would result in changes to clinical 
practice: 
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“Hard to comment – we are adhering to it and all urologists are on board 
and freely discussing patients at the MDT so successful from that point of 
view. Don’t know if it’s changed referral patterns or other behaviours.” 
{PU – Site 6] 
 
Three participants (10%) felt it was too early to tell if the study had been 
successful or not: 
“I think there needed to be a longer study period to continue to have an 
effect. It has been successful in showing us how few patients get referred 
for adjuvant radiotherapy and demonstrated the variation in practice 
within and across hospitals.” [PU – Site 7] 
 
Of the four participants (14%) who did not think the study was successful: two 
cited low participation (both from Site 2); one thought the study unsuccessful 
because it had not changed their own practice (Site 4); and one (Site 3) noted: 
“I think it could have been done better but we didn’t give a lot of 
consideration about how to implement the changes from a logistical point 
of view. The problem is that we have too many cases so we could have 
had a better crack at discussing all of them.” [CL – Site 3] 
Most helpful intervention components  
Flagging of cases by pathology for discussion at the MDT was considered the 
most helpful intervention component in achieving practice change and was 
mentioned by 21 of 29 interviewees (72%). The automatic nature of the 
system which ensured all patients were listed and required no action on the 
part of the urologist was frequently noted: 
“[MDT flagging of high-risk cases was] most important especially for high 
volume cancer centres where it is easy to provide excellent care but 
patients still fall through the cracks due to sheer numbers. The MDT list 
was manageable because the patients flagged are the right ones that 
should be given priority over others.” {CL – Site 6] 
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 “The automated nature of the study, not requiring the urologist who is 
already stretched for time to fill out 400 pages of a clinical trial scenario is 
a big positive. Data collection and feedback is external. I think flagging 
will continue. We think we have almost 100% MDT coverage. It seems to 
be working and done by the team – I haven’t had to do much more.” {CL – 
Site 9]  
A minority (2 of 29; 7%) did not find MDT flagging helpful because they 
considered it too early to discuss patients at the subsequent MDT following 
surgery: 
“I think the flagging was not helpful because of the timing – two weeks 
after the operation there is no progress, no six-week PSA and continence 
status is not known so you don’t have a feel if radiotherapy is appropriate, 
necessary or a hindrance. You almost become too pushy to force patients 
to have radiotherapy but if you wait for the PSA at six weeks (and it has 
been shown that there is no difference between two weeks and two 
months) you know better. The MDT has changed discussion to two 
months for that reason.” [PU – Site 8] 
“Initially [MDT flagging] was done through the MDT coordinator but I 
wasn’t given enough pre-warning to be prepared to discuss [the patient]. 
It works better now cases are emailed direct and I put them up when I 
have the post-operative PSA and knowledge of the patient’s recovery.” 
[PU – Site 2] 
Feedback reports were identified as a helpful intervention component by 
nearly half of the interviewees (14 of 29; 48%). While some were most 
interested in their own audit results others found it useful to make 
comparisons between sites and see how practice varied: 
“Individual reporting to the urologists enables them to see their own 
results – some were surprised by their low referral rates. I’m not sure the 
overall pattern data made much difference because there were only one 
or two funny outliers. Personal information is more useful.” [CL – Site 7] 
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“The study results and feedback help us keep an eye on our case load and 
allows us to monitor our margins and other factors that determine 
outcomes for patients.” [PU – Site 5] 
 “Interesting to see how our performance compares with others in terms 
of at risk features, in terms of positive margins and extracapsular 
extension rates, especially as a regional centre.” [CL – Site 5] 
Seven interviewees (24%) found the printed educational materials useful with 
four of these highlighting them as the most helpful element of the trial.  
“[Printed materials] were very clear about the way forward for the 
management of these patients.” [PU – Site 5] 
However, one participant noted: 
“This information has been around for a while but there are problems 
with the results so I guess that’s why we need to think about it.” [PU – Site 
3] 
While five of the 29 (17%) found the CLICC introductory video helpful, others 
considered it impersonal and the content too lay: 
“Flagging followed by the video – it was concise, pitched at the right level 
and did all the things a good educational video should.” [CL – Site 4] 
‘Clinical content was too simple. If you are attending conferences and up 
to date with Continuing Professional Development then you would know 
about adjuvant radiotherapy.” [PU – Site 4]    
Of the 20 urologist participant interviewees, four (20%) (Sites 4, 5, 7 and 8) 
noted the influence of the Clinical Leader as important in achieving desired 
outcomes but none articulated a reason for this. 
Effect(s) of the intervention on MDT decision-making 
Only four of the 20 urologist participant interviewees (20%) perceived that 
CLICC had affected MDT decision-making. Two reflected that this change 
predominantly related to increased awareness of the need to present patients 
to the MDT: 
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“Personally no, I was already having robust MDT meetings but it did 
highlight certain deficiencies in the MDT. So yes, it has, people are more 
mindful now about the MDT meetings.” [PU – Site 3] 
“I think so – we had a little summary chat about it the other night when 
[Clinical Leader] brought it up again… making sure everyone has the full 
opinion about ongoing management.’ [PU – Site 5] 
One participant considered that discussion of patients at the MDT translated 
into increases in referral patterns: 
“…patients who are eligible for discussion are discussed at the time and 
there is now a process in place for those patients to be presented. 
Discussing patients at the time encourages other referral to radiation 
oncology or medical oncology etc.”  [PU – Site 3] 
Conversely, another participant reported that MDT discussion decreased 
referral of patients who were considered inappropriate for adjuvant 
radiotherapy: 
“…it is helpful to discuss T3a cases – for guys with tiny volume 
extracapsular extension we don’t need to clog up the radiation oncology 
clinic for discussion if we discuss the patient at the MDT and the radiation 
oncologist says they don’t need to see them.” [PU – Site 7] 
Three quarters of urologist participants (15 of 20; 75%) did not consider that 
the trial had affected MDT decision-making. Four of these noted that although 
the MDT recommendations for patient management had not changed more 
cases were being discussed as a result of flagging: 
“No we haven’t changed – we have discussed more cases earlier than we 
normally would but we haven’t changed what the decision would be.” [PU 
– Site 7] 
Three others felt that MDT decision-making had not changed because they 
perceived all high-risk patients were already being discussed by the MDT prior 
to the implementation of patient flagging through CLICC. It was noted, 
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however, that individuals had no way of knowing whether their colleagues put 
all patients to the MDT: 
“Probably not because we were doing this before CLICC. I always put all 
my cases to the MDT – I am a stickler for it but I have no way of knowing 
if more cases are coming up from the others.” [PU – Site 6] 
“Of course, it may only be a perception that all cases were presented prior 
to CLICC – will be very useful to see before and after data.” [CL – Site 9] 
A group of three participant urologists reported that prior to CLICC they would 
generally not discuss high-risk patients at the MDT but would instead refer 
directly to a radiation oncologist for discussion of adjuvant radiotherapy: 
“… to me, a lot of the decision should not be made in the MDT but in the 
consulting rooms with the patient and the radiation oncologist – the 
radiation oncologist needs to see the patient to know if it is appropriate. 
They should not decide on radiotherapy without seeing the patient.” [PU – 
Site 8] 
One urologist participant (Site 7) was uncertain whether there had been a 
change in MDT decision-making but noted that he ‘hoped so’.   
Effect(s) of the intervention on relationships with colleagues 
The majority (23 of 28; 82%) did not perceive that CLICC had affected 
relationships with their colleagues. Predominantly these relationships were 
inferred to be with radiation oncology colleagues: 
“I don’t think the CLICC study has changed what is otherwise a very 
positive interaction. It’s frequent; we all collaborate and are very 
respectful of each other. The personalities of the radiotherapists and 
pathologists and oncologists that turn up are collaborative. All keen to 
make sure patients get the best care. It is not uncommon for treatment 
plans to be changed at the MDT due to agreed protocols (from surgery to 
RT or vice versa) but I appreciate it being measured and to get the 
feedback.” [CL – Site 9] 
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 “I don’t think so – we’ve had an excellent MDT for a long time and a good 
relationship with our radiation oncology colleagues. We were putting 
[patients] on RAVES long before CLICC…” [PU – Site 6] 
“Not really, people get on well with the radiation oncologist.” {PU – Site 7] 
Four participants (14%) considered that CLICC had positively affected 
relationships with colleagues, particularly with the radiation oncologists (n=3).  
“It has brought us together again. Before we had drifted apart. Many 
more patients are discussed and the radiation oncologists are seeing more 
people.” [CL – Site 8] 
“Yes – relationships are better. It has facilitated discussion.” [PU – Site 3] 
One participant reflected that CLICC had negatively affected relationships with 
colleagues: 
“It was annoying that my data were open and would be discussed at the 
MDT but colleagues were not prepared to present their own data.” [PU – 
Site 2] 
Concerns regarding the implementation of the intervention or unintended 
outcomes  
There were few concerns regarding implementation of the intervention. One 
participant (Site 3) noted that his high caseload meant there was not enough 
time to discuss all flagged patients. Another participant from the same site 
corroborated this view.  
One participant (Site 4) maintained the “impression that you were looking for 
something that was not discussed.”    
Two participants had concerns related to unwillingness of some 
urologists/MDTs to participate: 
“Disappointed that externally the lack of enthusiasm for audit reduced 
participation.” {CL – Site 8] 
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“It was annoying that as a small regional hospital we participated and 
some major city hospitals felt they did not need to and were not willing to 
have their practice looked at.” {PU – Site 5] 
There were no concerns about unintended outcomes. One participant (Site 1) 
noted as a positive outcome that the quality of public pathology reporting had 
improved due to the influence of the private pathology model, which he 
considered to be “disseminating into the general pathological community” as 
a result of MDT flagging. 
Perceptions of the extent to which the intervention resulted in change in 
practice and any wider changes in patterns of care 
Only one of the nine Clinical Leaders perceived that discussion of cases at the 
MDT meeting had changed their own referral patterns or those of colleagues: 
“More patients are being discussed and referred definitely. The radiation 
oncologists are very positive about the changes.” {CL – Site 8] 
The other eight Clinical Leaders (89%) felt discussion at the MDT had not 
resulted in change in referral patterns - either because referral was already 
happening or because colleagues remained unwilling to change practice: 
“No change in referral patterns – the MDT was saying the same thing 
we’ve been doing anyway, Our patients are offered observation or early 
adjuvant radiotherapy already then the radiation oncologist will mention 
RAVES if they decide to go for a consultation.” {CL – Site 4] 
“I think it stayed fairly much the same. Some of the group never referred 
unless the PSA rose so from that group you may sometimes get 
particularly high-risk cases being referred following discussion. It maybe 
changed that but otherwise no.” {CL – Site 1] 
“I tend to refer but some of the others for people with questionable 
extracapsular extension with low grade tumour at the margin or who 
have had a nerve sparing prostatectomy the don’t say so but they tend to 
wait – they are running their own mini RAVES trial. I’m not sure they will 
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change for those patients but for those with higher risk an increase in 
referral will be a good thing.” [CL – Site 7] 
The collective group of Clinical Leaders and participating urologists were 
divided in their opinions as to whether that had been any wider changes in 
patterns of care for men with locally advanced prostate cancer. More than 
half (15 of 27; 56%) maintained there had been no change. Of those that 
considered there had been wider changes (12 of 27; 44%) these were 
suggested to involve: 
1. Increased discussion with patients about the potential need for, and 
benefits of adjuvant radiotherapy, in consultation with the urologist 
(n=3) or through referral to radiation oncology (n=5) 
2. A tendency toward more aggressive treatment of prostate cancer (n=1) 
3. An increase in the use of robotic surgery (n=1) 
4. Improvements in surgical outcomes and targeted radiotherapy 
techniques (n=1) 
5. Declining use of adjuvant radiotherapy due to complications (n=1) 
Contributions of CLICC to patient care  
The perceived contributions of CLICC to patient care fell into five categories: 
1. Increased discussion of patients with high-risk features at the MDT (8 
of 27; 30%) 
“Enabling those patients who may benefit from adjuvant therapies to be 
identified and discussed on a routine basis.” [PU – Site 3] 
“For high-risk men we all accept they need multi-modal treatment. The 
MDT discussion has developed better understanding about timing and 
appropriate use of adjuvant radiotherapy.” [CL – Site 8] 
2. Increased discussion between urologists and patients about the 
potential need for further adjuvant treatment (6 of 27; 22%) 
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“We have seen patients who were treated elsewhere who have not had 
optimum treatment and haven’t had a discussion about radiotherapy – 
adjuvant or even salvage. Increasing that discussion is important.” {CL – 
Site 5] 
3. Audit of clinical practice to highlight differential patient outcomes and 
referral patterns between urologists and across institutions and the 
potential to use this data to drive change (6 of 27; 22%) 
“The most important thing is measurement against desirable patterns of 
care – you can’t manage what you can’t measure so the ability to 
provide us with data which drives patters of care is the main 
contribution CLICC has made and it’s reassuring to know we’re going the 
right way and out practice is good. It’s a matter of influencing overall 
quality of care across NSW that will be the big contribution.” [CL – Site 
9] 
“Audit results are good to show the outcomes achieved by different 
surgeons – it allows a patient to select a surgeon with a full 
understanding of their performance.”  {PU – Site 7] 
4. Increased patient referral to radiation oncology for discussion of 
adjuvant radiotherapy (4 of 27; 15%) 
“Exactly what the objective of the study is – to make sure all patients get 
referral in a timely fashion either before treatment or refer early. Don’t 
leave the radiation oncologist out of the picture.” [PU – Site 8] 
5. Increased urologist awareness that adjuvant radiotherapy should be 
considered as a treatment option for men with high-risk features 
following radical prostatectomy (3 of 27; 11%) 
“Raising urologists awareness that adjuvant radiotherapy should be 
considered.” [PU – Site 4] 
“To shed light on the issue. The study should be followed through and 
set the standard for care.” [PU – Site 6] 
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Benefits for participants 
The perceived benefits of CLICC for participants largely overlapped with 
contributions to patient care. 
Ten of the 27 interviewees (37%) noted the provision of audit data as the 
main benefit of participation both as a means to understand their own 
practice and as a mechanism to identify inappropriate practice: 
“The audit process is a very useful tool to show the percentage of high-risk 
men in different institutions – the presentation of results as proportions 
was very informative. Audit should be used to flag inappropriate surgery – 
if urologists have high percentages of cases with high-risk features then 
they shouldn’t be operating on those patients.” [PU – Site 7] 
“There is benefit in terms of measurement of high-risk parameters. It is 
nice to know what our overall margin rate is and whether we are 
operating on more high or low risk disease – so data has been very 
welcome and the reflection on patterns of care we currently have is 
important.” [CL – Site 9] 
 “The main message that came from this study is that pressure should be 
applied for all urologists to meet standards and be looked at by an 
outsider. We need to bring the recalcitrant into line and those who are not 
meeting the standard, their practice should be looked at.” [PU – Site 5] 
A third of interviewees (9 of 27; 33%) noted that increased discussion of all 
potential treatment options was the main benefit to participation, be that at 
the MDT or in consultation with the patient: 
“Because of the number of surgeries we always rationed the number of 
people discussed but we are developing systems to discuss more people, 
highlight the complex cases and deal with routine cases. In general, 
adherence to guidelines is a good thing and prior to CLICC and the MDT 
flagging there was very poor adherence to the adjuvant radiotherapy 
guideline.” [CL – Site 8] 
“The fact that it’s discussed at an open forum, that there is a benchmark 
of what is considered to be the best treatment. In our institute that is 
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largely covered by our attachment to RAVES. Within the MDT we can’t 
capture everybody but by providing the list the importance of following 
accepted evidence-based practice is being discussed.” [CL – Site 7] 
“I think no one knows what is the right answer in terms of treatment and 
there is variability in recommendations for care and what patients decide 
they want to have. Getting information will be helpful both for discussion 
of treatment options at the MDT then conveying that recommendation as 
discussed to patients.” [PU – Site 9] 
Six participants (22%) noted that CLICC would benefit participants by 
providing them with evidence. This evidence related to: 
1. The efficacy of the MDT:  
“…Whether the MDT makes a difference to the way we treat a patient 
and may also succeed in demonstrating that protocol driven referral to a 
MDT works.” [CL – Site 4] 
“Myself and other surgical colleagues are starting to question what 
difference the MDT makes in a well functioning centre if there are good 
relationships… where is the evidence that it makes a difference to patient 
outcomes.” [PU – Site 6]  
2. Whether embedding evidence-based care, specifically following the 
recommendation for adjuvant radiotherapy, will lead to improved 
patient outcomes: 
“I think getting more information on whether there is any solid evidence 
that high-risk patients benefit from early treatment over monitoring and 
early salvage.” [PU – Site 9] 
 “Whether or not patients are referred for a radiation oncology consult 
and whether they benefit from the adjuvant versus salvage radiotherapy 
opinion.”  [PU – Site 3] 
Two interviewees (7%) noted that they had benefited from the provision of 
support to ensure best practice in a time poor environment: 
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“…People are busy and doing their own thing – it’s good to have the 
nudging to remind you about best practice.” [PU – Site 5] 
“Acknowledgement of what urologists need – education and some 
logistical support such as setting up the mechanism by which those 
patients are automatically flagged.” [PU – Site 8] 
The final interviewee perceived that increased awareness of the potential 
need for adjuvant radiotherapy within the urological community was the main 
benefit of participating in the study. 
Context 
Factors that hindered or facilitated the role Clinical Leader 
The majority (7 of 9) reported no factors that hindered their role as Clinical 
Leader. One noted that colleague’s “paranoia” hindered participation of 
urologists at that site (Site 2). Another (Site 4) noted: 
“The main difficulties have been getting everyone together in one place at 
one time including for presentation of feedback reports.” [CL – Site 4] 
 
 
Two Clinical Leaders cited the receptiveness or reasonableness of colleagues 
as a facilitator.  
Two Clinical Leaders noted that support from the research team facilitated 
their role: 
“…Calls and emails and follow up were excellent. As a clinician, that level 
of reminder is needed as studies are low on priority so without reminders 
and follow-up it wouldn’t happen.” [CL – Site 5] 
Interaction with colleagues  
All Clinical Leaders perceived that they were able to interact with colleagues 
where necessary. Three noted that colleagues were “happy”, “already on 
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side” and “ultimately realised the importance of these sorts of studies” so they 
did not need to do much to fulfill their role in CLICC. 
 
Two Clinical Leaders (Sites 1 and 4) expressed that they did not perceive it as 
their role to influence colleagues or offer support to change practice: 
“Didn’t see my role was to tell my colleagues to follow the guideline and I 
didn’t do it.” [CL – Site 1] 
Contextual factors that hindered or facilitated the implementation of the 
project  
MDT coordinators and pathologists were considered by Clinical Leaders to be 
critical to the success of the study. Across all four sites where the Clinical 
Leaders noted issues with implementation of the MDT flagging process these 
related to resourcing for public pathology services (Sites 1, 5, 6 and 7). In 
addition, the lack of a dedicated MDT coordinator (Site 3) and lack of a 
secretarial facility to support the MDT (Site 7) resulted in inconsistent record 
keeping of the MDT recommendation for care.  
“The study demonstrates the variety in MDT structure as a tool for 
management of cancer patients. There is not enough regulation or 
impetus to get people to do it properly. Cancer Institute NSW provides 
funding but guidelines for MDT functioning are very vague. Funding 
should come with KPIs for administration and reporting etc.” {CL – Site 8} 
Conditions critical to the project’s success/lack of success 
Conditions considered necessary for the successful implementation of CLICC: 
were: 
1. Commitment and willingness of clinicians to participate (n=6) 
2. Existence of a well-functioning MDT through which to implement the 
flagging process and discuss patients with high-risk disease (n=5)  
3. The influence of the Clinical Leader or other champions (notably the 
radiation oncologist) in persuading people to participate (n=3) 
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4. Facilitation of the CLICC study team coupled with intervention 
elements that required minimal time commitment from participants 
(n=3) 
The predominant reason for perceived lack of success was disagreement with 
the clinical practice guideline recommendation and lack of clarity about which 
patients will benefit from adjuvant radiotherapy (n=8): 
“Whether the clinicians are convinced that hig- risk patients need certain 
interventions. The jury is still out about adjuvant radiotherapy so the 
result of the RAVES trial will be critical to the success of this study. The big 
confounder is not knowing the result of the RAVES trial.” [CL – Site 4] 
“In spite of all the best efforts there is still an underlying uncertainty 
about the benefit of immediate adjuvant radiotherapy rather than early 
salvage. RAVES is struggling and most surgeons have an uncertainty 
about risk benefit analysis. The CLICC study really brought it to a head but 
showed there are some men who benefit from early rather than late 
radiotherapy. Surgeons are getting better but we all know it’s the grade 
and stage of the cancer that matters.” [PU – Site 4] 
“The difference is around margin status – a patient with negative margins 
won’t get radiotherapy whoever you refer them to, and shouldn’t.” [PU – 
Site 4]  
Poor participation was noted as the reason for lack of success by both 
interviewees from Site 2 and was considered to be a reflection of general 
unwillingness to change practice or have current practice audited. 
Perception of the supportiveness of, and interaction with, the Clinical Leader 
Participating urologists from eight of the nine sites generally felt that the 
Clinical Leader was supportive of the study.   
 
Interviewees from six sites (Sites 3, 4 and 6-9) communicated that the Clinical 
Leader initiated regular discussion about CLICC at the MDT or in shared 
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consulting rooms. Notably all participating urologist interviewees at Site 7 
elaborated on the supportiveness of their Clinical Leader: 
“Yes – he was supportive and we had an adequate amount of interaction. 
We all spoke about the study at the MDT every time we received the 
individual and group feedback.” [PU – Site 7] 
“I share rooms with [Clinical Leader] so we spoke about the study a lot.” 
[PU – Site 7] 
“Yes. He’s been fantastic. We work in the same rooms.” [PU – Site 7]  
At Site 5 two of three interviewees noted that while the Clinical Leader was 
supportive they had not had much interaction with him about CLICC: 
“Yes he was supportive. There was not a lot of interaction with [Clinical 
Leader] but that’s normal as he has a lot on so don’t take it negatively.” 
[PU – Site 5] 
“Not a lot of interaction but he was supportive.” [PU – Site 5] 
At Site 3, none of the three interviewees felt they had sufficient interaction 
with the Clinical Leader about CLICC. One interviewee commented that the 
Clinical Leader was “moderately supportive”, one declined to comment 
claiming no direct interaction with him about CLICC but noting that the 
“feedback report sometimes got discussed in a group setting’. The third did 
not feel that the Clinical Leader was supportive of CLICC.  
 
Sustainability 
Continuation of CLICC elements 
All CLICC materials including: the CLICC introductory video; the CLICC printed 
resource; and feedback report templates were made available to participants 
via a DropBox folder for continued use. 
Clinical Leaders at six of the nine sites (Sites 4 – 9) reported that their 
colleagues had collectively decided flagging of patients for discussion at the 
  183 
MDT would continue beyond the end of the active intervention phase of 
CLICC.   
At one site (Site 3) a decision about continuation had not been made but the 
Clinical Leader indicated he was supportive if the department was favourable.  
At Site 2 where the Clinical Leader reported MDT flagging would not continue 
(but acknowledged that it “never really happened”) the process was adapted 
such that patients were not listed for discussion by the MDT coordinator as 
per the study protocol but were only added to an agenda at the request of the 
urologists. The public pathologist at that site additionally noted that flagged 
cases were not routinely brought to the MDT. 
At the remaining site (Site 1) the Clinical Leader commented: 
“Certainly in my own practice I would always discuss high-risk patients 
anyway and send them to [the radiation oncologist] for a chat but I 
probably won’t formally continue flagging.” [CL – Site 1] 
The other interviewee from the same site felt that discussion of all high-risk 
patients was largely adhered to before the study and would likely continue 
beyond it: 
“I think in many respects we had that process in track anyway with the MDT 
so anyone with high-risk disease would be discussed. We have a robust, 
frequent MDT so by and large it will continue.” [PU – Site 1] 
 
6.5 Discussion 
CLICC intervention elements were implemented with fidelity across the nine 
participating MDTs. All Clinical Leaders and participating urologists met the 
minimum requirement for exposure to: opinion leaders; the CLICC 
introductory video; printed educational materials; audit feedback reports; and 
flagging of eligible patients by pathology for discussion at multidisciplinary 
team meetings. Following implementation of the MDT flagging process, three 
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sites (Sites 2, 3 and 8) adapted the process by which flagged patients were 
added to a meeting agenda for discussion to suit local needs or preferences.  
Participation was high across eight of nine CLICC sites with all eligible 
urologists participating from five MDTs (Sites 1, 4, 5, 6 and 8). More than 
three quarters (76%) of eligible urologists participated overall. Site 2 
experienced low participation with the majority (nine of 11; 82%) declining or 
withdrawing consent. The Clinical Leader and the one other participating 
urologist at Site 2 considered poor participation due to lack of willingness to 
change practice and reluctance to provide access to medical records for 
review of current practice. The implementation of CLICC negatively affected 
relationships between participants and non-participants at Site 2, with the 
former annoyed by the latter’s ‘paranoia’ and lack of transparency. 
Interviewees also commented on non-participation of colleagues at Site 7 and 
Site 9, which was unanimously perceived as ‘lack of enthusiasm for the audit 
component’ and unwillingness to contribute patient outcome data through 
medical record review. Interviewees considered these the same reasons for 
non-participation of the two eligible MDTs that declined. 
 
Response to the CLICC implementation trial was varied. All nine Clinical 
Leaders and the majority of participating urologists (18 of 20; 90%) felt 
adequately informed about what the study was hoping to achieve. There was 
variability in participants’ perceptions of whether the study was successful 
both within and across study sites. Implementation of the MDT flagging 
process was considered the main success and was perceived to have 
increased discussion of eligible patients by more than half the interviewees 
(secondary outcome data are reported in Chapter Seven). MDT record review 
demonstrated that pathologists were able to flag 78% of eligible patients for 
discussion overall, with 85% of private patients and 49% of public patients 
flagged. Of those flagged, 68% of private patients and 79% of public patients 
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were discussed at the MDT. However, there was uncertainty as to whether 
increased MDT discussion would translate into increased referral of patients 
to radiation oncology for discussion of adjuvant radiotherapy (primary 
outcome data are presented in Chapter Seven). Flagging of cases by pathology 
for discussion at the MDT was attributed to be the most helpful intervention 
component in achieving practice change being mentioned by nearly three 
quarters of interviewees. The automatic nature of the flagging system, which 
ensured all patients were listed without action on the part of the Clinical 
Leader or participating urologist, was frequently noted as beneficial in 
reducing the burden on time poor clinicians, especially in CLICC sites with high 
patient volume. This would suggest that the hypothesised enabling factors 
within the CLICC conceptual program logic model, which addressed systems 
and processes and cultural barriers, were the most essential element in 
achieving desired practice change in the current context. Only two 
interviewees articulated that they did not find the MDT flagging process useful 
due to the timing of discussion immediately after surgery. One of these was 
from Site 2 where the flagging process deviated from the study protocol after 
implementation such that patients were added to the MDT agenda at the 
discretion of the urologist rather than the MDT coordinator, which did not 
represent a change from routine practice. The other interviewee that did not 
initially find the MDT flagging process helpful was from Site 8 where a 
collaborative decision was made by the MDT to adapt the process such that 
patients were added to the MDT agenda two months after surgery so the 6-
week post-operative PSA and continence status was known at the time of 
discussion. 
Nearly half considered audit feedback reports to be a helpful intervention 
component both on a personal level to monitor their own practice and as a 
means make comparisons with other institutions and the provision of audit 
data was considered the main benefit of participation in the trial. There was a 
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competitive reaction to feedback and the majority perceived their own results 
and those of colleagues within their MDT to indicate that they were 
performing well in comparison with others in terms of clinical indicators such 
as surgical margins or other high-risk features. As one interviewee noted, “it’s 
reassuring to know we’re going the right way and our practice is good.” [CL - 
Site 9]. Within the CLICC conceptual logic model, feedback reports were 
hypothesised to be a mechanism to reinforce desired behaviours (increased 
referral to radiation oncology for discussion of adjuvant radiotherapy) but 
participants placed more emphasis on clinical indicators than behavioural 
indicators in response to feedback and only one participant noted that his 
colleagues were “surprised by their low referral rates” [CL – Site 7]. Only one 
Clinical Leader perceived his role as one of a true opinion leader to reinforce 
desired behaviours and “constantly remind the urologists that men with 
unfavourable histological results from surgery should at least have the 
discussion and be considered for radiotherapy...” This would suggest that the 
reinforcing elements of CLICC might not have functioned as intended in 
relation to the primary outcome, defined a priori as patient referral within 4 
months after prostatectomy to either radiation oncology or to the RAVES trial. 
There was necessarily a delay in the presentation of feedback on the primary 
outcome given the need to wait more than 4 months after surgery to 
determine whether a referral had been made within the specified time frame. 
This meant that Sites 6, 7 and 8, the latest to enter the trial, did not receive 
the third feedback report, which provided individual, site and aggregate study 
level pre- and post-intervention outcome data. There was, therefore, no 
opportunity for participants at those sites to determine if their referral 
practice had changed or how any potential change compared with that of 
other sites.  
In view of participant response to the study and the perception of the 
importance of integration of the MDT flagging process as a measure of 
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success, a secondary outcome was added to the protocol during the trial but 
prior to any analysis, namely discussion of the patient at an MDT meeting 
within 4 months after prostatectomy. Data on the number of patients flagged 
and the proportion of those patients subsequently discussed at an MDT 
meeting was collected in real time meaning participants at all sites received at 
least one feedback report including individual, site and aggregate study level 
MDT discussion data following the implementation of the flagging process. 
This meant discussion rates could be directly compared with other sites and 
there was an opportunity to improve before the next quarterly feedback 
cycle. Results from participant interviews suggest that Clinical Leaders, 
through the presentation and discussion of feedback reports, may have 
served to reinforce this secondary outcome of discussion at the MDT rather 
than the primary outcome of referral. As one Clinical Leader noted “I told 
them to up their game so we would be better than everywhere else.” [CL – Site 
6]. Of note, this site (Site 6) had the highest rate of participation (100%) and 
response (100% of flagged cases discussed) highlighting the potential of the 
Clinical Leader to reinforce desired behaviours if they actively champion them.   
 
The most frequently cited reason for potential lack of success in achieving an 
increase in the primary outcome of referral to radiation oncology was 
continued disagreement with the clinical practice guideline recommendation 
for adjuvant radiotherapy and lack of clarity about which patients will benefit. 
This suggests that the predisposing CLICC elements (CLICC video; CLICC printed 
resource and other printed materials) may have been ineffective in addressing 
clinician level barriers associated with knowledge, attitudes and perceptions 
for some participants who noted, for example, that ‘this information has been 
around for a while but there are problems with the results…’ Knowledge and 
attitudinal outcomes are presented in Chapter Eight.  
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The ongoing RAVES trial, hypothesised a priori as a contributor to persisting 
norms as a clinician level barrier, was noted as a confounder by a number of 
interviewees who considered that the trial supports their view that there is 
insufficient evidence in favour of adjuvant radiotherapy over early salvage 
radiotherapy. These participants used lack of definitive results from the 
ongoing RAVES trial as justification for non-referral for consideration of 
immediate adjuvant radiotherapy and this position was not successfully 
redressed by the CLICC predisposing elements. 
A number of contextual factors adversely affected the implementation of 
CLICC elements. The most prominent of these was insufficient resourcing to 
support flagging of patients through public pathology services. This meant less 
than half of eligible public patients were flagged for discussion overall and no 
public patients were flagged at Sites 6, 7 or 8. Only two sites were able to 
achieve similar rates of public patients flagged as private patients. Both of 
these sites had higher public patient volume and had a lead pathologist that 
took responsibility for flagging and reporting on public patients at the MDT. 
Private pathology flagging was inconsistent across sites that did not 
exclusively use the predominant pathology provider and this suggests that 
centralised services are necessary for the successful implementation of these 
types of new systems and processes. The majority of sites integrated the 
flagging process into routine practice with a high proportion of flagged 
patients added to the MDT agenda for discussion. Site 3 was an outlier with 
only one third of flagged patients discussed at the MDT. High patient volume, 
insufficient logistical planning for implementation of the flagging process and 
lack of support from the Clinical Leader were all identified as issues at this 
site. In addition, this was the only site that did not have a designated MDT 
coordinator.   
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The MDT flagging process was the most sustainable CLICC element and was in 
continuation at six of the nine sites at the time of writing.  The provision of 
support for implementation was noted as a key facilitator in conjunction with 
the automatic nature of the process, requiring no action on the part of the 
urologist. Adequate resourcing for pathology services and MDT coordination 
will be necessary for sustainability of the flagging process in the long term. 
Many participants considered provision of audit feedback data beneficial, 
however, medical record review was time and labour intensive and found to 
be intrusive or inappropriate by some participants. The establishment of the 
NSW Prostate Cancer Registry may facilitate ongoing provision of feedback.  
The process evaluation of the CLICC trial demonstrates that CLICC elements 
could be implemented as they were designed. Within the CLICC conceptual 
program logic model, the hypothesised enabling factor, namely flagging of 
eligible cases by the pathologist to the MDT coordinator for discussion at the 
MDT, was considered by participants to be the most essential and sustainable 
element in achieving desired practice change and was integrated and adopted 
into routine practice at the end of the trial at a number of sites.  Analyses 
reporting whether there was significant change in the secondary outcome, 
discussion of the patient at an MDT meeting within 4 months after 
prostatectomy, and whether discussion translated into change in the primary 
outcome of patient referral within 4 months after prostatectomy to either 
radiation oncology or to the RAVES trial are presented in Chapter Seven.
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Chapter 7: Changes in provider behaviour  
 
7.1 Introduction 
This chapter presents results of Phase I of the CLICC implementation trial (1) in 
relation to the effects of the CLICC intervention on provider behaviour, specifically 
referral to radiation oncology and discussion of patients at a MDT meeting. 
Knowledge and attitudinal outcomes measured in Phase II are reported in Chapter 
Eight. 
7.2 Methods 
7.2.1 Study Design 
The CLICC implementation trial used a stepped wedge cluster randomised design. 
Participating MDTs crossed over from the control phase to the intervention phase at 
different time points throughout the study period across nine randomisation steps 
(Figure 7.1). The stepped wedge design increases statistical power compared with a 
parallel-group design (2, 3) because the intervention effect is estimated through both 
between-hospital and within-hospital comparisons. The order in which MDTs entered 
the intervention phase was determined randomly using a computer generated 
random number sequence. The intervention was rolled out during nine separate 
regularly scheduled MDT meetings between 13 December 2013 and 27 August 2014.  
7.2.3 Study participants 
Hospital sample 
All NSW hospitals that met the inclusion criteria of having: (i) a urological MDT; and 
(ii) a member(s) of the ACI Urology Network. Through the involvement of Network 
members the MDT represented the local Network node at each hospital.   
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Urologist sample 
Urologist who were eligible for inclusion were members of a participating MDT, who: 
(i) performed radical prostatectomy during the control or intervention phase; and (ii) 
reviewed their high-risk prostate cancer cases (post-radical prostatectomy) at the 
participating MDT at the time the intervention commenced at that site. The latter 
two eligibility criteria were specified after publication of the study protocol (1) to 
enable exclusion of urologists who: (i) did not perform any radical prostatectomies 
during the study period and, therefore, would not contribute any clinical data; and 
(ii) are members of a participating MDT for the purposes of other urological 
conditions but present radical prostatectomy patients for review at a different non-
participating MDT.  
Figure 7.1: Timing of the intervention rollout in relation to date of prostatectomy  
 
 
7.2.4 Data collection methods  
Data were extracted from clinical records for all patients who underwent radical 
prostatectomy by a participating urologist between 3 January 2013 and 31 March 
2015, and who were subsequently found to have one or more of three pre-specified 
adverse features (extracapsular extension, seminal vesicle invasion or positive 
surgical margins) upon pathological examination of the prostate specimen. Clinical 
data for included patients were obtained from a review of medical records for a 
minimum of 6 months after their prostatectomy. 
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Data extraction from patient’s medical records 
Information was collected through data extraction from urologists’ and radiotherapy 
patients’ medical records by independent, trained research assistants who were 
blind to the date that the intervention commenced at the hospital. Pre-intervention 
period data were collected retrospectively for patients who underwent radical 
prostatectomy between 1 January 2013 and the end of the month preceding cross 
over from the control to intervention phase.  
Information from medical records 
Data collected through medical record review were: referral to radiotherapy, taken 
from the urologist’s notes (including dates of surgery and referral) or the recorded 
reasons for not referring; uptake of radiotherapy and the date of commencement; 
enrolment into the RAVES trial from the radiation oncology database; and whether 
the patient was referred to a MDT meeting, date of the meeting and the MDT 
recommendation.  
Data were extracted from medical records at hospitals, cancer centres and 
urologists’ private consulting rooms using previously established methods.(4) MDT 
data obtained from medical records on whether the patient was referred to a MDT, 
date of the meeting and the MDT recommendation were supplemented with data 
extracted from MDT administrative records to increase accuracy and completeness.  
Patient level factors were collected from medical and hospital records including: 
month, year and country of birth, comorbidities, post-operative Gleason score, PSA 
level at diagnosis, maximum PSA level within four months of radical prostatectomy 
and private health insurance status (data collection forms are provided in Appendix 
XI). These patient level factors were considered to be potential barriers to referral to 
radiation oncology for consideration of radiotherapy. 
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7.2.5 Outcomes 
The primary outcome was defined a-priori as patient referral within 4 months after 
prostatectomy to either radiation oncology or to the RAVES trial.(1) The RAVES trial 
was designed to compare survival and quality of life outcomes for Australasian 
patients through randomisation to either salvage radiotherapy if and when a rise in 
Prostate Specific Antigen (PSA) is detected or immediate adjuvant radiotherapy. 
Referral to the RAVES trial was included as a primary outcome because the CLICC 
intervention could result in increased referral to radiation oncology for consideration 
of enrolment in the trial rather than for consideration of immediate adjuvant 
radiotherapy at sites actively recruiting to RAVES.  
 
Secondary outcomes were: an initial patient consultation with a radiation oncologist; 
enrolment in the RAVES trial; and commencement of radiotherapy. Each of the 
secondary outcomes was measured at 6 months after prostatectomy. Enrolment in 
the RAVES trial could not be measured due to insufficient data (date of enrolment in 
RAVES was documented in medical records for only 11 patients). An additional 
secondary outcome was added to the protocol during the trial but prior to any 
analysis: discussion of the patient at a MDT meeting within 4 months after 
prostatectomy.  
7.2.6 Statistical methods 
Data were systematically checked for errors and cleaned where appropriate. Patients 
were defined to be in the intervention group if their prostatectomy was performed 
after the introductory CLICC intervention session at the MDT to which the urologist 
belonged. Patients were defined to be in the control group if their prostatectomy 
was performed 4 months or more before the introductory CLICC intervention 
session. Those who underwent prostatectomy between the date of the introductory 
CLICC intervention session and 4 months prior were in the transition group (Figure 
7.1). This latter group was formed because some patients could potentially benefit 
from the intervention while others could be referred or discussed before the 
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intervention date and thus received no such benefit. Results relating to the transition 
group are reported for completeness but are of marginal importance to the main 
study hypothesis. Moreover, the transition group was included in all regression 
analyses because the additional sample size increases the reliability of confounder 
effect estimates, which in turn increases the reliability of intervention effect 
estimates. 
Generalised linear regression models with a Poisson distribution and log link, and 
generalised estimating equation (GEE) adjustment for the clustering of patients 
within urologists were used to estimate the relative proportions (RR) of patients 
who, within 4 months after prostatectomy, were: (1) referred to a radiation 
oncologist or to the RAVES trial; and (2) discussed at a MDT meeting. The same 
methods were used to estimate the relative proportions (RR) of patients who, within 
6 months after prostatectomy, had a consultation with a radiation oncologist and/or 
who commenced radiotherapy (with patients who were referred to RAVES excluded 
from these analyses because their patterns of care are dependent on the RAVES 
study protocol). The dichotomous dependent variable in each regression model was 
one of the defined outcomes mentioned above. Independent variables were study 
group (control, transition, intervention), age at prostatectomy (40-59, 60-69, 70+), 
extracapsular extension (No, Yes, Unsure), positive surgical margin (No, Yes, Unsure), 
seminal vesicle invasion (No, Yes, Unsure), regional lymph node involvement (No, 
Yes, Unsure), post-operative Gleason score (6-7, 8, 9-10, Unsure), maximum PSA 
level within 4 months after RP (<0.1 ng/ml, ≥ 0.1ng/ml, no PSA test recorded) 
number of co-morbidities (0, 1, 2+) and Site. The results for individual sites are de-
identified to maintain confidentiality. Exchangeable working correlation structures 
and robust standard errors were used in all models.  
Interaction terms were added where appropriate to assess potential modifiers of the 
effects of the intervention. In addition, a number of sensitivity analyses were also 
performed for the 2 outcomes “referred to a radiation oncologist or to the RAVES 
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trial” and “discussed at a MDT meeting”: (1) Excluding patients who were referred to 
radiation oncologist before radical prostatectomy; (2) Excluding patients whose 
urologist recorded the reason as salvage therapy, or no reason was recorded but 
they had a PSA level >0.1 (ng/ml) within 4 months after radical prostatectomy; (3) 
Excluding patients who were deemed to be lost to follow-up as they did not have at 
least one follow-up consultation with their urologist within 4 months after their 
radical prostatectomy; (4) Fitting minimally adjusted regression models to the data, 
adjusting only for study group, date of surgery, age at prostatectomy, and site with 
urologist again defined as the clustering variable; (5) Excluding patients of the 
urologist with the highest case-load comprising 13.9% of all radical prostatectomies 
in the study; (6) Excluding patients from the site with the highest case-load 
comprising 21.2% of all radical prostatectomies in the study; (7) Using linear mixed 
models with random effect terms for site and urologists nested within sites; (8) The 
two outcomes of referred and discussed were assessed at 6 months rather than 4 
months. 
Previously we have reported that our stepped wedge study design will have at least 
80% power to detect an increase in referral to a radiation oncologist from 15% to 
35%, or 20% to 40% if approximately 400 high-risk patients contributed data to the 
study (with roughly half allocated to the control and intervention groups 
respectively), and from 20% to 35% if approximately 670 high-risk patients 
contributed data to the study (1).  
 
7.3 Results  
Eleven NSW hospitals met the inclusion criteria. The urological MDTs from two of 
these declined to participate resulting in a total sample of nine sites. From these nine 
sites 55 urologists were invited to participate in the trial. Eight declined, six were 
ineligible as they performed no radical prostatectomies during the specified study 
period, and four withdrew consent, resulting in a total of 37 participants. The 37 
participating urologists operated on 1087 high-risk patients during the study (Figure 
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7.2). Of these, 1071 had sufficient clinical information to be included in one or more 
analyses comprising 505, 159 and 407 patients in the control, transition and 
intervention groups respectively. 
Figure 7.2: Participant flow diagram 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Clinical records reviewed for 1,087 high-risk 
patients who underwent RPs from 37 urologists 
between January 2013 and March 2015  
 
513 patients allocated 
control group 
 
8 declined 
6 ineligible- no RPs  
4 withdrew consent 
 
161 patients allocated 
transition group 
 
413 patients allocated 
intervention group 
 
505 control patients 
included in one or 
more analyses 
 
8 patients excluded; 
insufficient data to 
assess one or more 
outcomes 
 
2 patients excluded; 
insufficient data to 
assess one or more 
outcomes 
 
6 patients excluded; 
insufficient data to 
assess one or more 
outcomes 
 
159 transition patients 
included in one or 
more analyses 
 
407 intervention 
patients included in 
one or more analyses 
 
1,071 high-risk prostatectomy 
patients included in one or more 
analyses 
55 urologists from 9 
hospitals/MDTs invited to 
participate in CLICC  
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Table 7.1: Patient characteristics by study group 
  Study group       
 
Control  Transition Intervention TOTAL: 
 
 
Characteristic n (%) n (%) n (%) N (%)   p-value^ 
All patients: 505 (100%) 159 (100%) 407 (100%) 1071 (100%) 
  Age  
        Median (years) 65.0 65.0 65.0 65.0 
    Quartiles (years) 59-68 58-69 61-69 60-69 
    Age group 
      40-59 128 (25%) 43 (27%) 81 (20%) 252 (24%) 
 
0.145 
60-69 284 (56%) 84 (53%) 231 (57%) 599 (56%) 
  70+ 93 (18%) 32 (20%) 95 (23%) 220 (21%) 
  Extracapsular extension 
      No 96 (19%) 27 (17%) 69 (17%) 192 (18%) 
 
0.511 
Yes 406 (80%) 131 (82%) 338 (83%) 875 (82%) 
  Unsure 3 (1%) 1 (1%) 0 (0%) 4 (0%) 
  Positive surgical margin 
      No 229 (45%) 69 (43%) 198 (49%) 496 (46%) 
 
0.087 
Yes 276 (55%) 89 (56%) 204 (50%) 569 (53%) 
  Unsure 0 (0%) 1 (1%) 5 (1%) 6 (1%) 
  Seminal vesicle invasion 
      No 395 (78%) 131 (82%) 339 (83%) 865 (81%) 
 
0.231 
Yes 109 (22%) 28 (18%) 66 (16%) 203 (19%) 
  Unsure 1 (0%) 0 (0%) 2 (0%) 3 (0%) 
  Regional lymph node involvement 
     No 305 (60%) 98 (62%) 278 (68%) 681 (64%) 
 
0.035 
Yes 30 (6%) 5 (3%) 25 (6%) 60 (6%) 
  Unsure 170 (34%) 56 (35%) 104 (26%) 330 (31%) 
  Post-operative Gleason grade 
      6-7 395 (78%) 133 (84%) 344 (85%) 872 (81%) 
 
0.132 
8 30 (6%) 3 (2%) 18 (4%) 51 (5%) 
  9-10 77 (15%) 22 (14%) 42 (10%) 141 (13%) 
  Unsure 3 (1%) 1 (1%) 3 (1%) 7 (1%) 
  Number of co-morbidities 
      0 103 (20%) 19 (12%) 67 (16%) 189 (18%) 
 
0.149 
1 313 (62%) 108 (68%) 268 (66%) 689 (64%) 
  2+ 89 (18%) 32 (20%) 72 (18%) 193 (18%) 
  Maximum PSA level within 4 months after RP (ng/ml) 
    < 0.1 399 (79%) 137 (86%) 339 (83%) 875 (82%) 
 
0.224 
≥0.1 83 (16%) 16 (10%) 51 (13%) 150 (14%) 
  No PSA test recorded 23 (5%) 6 (4%) 17 (4%) 46 (4%) 
  Hospital 
      Site 1 27 (5%) 14 (9%) 48 (12%) 89 (8%) 
 
<0.001 
Site 2 11 (2%) 2 (1%) 12 (3%) 25 (2%) 
  Site 3 68 (13%) 39 (25%) 120 (29%) 227 (21%) 
  Site 4 51 (10%) 12 (8%) 54 (13%) 117 (11%) 
  Site 5 23 (5%) 3 (2%) 19 (5%) 45 (4%) 
  Site 6 77 (15%) 21 (13%) 36 (9%) 134 (13%) 
  Site 7 81 (16%) 26 (16%) 34 (8%) 141 (13%) 
  Site 8 120 (24%) 26 (16%) 52 (13%) 198 (18%) 
  Site 9 47 (9%) 16 (10%) 32 (8%) 95 (9%)     
Data are n (%) unless otherwise stated ^ p-values are for differences in % across the 3 groups from chi-squared tests 
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Patient characteristics (Table 7.1) were similar across groups with the exception of 
regional lymph node involvement (p=0.035). However, the proportions of patients 
with regional lymph node involvement were similar in the control and intervention 
groups (both 6%). 
7.3.1 Primary Outcome  
Referral within 4 months after prostatectomy to either radiation oncology or to the 
RAVES trial 
In the intervention group, 32% (130 of 407) of patients were referred within 4 
months after prostatectomy to either a radiation oncologist or to the RAVES trial 
compared with 30% (154 of 505) in the control group (Table 7.2). After adjustment 
for potential confounders, referral was not significantly different between the 
intervention and control groups (adjusted RR=1.05; 95% CI [0.74, 1.49]; p=0.892).  
A number of patient characteristics other than study group were associated with 
referral to a radiation oncologist or to the RAVES trial within 4 months of radical 
prostatectomy, including having extracapsular extension (RR=1.30; 95% CI [1.04, 
1.63]; p=0.023), seminal vesicle invasion (RR=1.78; 95% CI [1.46, 2.18]; p<0.001) and 
PSA ≥0.1ng/ml (RR=1.54 compared to PSA<0.1 ng/ml; 95% CI [1.26, 1.88]; p<0.001 
for overall PSA variable). Having positive surgical margins or regional lymph node 
involvement was not significantly associated with referral to a radiation oncologist or 
to the RAVES trial within 4 months of radical prostatectomy (p=0.059 and p=0.291 
respectively).  
The effect of the intervention on referral was not significantly modified by any of the 
potential effect modifiers examined (Supplementary Table S7.1) with the exceptions 
of comorbidities (p=0.029) and site (p<0.001). We found evidence that the 
intervention worked better in some sites than others. Specifically, the intervention 
appeared to work best in four sites, each with similar increases in referral rates: Site 
1 (RR=1.37; 95% CI [0.42-4.46]); Site 4 (RR=1.27; 95% CI [0.75-2.17]); Site 7 (RR=1.60; 
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95% CI [0.80-3.19]) and Site 8 (RR=1.57; 95% CI [1.01-2.43]). The intervention also 
worked better in those with two or more comorbidities (RR=1.27; 95% CI [1.02, 
1.58]). 
Table 7.2: Referral to radiation oncologist or RAVES, or case discussed at MDT 
within 4 months after prostatectomy 
    Referred
1
   Discussed
2
 
Characteristic 
 
N 
 
n (%) 
Adjusted # 
 RR (95%CI)   
 
n (%) 
Adjusted # 
 RR (95%CI) 
All patients: 1071 325 (30%) 
  
354 (33%) 
 Study group 
      Control  505 154 (30%) ref. 
 
88 (17%) ref. 
Transition 159 41 (26%) 0.99 (0.68, 1.44) 
 
26 (16%) 1.53 (0.90, 2.59) 
Intervention 407 130 (32%) 1.05 (0.74, 1.49) 
 
240 (59%) 4.31 (2.40, 7.75) 
p-value 
  
0.892 
  
<0.001 
Age group 
      40-59 252 75 (30%) ref. 
 
79 (31%) ref. 
60-69 599 200 (33%) 1.05 (0.92, 1.21) 
 
196 (33%) 0.94 (0.82, 1.07) 
70+ 220 50 (23%) 0.85 (0.70, 1.04) 
 
79 (36%) 0.98 (0.82, 1.19) 
p-value 
  
0.068 
  
0.587 
Extracapsular extension 
     No 192 42 (22%) ref. 
 
52 (27%) ref. 
Yes 875 282 (32%) 1.30 (1.04, 1.63) 
 
302 (35%) 1.14 (0.88, 1.48) 
Unsure 4 1 (25%) n/a^ 
 
0 (0%) n/a^ 
p-value 
  
0.023 
  
0.321 
Positive surgical margin 
     No 496 133 (27%) ref. 
 
167 (34%) ref. 
Yes 569 192 (34%) 1.19 (0.99, 1.42) 
 
184 (32%) 1.01 (0.84, 1.20) 
Unsure 6 0 (0%) n/a^ 
 
3 (50%) n/a^ 
p-value 
  
0.059 
  
0.947 
Seminal vesicle invasion 
     No 865 206 (24%) ref. 
 
275 (32%) ref. 
Yes 203 118 (58%) 1.78 (1.46, 2.18) 
 
78 (38%) 1.15 (0.95, 1.38) 
Unsure 3 1 (33%) n/a^ 
 
1 (33%) n/a^ 
p-value 
  
<0.001 
  
0.141 
Regional lymph node involvement 
     No 681 208 (31%) ref. 
 
225 (33%) ref. 
Yes 60 35 (58%) 0.84 (0.57, 1.24) 
 
31 (52%) 1.22 (0.83, 1.79) 
Unsure 330 82 (25%) 0.89 (0.76, 1.04) 
 
98 (30%) 1.01 (0.81, 1.27) 
p-value 
  
0.291 
  
0.609 
Post-operative Gleason grade 
     6-7 872 243 (28%) ref. 
 
282 (32%) ref. 
8 51 12 (24%) 0.81 (0.62, 1.06) 
 
17 (33%) 1.16 (0.84, 1.60) 
9-10 141 67 (48%) 1.17 (0.93, 1.46) 
 
51 (36%) 1.17 (0.88, 1.55) 
Unsure 7 3 (43%) n/a^ 
 
4 (57%) n/a^ 
p-value 
  
0.074 
  
0.481 
Number of co-morbidities 
     0 189 58 (31%) ref. 
 
53 (28%) ref. 
1 689 207 (30%) 0.99 (0.85, 1.16) 
 
232 (34%) 1.12 (0.92, 1.36) 
2+ 193 60 (31%) 1.13 (0.94, 1.36) 
 
69 (36%) 1.27 (1.02, 1.58) 
p-value 
  
0.383 
  
0.094 
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Table 7.2 (continued): Referral to radiation oncologist or RAVES, or case discussed 
at MDT within 4 months after prostatectomy 
    Referred
1
   Discussed
2
 
Characteristic 
 
N 
 
n (%) 
Adjusted # 
 RR (95%CI)   
 
n (%) 
Adjusted # 
 RR (95%CI) 
All patients: 1071 325 (30%)   354 (33%)  
Maximum PSA level within 
4 months after RP (ng/ml)       
< 0.1 875 231 (26%) ref.  284 (32%) ref. 
≥0.1 150 80 (53%) 1.54 (1.26, 1.88)  57 (38%) 1.11 (0.89, 1.38) 
No PSA test recorded 46 14 (30%) 1.12 (0.73, 1.73)  13 (28%) 0.91 (0.53, 1.57) 
p-value     <0.001     0.538 
Hospital 
      Site 1 89 22 (25%) 1.63 (0.82, 3.25) 
 
53 (60%) 2.74 (1.86, 4.02) 
Site 2 25 23 (92%) 2.38 (1.27, 4.47) 
 
8 (32%) 1.84 (0.88, 3.84) 
Site 3 227 34 (15%) ref. 
 
51 (22%) ref. 
Site 4 117 16 (14%) 1.14 (0.32, 4.03) 
 
40 (34%) 1.72 (1.13, 2.61) 
Site 5 45 18 (40%) 2.18 (1.09, 4.35) 
 
15 (33%) 1.79 (0.94, 3.38) 
Site 6 134 61 (46%) 3.14 (1.66, 5.94) 
 
75 (56%) 3.76 (2.40, 5.91) 
Site 7 141 43 (30%) 1.75 (0.94, 3.27) 
 
27 (19%) 1.49 (0.76, 2.91) 
Site 8 198 69 (35%) 1.68 (0.84, 3.34) 
 
52 (26%) 1.89 (1.26, 2.83) 
Site 9 95 39 (41%) 2.11 (1.13, 3.95) 
 
33 (35%) 2.21 (1.36, 3.60) 
p-value     <0.001     <0.001 
1
Patient referral within 4 months after RP to either a radiation oncologist or the RAVES trial 
2
Patient discussed at MDT meeting within 4 months after RP 
# Adjusted for study group, age at prostatectomy, extracapsular extension, positive surgical margin, seminal 
vesicle invasion, regional lymph node involvement, post-operative Gleason score, number of co-morbidities, 
maximum PSA within 4 months of RP, date of surgery, hospital/MDT and urologist as the clustering variable 
^ 7 control, 3 transition and 10 intervention patients within these categories were excluded from regression 
modelling due to the low numbers prohibiting the convergence of model estimates 
 
7.3.2 Secondary outcomes 
Discussion of the patient at a MDT meeting within 4 months after prostatectomy  
Discussion of the patient at a MDT meeting within 4 months after prostatectomy was 
significantly higher in the intervention group (adjusted RR=4.31; 95% CI [2.40, 7.75]; 
p<0.001) (Table 7.2). Fifty-nine per cent of intervention patients (240 of 407) were 
discussed at a MDT meeting within 4 months after prostatectomy compared with 
17% of control patients (88 of 505).  
The effect of the intervention on discussion of the patient at a MDT meeting within 4 
months after prostatectomy was significantly modified by a number of patient 
characteristics (Supplementary Table S7.2) including seminal vesicle invasion 
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(p=0.039), regional lymph node involvement (p < 0.001), post-operative Gleason 
score (p<0.019) and maximum PSA level within 4 months after prostatectomy 
(p<0.001). In general for these characteristics, categories corresponding to lower risk 
of prostate cancer recurrence, such as no seminal vesicle invasion, Gleason score 6-7, 
or PSA ≤ 0.1 ng/ml, corresponded to larger relative increases in the rates of 
discussion at a MDT meeting.  
The effect of the intervention on discussion of the patient at a MDT meeting was 
significantly modified by site (p<0.001).  
An initial patient consultation with a radiation oncologist 
Ninety-four per cent of patients (137 of 146) referred to radiotherapy within four 
months after prostatectomy (excluding those referred to the RAVES trial) attended 
an initial consultation with a radiation oncologist within 6 months after 
prostatectomy (Supplementary Table S7.3). Patients with a PSA ≥ 0.1ng/ml were 
more likely to attend an initial consultation with a radiation oncologist than those 
with a PSA <0.1ng/ml (RR=1.14; 95% CI [1.03, 1.27]; p=0.016). Patients with 
comorbidities were less likely to attend an initial consultation with a radiation 
oncologist than those with none (p<0.001). There was no significant variation in the 
proportion referred to radiotherapy within 4 months after prostatectomy that 
subsequently attended an initial consultation with a radiation oncologist between 
sites (p=0.059).  
Commencement of radiotherapy 
After excluding 186 patients who were referred to RAVES (who would be randomised 
to adjuvant radiotherapy or observation as per the RAVES protocol), 83 of 885 
patients (9%) commenced radiotherapy within 6 months after prostatectomy. 
Twenty-eight of 330 patients (8%) with adverse pathological features post-surgery 
commenced radiotherapy with 6 months after prostatectomy in the intervention 
group compared with 39 of 361 (11%) in the control group (RR 0.93; 95% CI [0.26, 
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3.31]; p=0.957) (Table 7.3). After excluding an additional 710 patients who were not 
referred to radiotherapy within 4 months after prostatectomy, 47% (27 of 57) 
commenced radiotherapy within 6 months after prostatectomy compared with 61% 
(38 of 62) in the control group (RR 0.40; 95% CI [0.13, 1.24]; p=0.067). The likelihood 
of commencing radiotherapy within 6 months after prostatectomy varied 
significantly by site (p<0.001). 
A number of patient characteristics other than study group were associated with 
patients referred within 4 months after RP commencing radiotherapy within 6 
months after prostatectomy. Specifically, there was an increased likelihood of 
referred patients commencing radiotherapy within 6 months after prostatectomy for 
those with post-operative Gleason grade 9-10 (RR 1.37 compared to grade 6-7; 95% 
CI [1.05, 1.77]; p=0.015 for overall Gleason grade variable) and a maximum PSA level 
within 4 months of prostatectomy ≥0.1ng/ml (RR 1.61 compared to PSA<0.1ng/ml; 
95% CI [1.17, 2.21]; p=0.011 for overall maximum PSA variable), perhaps indicating 
these patients commenced salvage rather than adjuvant radiotherapy.  
Referred patients with 2 or more co-morbidities were less likely to commence 
radiotherapy than those with no co-morbidities (RR 0.53; 95% CI [0.33, 0.87]; 
p=0.029 for overall co-morbidities variable). The effect of the intervention on 
commencement of radiotherapy within 6 months after prostatectomy was also 
significantly modified by site (p<0.001). 
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Table 7.3: Proportion of patients who commenced radiotherapy within 6 months 
after prostatectomy 
    Excludes patients referred to RAVES 
 
Excludes patients referred to RAVES 
and patients not referred to a 
radiation oncologist within 4 months 
after RP 
   
Started radiation within 6 
months after RP 
  
Started radiation within 6 
months after RP 
Characteristic   N
~
 
 
n (%) 
Adjusted # 
 RR (95%CI) 
 
N
~@
 
 
n (%) 
Adjusted # 
 RR (95%CI) 
All patients: 
 
885 82 (9%) 
  
146 80 (55%) 
 Study group 
        Control  
 
361 39 (11%) ref. 
 
62 38 (61%) ref. 
Transition 
 
194 15 (8%) 0.91 (0.43, 1.95) 
 
27 15 (56%) 0.36 (0.15, 0.87) 
Intervention 
 
330 28 (8%) 0.93 (0.26, 3.31) 
 
57 27 (47%) 0.40 (0.13, 1.24) 
p-value 
   
0.957 
   
0.067 
Age group 
        40-59 
 
204 18 (9%) ref. 
 
30 18 (60%) ref. 
60-69 
 
488 52 (11%) 1.08 (0.71, 1.64) 
 
91 52 (57%) 1.06 (0.73, 1.54) 
70+ 
 
193 12 (6%) 0.58 (0.32, 1.05) 
 
25 10 (40%) 0.68 (0.34, 1.36) 
p-value 
   
0.051 
   
0.230 
Extracapsular extension 
No 
 
168 9 (5%) ref. 
 
18 8 (44%) ref. 
Yes 
 
713 72 (10%) 1.73 (0.99, 3.03) 
 
127 71 (56%) 1.43 (0.85, 2.41) 
Unsure 
 
4 1 (25%) n/a^ 
 
1 1 (100%) n/a^ 
p-value 
   
0.053 
   
0.180 
Positive surgical margin 
No 
 
404 23 (6%) ref. 
 
47 23 (49%) ref. 
Yes 
 
475 59 (12%) 1.40 (0.93, 2.10) 
 
99 57 (58%) 1.01 (0.81, 1.27) 
Unsure 
 
6 0 (0%) n/a^ 
 
0 0 (.) n/a^ 
p-value 
   
0.111 
   
0.904 
Seminal vesicle invasion 
No 
 
729 39 (5%) ref. 
 
77 38 (49%) ref. 
Yes 
 
154 42 (27%) 2.24 (1.21, 4.13) 
 
69 42 (61%) 1.33 (0.89, 1.96) 
Unsure 
 
2 1 (50%) n/a^ 
 
0 0 (.) n/a^ 
p-value 
   
0.010 
   
0.160 
Regional lymph node involvement 
No 
 
558 50 (9%) ref. 
 
91 48 (53%) ref. 
Yes 
 
56 19 (34%) 0.85 (0.41, 1.76) 
 
31 19 (61%) 0.87 (0.64, 1.19) 
Unsure 
 
271 13 (5%) 0.68 (0.36, 1.29) 
 
24 13 (54%) 1.17 (0.81, 1.68) 
p-value 
   
0.488 
   
0.475 
Post-operative Gleason grade 
6-7 
 
719 51 (7%) ref. 
 
97 50 (52%) ref. 
8 
 
47 2 (4%) 0.45 (0.14, 1.44) 
 
8 2 (25%) 0.37 (0.09, 1.54) 
9-10 
 
114 28 (25%) 1.83 (1.18, 2.83) 
 
40 27 (68%) 1.37 (1.05, 1.77) 
Unsure 
 
5 1 (20%) n/a^ 
 
1 1 (100%) n/a^ 
p-value 
   
0.008 
   
0.015 
Number of co-morbidities 
0 
 
149 14 (9%) ref. 
 
20 13 (65%) ref. 
1 
 
573 55 (10%) 1.00 (0.66, 1.53) 
 
95 54 (57%) 0.69 (0.47, 1.03) 
2+ 
 
163 13 (8%) 0.87 (0.46, 1.66) 
 
31 13 (42%) 0.53 (0.33, 0.87) 
p-value 
   
0.905 
   
0.029 
Continued next page 
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    Excludes patients referred to RAVES 
 
Excludes patients referred to RAVES 
and patients not referred to a 
radiation oncologist within 4 months 
after RP 
   
Started radiation within 6 
months after RP 
  
Started radiation within 6 
months after RP 
Characteristic   N
~
 
 
n (%) 
Adjusted # 
 RR (95%CI) 
 
N
~@
 
 
n (%) 
Adjusted # 
 RR (95%CI) 
Maximum PSA level within 4 months after RP (ng/ml) 
< 0.1 
 
710 34 (5%) ref. 
 
73 34 (47%) ref. 
≥0.1 
 
137 46 (34%) 3.36 (1.85, 6.12) 
 
67 44 (66%) 1.61 (1.17, 2.21) 
No PSA test 
recorded 
 
38 2 (5%) 0.65 (0.21, 2.07) 
 
6 2 (33%) 0.88 (0.49, 1.59) 
p-value      <0.001      0.011 
Hospital 
Site 1 
 
89 14 (16%) 5.57 (2.30, 13.49) 
 
22 13 (59%) 3.05 (1.84, 5.08) 
Site 2 
 
11 5 (45%) 11.97 (3.56, 40.22) 
 
9 5 (56%) 1.85 (1.15, 3.00) 
Site 3 
 
207 6 (3%) ref. 
 
14 5 (36%) ref. 
Site 4 
 
108 5 (5%) 1.73 (0.50, 6.00) 
 
8 5 (63%) 2.44 (1.46, 4.08) 
Site 5 
 
38 7 (18%) 5.33 (2.11, 13.44) 
 
12 7 (58%) 1.34 (0.76, 2.38) 
Site 6 
 
86 10 (12%) 3.99 (1.43, 11.18) 
 
16 10 (63%) 1.42 (0.88, 2.29) 
Site 7 
 
116 12 (10%) 2.87 (1.04, 7.92) 
 
19 12 (63%) 2.06 (1.34, 3.18) 
Site 8 
 
153 13 (8%)                   2.04 (0.66, 6.26) 
 
24 13 (54%) 1.58 (1.15, 2.17) 
Site 9 
 
77 10 (13%) 4.07 (1.32, 12.52) 
 
22 10 (45%) 1.31 (0.70, 2.45) 
p-value       <0.001      <0.001 
~
Excludes 186 patients referred to the RAVES trial 
@ Excludes an additional 710 patients who were not referred to a radiation oncologist within 4 months after RP 
# Adjusted for study group, age at prostatectomy, extracapsular extension, positive surgical margin, seminal 
vesicle invasion, regional lymph node involvement, post-operative Gleason score, number of co-morbidities, 
maximum PSA within 4 months after RP, time period of surgery, hospital/MDT and urologist as the clustering 
variable  
^ Patients within these categories were excluded from regression modelling due to the low numbers prohibiting 
the convergence of model estimates 
 
 
7.3.3 Subgroup analyses 
MDT recommendation  
The MDT recommendation was known for 217 of 240 patients discussed at a MDT 
meeting within 4 months after prostatectomy. The MDT recommendation was 
referral to radiotherapy or RAVES for 58% of discussed patients (140 of 240). Only 
sixty-two of these 140 patients (44%) with a MDT recommendation for referral were 
actually referred to radiation oncology within 4 months after prostatectomy (Table 
7.4). 
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Table 7.4: MDT recommendations by referral status among intervention patients 
discussed at a MDT meeting within 4 months after prostatectomy 
 
    Actual referral 
  
Referred 
within 4 
months 
after RP
1
 
 
Referred 
within 6 
months 
after RP
2
 
MDT recommendation  
 
N 
 
n (%)   
 
n (%) 
Referral to RT or RAVES 140 62 (44%) 
 
67 (48%) 
Watch and wait 42 6 (14%) 
 
8 (19%) 
Other recommendation 35 14 (40%) 
 
14 (40%) 
Recommendation not recorded 23 12 (52%) 
 
12 (52%) 
Case not discussed within 4 months after RP 167 36 (22%) 
 
47 (28%) 
TOTAL (all intervention patients): 407 130 (32%)   148 (36%) 
1
Patient referral within 4 months after prostatectomy to either a radiation oncologist or the RAVES trial 
2
Patient referral within 6 months after prostatectomy to either a radiation oncologist or the RAVES trial 
Reasons for non-referral among patients with a MDT recommendation for referral  
Among the 78 patients with a MDT recommendation for referral who were not 
referred the most common reason for non-referral, as recorded in urologists notes, 
was a low or undetectable post-operative PSA (45 of 78; 58%), followed by good 
post-operative continence (28 of 78; 36%), then watch and wait for salvage 
radiotherapy (12 of 78; 15%),  (Table 7.6). This is consistent with the documented 
reasons for non-referral among all 746 patients (351 baseline, 118 transition, 277 
intervention) that were not referred to radiotherapy or RAVES within 4 months after 
prostatectomy: reasons recorded were a low or undetectable post-operative PSA 
(407 of 746; 55%), followed by good post-operative continence (92 of 746; 12%), 
then watch and wait for salvage radiotherapy  (92 of 746; 12%) (data not shown). 
There were no instances where the reason for non-referral of one of the 78 
discussed patients with a MDT recommendation for referral was documented as 
patient preference. Overall, patient preference was recorded as the reason for non-
referral 2% of patients (14 of 746) who were not referred. It should be noted, 
however, that there was no recorded reason for non-referral for more than a third of 
these patients (274 of 746; 37%). 
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Table 7.6: Reasons for non-referral as recorded in urologist notes among the 78 
intervention group cases with a MDT recommendation for referral who were not 
referred within 4 months of prostatectomy 
Possible reasons recorded 
# of 
responses 
% of n=78  
non-referred 
cases^ 
PSA low or undetectable 45 58% 
Continence is good 28 36% 
Watch and wait for salvage 12 15% 
Continence is bad 4 5% 
Patient preference 0 0% 
Other 4 5% 
No reason recorded in notes 25 32% 
^ Total of percentages exceeds 100% because each patient could have more than one reason recorded for 
non-referral 
 
7.3.4 Sensitivity analyses 
Sensitivity analyses showed that our results were robust to a variety of different 
assumptions and/or statistical methods (Supplementary Figure S7.1). 
 
7.4 Discussion 
The CLICC implementation trial did not result in a significant increase in the primary 
outcome of referral to radiotherapy or the RAVES trial within 4 months after 
prostatectomy. Nevertheless, there was evidence that the CLICC intervention was 
more effective in certain sites than others.  
As a result of the CLICC intervention, there was a more than threefold proportional 
increase in the secondary outcome of patient discussion at a MDT meeting within 4 
months after prostatectomy with 56% being discussed in the intervention group 
compared with 17% in the control group. Of note, the four sites that had the highest 
proportional increases in referral to radiotherapy or RAVES within 4 months after 
prostatectomy (Sites 1, 4, 7 and 8) were amongst the 5 sites with the highest 
proportional increases in patients discussed at a MDT meeting. This is consistent with 
the notion that increasing discussion of patients at a MDT meeting has the potential 
to enable change in subsequent referral behaviours. The intervention had less of an 
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effect on patient discussion at a MDT meeting within 4 months after prostatectomy 
at Site 3. Through the CLICC process evaluation (Chapter Six), several issues were 
revealed at Site 3 including high patient volume, insufficient logistical planning for 
implementation of the flagging process and lack of support from the Clinical Leader. 
In addition, this was the only site that did not have a designated MDT coordinator to 
add flagged patients to the MDT agenda for discussion.  
Within the CLICC conceptual program logic model, flagging of eligible cases by the 
pathologist to the MDT coordinator for discussion at a MDT meeting was 
hypothesised to enable referral to radiotherapy or RAVES within 4 months after 
prostatectomy by overcoming clinician level barriers associated with variable 
engagement with, and selective presentation of cases to, the MDT. The significant 
increase in the proportion of patients with adverse pathological features discussed at 
the MDT demonstrates that the MDT flagging element of CLICC successfully 
addressed selective presentation of cases. Following discussion at the MDT, 
however, less than half of patients with a MDT recommendation for referral were 
actually referred to radiotherapy or RAVES within 4 months after prostatectomy. This 
could indicate that, while they adhered to the MDT flagging process, some 
participants were still not actively engaged with the MDT and, therefore, did not 
change their referral behaviour in line with the MDT recommendation. This may in 
part be due to the larger relative increase in the number of patients who could be 
considered at the lower end of the ‘high risk” spectrum such as those without 
seminal vesicle invasion, a lower Gleason score, or low or undetectable PSA (≤ 0.1 
ng/ml). In the CLICC process evaluation (Chapter Six), a number of features were 
suggested to reduce the likelihood of patients being referred to radiation oncology, 
including “tiny volume extracapsular extension” [PU - Site 7], “low grade tumour at 
the margin” (CL – Site 7] or “negative margins” [PU – Site 3]. As another participant 
noted, “Surgeons are getting better but we all know it’s the grade and stage of the 
cancer that matters.” [PU – Site 4].  While the clinical practice guideline 
recommendation for adjuvant radiotherapy does not distinguish between high-risk 
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features, established post-prostatectomy nomograms indicate that not all adverse 
pathologic features are equal in terms of risk of relapse.(5) For example, a patient 
with a pre-operative PSA of 5, Gleason 7 disease with some extracapsular extension 
and clear margins has a less than 10% risk of relapse compared with an 89% risk of 
relapse in a patient with Gleason 4+4=8 carcinoma with multifocal sites of 
extracapsular extension, seminal vesicle involvement and positive surgical margins. 
This could explain the uncertainty expressed in the CLICC process evaluation 
(Chapter Six) as to whether increased MDT discussion based on flagging all patients 
with any of the three adverse pathological features would translate into increased 
referral of patients to radiation oncology.  
Where documented, the reason for non-referral of patients with a MDT 
recommendation for referral was predominantly attributed to a low or undetectable 
post-operative PSA. This is contrary to the clinical practice guideline, which does not 
specify PSA level but recommends that all men with extracapsular extension, seminal 
vesicle invasion or positive surgical margins should be referred to radiation oncology 
for discussion of adjuvant radiotherapy.(6-8) By its definition, adjuvant radiotherapy 
is that delivered when the patient has an undetectable or low PSA  (<0.1ng/ml). 
Radiotherapy commenced when the patient has a post-operative PSA equal to or 
greater than 0.1ng/ml would, therefore, be classified as salvage, rather than 
adjuvant, due to detection of residual or recurrent disease. Data obtained from 
radiation oncology records for men who commenced radiotherapy within 6 months 
after prostatectomy showed that patients with PSA levels ≥0.1ng/ml were more 
likely to commence radiation than those with PSA levels <0.1ng/ml. However, those 
with PSA levels ≥0.1ng/ml were actually receiving salvage rather than adjuvant 
radiotherapy. This aligns with the CLICC process evaluation (Chapter Six) in which a 
number of participants indicated post-intervention that their preference continued 
to be referral for early salvage radiotherapy at the time of a confirmed PSA rise 
rather than referral for immediate adjuvant radiotherapy.  
  211 
The overall proportion of patients that commenced radiotherapy within 6 months 
was 9% with a slight non-significant decrease from 11% in the control group to 8% in 
the intervention group. This is consistent with data from a number of published 
studies, which consistently report only 10-20% of eligible patients receive adjuvant 
treatment in Australia (4, 9-11), Canada (12, 13) and the US (14-17). The most recent 
Australian data, from eligible patients who were notified to the Victorian Prostate 
Cancer Registry between 2008 and 2011, showed that only 9.4% (78 of 833) of men 
with an adverse pathologic feature received adjuvant radiotherapy within 6 months 
after prostatectomy.(11) In part, low rates of adjuvant radiotherapy are due to low 
rates of referral; a patient cannot commence radiotherapy without first being 
referred to a radiation oncologist. However, within the subset of patients who were 
referred to a radiation oncologist only a little over half commenced radiotherapy 
within 6 months of prostatectomy despite more than 90% attending an initial 
consultation. Further, the proportion commencing radiotherapy within 6 months 
after prostatectomy decreased between the control, transition and intervention 
groups. This is consistent with a retrospective analysis of data from the US National 
Cancer Data Base that indicated declining use of radiotherapy for adverse features 
after radical prostatectomy in line with the trend in our data. That study, including 
nearly 100,000 patients, found receipt of postoperative radiotherapy significantly 
decreased from 9.1% to 7.3% between 2005 and 2011 (p < 0.001).(18) While that 
study did not explore the reason for the decrease in adjuvant radiotherapy in men 
with adverse pathologic features, a US survey found urologists were less confident in 
the benefit of adjuvant radiotherapy in terms of overall survival or durable 
biochemical control and predicted higher rates of erectile dysfunction due to 
radiotherapy than radiation oncologists.(19) Results from the CLICC process 
evaluation (Chapter Six) highlight similar concerns and indicate that continued 
disagreement with the clinical practice guideline recommendation and lack of clarity 
about which patients will benefit from adjuvant radiotherapy are the most likely 
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reasons for lack of success in increasing rates of referral to radiotherapy or RAVES 
within 4 months after prostatectomy within the local context.   
Limitations 
Power calculations were based on estimated sample sizes from Medicare claims 
data, extrapolating that 3,517 NSW men would undergo radical prostatectomy in 
2013 and that 46% would have surgery in one of the nine participating sites. This 
equated to 1,348 radical prostatectomies over the 10 months of CLICC 
implementation trial with 20% to 50% or 270 to 671 men at ‘high risk’ following 
surgery. A downward trend in prostate cancer diagnoses and a plateau in the 
proportion undergoing radical prostatectomy during the study period resulted in an 
overestimate of the number of cases treated with surgery. However, this was 
balanced by an underestimate of the proportion of men with high-risk features, 
meaning more men than anticipated contributed data to the study, giving a total 
sample of 1,087 men. Overall these trends balanced out and did not affect the power 
of the study to find a significant result.  
Medicare claims data for the period 1 January 2013 to 30 June 2014 indicate that 
nearly half (47%) of all radical prostatectomies in NSW over that period were 
performed in the nine study sites consistent with our estimate. While this implies 
results should be generalisable it is acknowledged that the effect of the intervention 
on primary and secondary outcomes was significantly modified by site due to 
inconsistencies in practice and contextual factors so there is potential for this 
variation to be evident more widely. 
The effect size of the CLICC implementation trial was a 2% increase in referrals at 4 
months after prostatectomy (30% to 32%) and a 4% increase at 6 months after 
prostatectomy (32% to 35%) (Figure S7.1). This is considerably less than the 
estimated 15% to 20% increase in referrals which was perhaps unrealistic given that 
many implementation trials show only small to moderate effects (20) and typically 
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interventions such as audit and feedback or educational outreach result in a 4% to 
5% increase respectively in dichotomous outcomes.(21)  
 
In order to determine whether the lack of significant change in the primary outcome 
of referral to radiotherapy or RAVES within 4 months after prostatectomy is related 
to the persisting clinician level barriers identified in the CLICC process evaluation 
(Chapter Six), knowledge and attitudinal outcomes are presented in Chapter Eight.  
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Table S7.1: Potential effect modifiers of the effects of the intervention on 
prevalence of referral to radiation oncologist or RAVES within 4 months 
after prostatectomy 
  Referred
1
/Total (%)     
Potential effect modifier Control Intervention 
Adjusted RR# for 
intervention 
effect 
 (95%CI) 
p-value for 
interaction 
All patients: 154/505 (30%) 130/407 (32%) 
1.05 (0.74, 
1.49)^^ n/a 
Age group 
    40-59 36/128 (28%) 28/81 (35%) 1.25 (0.81, 1.94) 0.198 
60-69 96/284 (34%) 78/231 (34%) 0.93 (0.62, 1.39) 
 70+ 22/93 (24%) 24/95 (25%) 1.17 (0.80, 1.70) 
 Extracapsular extension 
   No 22/96 (23%) 15/69 (22%) 0.85 (0.53, 1.36) 0.168 
Yes 131/406 (32%) 115/338 (34%) 1.10 (0.76, 1.58) 
 Unsure 1/3 (33%) 0/0 (.) n/a^ 
 Positive surgical margin 
    No 64/229 (28%) 54/198 (27%) 1.01 (0.71, 1.42) 0.680 
Yes 90/276 (33%) 76/204 (37%) 1.07 (0.72, 1.61) 
 Unsure 0/0 (.) 0/5 (0%) n/a^ 
 Seminal vesicle invasion 
    No 93/395 (24%) 88/339 (26%) 1.03 (0.71, 1.49) 0.473 
Yes 61/109 (56%) 41/66 (62%) 1.14 (0.77, 1.70) 
 Unsure 0/1 (0%) 1/2 (50%) n/a^ 
 Regional lymph node involvement 
   No 94/305 (31%) 87/278 (31%) 1.07 (0.76, 1.52) 0.891 
Yes 19/30 (63%) 14/25 (56%) 1.18 (0.66, 2.10) 
 Unsure 41/170 (24%) 29/104 (28%) 1.01 (0.65, 1.56) 
 Post-operative Gleason 
score 
    6-7 109/395 (28%) 103/344 (30%) 1.08 (0.75, 1.55) 0.517 
8 8/30 (27%) 3/18 (17%) 0.67 (0.32, 1.40) 
 9-10 35/77 (45%) 23/42 (55%) 1.03 (0.60, 1.76) 
 Unsure 2/3 (67%) 1/3 (33%) n/a^ 
 Number of co-morbidities 
    0 32/103 (31%) 19/67 (28%) 0.74 (0.52, 1.05) 0.029 
1 98/313 (31%) 85/268 (32%) 1.05 (0.71, 1.56) 
 2+ 24/89 (27%) 26/72 (36%) 1.34 (0.85, 2.11) 
 Maximum PSA level within 4 months after RP (ng/ml) 
  < 0.1 103/399 (26%) 99/339 (29%) 1.13 (0.79, 1.60) 0.445 
≥0.1 44/83 (53%) 26/51 (51%) 0.89 (0.53, 1.48) 
 No PSA test recorded 7/23 (30%) 5/17 (29%) 0.91 (0.37, 2.25) 
 Hospital 
    Site 1 5/27 (19%) 14/48 (29%) 1.37 (0.42, 4.46) <0.001 
Site 2 10/11 (91%) 12/12 (100%) 0.83 (0.56, 1.23) 
 Site 3 15/68 (22%) 16/120 (13%) 0.80 (0.58, 1.10) 
 Site 4 4/51 (8%) 9/54 (17%) 1.27 (0.75, 2.17) 
 Site 5 9/23 (39%) 8/19 (42%) 0.75 (0.35, 1.60) 
 Site 6 36/77 (47%) 20/36 (56%) 1.13 (0.82, 1.55) 
 Site 7 20/81 (25%) 15/34 (44%) 1.60 (0.80, 3.19) 
 Site 8 33/120 (28%) 24/52 (46%) 1.57 (1.01, 2.43) 
 Site 9 22/47 (47%) 12/32 (38%) 0.75 (0.46, 1.21)   
1
Patient referral within 4 months after RP to either a radiation oncologist or the RAVES trial 
(continued next page) 
  218 
# Adjusted for study group, age at RP, extracapsular extension, positive surgical margin, seminal 
vesicle invasion, regional lymph node involvement, post-operative Gleason score, number of co-
morbidities, maximum PSA within 4 months after RP, time period of surgery and site where 
appropriate, and urologist as the clustering variable 
¥ Time after intervention is the time between RP and intervention for patients with RPs that occurred 
after the intervention or equal to zero otherwise 
^^ Results from original analyses repeated here for convenience 
^ 7 control and 9 intervention patients were excluded from regression modelling due to low numbers 
prohibiting the convergence of model estimates 
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Table S2: Potential effect modifiers of the effects of the intervention on 
prevalence of patients being discussed at MDT meeting within 4 months 
after prostatectomy  
  Discussed
1
/Total (%)     
Potential effect modifier Control Intervention 
Adjusted RR# for 
intervention 
effect 
 (95%CI) 
p-value for 
effect 
modification 
All patients: 
88/505 
(17%) 240/407 (59%) 
4.31 (2.40, 
7.75)^^ n/a 
Age group 
    
40-59 
23/128 
(18%) 50/81 (62%) 4.09 (2.25, 7.44) 0.326 
60-69 
45/284 
(16%) 136/231 (59%) 4.78 (2.43, 9.40) 
 70+ 20/93 (22%) 54/95 (57%) 3.62 (1.94, 6.78) 
 Extracapsular extension 
    No 13/96 (14%) 35/69 (51%) 4.83 (2.41, 9.68) 0.613 
Yes 
75/406 
(18%) 205/338 (61%) 4.22 (2.32, 7.68) 
 Unsure 0/3 (0%) 0/0 (.) n/a^ 
 Positive surgical margin 
    
No 
39/229 
(17%) 115/198 (58%) 4.70 (2.31, 9.56) 0.548 
Yes 
49/276 
(18%) 122/204 (60%) 4.07 (2.29, 7.23) 
 Unsure 0/0 (.) 3/5 (60%) n/a^ 
 Seminal vesicle invasion 
    
No 
59/395 
(15%) 199/339 (59%) 5.01 (2.67, 9.38) 0.039 
Yes 
29/109 
(27%) 40/66 (61%) 2.90 (1.46, 5.76) 
 Unsure 0/1 (0%) 1/2 (50%) n/a^ 
 Regional lymph node involvement 
   
No 
53/305 
(17%) 154/278 (55%) 3.86 (2.02, 7.38) <0.001 
Yes 18/30 (60%) 12/25 (48%) 1.06 (0.50, 2.25) 
 
Unsure 
17/170 
(10%) 74/104 (71%) 7.94 (4.16, 15.14) 
 Post-operative Gleason score 
6-7 
58/395 
(15%) 205/344 (60%) 4.84 (2.53, 9.28) 0.019 
8 5/30 (17%) 11/18 (61%) 4.41 (1.86, 10.47) 
 9-10 24/77 (31%) 21/42 (50%) 2.22 (1.17, 4.22) 
 Unsure 1/3 (33%) 3/3 (100%) n/a^ 
 Number of co-morbidities 
0 
15/103 
(15%) 35/67 (52%) 4.53 (2.55, 8.06) 0.937 
1 
56/313 
(18%) 162/268 (60%) 4.25 (2.30, 7.88) 
 2+ 17/89 (19%) 43/72 (60%) 4.56 (2.17, 9.59) 
 Maximum PSA level within 4 months after RP (ng/ml) 
  
< 0.1 
58/399 
(15%) 204/339 (60%) 5.04 (2.64, 9.61) <0.001 
≥0.1 25/83 (30%) 29/51 (57%) 2.50 (1.44, 4.35) 
 No PSA test recorded 5/23 (22%) 7/17 (41%) 2.46 (1.17, 5.14) 
    Continued next page 
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  Discussed
1
/Total (%)     
Potential effect modifier Control Intervention 
Adjusted RR# for 
intervention 
effect 
 (95%CI) 
p-value for 
effect 
modification 
Hospital 
    Site 1 7/27 (26%) 38/48 (79%) 4.77 (1.98, 11.44) <0.001 
Site 2 1/11 (9%) 6/12 (50%) 8.78 (0.89, 86.52) 
 Site 3 14/68 (21%) 33/120 (28%) 1.87 (0.79, 4.47) 
 
Site 4 4/51 (8%) 36/54 (67%) 
11.24 (3.63, 
34.84) 
 Site 4 2/23 (9%) 12/19 (63%) 7.09 (2.74, 18.33) 
 Site 6 34/77 (44%) 36/36 (100%) 2.54 (1.24, 5.21) 
 Site 7 7/81 (9%) 19/34 (56%) 6.74 (3.20, 14.20) 
 
Site 8 9/120 (8%) 40/52 (77%) 
11.37 (6.48, 
19.98) 
 Site 9 10/47 (21%) 20/32 (63%) 3.01 (1.30, 7.01)   
1
Patient discussed at MDT meeting within 4 months after RP 
# Adjusted for study group, age at RP, extracapsular extension, positive surgical margin, seminal 
vesicle invasion, regional lymph node involvement, post-operative Gleason score, number of co-
morbidities, maximum PSA within 4 months after RP, time period of surgery and hospital/MDT where 
appropriate, and urologist as the clustering variable 
¥ Time after intervention is the time between RP and intervention for patients with RPs that occurred 
after the intervention or equal to zero otherwise 
^^ Results from original analyses repeated here for convenience 
^ 7 control and 9 intervention patients within these categories were excluded from regression 
modelling due to the low numbers prohibiting the convergence of model estimates 
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Table S7.3: Had consultation with radiation oncologist within 6 months of 
prostatectomy 
  
All patients excluding RAVES 
referrals   
Patients referred to a radiation 
oncologist within 4 months after RP 
excluding RAVES referrals 
  
Had consultation with 
radiation oncologist within 6 
months after RP 
  
Had consultation with 
radiation oncologist within 6 
months after RP 
Characteristic 
 
N
~
 
 
n (%) 
Adjusted # 
 RR (95%CI) 
 
 
N
~
@ 
 
n (%) 
Adjusted # 
 RR (95%CI) 
All patients: 885 152 (17%) 
  
146 137 (94%) 
 Study group 
       Control  361 65 (18%) ref. 
 
62 59 (95%) ref. 
Transition 194 28 (14%) 1.20 (0.81, 1.78) 
 
27 26 (96%) 0.93 (0.79, 1.09) 
Intervention 330 59 (18%) 1.45 (0.77, 2.70) 
 
57 52 (91%) 0.97 (0.80, 1.18) 
p-value 
  
0.514 
   
0.638 
Age group 
       40-59 204 34 (17%) ref. 
 
30 29 (97%) ref. 
60-69 488 94 (19%) 1.05 (0.75, 1.47) 
 
91 87 (96%) 1.00 (0.91, 1.11) 
70+ 193 24 (12%) 0.69 (0.48, 0.98) 
 
25 21 (84%) 0.86 (0.70, 1.05) 
p-value 
  
0.005 
   
0.269 
Extracapsular extension 
     No 168 18 (11%) ref. 
 
18 16 (89%) ref. 
Yes 713 133 (19%) 1.59 (1.13, 2.24) 
 
127 120 (94%) 1.08 (0.90, 1.30) 
Unsure 4 1 (25%) n/a^ 
 
1 1 (100%) n/a^ 
p-value 
  
0.008 
   
0.430 
Positive surgical margin 
     No 404 49 (12%) ref. 
 
47 45 (96%) ref. 
Yes 475 103 (22%) 1.35 (1.00, 1.82) 
 
99 92 (93%) 0.94 (0.85, 1.04) 
Unsure 6 0 (0%) n/a^ 
 
0 0 (.) n/a^ 
p-value 
  
0.047 
   
0.236 
Seminal vesicle invasion 
     No 729 83 (11%) ref. 
 
77 72 (94%) ref. 
Yes 154 68 (44%) 1.74 (1.37, 2.22) 
 
69 65 (94%) 1.02 (0.93, 1.12) 
Unsure 2 1 (50%) n/a^ 
 
0 0 (.) n/a^ 
p-value 
  
<0.001 
   
0.632 
Regional lymph node involvement 
     No 558 96 (17%) ref. 
 
91 86 (95%) ref. 
Yes 56 31 (55%) 0.93 (0.56, 1.54) 
 
31 30 (97%) 0.97 (0.87, 1.09) 
Unsure 271 25 (9%) 0.67 (0.42, 1.08) 
 
24 21 (88%) 0.95 (0.81, 1.12) 
p-value 
  
0.257 
   
0.819 
Post-operative Gleason grade 
     6-7 719 101 (14%) ref. 
 
97 91 (94%) ref. 
8 47 6 (13%) 0.61 (0.36, 1.03) 
 
8 6 (75%) 0.75 (0.52, 1.09) 
9-10 114 44 (39%) 1.36 (0.96, 1.92) 
 
40 39 (98%) 1.04 (0.95, 1.15) 
Unsure 5 1 (20%) n/a^ 
 
1 1 (100%) n/a^ 
p-value 
  
0.024 
   
0.202 
Number of co-morbidities 
     0 149 22 (15%) ref. 
 
20 20 (100%) ref. 
1 573 98 (17%) 1.11 (0.83, 1.48) 
 
95 88 (93%) 0.87 (0.81, 0.94) 
2+ 163 32 (20%) 1.31 (0.91, 1.88) 
 
31 29 (94%) 0.91 (0.83, 0.99) 
p-value 
  
0.350 
   
<0.001 
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Table S7.3 (continued): Had consultation with radiation oncologist within 6 
months of prostatectomy 
  
All patients excluding RAVES 
referrals   
Patients referred to a radiation 
oncologist within 4 months after RP 
excluding RAVES referrals 
  
 
Had consultation with 
radiation oncologist within 6 
months after RP 
  
Had consultation with 
radiation oncologist within 6 
months after RP 
Characteristic 
 
N
~
 
 
n (%) 
Adjusted # 
 RR (95%CI)   
 
N
~
@ 
 
n (%) 
Adjusted # 
 RR (95%CI) 
All patients: 885 152 (17%) 
  
146 137 (94%) 
 Maximum PSA level within 4 months after RP (ng/ml)   
< 0.1 710 73 (10%) ref.  73 65 (89%) ref. 
≥0.1 137 71 (52%) 2.68 (1.90, 3.78)  67 66 (99%) 1.14 (1.03, 1.27) 
No PSA test 
recorded 38 8 (21%) 1.39 (0.72, 2.66)  6 6 (100%) 1.19 (1.04, 1.36) 
p-value     <0.001       0.016 
Hospital 
       Site 1 89 24 (27%) 2.22 (1.18, 4.17) 
 
22 21 (95%) 1.11 (0.93, 1.33) 
Site 2 11 8 (73%) 
3.86 (1.41, 
10.54) 
 
9 8 (89%) 1.01 (0.83, 1.23) 
Site 3 207 16 (8%) ref. 
 
14 13 (93%) ref. 
Site 4 108 11 (10%) 1.26 (0.44, 3.59) 
 
8 8 (100%) 1.16 (0.93, 1.45) 
Site 5 38 11 (29%) 2.60 (1.21, 5.59) 
 
12 11 (92%) 0.96 (0.81, 1.15) 
Site 6 86 15 (17%) 2.46 (1.21, 5.01) 
 
16 15 (94%) 0.96 (0.83, 1.11) 
Site 7 116 18 (16%) 1.45 (0.67, 3.13) 
 
19 18 (95%) 1.05 (0.86, 1.29) 
Site 8 153 25 (16%) 1.47 (0.71, 3.06) 
 
24 22 (92%) 1.01 (0.85, 1.21) 
Site 9 77 24 (31%) 2.68 (1.33, 5.38) 
 
22 21 (95%) 1.05 (0.90, 1.23) 
p-value     <0.001       0.059 
~
Excludes 186 patients referred to the RAVES trial (includes 7 patients referred to RAVES after the 4 
month CLICC cut off within 6 months after RP as per the RAVES recruitment protocol) 
@ Excludes an additional 739 patients who were not referred to a radiation oncologist within 4 
months after RP 
# Adjusted for study group, age at prostatectomy, extracapsular extension, positive surgical margin, 
seminal vesicle invasion, regional lymph node involvement, post-operative Gleason score, number of 
co-morbidities, maximum PSA within 4 months after RP, time period of surgery, site and urologist as 
the clustering variable 
^ Patients within these categories were excluded from regression modelling due to low numbers 
prohibiting the convergence of model estimates  
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Figure S7.1: Sensitivity Analyses 
 
 
a 
Patient referral within 4 months after RP to either a radiation oncologist or to the RAVES trial 
b 
Patient discussed at MDT meeting within 4 months after RP 
# All analyses with the exception of #4 were adjusted for study group, age at prostatectomy, 
extracapsular extension, positive surgical margin, seminal vesicle invasion, regional lymph node 
involvement, post-operative Gleason score, number of co-morbidities, maximum PSA within 4 months 
of RP and time period of surgery. In addition: GEE analyses (analyses #1-6 and #8) included site as a 
fixed effect and urologist as the panel variable; the linear mixed model analysis (analyses #7) included 
random effect terms for sitel and urologists nested within sites 
^ Results from original analyses repeated convenience 
(1) Excludes patients referred to radiation oncologist before RP  
(2) For each of the 2 outcomes, respectively, patients were excluded if they were referred or 
discussed within 4 months after RP but their urologist recorded the reason as salvage therapy or they 
had a PSA ≥0.1ng/ml within 4 months after RP 
(3) Excludes patients who did not have a post surgical consultation within 4 months after RP 
(4) Adjusted only for time period of surgery, age at RP and site with urologist defined as the panel 
variable and includes 7 control and 10 intervention patients excluded from original analyses because 
of missing clinical data 
(5) Excludes patients of the urologist with highest caseload comprising 13.9% of all RPs 
(6) Excludes patients from the site with highest caseload comprising 21.2% of all RPs (continued next 
page) 
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Control
n/N (%)
Intervention
n/N (%)
Adjusted RR #
95% (CI)
88/505 (17%)
67/406 (17%)
78/482 (16%)
88/498 (18%)
88/505 (17%)
83/457 (18%)
74/437 (17%)
88/505 (17%)
81/427 (19%)
240/407 (59%)
178/309 (58%)
229/392 (58%)
240/398 (60%)
240/407 (59%)
220/336 (65%)
207/287 (72%)
240/407 (59%)
244/407 (60%)
4.31 (2.40, 7.75)
4.55 (2.50, 8.27)
4.21 (2.27, 7.81)
4.41 (2.46, 7.92)
4.30 (2.39, 7.75)
4.05 (2.24, 7.32)
4.76 (2.58, 8.76)
4.65 (2.43, 8.88)
3.44 (2.04, 5.79)
Control
n/N (%)
Intervention
n/N (%)
Adjusted RR #
95% (CI)
             Sensitivity analyses:
Original analysis^
Excludes pre-RP referrals (1)
Excludes salvage (2)
Excludes loss to follow-up (3)
Minimally adjusted model (4)
Excludes one urologist (5)
Excludes one hospital (6)
Linear mixed model (7)
6 month outcome (8)
             Sensitivity analyses:
Original analysis^
Excludes pre-RP referrals (1)
Excludes salvage (2)
Excludes loss to follow-up (3)
Minimally adjusted model (4)
Excludes one urologist (5)
Excludes one hospital (6)
Linear mixed model (7)
6 month outcome (8)
1 2 3
Referred
a
Discussed
b
                                                                                                 Adjusted RR (95% CI)
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(7) Results from a linear mixed model analyses with random effect terms for site and urologists 
nested within sites 
(8) The two outcomes of referred and discussed assessed at 6 months rather than 4 months 
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Chapter 8: Changes in provider knowledge, attitudes and beliefs 
 
8.1 Introduction 
Results presented in Chapter Seven, show that while the CLICC implementation trial 
significantly increased the secondary outcome of discussion of the patient at an MDT 
meeting within 4 months after prostatectomy, it did not result in significant change 
in the primary outcome of patient referral within 4 months after prostatectomy to 
either radiation oncology or to the RAVES trial. To understand the reasons for this 
lack of change in the primary outcome it is necessary to further explore participants’ 
response to the intervention through assessment of knowledge and attitudinal 
outcomes.(1) 
As outlined in Chapter Six, response was defined as the extent to which 
multidisciplinary teams integrated and adopted new knowledge, systems and 
processes into their routine practice. The significant increase in the secondary 
outcome, discussion of the patient at an MDT meeting within 4 months after 
prostatectomy, indicates that flagging of eligible cases through the pathologist to the 
MDT coordinator successfully addressed the systems and processes and cultural 
barriers of variable engagement with, and selective presentation of cases to, the 
MDT. However, subgroup analyses (Chapter Seven; Table 7.4) demonstrated that for 
patients where the MDT recommendation was referral to radiotherapy, only 44% 
were actually referred within 4 months after radical prostatectomy. Where recorded, 
the main reasons for non-referral were an undetectable or low PSA (58%) and good 
continence (36%). This suggests that persisting clinician knowledge or attitudinal 
barriers are the reason there was no increase in the primary outcome of referral to 
radiotherapy or RAVES within four months of prostatectomy. 
Clinician level barriers, identified through the needs and barriers analysis presented 
in Chapter Four, predominantly related to negative attitudes regarding the evidence 
to support the clinical practice recommendation for adjuvant radiotherapy for locally 
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advanced disease. This was coupled with perceptions of the potential for 
overtreatment in some patients whose cancer may not recur and concerns about 
radiotherapy associated toxicity or side effects such as impotence, urinary or fecal 
incontinence and urethral stricture; proposed by radiation oncologist interviewees to 
be due to insufficient knowledge about current radiotherapy techniques. The 
ongoing RAVES trial (2), comparing survival and quality of life outcomes for 
Australasian patients at high-risk of recurrence post-prostatectomy through 
randomisation to either salvage radiotherapy at the time of a PSA rise or immediate 
adjuvant radiotherapy, contributed to persisting norms.   
Through the CLICC conceptual program logic model these knowledge and attitudinal 
barriers were mapped to physician-focused intervention components, specifically:  
 Non-didactic, interactive provider education: CLICC introductory session 
facilitated by the Clinical Leader; CLICC introductory video (predisposing 
factors 
 Dissemination of printed materials: CLICC printed resource; full copy of the 
Australian Cancer Network Clinical Practice Guideline for the Management of 
Men with Locally Advanced and Metastatic Prostate Cancer; peer review 
journal publications reporting the results and long-term follow up of the 
EORTC (3, 4), SWOG (5-7) and ARO (8, 9) randomised controlled trials that 
form the evidence base for the clinical practice guideline recommendation for 
adjuvant radiotherapy for locally advanced disease (predisposing factor) 
 
To evaluate the extent to which participants integrated and adopted new knowledge 
from these CLICC intervention elements, and the degree to which they addressed 
clinician level barriers, we conducted baseline and post-intervention surveys to 
assess knowledge, attitudes and beliefs.  
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We hypothesised that compared with pre-intervention measures, urologists post-
intervention would have increased knowledge about the evidence for appropriate 
adjuvant radiotherapy for high-risk prostate cancer patients after radical 
prostatectomy and the associated risks and benefits of treatment; and more positive 
attitudes towards the need for referral to radiation oncology as a means to support 
fully informed patient decision making.(1)  
 
8.2 Methods 
8.2.1 Study sample 
Nine Clinical Leaders and 28 urologist participants involved in the CLICC 
implementation trial. 
8.2.2 Survey domains 
The CLICC baseline and post-intervention surveys were abbreviated versions of that 
developed for the nationwide surveys of urologist members of the Urological Society 
of Australia and New Zealand (USANZ) reported in Chapters Three and Nine. Briefly, 
the CLICC participant surveys related to: clinical equipoise; and knowledge, attitudes 
and beliefs regarding the clinical practice recommendation for adjuvant radiotherapy 
for men with locally advanced prostate cancer following radical prostatectomy. The 
baseline survey additionally collected demographic information. Where a baseline 
survey was not received from a participant this was collected in the post-intervention 
survey. Full surveys and the scoring key are included in Appendix XI. The survey 
predominantly used a five-point Likert scale (“strongly disagree” = 1 to “strongly 
agree” = 5) coded as consecutive integers for analysis (with an additional “don’t 
know” option coded as missing). Negatively worded items were reverse coded 
around the mid-point (“strongly disagree” = 5 to “strongly agree” = 1). A summary 
score was calculated from respondents’ total scores on questions within domains by 
summing the values for all non-missing items and dividing by the total number of 
items completed to assess overall attitudes and beliefs relating to the clinical practice 
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recommendation for patients with extracapsular extension, seminal vesicle 
involvement or positive surgical margins to receive adjuvant radiotherapy within 4 
months of surgery. The CLICC participant survey was provided in hard copy only. 
8.2.3 Clinical Equipoise 
Three clinical scenarios were given to urologists as outlined in Box 8.1. Each reflected 
a different risk of recurrence but all fell under the “high-risk” category as outlined in 
the Australian Cancer Network Guidelines.(10) Cases 1, 2 and 3 had a 19%, 10% and 
89% 10-year risk of biochemical relapse respectively according to Memorial Sloan 
Kettering Cancer Center nomograms (11). Respondents were asked to indicate the 
strength of their preference for watchful waiting or adjuvant radiotherapy on a linear 
analog scale with one treatment option anchored at each end of the scale. The scale 
was centered on zero to represent ‘‘undecided’’ and marked from ‘‘1’’ to ‘‘5’’ toward 
each end to represent increasing certainty in the treatment approach.(12). 
For descriptive analysis, treatment preferences were categorised as follows: 0 – 3 = 
watchful waiting is preferable; 4 – 6 = undecided; 7 – 10 = adjuvant radiotherapy is 
preferable. Consistent with the definition used in the 2012 USANZ survey (13) and 
other equipoise studies (12), we define clinical equipoise as a situation in which less 
than 80% of clinicians are in agreement about the most appropriate treatment for a 
given scenario. For regression analysis, responses to clinical scenarios were 
transposed to a continuous 0 to 10 point scale, with lower scores indicating greater 
preference for watchful waiting. 
8.2.4 Survey administration 
Pre-intervention surveys were included in the information pack provided at the CLICC 
introductory session (or mailed to participants who did not attend the session). 
Three reminders, including further copies of the survey, were sent according to 
established protocols. 
Post-intervention surveys were mailed to all Clinical Leaders and participating 
urologists on 31 March 2015 at the end of the active intervention phase. Three 
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reminders, including further copies of the survey, were sent according to established 
protocols. 
In a deviation to the published study protocol (1) the survey was conducted at two 
time points (baseline and post-intervention) rather than three (baseline, 6 months 
after roll-out of the intervention, and end of study). This was because the six-month 
survey coincided with the post-intervention survey for Sites 8 and 9, which were the 
last to enter the active intervention phase of the study.   
Box 8.1: Clinical case scenarios 
 
8.2.5 Statistical methods 
Data were analysed using IBM SPSS Statistics Version 23.0 and STATA version 11.0.  
To compare differences between responses to baseline and post-intervention survey 
questions, generalised estimating equations (GEEs) were used to account for repeat 
responses from the same urologists across both surveys in instances where the 
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urologist had complete both surveys. Participants who completed only one survey, 
either baseline or post-intervention, were necessarily analysed as though they were 
unique in each survey and, as a consequence, confidence intervals for effect 
estimates are likely to be conservative, but point estimates should remain unbiased. 
Responses to survey questions were treated as the outcomes in regression models. 
Link functions and distributions for the GEEs were dependent on the nature of the 
responses options. Binomial distributions and logit link functions were assumed for 
dichotomous response items producing odds ratios as the measure of effect. 
Gaussian distributions and identity link functions were assumed for Likert and other 
ordinal scale response items producing mean differences as the measure of effect. P-
values for multinomial outcomes were calculated using multinomial regression with a 
random effect to account for repeat responses from the same urologists (where 
relevant). 
Qualitative textual data were explored thematically to identify collective attitudes 
and beliefs relating to the clinical practice recommendation that ‘patients with 
extracapsular extension, seminal vesicle involvement or positive surgical margins 
receive post-operative external beam radiation therapy within four months of 
surgery’.  
8.3 Results 
8.3.1 Response rate 
29 of 37 participants (78%) completed the baseline survey and 24 of 37 (65%) 
completed the post-intervention survey. More than half (20 of 37; 54%) completed 
both surveys. Participant characteristics by survey are included in Table 8.1.  
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Table 8.1: Participant characteristics by survey 
  Survey     
 
Baseline 
Post-
intervention 
 
 
Characteristic (n=29) (n=24)   p-value^ 
Sex 
    Male 28 (97%) 19 (79%) 
 
0.080 
Female 0 (0%) 0 (0%) 
  Missing 1 (3%) 5 (21%) 
  Age at survey 
    20-30 0 (0%) 0 (0%) 
 
0.154 
31-40 4 (14%) 4 (17%) 
  41-50 10 (34%) 8 (33%) 
  51-60 5 (17%) 1 (4%) 
  >60 10 (34%) 7 (29%) 
  Missing 0 (0%) 4 (17%) 
  Type of practice 
    VMO/Consultant 28 (97%) 20 (83%) 
 
0.036 
Registrar/Junior Medical Officer 0 (0%) 0 (0%) 
  Salaried University Academic 0 (0%) 0 (0%) 
  Staff Specialist 1 (3%) 0 (0%) 
  Other 0 (0%) 0 (0%) 
  Missing 0 (0%) 4 (17%) 
  Years of practice 
    0-5 4 (14%) 4 (17%) 
 
0.528 
6-10 4 (14%) 3 (13%) 
  11-15 6 (21%) 5 (21%) 
  16-20 4 (14%) 2 (8%) 
  21-25 1 (3%) 1 (4%) 
  26-30 7 (24%) 4 (17%) 
  >30 3 (10%) 1 (4%) 
  Missing 0 (0%) 4 (17%) 
  Perform radical prostatectomy 
    Yes 29 (100%) 20 (83%) 
 
0.036 
No 0 (0%) 0 (0%) 
  Missing 0 (0%) 4 (17%) 
  Practice location 
    Capital city 16 (55%) 11 (46%) 
 
0.185 
Other major urban area 8 (28%) 6 (25%) 
  Rural 5 (17%) 3 (13%) 
  Missing 0 (0%) 4 (17%) 
  Setting for majority of patients 
    Private 19 (66%) 14 (58%) 
 
0.101 
Public 10 (34%) 6 (25%) 
  Missing 0 (0%) 4 (17%) 
  New patients per month (mean) 10.9 11.7 
 
0.544 
% of practice for PC patients (mean) 26.3 27.9 
 
0.264 
% of PC patients in active treatment (mean) 39.5 35.8   0.187 
^ p-values correspond to tests of no difference between surveys  
Numbers are n (%) unless otherwise stated       
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There was a significant difference in type of practice between the baseline and post-
intervention groups (p=0.036); however, this is likely due to the higher proportion of 
participants with missing demographic information in the post-intervention survey.  
There was also a significant difference in the number who reported that they 
perform radical prostatectomy (p=0.036). This was due to missing demographic 
information since eligibility criteria specified that CLICC participants must have 
performed one or more radical prostatectomies during the baseline and/or study 
period. 
8.3.2 Treatment preference for adjuvant versus salvage radiotherapy post-
prostatectomy 
Treatment preferences for the three hypothetical clinical scenarios (Box 8.1) are 
detailed in Table 8.2 and Figure 8.1.  
Table 8.2: Comparison between baseline and post-intervention survey responses - 
current level of certainty about which treatment option is better 
 Watchful waiting is 
preferable 
Undecided Adjuvant 
radiotherapy is 
preferable 
Missing 
 N % 95% CI (%) N % 95% CI (%) N % 95% CI (%) N % 95% CI (%) 
     
Case 1 
Baseline 
5 17 3, 31 6 21 6, 36 17 59 41, 77 1 3 - 
Case 1 Post-
intervention 
4 17 2, 32 3 18 3, 33 17 71 53, 89 0 0 - 
     
Case 2 
Baseline 
21 72 56, 88 2 7 0, 16 6 21 6, 36 0 0 - 
Case 2 Post-
intervention 
17 71 52, 90 2 8 0, 19 4 17 2, 32 1 4 - 
     
Case 3 
Baseline 
0 0 - 1 3 0, 9 28 97 91, 100 0 0 - 
Case 3 Post-
intervention 
2 8 0, 19 0 0 - 22 92 81, 100 0 0 - 
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There was no change in CLICC participants’ treatment preferences between 
baseline and post-intervention surveys. At baseline, according to our 
definition, there was clinical equipoise for Case 1 (19% 10-year risk of 
biochemical relapse). However, a greater proportion indicated a preference 
for adjuvant radiotherapy than watchful waiting: 59% indicated that adjuvant 
radiotherapy is preferable, 21% were undecided and 17% indicated that 
watchful waiting is preferable. Post-intervention for Case 1 71% indicated a 
preference for adjuvant radiotherapy, 18% were undecided and 17% indicated 
a preference for watchful waiting. While there was an increase in the 
proportion that indicated a preference for adjuvant radiotherapy post-
intervention, this change was not significant; urologists were on average 0.2 
more favourable towards Case 1 receiving adjuvant radiotherapy post-
intervention than they were at baseline with mean scores of 6.8 and 7.0 
respectively (mean difference 0.2; 95% CI [-0.8, 1.2]; p=0.666). There was also 
clinical equipoise for Case 2 (10% 10-year risk of biochemical relapse) at 
baseline, with a stronger preference for watchful waiting, and this did not 
change post-intervention. Seventy-two per cent indicated a preference for 
watchful waiting at baseline compared with 71% post-intervention while the 
proportion that considered adjuvant radiotherapy preferable decreased from 
21% at baseline to 17% post-intervention but this change was not significant 
(mean scores 2.7 and 2.8 respectively; mean difference 0.1; 95% CI [-1.4, 1.6]; 
p=0.869). For Case 3 (89% 10-year risk of biochemical relapse) adjuvant 
radiotherapy was considered preferable by 97% at baseline decreasing to 92% 
post-intervention (mean scores 9.4 and 9.0). This change was not significant 
(mean difference -0.5; 95% CI [-1.5, 0.6]; p=0.360).  
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Figure 8.1: Comparison between baseline and post-intervention survey 
responses - level of certainty about which treatment option is better 
 
 
^ Scores were measured on a scale from 0 to 10 with lower scores indicating greater preference for 
watchful waiting, higher scores indicating greater preference for adjuvant radiotherapy and a score of 
5 indicating undecided 
Survey #1 = Baseline Survey #2 = Post-intervention 
8.3.4 Knowledge  
There were no significant changes in participants’ understanding of the 
current literature and evidence for the treatment of prostate cancer (Figure 
8.2). There was no difference in agreement between baseline and post-
intervention surveys that immediate external irradiation after radical 
prostatectomy improves biochemical progression-free survival and local 
control in patients with positive surgical margins or pT3 prostate cancer who 
are at high risk of progression (Q2a. mean difference -0.0; 95% CI [-0.4, 0.4]; 
p=0.840).  There was less agreement post-intervention that relapse after local 
therapy is defined by prostate-specific antigen (PSA) values >0.2 ng/ml 
following radical prostatectomy (RP) and >2 ng/ml above the nadir PSA after 
radiation therapy (RT) but this was not significant (Q2b. mean difference -0.2; 
95% CI [-0.6, 0.3]; p=0.531]. Notably, there was less agreement post-
intervention that all high risk patients should have multidisciplinary input and 
be referred by their urologist to a radiation oncologist before treatment to 
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ensure informed decision making based on discussion of the relative 
advantages and disadvantages of adjuvant radiotherapy or watchful waiting 
but this change was not significant (Q2c. mean difference -0.1; 95% CI [-0.4, 
0.2]; p=0.561). Further, there was slightly more agreement post-intervention 
that there are no data from randomised controlled trials to define the benefits 
of salvage radiation versus adjuvant therapy or salvage radiation versus 
systemic therapy (either at time of PSA rise or at time of radiographic 
progression) but this was not significant (Q2d. mean difference 0.2; 95% CI [-
0.3, 0.6]; p=0.440). 
Figure 8.2: Comparison between baseline and post-intervention survey 
responses - understanding of current literature and evidence for the 
treatment of prostate cancer 
 
^ Scores correspond to a 4-point Likert type scale with scoring 1=Strongly disagree, 2=Somewhat 
disagree, 3=Somewhat agree, 4=Strongly agree; “Don’t know” and missing responses were excluded 
from analyses 
Survey #1 = Baseline Survey #2 = Post-intervention 
*Full survey questions are available in Appendix X.  
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between baseline and post-intervention (mean difference -0.1; 95% CI [-0.3, 
0.1]; p=0.490) (Figure 8.3). This reflects lack of significant change across the 
majority of underlying attitudes within this domain. Notably, there was no 
change in the level of agreement that the recommendation is based on a valid 
interpretation of underpinning evidence (mean difference 0.2; 95% CI [-0.2, 
0.6]; p=0.236). Further, there was no change in agreement post-intervention 
that the recommendation reflects evidence that is emerging on the topic 
(mean difference -0.1; 95% CI [-0.5, -0.3]; p=0.570). The only significant 
change in attitudes was less agreement post-intervention that the 
recommendation is consistent with the opinions of respected clinical 
colleagues (mean difference -0.4; 95% CI [-0.7, 0.0]; p=0.027).  
 
Figure 8.3: Comparisons between baseline and post-intervention responses - 
attitudes towards recommendation that ‘patients with extracapsular 
extension, seminal vesicle involvement or positive surgical margins receive 
post-operative external beam radiation therapy within four months of 
surgery’ 
 
*This recommendation: 
 
 
^ Scores correspond to a 5-point Likert type scale with scoring 1=Strongly disagree, 2=Disagree, 
3=Neither agree nor disagree, 4=Agree, 5=Strongly agree; “Don’t know” and missing responses were 
excluded from analyses 
Survey #1 = Baseline Survey #2 = Post-intervention 
*Full survey questions are available in Appendix X. Some items were reverse coded for analyses and 
these are reflected in question labels. 
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8.3.6 Beliefs  
Post-operative treatment decisions  
There was no significant difference between the baseline and post-
intervention surveys in opinions about who is best placed to make post-
operative treatment decisions (p=0.75; Table 8.3). The majority of participants 
in both surveys (76% baseline and 74% post-intervention) considered that the 
MDT is best placed to decide on the most appropriate post-operative 
treatment followed by the urological surgeon. No participants considered the 
radiation oncologist best placed to make post-operative treatment decisions 
at either baseline or post-intervention.  
 
Table 8.3: Comparison between baseline and post-intervention responses - 
following radical prostatectomy, who is the person best placed to decide on 
the most appropriate post-operative treatment option? 
  Survey 
 
Baseline 
Post-
intervention 
Following surgery who should decide further treatment? (n=29) (n=23) 
The urological surgeon is best placed to decide 6 (21%) 4 (17%) 
The radiation oncologist is best placed to decide 0 (0%) 0 (0%) 
The MDT is best placed to decide 22 (76%) 17 (74%) 
The patient is best placed to decide 1 (3%) 2 (9%) 
The medical oncologist is best placed to decide 0 (0%) 0 (0%) 
p=0.75 for test equal proportions across surveys 
n and % are for frequencies and % of individuals; missing responses were excluded from analysis 
Survival benefit and toxicity associated with adjuvant radiotherapy 
Participants did not vary significantly between baseline and post-intervention 
in their views of the minimum survival benefit considered acceptable for them 
to follow the recommendation for adjuvant radiotherapy for locally advanced 
disease (mean difference -0.3; 95% CI [-1.5, 1.0]; p=0.690). Nor was there a 
significant change in the maximum proportion of men who suffer from rectal 
damage or develop faecal incontinence as a result of radiotherapy for this 
treatment to be unacceptable (mean difference -2.1; 95% CI [-9.4, 9.2]; 
p=0.572) (data not shown).  
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Open text responses 
Eighteen of 29 (62%) of participants provided comments in the baseline 
survey and 13 of 24 (54%) provided comments in the post-intervention 
survey. Thematic analysis of open text indicated a number of common beliefs 
evident in the baseline surveys that persisted in the post-intervention surveys:  
1. Concerns about side effects / overtreatment resulting in a preference 
for early salvage over adjuvant radiotherapy – 6 of 18 (33%) at baseline 
and 5 of 13 (38%) post-intervention noted that:  
“in men who are low to moderate risk of recurrence it is difficult to push 
adjuvant radiation as it has side effects which are often understated by the 
Radiation Oncologist.” [Baseline]  
“High % of patient will have treatment & side effects unnecessarily. With 
ultra-sensitive PSA, f/u [follow up] selective salvage Rx [radiotherapy] may 
give specific similar benefit i.e. RAVES trial.” [Post-intervention] 
 
2. Need for individualised care – a number of participants (4 of 18 (22%) at 
baseline and 3 of 13 (23%) post-intervention) noted that post-operative 
adjuvant radiotherapy should be considered on a case-by-case basis: 
 “Nuanced decision. Depends on risk of relapse. Positive margin group is 
different from ECE group with negative margins. Some patients clearly benefit. 
Others are best to wait for any PSA recurrence. A 'one size fits all' 
recommendation is poor medicine.” [Baseline]  
“Recommendations strongly depend on grade of glands at margin, extent of 
margin + PSA. For some patients it is appropriate. For some it is not. The 
recommendation is not nuanced enough.”[Post-intervention]  
 
3. Perceived lack of evidence / lack of confidence in trial data – 22% (4 of 
18) commented on the level of evidence supporting adjuvant 
radiotherapy following radical prostatectomy at baseline: 
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 “I remain unconvinced on the quality of benefit of adjuvant RTx [radiotherapy] 
over early salvage RTx [radiotherapy], but agree the available evidence 
supports early intervention.” [Baseline].  
Only one participant (8%) expressed similar concerns about 
evidence post-intervention: 
 “Absolute numbers in randomised trials to date who have had events (e.g. 
death) is low. So evidence is not as strong as Rad Onc [radiation oncologist] 
likes to think.” [Post-intervention] 
 
4. Positive beliefs about adjuvant radiotherapy - In both baseline (4 of 18; 
22%) and post-intervention (3 of 13; 33%) surveys a number 
commented favourably on adjuvant radiotherapy following radical 
prostatectomy and indicated they support its use: 
 “I support it but less so if: lower risk - local positive margins and 3+3 at 
margin; young and wants erection.” [Baseline] 
“Adjuvant radiotherapy has a place in selected patients after risk stratification 
for progression of disease.” [Baseline]  
 Post-intervention comments were more positive without caveats, with 
 participants noting it is “really good”, “I do it” and there should be 
 “more”. 
Discussion 
The results of CLICC participant surveys did not support the hypothesis that 
post-intervention urologists would have increased knowledge about the 
evidence for appropriate adjuvant radiotherapy for high-risk prostate cancer 
patients after radical prostatectomy and the associated risks and benefits of 
treatment post-intervention; and more positive attitudes towards the need 
for referral to radiation oncology as a means to support fully informed patient 
decision-making.  
It is a limitation that not all CLICC participants completed both baseline and 
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post-intervention surveys. Those that only completed one survey, either 
baseline or post-intervention, were necessarily analysed as though they were 
unique in each survey and, as a consequence, confidence intervals for effect 
sizes are likely to be conservative but point estimates should remain unbiased. 
More than half (54%), however, completed both surveys enabling comparison 
of differences in responses between baseline and post-intervention surveys. 
“Don’t know” responses were coded as missing which reduced the 
denominator for some questions but there were very few instances (less than 
10 in the baseline survey and 2 in the post-intervention survey) where “don’t 
know” responses were selected across all survey questions.  It is a further 
potential limitation that the psychometric properties of the survey have not 
been assessed. The response rate (78% baseline and 65% post-intervention) is 
higher than that reported for similar clinician surveys.(14, 15) 
The results correspond with comments made in semi-structured interviews, 
conducted as part of the CLICC process evaluation (Chapter Six), and in open 
text survey responses in which a number of participants noted that they had 
knowledge of the evidence from these trials but continued to challenge its 
efficacy; “Absolute numbers in randomised trials to date who have had events 
(e.g. death) is low. So evidence is not as strong as [the radiation oncologist] 
likes to think.” [Post-intervention survey]  CLICC printed materials included all 
data relating to the three randomised controlled trials (EORTC Trial 22911 (3, 
4); SWOG S8794 (5, 6, 16); ARO Trial 96–02/AUP AP 09/95 (8, 9)) that form the 
evidence base for this clinical practice recommendation published at the 
commencement of the active intervention phase. However, with the 
exception of longer-term follow-up results for the EORTC Trial (4) no new data 
were published between the release of clinical practice guidelines (10, 17-20) 
and commencement of CLICC in 2014. Results from the RAVES trial (2) which 
were anticipated to provide evidence directly comparing outcomes and 
quality of life associated with adjuvant radiotherapy and early salvage 
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radiotherapy were frequently mentioned. This highlights the continued 
influence of RAVES as a confounder to reinforce the normative behaviour of 
watchful waiting rather than immediate referral for consideration of adjuvant 
radiotherapy, which is the evidence-based guideline recommended care. As 
one participant in the baseline survey noted, “My own practice is to refer to 
practitioners involved in the RAVES trial as I feel that time will show one can 
watch safely these men rather than commence immediate RT.”  In recognition 
of the potential for RAVES to act as a confounder in the CLICC implementation 
trial, the primary outcome included patient referral within 4 months after 
prostatectomy to either radiation oncology or to the RAVES trial. Subgroup 
analysis of RAVES referral patterns (Chapter Seven) showed that only 15% of 
eligible patients (75 of 505 baseline; 24 of 159 transition) were referred to 
RAVES within 4 months of radical prostatectomy prior to CLICC and referral 
rates did not change post-intervention (16%; 64 of 407 intervention patients). 
The RAVES trial was closed to accrual on 31 December 2015 due to poor 
recruitment and the low event rate, which the RAVES Independent Data 
Monitoring Committee considered would make it “highly unlikely that early 
salvage radiotherapy will be shown to be 10% inferior to adjuvant therapy in 
biochemical control, even if a further 140 patients were recruited to the study 
to reach the original sample size of 470”.(21) This means that the current 
randomised controlled trial data from the EORTC (3, 4); SWOG (5, 6, 16) and 
ARO trials (8, 9) remains the best evidence to inform the treatment of men 
with locally advanced prostate cancer following radical prostatectomy. 
In addition to the summary of evidence, the CLICC printed resource provided 
high-level information on current radiotherapy techniques. It was not 
appropriate to provide more detailed information, as decisions regarding dose 
should be made by the treating radiation oncologist who has full knowledge of 
the patient’s functional status, history and toxicity tolerance.(22) The CLICC 
printed resource, therefore, advocated referral to radiation oncology to 
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discuss what radiation treatment would involve at the patient’s local 
radiotherapy unit. However, survey responses indicate that post-intervention 
participants did not have more positive attitudes towards the need for referral 
to radiation oncology as a means to support fully informed patient decision-
making. In fact, while the change was not significant, fewer participants post-
intervention agreed that all high risk patients should have multidisciplinary 
input and be referred by their urologist to a radiation oncologist before 
treatment to ensure informed decision making based on discussion of the 
relative advantages and disadvantages of adjuvant radiotherapy or watchful 
waiting. Open text responses indicated this is likely due to perceptions that 
radiation oncologists do not present a balanced view of radiotherapy 
associated side effects and toxicity: “The side effects, when they occur, are not 
managed by radiation oncologists. As a result, radiation oncologists do not 
present a balanced view of risks versus benefits.” [Baseline] Post-intervention, 
however, one participant acknowledged that the lack of a balanced view was 
equally applicable to urologists: “Urologists overestimate side effects. Rad 
Oncs [radiation oncologists] underestimate side effects.”  
Somewhat contrarily, while participants did not have more positive attitudes 
towards the need for referral to radiation oncology as a means to support 
fully informed patient decision-making, there was persisting belief, evident in 
both baseline and post-intervention surveys, in the need for individualised 
care. This, however, was perceived by participants to relate to consideration 
of clinical factors such as margin status, post-operative PSA and continence 
rather than providing patients with an opportunity to discuss adjuvant 
treatment options with a radiation oncologist.   
Whilst acknowledging the potential limitations associated with self-reported 
practice, there was an increase in the proportion of participants who indicated 
a preference for adjuvant radiotherapy for the hypothetical Case 1 but this 
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change was not significant and overall there was no change in treatment 
preference for any of the three given scenarios. This is consistent with results 
from independent, blinded medical record review (Chapter Seven), which 
found no increase in actual rates of referral to radiotherapy or RAVES within 4 
months after prostatectomy, and reflects a lack of change in attitudes towards 
adjuvant radiotherapy for locally advanced disease. The only underlying 
attitude to change within the domain was a significant decrease in the 
proportion post-intervention that agreed the recommendation for adjuvant 
radiotherapy is consistent with the opinions of respected colleagues. This 
suggests that within the wider urological community there is potentially less 
agreement with the recommendation for adjuvant radiotherapy than was 
considered the case at baseline.  
To determine whether urologists’ attitudes towards adjuvant radiotherapy for 
locally advanced disease following radical prostatectomy have shifted 
nationally, outside of the CLICC participant group, we conducted a follow up 
survey of urologist members of the Urological Society of Australia (USANZ). 
Results of that survey are presented in Chapter Nine.  
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Chapter 9: Changing attitudes toward management of men 
with locally advanced prostate cancer following radical 
prostatectomy: a follow-up survey of Australian-based 
urologists 
 
Publication arising from this chapter 
Publication arising from this chapter: Brown B, Egger S, Young J, Kneebone AB, 
Brooks AJ, Dominello A & Haines M. Changing Attitudes toward Management 
of Men with Locally Advanced Prostate Cancer following Radical 
Prostatectomy: A Follow-up Survey of Australian-based Urologists. Journal of 
Medical Imaging and Radiation Oncology. 2016 June 27. doi:10.1111/1754-
9485.12483.  
 
9.1 Abstract 
Introduction: This study examined whether there has been change among 
Australia-based urologists’ knowledge, attitudes and beliefs relating to 
guideline-recommended adjuvant radiotherapy for men with adverse 
pathologic features following radical prostatectomy since a prior survey in 
2012 and investigated associations between attitudes and treatment 
preferences.  
Methods: A nationwide survey of Australia-based urologist members of the 
Urological Society of Australia and New Zealand. 
Results: 96 respondents completed the 2015 survey (30% response rate) 
compared with 157 (45% response rate) in 2012. There was no significant 
change in awareness of national clinical practice guidelines for the 
management of prostate cancer. When considering adjuvant against salvage 
radiotherapy, urologists were significantly less favourable towards adjuvant 
radiotherapy in 2015 than in 2012 for two of three hypothetical clinical case 
scenarios with a high 10-year risk of biochemical relapse according to 
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Memorial Sloan Kettering Cancer Center nomograms (p<0.001 for both cases). 
In 2015, urologists’ were less positive overall towards the recommendation 
for post-operative adjuvant radiotherapy for men with locally advanced 
prostate cancer than in 2012 (p<0.001), reflecting a significant change across a 
number of attitudes and beliefs. Of note, urologists felt other urologists would 
more likely be critical if they routinely referred the target patient group for 
radiotherapy in 2015 compared with 2012 (p=0.007).  
Conclusion: In 2015 Australian-based urologists were less favourable towards 
adjuvant radiotherapy over watchful waiting for men with high-risk pathologic 
features post-prostatectomy than in 2012. We could find no new published 
research that precipitated this change in attitude. 
 
9.2 Introduction 
On the basis of evidence from three randomised controlled trials 
demonstrating the efficacy of adjuvant radiotherapy after radical 
prostatectomy for patients with high-risk pathologic features, (1-5) several 
international clinical practice guidelines (CPGs) (6-10) were published 
between 2010 and 2013 with a recommendation that men with extracapsular 
extension, seminal vesicle invasion or positive surgical margins should be 
offered adjuvant radiotherapy after radical prostatectomy.  
In 2012, two years after release of the Australian Cancer Network Clinical 
Practice Guidelines for the Management of Locally Advanced and Metastatic 
Prostate Cancer (8), we conducted a nationwide survey to investigate 
Australian urologists’ knowledge, attitudes and beliefs, and the association of 
these with treatment preferences relating to guideline-recommended 
adjuvant radiotherapy for men with adverse pathologic features following 
radical prostatectomy.(11) The survey provided baseline data to inform the 
development of the “Clinician-Led Improvement in Cancer Care (CLICC)” 
implementation trial.(12)  
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Results from the 2012 survey indicated that urologists varied in their attitudes 
and beliefs regarding adjuvant radiotherapy after radical prostatectomy for 
men with adverse pathologic features.(11) Less than one third agreed that 
adjuvant radiotherapy would lead to improved outcomes, while more than 
two thirds agreed that it may result in unnecessary patient discomfort. 
Consequently there was clinical equipoise for a hypothetical clinical scenario 
that would indicate its use (Box 9.1; Case 1). Forty per cent of respondents in 
2012 expressed concerns about the appropriateness of adjuvant radiotherapy 
for patients with post-surgical incontinence or those worried about 
impotence. This was reflected in a preference to keep those patients under 
surveillance and refer for early salvage radiotherapy if there is a Prostate 
Specific Antigen (PSA) rise. This finding was in line with the results of a US 
survey, which indicated urologists were less confident in the benefit of 
adjuvant radiotherapy in terms of overall survival or durable biochemical 
control and predicted higher rates of side effects and toxicity due to 
radiotherapy than radiation oncologists.(13)  
Numerous patterns of care studies demonstrate that ongoing controversy 
surrounding adjuvant radiotherapy and persisting clinical uncertainty is 
reflected in historically low rates of utilisation of adjuvant radiation in this 
patient group. These studies consistently report only 10-20% of eligible 
patients receive treatment in Australia (14-17), Canada (18, 19) and the US 
(20-23) and rates did not increase following publication of randomised 
controlled trial data. Further, a retrospective analysis of data from the US 
National Cancer Data Base indicates declining use of radiotherapy for adverse 
features after radical prostatectomy. That study, including 97,270 patients 
diagnosed with prostate cancer between 2005 and 2011, found receipt of 
postoperative radiotherapy significantly decreased from 9.1% to 7.3% (p < 
0.001).(24)  
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Box 9.1: Clinical Case Scenarios 
 
Therefore, we conducted a follow up survey in 2015 to determine whether 
there has been a shift in prevailing attitudes and beliefs among Australian 
urologists regarding adjuvant radiotherapy after radical prostatectomy and 
their preferences for adjuvant or salvage radiotherapy for men with adverse 
pathological features. 
 
9.3 Subjects and Methods 
Study sample 
Australia-based currently practicing urologists and trainees of the Urological 
Society of Australia and New Zealand (USANZ).  Urologist participants in the 
CLICC implementation trial (n=37) (12) who have been exposed to an 
intervention strategy to increase referral for discussion of guideline 
recommended radiation treatment following surgery were ineligible to 
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participate in this survey, which they completed as a requirement of CLICC 
(reported elsewhere). 
Survey domains 
Full details of survey development have been previously published.(11) 
Briefly, the survey comprised 6 sections relating to: 1. clinical equipoise; 2. the 
use of, and attitudes and beliefs towards, clinical guidelines in practice; 3. 
innovation and current clinical practice; 4. barriers to adherence to a clinical 
practice recommendation; 5 perceptions of organisational readiness for 
change; and 6. demographic information. The full survey and the scoring key 
can be found in Appendix IV. The survey predominantly used a five-point 
Likert scale (“strongly disagree” = 1 to “strongly agree” = 5) coded as 
consecutive integers for analysis (with an additional “don’t know” option 
coded as missing). Negatively worded items were reverse coded around the 
mid-point (“strongly disagree” = 5 to “strongly agree” = 1).  A summary score 
was calculated from respondents’ total scores on questions within domains by 
summing the values for all non-missing items and dividing by the total number 
of items completed to assess overall attitudes and beliefs relating to clinical 
practice guidelines (CPGs). The survey was formatted in both web-based and 
hard copy versions. 
Clinical Equipoise 
Three clinical scenarios were given to urologists as outlined in Box 9.1. Each 
reflected a different risk of recurrence but all fell under the “high-risk” 
category as outlined in the Australian Cancer Network Guidelines.(8) Cases 1, 
2 and 3 had a 19%, 10% and 89% 10-year risk of biochemical relapse 
respectively according to Memorial Sloan Kettering Cancer Center nomograms 
(25) highlighting the heterogeneity of patients in the “high-risk” cohort.  
For descriptive analysis (Table 2), treatment preferences were categorised as 
follows: 0 – 3 = watchful waiting is preferable; 4 – 6 = undecided; 7 – 10 = 
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adjuvant radiotherapy is preferable. Consistent with the definition used in the 
2012 survey (11) and other equipoise studies (26), we define clinical equipoise 
as a situation in which less than 80% of clinicians are in agreement about the 
most appropriate treatment for a given scenario. For regression analysis, 
responses to clinical scenarios were transposed to a continuous 0 to 10 point 
scale, with lower scores indicating greater preference for watchful waiting 
(Figure 9.1). 
Survey administration 
The survey was administered following an established protocol used for the 
prior 2012 survey.(11) Respondents who completed the survey were eligible 
to enter a competition to win an iPad.  
Statistical methods 
Data were analysed using IBM SPSS Statistics Version 23.0 and STATA version 
11.0. Only surveys that provided responses beyond the three clinical scenarios 
were included in analyses.  
To compare differences between responses to 2012 and 2015 survey 
questions, generalised estimating equations (GEEs) were used to account for 
repeat responses from the same urologists across both surveys in instances 
where the urologist could be identified. However, because name disclosure 
was voluntary in both surveys to comply with confidentiality and ethical 
requirements, we were unable to match urologists who participated in both 
surveys but chose to remain anonymous in at least one of the surveys. These 
participants were necessarily analysed as though they were unique in each 
survey and, as a consequence, confidence intervals for effect estimates are 
likely to be conservative, but point estimates should remain unbiased. 
Responses to survey questions were treated as the outcomes in regression 
models. Link functions and distributions for the GEEs were dependent on the 
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nature of the responses options. Binomial distributions and logit link functions 
were assumed for dichotomous response items producing odds ratios as the 
measure of effect. Gaussian distributions and identity link functions were 
assumed for Likert and other ordinal scale response items producing mean 
differences as the measure of effect. P-values for multinomial outcomes were 
calculated using multinomial regression with a random effect to account for 
repeat responses from the same urologists (where identifiable). 
T-tests were used to explore relationships between knowledge and treatment 
preference. 
Two lots of sensitivity analysis were conducted. First, regression models were 
additionally adjusted for age, sex and type of practice to account for any 
imbalances on these variables between surveys. Second, Likert and other 
ordinal outcomes were analysed alternatively using proportional odds ordinal 
logistic regression with cluster robust standard errors. This second sensitivity 
analysis was performed because the debate over the most appropriate 
statistical method for analysing Likert-type scales has been ongoing for more 
than 50 years.(27) In our main analyses, we chose to analyse Likert and other 
ordinal scales continuously using linear regression because, in our opinion, 
there is good evidence that this method is robust while providing more 
statistical power than other methods.(28, 29) Nonetheless, we also accept 
that ordinal logistic regression is an alternative appropriate method for 
analysing these data. 
Qualitative textual data were explored thematically to identify persisting 
barriers to the implementation of the clinical practice recommendation that 
‘patients with extracapsular extension, seminal vesicle involvement or positive 
surgical margins receive post-operative external beam radiation therapy 
within four months of surgery’. 
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9.4 Results 
Response Rate 
Ninety-five of 322 urologists (30%) invited to participate responded in 2015, 
compared with 157 of 350 (45%) in 2012. Respondent characteristics for the 
2012 and 2015 surveys are summarized in Table 1. There was no significant 
difference in respondent demographics in the two surveys. 
 
Table 9.1: Participant characteristics by survey 
  Survey   
 
2012 2015  
Characteristic (n=157) (n=96) p-value^ 
Sex 
   Male 126 (80%) 78 (81%) 0.131 
Female 14 (9%) 13 (14%) 
 Missing 17 (11%) 5 (5%) 
 Age at survey 
   20-30 1 (1%) 1 (1%) 0.124 
31-40 38 (24%) 22 (23%) 
 41-50 48 (31%) 35 (36%) 
 51-60 27 (17%) 25 (26%) 
 >60 26 (17%) 7 (7%) 
 Missing 17 (11%) 6 (6%) 
 Type of practice 
   VMO/Consultant 117 (75%) 79 (82%) 0.643 
Registrar/Junior Medical Officer 5 (3%) 2 (2%) 
 Salaried University Academic 5 (3%) 2 (2%) 
 Staff Specialist 11 (7%) 6 (6%) 
 Other 2 (1%) 2 (2%) 
 Missing 17 (11%) 5 (5%) 
 Years of practice 
   0-5 38 (24%) 19 (20%) 0.494 
6-10 24 (15%) 20 (21%) 
 11-15 19 (12%) 13 (14%) 
 16-20 17 (11%) 13 (14%) 
 21-25 16 (10%) 14 (15%) 
 26-30 11 (7%) 6 (6%) 
 >30 15 (10%) 6 (6%) 
 Missing 17 (11%) 5 (5%) 
 Perform radical prostatectomy 
   Yes 113 (72%) 79 (82%) 0.131 
No 27 (17%) 12 (13%) 
 Missing 17 (11%) 5 (5%) 
 Continued next page 
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  Survey   
 
2012 2015  
Characteristic (n=157) (n=96) p-value^ 
Practice location 
Capital city 91 (58%) 54 (56%) 0.238 
Other major urban area 28 (18%) 24 (25%) 
 Rural/remote 20 (13%) 13 (14%) 
 Missing 18 (11%) 5 (5%) 
 Setting for majority of patients 
   Private 78 (50%) 48 (50%) 0.684 
Public 59 (38%) 39 (41%) 
 Missing 20 (13%) 9 (9%) 
 New patients per month (mean) 10.1 8.8 0.150 
% of practice for PC patients (mean) 31.1 28.2 0.228 
% of PC patients in active treatment (mean) 44.5 37.4 0.057 
^ p-values correspond to tests of no difference between surveys 
Numbers are n (%) unless otherwise stated 
 
Knowledge – awareness of the Australian Cancer Network Clinical Practice 
Guidelines  
Just over half of respondents (54%) reported that they were aware of the 
Guidelines in 2012 and there was no increase in awareness in 2015 (53%). Of 
those who were aware of the guideline, the primary source of referral was 
USANZ in both 2012 and 2015 (45% and 56% respectively). 
Treatment preference for adjuvant versus salvage radiotherapy post-
prostatectomy 
Treatment preferences for the three hypothetical clinical scenarios (Box 9.1) 
are detailed in Table 9.2 and Figure 9.1. In 2012 there was clinical equipoise 
for Case 1 (19% 10-year risk of biochemical relapse): 45% indicated that 
watchful waiting is preferable; 12% were undecided; 43% indicated that 
adjuvant radiotherapy is preferable. In 2015 for Case 1, while there remained 
clinical equipoise according to our definition, urologists indicated a preference 
for watchful waiting (71%) over adjuvant radiotherapy (23%), with only 5% 
undecided. Urologists were on average 1.8 points less favourable towards 
Case 1 receiving adjuvant radiotherapy in 2015 than they were in 2012 with 
mean scores of 2.9 and 4.7 respectively (mean difference -1.8; 95% CI [-2.6, -
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1.0]; p<0.001) representing a significant shift away from adjuvant 
radiotherapy as the preferred treatment choice. Treatment preference for 
Case 2 (10% 10-year risk of biochemical relapse) was watchful waiting in both 
2012 (86%) and 2015 (97%) (mean scores 1.5 and 0.6 respectively) with 
urologists significantly less likely to favour adjuvant radiotherapy in 2015 than 
2012 (mean difference -0.9; 95% CI [-1.4, -0.5]; p<0.001). For Case 3 (89% 10-
year risk of biochemical relapse) adjuvant radiotherapy was considered 
preferable by 89% in 2012 decreasing to 82% in 2015 (mean scores 8.5 and 
7.9). This change was not significant (mean difference -0.6; 95% CI [-1.3, 0.0]; 
p=0.057) but does provide weak evidence that adjuvant radiotherapy might 
be less preferred in 2015 than 2012, even for very high-risk patients.  
Consistent with findings of the 2012 survey, for Case 1 where there was 
clinical equipoise, there was no significant difference in treatment preferences 
in 2015 between those who were aware of the Guidelines (M=2.68, SD=3.242) 
and those who were not (M=3.32, SD=3.476); t (92)=0.921, p=0.36.  
 
Table 9.2: Current level of certainty about which treatment option is better 
 Watchful waiting is 
preferable 
Undecided Adjuvant radiotherapy is 
preferable 
 N % 95% CI 
(%) 
N % 95% CI 
(%) 
N % 95% CI 
(%) 
    
Case 1 2012 71 45 37, 53 18 12 7, 17 68 43 35, 51 
Case 1 2015 67 71 61, 79 5 5 2, 12 22 23 16, 33 
    
Case 2 2012 135 86 81, 91 11 7 3, 11 11 7 3, 11 
Case 2 2015 91 97 91, 99 2 2 1, 7 1 1 0, 6 
    
Case 3 2012 14 9 5, 13 3 2 0, 4 140 89 84, 94 
Case 3 2015 9 10 5, 17 8 8 4, 16 77 82 73, 88 
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Figure 9.1: Level of certainty about which treatment option is better^ 
 
^ Scores were measured on a scale from 0 to 10 with lower scores indicating greater preference for 
watchful waiting, higher scores indicating greater preference for adjuvant radiotherapy and a score of 
5 indicating undecided 
ART: Adjuvant radiotherapy 
 
Attitudes and beliefs related to the recommendation for adjuvant radiotherapy 
for locally advanced disease   
Overall there was less agreement with the clinical practice recommendation 
for adjuvant radiotherapy for locally advanced disease in 2015 than in 2012 
(mean difference -0.3; 95% CI [-0.4, -0.1]; p<0.001) (Figure 2). This is a 
reflection of significant change across a number attitudes and beliefs. In 2015, 
there was significantly less agreement than 2012 that the recommendation is 
based on a valid interpretation of underpinning evidence (mean difference -
0.4; 95% CI [-0.6, -0.1]; p=0.004 or that following the recommendation would 
lead to improved patient outcomes (mean difference -0.2; 95% CI [-0.4, 0.0]; 
p=0.019). Specifically, there was significantly less agreement in 2015 than 
2012 that published literature provides evidence that immediate external 
irradiation after radical prostatectomy improves biochemical progression-free 
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survival and local control (mean difference -0.2; 95% CI [-0.4, -0.0]; p=0.012) 
(data not shown). Further, there was significantly less agreement in 2015 than 
in 2012 that the recommendation is consistent with the urologist’s clinical 
experience with this patient group (mean difference -0.4 95% CI [-0.7, -0.2]; 
p<0.001) or with the opinions of respected clinical colleagues (mean 
difference -0.5; 95% CI [-0.8, -0.3]; p<0.001). There was significantly more 
agreement in 2015 than 2012 that the side effects of adjuvant radiotherapy 
for patients with locally advanced prostate cancer outweigh the benefits 
(mean difference -0.3; 95% CI [-0.5, -0.1]; p=0.007) and that the 
recommendation does not reflect evidence that is emerging on the topic 
(mean difference -0.3; 95% CI [-0.5, -0.0]; p=0.024). Significantly more 
urologists supported external beam radiation therapy for patients but not 
within four months of surgery (mean difference -0.3; 95% CI [-0.6, -0.1]; 
p=0.004). 
Other factors related to the recommendation for adjuvant radiotherapy for 
locally advanced disease   
Urologists were significantly more agreeable in 2015 than 2012 to the 
proposition that other urologists would be critical if they routinely referred 
this patient group for radiotherapy (mean difference 0.3; 95% CI [0.1, 0.5]; 
p=0.007) (Figure 9.3). There was no significant change in attitudes across 
others factors 
Evidence from randomised controlled trials 
There were no significant changes in the levels of evidence considered 
necessary for urologists to be convinced of the benefit of adjuvant 
radiotherapy. See Table 9.3. 
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Figure 9.2: Comparisons between 2012 and 2015 survey responses - 
attitudes towards the Australia Cancer Network Guidelines recommendation 
that ‘patients with extracapsular extension, seminal vesicle involvement or 
positive surgical margins receive post-operative external beam radiation 
therapy within four months of surgery’^ 
 
*This recommendation: 
 
^ Scores correspond to a 5-point Likert type scale with scoring 1=Strongly disagree, 2=Disagree, 
3=Neither agree nor disagree, 4=Agree, 5=Strongly agree; “Don’t know” and missing responses were 
excluded from analyses 
*Full survey questions are available from the corresponding author. Some items were reverse coded 
for analyses and these are reflected in question labels. 
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Figure 9.3: Comparisons between 2012 and 2015 survey responses - other 
factors relating to the recommendation ‘patients with extracapsular 
extension, seminal vesicle involvement or positive surgical margins receive 
post-operative external beam radiation therapy within four months of 
surgery’^ 
 
*This recommendation: 
 
^ Scores correspond to a 5-point Likert type scale with scoring 1=Strongly disagree, 2=Disagree, 
3=Neither agree nor disagree, 4=Agree, 5=Strongly agree; “Don’t know” and missing responses were 
excluded from analyses 
*Full survey questions are available from the corresponding author.  
ART: Adjuvant radiotherapy 
 
-0·1 (-0·3, 0·1)
-0·2 (-0·4, 0·0)
0·3 (0·1, 0·5)
0·2 (-0·0, 0·4)
-0·2 (-0·5, 0·0)
0.347
0.096
0.007
0.093
0.071
3.8 (0.7)
2.8 (0.9)
2.2 (0.8)
3.5 (1.0)
2.5 (1.0)
3.8 (0.7)
2.6 (0.9)
2.5 (0.9)
3.7 (0.8)
2.3 (1.0)
140
131
135
139
137
91
87
92
91
91
 
p-value
 
Mean
Difference
(95%CI)
2012
Mean (SD)^
2015
Mean (SD)^
 
N
 
N
could be easily incorporated
will be followed by colleagues
will lead to criticism from colleagues
will increase costs
considers patient needs and preferences
-1 0 1
 
               Favours ART less in 2015 than 2012               Favours ART more in 2015 than 2012      
  
 
260 
Table 9.3: Comparison between 2012 and 2015 survey responses – levels of evidence to support the recommendation ‘patients with 
extracapsular extension, seminal vesicle involvement or positive surgical margins receive post-operative external beam radiation therapy within 
four months of surgery’ 
  2012   2015 
Mean  
difference 
(95%CI) 
  
  N 
Mean 
(SD)   N 
Mea
n 
(SD) 
p-
value 
Number of trials 
necessary to provide an 
acceptable level of 
evidence 139 
3.2 
(1.2) 
 
84 
3.1 
(1.2) 
-0.1  
(-0.5, 0.2) 0.439 
Number of years follow-
up necessary 140 
8.9 
(2.2) 
 
92 
8.7 
(2.4) 
-0.2  
(-0.8, 0.5) 0.613 
Number of years of 
survival benefit 135 
2.3 
(2.6) 
 
88 
2.1 
(2.3) 
-0.2  
(-0.8, 0.4) 0.560 
Maximum proportion of 
men suffering rectal 
damage or faecal 
incontinence as a result 
of radiotherapy 141 
14.5 
(12.0)   90 
13.3 
(11.0
) 
-1.1  
(-3.9, 1.6) 0.422 
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Post-operative treatment decisions  
There was no significant difference between the two surveys in opinions 
about who is best placed to make post-operative treatment decisions (p=0.88; 
Table 9.4).  
Table 9.4: Comparison between 2012 and 2015 survey responses – following 
radical prostatectomy who is the person best placed to decide on the most 
appropriate post-operative treatment option? 
 
  Survey 
 
2012 2015 
Q2.4 Who should decide future treatment (n=149) (n=92) 
The urological surgeon is best placed to decide 42 (28%) 25 (27%) 
The radiation oncologist is best placed to decide 1 (1%) 0 (0%) 
The MDT is best placed to decide 85 (57%) 55 (60%) 
The patient is best placed to decide 19 (13%) 12 (13%) 
The medical oncologist is best placed to decide 2 (1%) 0 (0%) 
p=0.88 for test equal proportions across surveys, adjusted for sex and age at survey 
n and % are for frequencies and % of individuals; missing responses were excluded from analysis 
 
Attitudes and beliefs related to clinical practice guidelines in general 
Overall, attitudes towards CPGs in general were positive and remained 
relatively unchanged from 2012 to 2015 (mean difference 0.0 95% CI [-0.1, 
0.2]; p=0.414; Figure 9.4). The proportion of urologists reporting they use 
CPGs in their practice increased marginally from 78% to 85% but this change 
was not significant (odds ratio 1.59; 95% CI [0.75, 3.49]; p=0.187; data not 
shown) and there was no change in the number of different guidelines used in 
practice (mean difference 0.2; 95% CI [-0.7, 1.0]; p=0.710; data not shown). 
There was significantly more agreement in 2015 than 2012 that CPGs are good 
educational tools (mean difference 0.2; 95% CI [0.1, 0.4]; p=0.005).  
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Figure 9.4: Comparisons between 2012 and 2015 survey responses – 
attitudes and beliefs related to clinical practice guidelines in general^ 
 
*In general, clinical practice guidelines: 
 
^ Scores correspond to a 5-point Likert type scale with scoring 1=Strongly disagree, 2=Disagree, 
3=Neither agree nor disagree, 4=Agree, 5=Strongly agree; “Don’t know” and missing responses were 
excluded from analyses 
*Full survey questions are available in Appendix IV. Some items were reverse coded for analyses and 
these are reflected in question labels. 
CPG: Clinical Practice Guidelines 
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comorbidities, continence and potency post-surgery”. A number also 
reported that referral is dependent upon the post-operative PSA “Given 
super-sensitive PSA assays I think it is reasonable to wait until a rise is 
confirmed before initiating adjuvant XRT”.  
2. Perceived lack of evidence / lack of confidence in trial data – 30% 
(24/80) in 2012 and 28% (13/47) in 2015 reported concerns about the 
evidence base underlying the recommendation. “ARO, EORTC and 
SWOG were flawed studies. There is a difference between early salvage 
versus late salvage. The question of adjuvant versus early salvage has 
not been addressed.” “Improved biochemical recurrence but not 
difference in overall survival. SWOG study fundamentally flawed (poor 
recruitment/mid study alteration of intended analysis/one sided 
significance analysis) and should be discounted.” 
3. Concerns about side effects / overtreatment – 25% (20/80) of 
respondents in 2012 and 35% (16/46) in 2015 noted that toxicities 
related to radiotherapy and potential unnecessary treatment are a 
barrier to the implementation of this recommendation. “Other 
specialists underestimate the side effects e.g. bladder neck contracture, 
haemorrhagic cysts, stricture, LUTS of this modality. Causes decreased 
QoL, increased return to theatres, IDC usage etc. Needs to be 
INDIVIDUALISED!” “Whilst I refer patients for adjuvant radiotherapy 
selectively, it would not take much more evidence of long term negative 
side effects to convince me not to recommend it at all.” 
Innovation, current practice and readiness for change 
There was no significant difference between 2012 and 2015 in the proportions 
of urologists’ willing to experiment with new procedures in their practice (13% 
versus 20%), who prefer to wait until others have tried new procedures (29% 
versus 34%) or who prefer to wait until procedures have been established for 
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a while (52% versus 43%) (p=0.23; data not shown).  Consistent with 2012, no 
urologists in 2015 reported that they only try new procedures when 
regulations require them.  
Urologists generally believed there is readiness for change in their 
organisation and this largely remained unchanged over time (Figure 9.5). 
However, urologists were significantly more agreeable in 2015 than 2012 to 
the proposition that urology leaders are willing to try new protocols (mean 
difference 0.2; 95% CI [0.0, 0.3]; p=0.014). 
Figure 9.5: Comparisons between 2012 and 2015 survey responses – 
readiness for change^ 
*Urology leaders in my organisation: 
 
^ Scores correspond to a 5-point Likert type scale with scoring 1=Strongly disagree, 2=Disagree, 
3=Neither agree nor disagree, 4=Agree, 5=Strongly agree; “Don’t know” and missing responses were 
excluded from analyses 
*Full survey questions are available in Appendix IV.  
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similar to non-adjusted analyses. Sensitivity analyses using proportional odds 
regression provided almost identical results in terms of statistically significant 
p-values.    
 
9.5 Discussion 
We conducted a follow up survey of urologists across Australia. There was no 
increase in awareness of the Australia Cancer Network Clinical Practice 
Guidelines for the Management of Men with Locally Advanced and Metastatic 
Prostate Cancer (8) over the three year period from 2012 to 2015. This 
suggests a need for improved knowledge translation that goes beyond passive 
dissemination of evidence through publication of guidelines.  
The results highlight a persisting view that early salvage radiotherapy at the 
first sign of a PSA relapse is likely to have similar efficacy to adjuvant 
radiotherapy following radical prostatectomy, whilst avoiding radiotherapy 
associated toxicity in some patients who might not need further treatment. 
Urologists were significantly less favourable towards adjuvant radiotherapy 
for scenarios that would indicate its use according to clinical practice 
recommendations in 2015 than in 2012. The proportion indicating a 
preference for watchful waiting over adjuvant radiotherapy for a patient with 
a 10% 10-year risk of biochemical relapse increased significantly between 
2012 and 2015. There remained clinical equipoise for a scenario describing a 
patient with a 19% 10-year risk of biochemical relapse, however, there was a 
significant increase in the proportion that favoured watchful waiting over 
adjuvant radiotherapy (less than half in 2012 and nearly three quarters in 
2015). Continuing this trend, even for a given clinical scenario with an 89% 10-
year risk of biochemical relapse there was a small, non-significant decrease in 
the proportion that considered adjuvant radiotherapy preferable in 2015. This 
is consistent with figures from the US National Cancer Data Base (24), which 
demonstrated less than one third of patients at the highest risk of recurrence 
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(pT3-4 disease with a positive margin and Gleason 8-10) with no comorbidities 
and a projected long life expectancy (<60 years old) received postoperative 
radiotherapy. In combination, these results suggest an increasing divergence 
between clinical opinion and the recommendations of published CPGs.  
Urologists’ attitudes and beliefs and the lesser overall agreement with the 
clinical practice recommendation for adjuvant radiotherapy may help explain 
why there is reduced self-reported compliance. From 2012 to 2015 there was 
increased perception that the recommendation is not based on valid 
interpretation and does not reflect emerging evidence, perhaps due to 
frequently cited criticisms relating to the absence of a well-defined salvage 
radiotherapy arm in the randomised trials on which it is based and the lack of 
a consistent survival benefit at longer term follow up.(1-5) There was 
significantly less agreement in 2015 than 2012 that the recommendation is 
consistent with current clinical practice or with the opinions of colleagues, 
while there was more agreement with the proposition that other urologists 
would be critical if they routinely referred this patient group for radiotherapy. 
Coupled with greater agreement that side effects of adjuvant radiotherapy 
outweigh the benefits, and less agreement that it will lead to improved 
patient outcomes, these beliefs provide a powerful disincentive.  
Paradoxically, urologists were significantly more agreeable in 2015 than 2012 
to the proposition that they support external beam radiation therapy for 
patients but not within four months of surgery. This aligns with the commonly 
held view that treatment should not be initiated until there is optimal 
postoperative recovery, particularly in urinary continence and potency and 
supports the need for individualised care that was raised in both the 2012 and 
2015 surveys. The propensity to delay treatment may also be due in part to 
the emergence of ultra-sensitive PSA assays, which enable referral for salvage 
radiotherapy at the time of a confirmed PSA rise at lower levels than were 
previously detectable. However, the most recent US patterns of care study  
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(24) did not find a rise in radiotherapy between six months (their cut off point 
for adjuvant radiotherapy) and five years after radical prostatectomy leading 
the authors to conclude that a shift to salvage radiotherapy does not entirely 
explain the declining use of adjuvant radiotherapy.  
Overall, attitudes towards CPGs in general remained positive and they were 
consistently viewed as good educational tools. This reinforces the need to 
optimise usability and adaptability of CPGs to increase impact on practice, for 
example, by offering alternate versions across different communication 
platforms including electronic versions that can be embedded within decision 
support systems. This can be achieved through appropriate planning to ensure 
guidelines are implementable.(30)   
A potential limitation of this study is the lower response rate (30%) in the 
2015 survey than that of the 2012 survey (45%). However, it is similar to the 
average response rate for other online surveys (33%) (31) and higher than 
other published clinician surveys.(13) Tests of no difference between the 2012 
and 2015 survey samples indicated that there were no major differences in 
respondent demographics. It is a further potential limitation that the 
psychometric properties of the survey have not been assessed. 
While this study necessarily presents self-reported practice, the CLICC 
implementation trial will provide independent data from medical record 
review on actual referral patterns for nearly 1000 men with adverse 
pathological features who underwent radical prostatectomy between 2011 
and 2015 in participating NSW hospitals. Full details of CLICC elements and 
data collection methods are detailed in the study protocol.(12) 
In conclusion, this survey highlights persisting clinical equipoise among 
Australian urologists in relation to adjuvant radiotherapy for men with 
adverse pathologic features following radical prostatectomy. Further it 
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suggests declining use of adjuvant radiotherapy in practice contrary to 
Guideline recommended care.     
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Chapter 10: Discussion and conclusion 
 
This thesis presents a series of iterative studies to develop and test a clinical 
network embedded intervention to increase referral of men with adverse 
pathological features post-prostatectomy to radiation oncology for discussion 
of adjuvant radiotherapy in line with clinical practice guideline recommended 
care. It is the first rigorous evaluation involving a clinical network in the 
implementation of an intervention through a phased randomised cluster trial.      
The systematic review presented in Chapter Two provided evidence that the 
ACI Urology Network was an appropriate vehicle through which to develop 
and embed the CLICC implementation trial within NSW hospitals linked to the 
network. While noting limitations with the quality of included quantitative 
studies, which predominantly used observational designs, the review found 
that clinical networks were able to achieve improvements based on several 
endpoints relating to both service delivery (such as adherence to clinical 
practice guidelines and protocols, development of clear patient pathways, and 
use of clinical tools) and patient outcomes (such as reduced mortality or 
improved time to treatment) across a range of clinical specialties. Of 
relevance to this thesis, the review found some evidence that clinical 
networks may be effective in engaging clinicians in developing and 
implementing clinical practice guidelines.    
Through a survey of Australian-based urologist members of the Urological 
Society of Australia and New Zealand (USANZ) (1) (Chapter Three) a number of 
barriers to the implementation of the Australian Cancer Network Guidelines 
recommendation for adjuvant radiotherapy for locally advanced disease were 
identified. The most commonly cited barrier was the need for individualised 
care, taking account of the patient’s post-operative recovery and treatment 
preference. There was also a lack of confidence in the randomised controlled 
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trial data that were the basis for the recommendation. This particularly 
related to the absence of a salvage radiotherapy arm to provide direct 
comparison of the efficacy of adjuvant versus early salvage radiotherapy. 
Survey participants also expressed concerns about the potential for 
overtreatment in patients whose cancer may never recur, as well as concerns 
about radiotherapy associated toxicity and side effects. Similar concerns were 
identified through the needs and barriers analysis to inform the development 
of the CLICC implementation trial (Chapter Four). Barriers were considered at 
three levels: (i) clinician; (ii) patient; and (iii) hospital systems and processes. 
In addition to some lack of knowledge, clinician level barriers included 
concerns about the quality of evidence, the potential for overtreatment, and 
radiotherapy associated toxicity and side effects. In addition, the ongoing 
RAVES clinical trial (2) comparing the efficacy of adjuvant radiotherapy with 
early salvage radiotherapy at the time of a confirmed PSA recurrence, being 
conducted locally in Australia, raised doubt about routine referral for 
radiotherapy. Alongside clinician level barriers, variation in engagement with, 
and selective presentation of cases to, the MDT were identified as cultural and 
systems and processes barriers within CLICC trial sites. Patient level barriers 
(namely treatment preference) were excluded because research governance 
and ethical approvals did not permit direct patient interaction. Using the 
PRECEDE-PROCEED model of behaviour change (3-5) as a foundation for the 
CLICC conceptual program logic framework, barriers were mapped to 
physician- and context-focused CLICC intervention elements. These included: 
predisposing factors - provider education and printed materials; reinforcing 
factors - opinions leaders and audit and feedback; and enabling factors – 
automated systems (flagging of eligible cases by the pathologist to the MDT 
coordinator for addition to the MDT agenda for discussion at a MDT meeting). 
The CLICC intervention was rolled out across nine participating sites using a 
stepped wedge cluster randomised design as per the trial protocol (6) 
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(Chapter Five). At the end of the active intervention phase the CLICC process 
evaluation (Chapter Six) was conducted to aid interpretation of outcomes and 
identify mechanisms of provider and organisational change, which were 
assessed using three domains: (i) implementation: whether the intervention 
was implemented as intended; (ii) participation and response: why the 
intervention did or did not result in evidence-based care; and (iii) context: why 
was or was not the intervention implemented or sustained across 
implementation sites. Results of the CLICC process evaluation demonstrated 
that CLICC elements could be implemented with fidelity. Within the CLICC 
conceptual program logic model, the hypothesised enabling factor, namely 
flagging of eligible cases by the pathologist to the MDT coordinator for 
addition to the MDT agenda for discussion at a MDT meeting, was considered 
by participants to be the most essential and sustainable element in achieving 
desired practice change. The automatic nature of the MDT flagging process, 
requiring no action on the part of the urologist, was noted as a key facilitator 
in the uptake of the process. Several contextual factors, most prominently 
insufficient resourcing to support flagging of patients through public 
pathology services, adversely affected implementation of the MDT flagging 
process with the result that private patients were significantly more likely to 
be flagged by pathology for discussion than public patients. 
It is of note, that while participants integrated and adopted the MDT flagging 
process into routine practice, which resulted in a significant increase in the 
secondary outcome of discussion of the patient at a MDT meeting within 4 
months after prostatectomy, they expressed uncertainty as to whether 
increased discussion would translate into an increase in the primary outcome 
of referral to radiotherapy or RAVES within 4 months after prostatectomy. 
Analyses of patient level data collected through medical record review, 
presented in Chapter Seven, indicate that this perception was correct and, 
after adjustment for potential confounders, referral was not significantly 
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different between the intervention and control groups. Thirty per cent of 
patients in the control group were referred to radiotherapy or RAVES within 4 
months after prostatectomy compared with 32% in the intervention group. 
For intervention patients who were discussed at a MDT meeting, the MDT 
recommendation was referral to radiotherapy or RAVES for 58% but this did 
not translate to an increase in the primary outcome because less than half of 
these patients were actually referred to radiation oncology by the consulting 
urologist within 4 months after surgery. One possible solution to address this 
lack of referral could be the implementation of a direct care pathway to 
radiotherapy for those with a MDT recommendation for referral, for example, 
through a letter of MDT recommendation sent to the patients’ general 
practitioner or directly to the radiation oncology unit for follow-up.  
Where documented, the most commonly cited reason for non-referral of the 
subset of patients with a MDT recommendation for referral was a low or 
undetectable PSA (<0.1ng/ml). This is fundamentally the group of patients 
that should be referred to radiation oncology for discussion of adjuvant 
radiotherapy, in line with the evidence-based clinical practice 
recommendation, and lack of referral can be considered indicative of a 
continued preference for early salvage radiotherapy at the time of a 
confirmed PSA rise. This is consistent with the results of the CLICC process 
evaluation (Chapter Six). It is also consistent with the results of CLICC 
participant surveys, conducted to assess change in knowledge and attitudinal 
outcomes (Chapter 8), which found no significant difference in treatment 
preferences, knowledge, attitudes or beliefs between baseline and post-
intervention surveys. In combination, these results suggest that the 
predisposing CLICC elements (provider education and printed materials) were 
not effective in addressing clinician level barriers associated with knowledge, 
attitudes, perceptions and norms.  
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A common denominator across Chapters Six and Seven reporting knowledge 
and attitudinal outcomes for CLICC participants and Chapters Three and Nine 
reporting the same outcomes for the wider Australian urological community 
was the continued influence of the RAVES trial on the persisting belief that 
there is insufficient evidence to support adherence to the guideline 
recommendation. Lack of definitive results from the RAVES trial was 
repeatedly used as justification for non-referral to radiation oncology for 
discussion of adjuvant radiotherapy in surveys and interviews. Of note, 
however, as reported in Chapter Seven, there was no significant change in 
referral to the RAVES trial, which closed to accrual during the course of the 
CLICC study due to a combination of a low event rate and poor recruitment. 
The low rate of referral to RAVES suggests that the trial was used by some as a 
way to opt out rather than a genuine alternative referral option that would 
generate new evidence. 
 
It was not possible to make formal statistical comparisons of knowledge and 
attitudinal changes between CLICC participant baseline and post-intervention 
surveys and changes between the 2012 and 2015 USANZ surveys. This is 
because, although CLICC participants were excluded from the 2015 USANZ 
survey, some may have completed the 2012 USANZ, which was conducted 
prior to recruitment to the CLICC implementation trial. To comply with ethical 
approvals, both USANZ surveys were anonymous unless respondents 
voluntarily provided identifying information. Without linking identifiers it was 
not possible to retrospectively exclude CLICC participants from the 2012 
USANZ sample. Analyses including individuals who participated in both CLICC 
and USANZ surveys would result in standard errors and p-values that are too 
low, potentially producing falsely significant results. The results of the follow-
up survey of urologist members of USANZ (Chapter Nine) do, however, shed 
light on external factors and broader attitudinal changes within the wider 
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urological community that may have lessened the effects of the CLICC 
intervention in a more stable environment. While there was no significant 
change in agreement with the clinical practice recommendation for adjuvant 
radiotherapy for locally advanced disease between baseline and post-
intervention among CLICC participants, there was significantly less agreement 
with the recommendation in the wider urological community in 2015 than in 
2012. There was a small but not significant increase in the proportion of CLICC 
participants who indicated a preference for adjuvant radiotherapy for a 
hypothetical clinical case between baseline and post-intervention surveys. For 
the same hypothetical clinical case there was a significant decrease in the 
proportion that indicated a preference for adjuvant radiotherapy between the 
2012 and 2015 USANZ surveys. Even after adjusting for the different time 
periods between the 2012 and 2015 USANZ surveys (on average 30 months) 
and baseline and post-intervention CLICC participant surveys (on average 10 
months) there is still a difference in point estimates (USANZ respondents were 
on average -0.6 points less favourable towards adjuvant radiotherapy over 10 
months; CLICC respondents were on average 0.2 points more favourable 
towards adjuvants radiotherapy over 10 months). There was significantly less 
agreement that the recommendation is consistent with the opinions of 
respected clinical colleagues between both the CLICC baseline and post-
intervention surveys and the USANZ 2012 and 2015 surveys. This implies that 
external peer influence served to reinforce the normative behaviour of 
watchful waiting over the evidence-based clinical practice recommendation 
for immediate referral to radiotherapy for discussion of adjuvant radiotherapy 
and this was not sufficiently addressed by the CLICC opinion leader element. 
This is perhaps not surprising given that only three of the nine Clinical Leaders 
perceived their role as one of an opinion leader to actively influence and 
promote participating urologist behaviour change. Further, given the lack of 
heterogeneity between the nine participating CLICC trial sites and generally 
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low referral patterns within the cohort, it is also possible that the provision of 
audit feedback data may have counter intuitively reinforced the status quo 
and provided justification to maintain current referral practices that were 
perceived to be in alignment with those of colleagues both within and across 
sites.   
There was some perception amongst CLICC participants, in both the CLICC 
process evaluation and participant surveys, that referral to radiation oncology 
for discussion of adjuvant radiotherapy would result in commencement of 
radiotherapy in the majority of instances. However, data from medical record 
review show that overall 9% of patients commenced radiotherapy within this 
six months of surgery. This figure is identical to recently published data from 
the Victorian Prostate Cancer Registry.(7) Within the subset of patients who 
were referred to a radiation oncologist only a little over half commenced 
radiotherapy within 6 months of prostatectomy despite more than 90% 
attending an initial consultation. This demonstrates that radiation oncologists 
do not follow the clinical practice recommendation for adjuvant radiotherapy 
for locally advanced prostate cancer uniformly for all patients. This lends 
weight to the view expressed through the CLICC process evaluation and 
participant and USANZ surveys that the clinical practice recommendation is 
not nuanced enough and does not take account of other factors such as the 
patient’s postoperative recovery, continence, potency and treatment 
preference. These factors aside, patients who are referred to a radiation 
oncologist to discuss the risks and benefits of adjuvant radiotherapy are 
arguably better able to make a fully-informed decision about what they 
consider to be the most appropriate treatment for them.  
The results of the studies included in this thesis indicate that, while 
implemented with fidelity and adopted and integrated into routine practice, 
the CLICC elements did not result in provider behaviour and knowledge and 
 279 
 
attitudinal changes, as hypothesised through the CLICC conceptual program 
logic framework, across the nine trial sites as a whole. However, the effect of 
the intervention on referral was significantly modified by site with evidence 
that the intervention worked better in some sites than others. Specifically, the 
intervention appeared to work best in four of the nine sites (Sites 1, 4, 7 and 
8), each with similar increases in referral rates. While there was a significant, 
more than threefold, increase in the secondary outcome of discussion of 
patients at a MDT meeting within 4 months of prostatectomy this did not 
translate to an increase in the primary outcome of referral to radiotherapy or 
RAVES within 4 months after prostatectomy. The CLICC trial did not have 
sufficient power to detect site level intervention effects due to small sample 
sizes associated with low caseload at some sites, however, the four sites that 
had the highest proportional increases in referral to radiotherapy or RAVES 
within 4 months after prostatectomy (Sites 1, 4, 7 and 8) were amongst the 5 
sites with the highest proportional increases in patients discussed at a MDT 
meeting. This is consistent with the hypothesis that introducing new systems 
or processes, tailored to identified barriers, can enable desired behaviour 
change if they are integrated and adopted into routine clinical practice as 
designed. Further research is necessary to explore the reasons for 
heterogeneity of CLICC intervention effectiveness between sites, and the 
determinants of effectiveness, to contribute to wider knowledge about how 
to make this type of intervention transferable across settings.(8, 9) A strength 
of the studies within this thesis was the use of mixed methods to assess 
knowledge, attitudinal and process outcomes alongside clinician behavioural 
outcomes from independent medical record review, which will enable further 
exploration of whether there is a causative relationship between them. 
It must be acknowledged that there are more than 60 theories, models and 
frameworks relevant to the dissemination and implementation of research 
into practice (10, 11). These incorporate a variety of constructs from social 
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psychology, organisational behaviour theories and socio-technical systems 
theory (12), and basing the CLICC conceptual program logic framework any 
one of these may have yielded different results. However, there is a 
recognised need to build upon and advance established theories and 
frameworks through empirical testing to increase their validity and utility for 
future implementation efforts.(9) The eight phases of the PRECEDE-PROCEED 
model of behaviour change guided each step in the development of the CLICC 
implementation trial, from social assessment of the need to improve health 
related quality of life for men with locally advanced prostate cancer, through 
tailoring of the intervention, and beyond implementation to provide a 
structured framework for the CLICC process evaluation to assess the extent to 
which elements were able to overcome barriers as hypothesised.(13) While 
the CLICC intervention was not as successful as hypothesised, this is in line 
with results of the 2015 update of the Cochrane systematic review of the 
effectiveness of tailored interventions to overcome determinants of practice 
(14), which concluded that while tailored interventions can be effective, their 
effect is variable and tends to be small to moderate. The review challenged 
the cost-effectiveness of tailored interventions compared with other 
interventions given their variable effect but through the CLICC process 
evaluation it emerged that the most tailored aspect of CLICC, namely MDT 
flagging, was the most effective element. This would suggest that a non-
tailored, single or multi-faceted, intervention incorporating more generic 
elements such as provider education, clinical champions, or audit and 
feedback would have been less effective. 
A limitation of the CLICC implementation trial was the lack of community or 
consumer engagement due to ethical restrictions. There is potential for future 
research to examine whether a patient-oriented intervention can effect 
change on clinical practice. A recent editorial (15) proposed that poor uptake 
of adjuvant radiotherapy is due to a “failure of marketing-based medicine”. 
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The introduction of patient-centred tools such as decision aids or the targeted 
dissemination of small media such as a consumer version of the clinical 
practice guideline offers the opportunity to convey evidence directly to 
patients, at the appropriate point in the care pathway, to determine whether 
they might make a different assessment of the best-available evidence in 
terms of potential risks and benefits and arrive at a different treatment 
decision than one made on their behalf by their care provider. 
More broadly, the results of the CLICC implementation trial highlight several 
general issues in relation to clinical practice guideline implementation: 
(i) Guidelines need to be implementable and this starts during the 
guideline development process.(16, 17) Ensuring that target end 
users are represented on guideline review committees or working 
parties will help overcome issues relating to the perceived lack of 
applicability or veracity that were evident in the CLICC 
implementation trial. Continued disagreement with the 
recommendation for adjuvant radiotherapy was the most persistent 
clinician level barrier to achieving desired practice change and this 
may have been mitigated by greater representation of the target 
clinical group to inform more acceptable or persuasive 
communication of the recommendation. Further, involving end 
users early in the guideline development process can help to 
achieve engagement that can be leveraged to champion subsequent 
implementation of clinical practice recommendations and reinforce 
desired changes. Gaps in knowledge can be overcome by producing 
multiple abbreviated versions of guidelines for different end users. 
For clinicians this could include, shortened versions that focus on 
treatment algorithms (nomograms in the current context) and 
clinical pathways to add the degree of nuance considered lacking 
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from the guideline recommendation for adjuvant radiotherapy and 
enable better identification of patients that will benefit. As noted 
above, patients also need to be aware of recommended care 
through consumer versions of guidelines so that they are better 
able to make fully-informed decisions and request information 
about available treatment options if this is not offered.    
(ii) Implementation of clinical practice guideline recommendations 
needs to be timely. By its very nature an implementation trial is a 
long protracted endeavour. Including the development phase, 
ethical and governance approval phase for nine separate trial sites, 
the active intervention phase, and patient follow-up, the CLICC 
implementation trial took nearly five years to complete. During this 
period, as can be seen from the 2012 and 2015 USANZ surveys, the 
external environment was changing, and forces outside the CLICC 
implementation trial were creating momentum away from the 
direction of desired behaviour change even though there was no 
new published evidence to precipitate this change in attitude. The 
CLICC implementation trial was designed to test the effectiveness of 
different implementation strategies through a randomised 
controlled trial design but other clinical practice guidelines can be 
implemented through rapid cycle quality improvement initiatives 
taking on board the lessons learned from CLICC.   
(iii) Clinicians are not necessarily able to accurately assess their own 
practice without access to data. For example, it emerged through 
the CLICC process evaluation that many participants perceived all 
high-risk cases were already being discussed at the MDT but in 
actuality less that 20% of patients were discussed pre-intervention. 
As one Clinical Leader noted, “the most important thing is the 
measurement against desirable patterns of care – you can’t manage 
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what you can’t measure so the ability to provide us with data which 
drives patterns of care positively is the main contribution CLICC has 
made”. There is a need for ongoing provision of data to ensure 
clinical practice is consistent with current evidence-based best 
practice. While acknowledging that the medical record review 
component of the CLICC implementation trial was time and labour 
intensive there is scope to provide ongoing feedback data through 
centralised cancer (or other specialty) registries to enable clinicians 
to better monitor their own practice. 
In conclusion, this thesis found some evidence that the CLICC intervention 
resulted in desired practice change. Although there was no statistically 
significant difference in the primary outcome of referral to radiotherapy or 
RAVES within 4 months after prostatectomy, self-reported treatment 
preferences for, and attitudes towards, adjuvant radiotherapy remained 
stable amongst CLICC participants despite a shift in momentum away from 
adjuvant radiotherapy in the wider urological community (albeit without any 
evidence to precipitate this change in attitude). The introduction of a new 
process for flagging patients eligible patients by the pathologist to the MDT 
coordinator for addition to the MDT agenda for discussion at the MDT 
meeting achieved a significant increase in the secondary outcome of 
discussion of patients at a MDT meeting within 4 months of surgery. This 
suggests that implementation strategies that enable clinician behaviour 
change are more effective than those designed to predispose or reinforce 
desired behaviours.  
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Detailed description of systematic review methodology
1	  
Supplementary File 1 – Detailed description of systematic review methodology 
Overall Approach  
This systematic review was conducted in accordance with the PRISMA approach to ensure 
the transparent and complete reporting of our sensitive searching, systematic screening and 
independent quality assessment [1].  The concepts and overarching methods for systematic 
reviews [2] have been adapted to be applicable for a mixed methods systematic review [3, 4]. 
Eligibility – inclusion and exclusion criteria 
Articles were eligible for inclusion in this review if: 
i) The primary focus of the paper was on clinical networks in any healthcare setting
(e.g. acute, primary, community, vertical integration)
ii) The networks corresponded with the category of network that would be included -
that is a managed or non-managed clinical network
iii) The paper reported an outcome related to improvement of quality of care or
patient outcomes (based on objective measures)
Excluded were: 
i) Abstracts and titles with the term ‘clinical network’ that were not referring to
actual clinical networks (e.g. clinical network guidelines, simulation studies for
proposed networks, protocol papers detailing study plans of networks, information
technology or infrastructure networks)
ii) Research networks
iii) Clinical trial networks
iv) Clinical guideline networks
2	  
	  
v) Integrated service delivery networks (sometimes called regional networks or 
networked hospitals, Health Management Organisations and managed care 
organisations in the United States) 
vi) Articles that used clinical networks as vehicles for samples for studies 
vii) Articles that were not published in peer review journals (e.g. conference 
proceedings)  
 
Identification and selection of publications  
Initial search (1996-2010) 
Authors BB and MH conducted the initial literature search with the assistance of a 
librarian/information scientist. Figure 1 (in the main text of the article) outlines the search 
process. We searched Medline, Embase and CINAHL to locate all research publications for 
the period 1996 to 2010 that focused on clinical networks. None of these databases have 
subject terms (i.e. MESH terms for Medline) that cover the concept of clinical networks so 
the search terms were developed based on 58 papers that were obtained through an initial 
search using the term ‘clinical networks’ and iterative searching. Box 1 contains the search 
terms used, restricted to the English language, with a year of publication between 1996 and 
2010.   
 
After duplicates were removed (N=57), researchers screened abstract titles (N=843) for 
inclusion.  Abstracts with titles that had: a) the terms ‘clinical network/s’; clinical specialty 
network (e.g. cancer network); or the word ‘network’; and b) were referring to a clinical 
network, were included (N=151).  In the case where a judgement could not be made on the 
basis of the abstract then the authors reviewed the whole publication to make a judgement on 
whether it should be included in the review.  
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Two authors (MH, BB) independently reviewed the identified abstracts for eligibility and 
cross-checked their classifications.  There was 96% agreement between the authors’ initial 
Box 1 – Search terms used to identify articles for this systematic review 
 
EMBASE 
Query 1     *National Health Service/ or *public relations/ or *Integrated Health 
Care System/ or *managed care/ or exp *cooperation/ or exp *patient care/ or exp 
*health care quality/ or exp *disease management/ or *health care management/ or 
exp Health Care System/  
 
Query 2     ((regional adj2 network*) or (national adj2 network*) or clinical 
network*).mp. [mp=ti, ab, sh, hw, tn, ot, dm, mf, nm 
 
Query 3     Combine queries 1 and 2  
 
Query 4     Limit 3 to (english language and yr="1996 - 2008") 
 
MEDLINE 
Query 1     *state medicine/ or *interinstitutional relations/ or *delivery of health 
care integrated/ or *managed care programs/ or *cooperative behavior/ or exp 
patient care management/ or exp "Quality of Health Care"/ 
 
Query 2    ((regional adj2 network*) or (national adj2 network*) or clinical 
network*).mp.  
 
Query 3      Combine queries 1 and 2  
 
Query 4     Limit 3 to (english language and yr="1996 - 2008") 
 
CINAHL 
Query 1     mm National Health Programs or mm Interinstitutional Relations or mm 
Health Care Delivery, Integrated or mm Managed Care Programs or mm 
Cooperative Behavior or mm Patient Care+ or mm Quality of Health Care+ or mm  
Disease Management or mm Health Care Delivery+ 
 
Query 2     ((regional adj2 network*) or (national adj2 network*) or clinical 
network*).mp. [mp=ti, ab, sh, hw, tn, ot, dm, mf, nm 
 
Query 3     Limit 2 to (english language and yr="1996 - 2008") 
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codes (145/151) and after discussion there was 100% agreement on whether the abstract 
should be included (n=89).  
 
After excluding abstracts for which the full text was unavailable (n=28) and including 
publications identified through screening of reference lists of included articles (n=3), two 
authors (MH, BB) independently reviewed these full text articles (n=64) and cross-checked 
their classifications to confirm whether the publication should be included in the analysis 
based on the criterion of whether the study was focused on a mandatory or non-mandatory 
clinical network.  There was 94% agreement between reviewers (60/64) and, following 
discussion, 23 articles were excluded. The remaining 41 eligible papers were coded into 
empirical (n=20) and commentary contributions (n=21).  Empirical studies were defined as 
original research and presented new data - either qualitative or quantitative. The commentary 
pieces were excluded.  As a further quality assurance measure, a third author (CP) assessed 
the eligibility of the 20 empirical studies against the above criteria. This resulted in three 
further exclusions with reasons.  
 
The remaining 17 empirical studies were included regardless of country, number of networks 
studied, clinical focus of the networks, study design or outcomes assessed in relation to the 
networks.   
 
Updated search (2011-2014) 
Following the steps outlined above, two authors (BB, CP) performed an updated literature 
search for the period covering 1 January 2011 to 30 September 2014 (PubMed and CINAHL 
were searched to update the search from 1 January 2013 to 30 September 2014). A separate 
search using the search term “clinical network” was also performed given the more frequent 
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use of this term in recent years. The search procedure is outlined in Figure 2. Following the 
same procedure as the initial search, 2,035 titles were screened, duplicates removed and 
assessed for eligibility, with 95 abstracts remaining. Based on the inclusion and exclusion 
criteria above and excluding commentary articles, we excluded 44 abstracts, leaving 51 
eligible abstracts. Both authors independently reviewed 50 full-text publications (one full-text 
was unavailable) to determine whether they should be included in the review. Forty-three 
articles were excluded, as they did not meet the eligibility criteria. Queries were resolved by 
consultation with a third author (MH). After discussion, there was 100% agreement between 
the three authors on which articles met the eligibility criteria for inclusion. Reference lists of 
the included papers and relevant commentary papers were reviewed for inclusion of 
additional eligible articles, but none meeting our criteria were found. The updated search 
yielded an additional five papers to be included in this review.   
 
With 17 articles from the initial search and 5 from the updated search, a total of 13 qualitative 
and 9 quantitative studies were included over our search period from 1996 to 30 September 
2014. 
 
Quality and assessment of risk bias 
The risk of bias and quality assessment of the quantitative studies and qualitative studies were 
assessed separately [2, 5].   
 
Quantitative Studies 
The quantitative study designs were assessed on the basis of whether they would meet the 
study design acceptable for a Cochrane Effective Practice and Organisation of Care Group 
(EPOC) review with those being: a) patient or cluster randomised control trials; b) non-
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randomised cluster control trials; c) controlled before and after studies; and d) interrupted 
time series [6, 7]. Given the lack of high quality study designs found in the included articles, 
study designs were coded into the followed grades of evidence used previously for a 
communities of practice review [8]: 
1. Experimental  
2. Quasi-experimental studies (controlled trials, time series, controlled before and after 
designs)  
3. Observational designs (before and after studies, cross-sectional studies).   
 
The assessment of the quality of the methods and reporting drew on elements of EPOC and 
the Agency for Healthcare Research and Quality [6, 9]: 
• Was the study free from selective outcome reporting? (yes/no/unclear) 
• For comparative studies, was the control/comparison group used equivalent to the 
intervention group? (yes/no) (where appropriate)  
• For non-comparative studies, were the cases representative (i.e. all eligible cases over 
a defined period of time, all cases in a defined catchment area, all cases in a defined 
hospital, clinic or group, or an appropriate sample of those cases)? [10] (yes/no) 
(where appropriate)  
• Was there a clear description of the exposure or intervention? (yes/no) 
• Was the study adequately protected against contamination? (yes/no/unclear) (where 
appropriate) 
• Statistical analysis – were the methods appropriate and was reporting adequate? 
(yes/no) 
• Was there a declaration of funding or sponsorship? (yes/no) 
• Was the study free from other risks of bias? (yes/no) 
7	  
	  
 
The studies were grouped into three categories on the basis of quality of methods and 
reporting [11]: 
• High quality – design and conduct of study address risk of bias, appropriate 
measurement of outcomes, appropriate statistical and analytical methods, low drop-
out rates, adequate reporting; 
• Moderate quality – do not meet all criteria for a rating of good quality but no flaw is 
likely to cause major bias, some missing information; 
• Low quality – significant biases including inappropriate design, conduct, analysis or 
reporting, large amounts of missing information, discrepancies in reporting. 
 
Two authors (BB, CP) independently assessed each quantitative study against the criteria 
above. There was 50% agreement (5/10 articles) and through discussion there was 90% 
agreement (9/10 articles) with final ratings given to 8 articles (see Table 1).  A third author 
(MH) resolved one instance where there was disagreement and two instances where 
additional input was sought.  The authors agreed that observational articles would not be 
given a “high” quality rating even when bias was minimised in the study due to the inherent 
flaws of an observational study design. At this stage, one article in question was deemed to be 
ineligible and excluded from this review. There was 100% agreement on the quality 
assessment rating of the nine included articles between the three authors.  
 
Qualitative Studies  
There is lack of consensus about how to assess risk of bias for qualitative studies [12]. For 
this review we considered that assessing the validity of the methods and quality of the 
reporting was the most appropriate approach to take [13, 14]. To do this, we used nine criteria 
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to assess the quality of qualitative studies recently developed by Harden and colleagues [4] 
and two criteria on the extent to which the ‘participant voice’ [15] was elucidated using a 
definition suggested by Mays and Pope [13] (see Box 2).   
 
Box 2 - Criteria used to assess the quality of the qualitative studies. 
 
Quality of reporting [4] 
1. Were the aims and objectives clearly reported? 
2. Was there an adequate description of the context in which the research was carried 
out? 
3. Was there an adequate description of the network and the methods by which the 
sample was identified and recruited? 
4. Was there an adequate description of the methods used to collect data? 
5. Was there an adequate description of the methods used to analyse data? 	  
Use of strategies to increase reliability and validity [4]	  
6. Were there attempts to establish the reliability of the data collection tools (for 
example, by use of interview topic guides)? 
7. Were there attempts to establish the validity of the data collection tools (for example, 
with pilot interviews)? 
8. Were there attempts to establish the reliability of the data analysis methods (for 
example, by use of independent coders)? 
9. Were there attempts to establish the validity of data analysis methods (for example, by 
searching for negative cases)? 
 
Quality of the application of the methods [13] 
10. The extent to which qualitative studies are grounded in and reflect study participants’ 
perspective and experiences (as evidenced by the use of supporting quotes) 
11. Whether the studies produce also rich or ‘thick’ descriptions of the investigation and 
explanatory insights rather than ‘thin’ descriptions or flat summaries of the findings. 
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We grouped these studies into three categories on the basis of quality in accordance with the 
approach used by Harden and colleagues [4] and the Cochrane qualitative research methods 
group [16].  Arbitrary cut offs were selected as:   
• High quality – those meeting 8 or more criteria 
• Medium quality – those meeting between 5 and 7 criteria 
• Low quality – those meeting fewer than five criteria 
 
Data extraction and synthesis 
Given the lack of high quality evidence from randomised controlled trial data, we adopted a 
pragmatic approach of examining all available evidence from primary observational studies, 
and assessing study quality within this lower level of the evidence hierarchy. Studies were 
first categorised as either qualitative or quantitative. Quantitative papers were then further 
categorised according to the focus of the study linked to the review objectives into two 
categories:  
1. Improving quality of care: These papers examined whether clinical networks were 
successful in improving the delivery of health care. 
2. Improving patient outcomes: These papers examined whether reorganisation into clinical 
networks or interventions implemented by networks were effective in improving patient 
outcomes.  
 
Qualitative methods were used to thematically analyse and synthesise textual data extracted 
from the qualitative studies [17]. Two authors (BB and CP) independently identified the 
focus of the qualitative papers and categorised them into four themes. As several papers 
could have been classified under more than one theme, articles were categorised on the basis 
of the most prominent theme. The four themes were:  
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1. Features and outcomes of effective networks: These papers examined what features of a 
network enabled it to be successful, and what successful networks have achieved. 
2. Network implementation: These articles described the process of implementing a clinical 
network and the key lessons learned from the implementation process. 
3. Organisational structure: These articles looked at how networks were structured and how 
its structure impacted the way the network worked (namely, the network’s ability to 
achieve its desired outcomes). 
4. Organisational learning and knowledge: These articles examined the organisational 
learning and education role of clinical networks.  
 
Due to the heterogeneity of the included studies, data were extracted directly into a data 
extraction table. Information was extracted on: i) country; ii) description of network studied; 
iii) description of the sample and size in terms of networks and participants; iv) study aim; v) 
intervention (quantitative studies); vi) design; vii) data collection method; viii) outcomes 
assessed; ix) results. One author (BB) extracted all the information from the initial search on 
the basis of what was available in the publications and a second (CP) checked all the 
extracted information. There was majority agreement between the reviewers on the data 
extracted and queries were resolved through consensus.  For the updated search, two authors 
(BB, CP) extracted information from the articles and agreed on the data extracted through 
consensus. The main findings of the quantitative and qualitative studies were first examined 
separately, and then integrated to identify recurrent themes and findings to enable 
conclusions to be drawn. 
 
Due to the heterogeneity of the included quantitative studies and their outcomes, results were 
reported narratively. Key outcomes demonstrating the effectiveness of clinical networks were 
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reported. Qualitative methods were used to synthesise textual data extracted from the 
qualitative studies. Results from the quantitative narrative analysis were then integrated with 
the qualitative synthesis in the discussion to identify recurrent themes and findings to enable 
conclusions to be drawn. Details on the findings of each of the included articles can be found 
in Additional File 2. 
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Appendix II
Detailed findings of articles included in the systematic review
1 
Additional File 2 – Detailed findings of articles included in the systematic review 
Quantitative Articles 
Reference Country Type of Network Sample Study Aim, Design, Method and 
Indicators 
Primary Results 
 Improving Quality of Care
Gale et al 2012 UK Managed clinical 
network for 
neonatal services 
Before 
reorganisation: 
from report of 
the Confidential 
Enquiry into 
Stillbirths and 
Death in 
Infancy 
(CESDI) 
Project 27/28, 
data from 1 Sep 
1998 to 30 Aug 
2000. Data was 
from England, 
Wales and 
Northern 
Ireland and was 
not 
disaggregated. 
After 
reorganisation: 
from National 
Neonatal 
Research 
Database held 
by the Neonatal 
Data Analysis 
Unit, data from 
1 Jan 2009 to 
31 Dec 2010. 
Aim 
To assess the impact of 
reorganisation of neonatal 
specialist care services in England 
following the formation of 
managed clinical networks, 
specifically the impact on access 
to specialist care for pre-term 
births  
Intervention 
National reorganisation of 
neonatal services in England into 
managed clinical neonatal 
networks 
Design 
Population-wide observational 
comparison of outcomes before 
and after the establishment of 
managed clinical neonatal 
networks. 
Method 
 Analysis of data on live births
born at 27-28 weeks’
gestation held by the Neonatal
Data Analysis Unit and
CESDI Project 27/28
Indicators 
 Proportion of babies born at
hospitals providing the
highest volume of neonatal
 The proportion of babies delivered at 27-28
weeks’ gestation in hospitals with the highest
specialist care activity increased significantly
from 18% (England, Wales and Northern Ireland)
to 49% (England only) (risk difference 31%, 95%
CI: 28 to 33; odds ratio 4.30, 3.83 to 4.82;
P<0.001), indicating success of the networks in
increasing high risk transfers
 The proportion of babies undergoing acute and
late postnatal transfer in England increased
significantly from 7% to 12% and 18% to 22%,
respectively (χ2 P<0.001)
 No difference in proportion of transferred
twins/triplets (33% vs 29%, odds ratio 0.86, 95%
CI: 0.50 to 1.46; P=0.57)
 Survival in England increased from 88% to 94%
(risk difference 5.6% (95% CI: 4.2 to 7.0); odds
ratio 2.00 (95% CI: 1.67 to 2.40); P<0.001)
 However given over half of the study population
were not delivered at a centre providing the
highest volume of neonatal intensive care
activity, poor adherence to the guidelines of the
National Audit Office and National Institute for
Health and Clinical Excellence is ongoing,
underlining the limitations of a major
reorganisation of one aspect of service provision
rather than the entire pathway of care.
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Reference  
 
Country  Type of Network  
 
Sample  Study Aim, Design, Method and 
Indicators 
 
Primary Results  
 
This data was 
from England 
only.  
specialist care 
 Proportion of acute transfer 
and/or late transfer 
 Proportion of babies in 
multiple births separated by 
transfer 
Greene et al 2009 UK Tayside Diabetes 
Managed Clinical 
Network 
13,527 patients 
with diabetes in 
the region 
treated by 72 
general 
practices and 2 
district 
hospitals. 
36 in-depth 
interviews with 
a purposive 
sample of 
people with 
high and low 
commitment to 
managed 
clinical 
networks: 
Network core 
management 
group (n=9); 
GPs (n=3); 
Hospital 
professionals 
(n=8); patients 
(n=4); patient 
representatives 
and Trust 
managers (n=5) 
Aim 
To evaluate the form and impact 
of quality improvement (QI) 
strategies used by the Tayside 
Diabetes Managed Clinical 
Network between 1998 and 2005 
Intervention 
Progressive implementation of 
multiple quality improvement 
strategies including; guideline 
development and dissemination; 
education; clinical audit, feedback 
and benchmarking; 
encouragement of 
multidisciplinary team working; 
task redesign; and care pathway 
redesign 
Design  
 Retrospective observational 
mixed-methods evaluation 
Method 
 Analysis of network 
documents (annual reports, 
planning documents, minutes 
of network meetings), 
observation of meetings and 
qualitative semi-structured 
interviews with 
multidisciplinary team 
 Simple process indicators such as measuring 
glycated haemoglobin, blood pressure and 
cholesterol rapidly improved, while there was 
slow continuous improvement for complex 
processes that required more intensive 
professional education or redesign of care 
pathways such as assessment of foot vascular and 
neurological status and retinal screening. 
 Improvements were greater for type 2 than type 1 
diabetes. 
 Between 2002 and 2006, there was a 13% 
(95%CI: 11.6% to 14.1%; p<0.001) fall in the 
proportion of newly diagnosed patients with type 
2 diabetes attending the hospital in the previous 
15 months. However the number of patients 
treated in hospital remained unchanged due to 
rising prevalence.  
 Network organisation and leadership with a clear 
vision for care were important facilitators in 
delivering QI in particular, achieving widespread 
clinical engagement through persuasion and 
appeal to shared professional values by clinical 
leaders. 
 Information technology played a supportive role 
but was not perceived to deliver QI by itself.  
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Reference  
 
Country  Type of Network  
 
Sample  Study Aim, Design, Method and 
Indicators 
 
Primary Results  
 
 members and patients 
 Analysis of impact of QI 
strategies using data extracted 
from the regional diabetes 
register at two time points – 
1/1/1998 and 1/1/2005 
Indicators 
 17 indicators of clinical 
processes and outcomes for 
patients with type 1 and type 
2 diabetes (e.g. blood pressure 
measured, foot neurological 
status assessed, mean 
glycated haemoglobin %) 
 Shifting care for 
uncomplicated type 2 diabetes 
into primary care, measured 
by rates of hospital referral 
for newly diagnosed patients 
Hamilton et al 2005 Scotland Managed clinical 
network for 
cardiac services  
N = 202 
myocardial 
infarction 
patients  < 76 
years old 
admitted 
between 1st July 
2000 and 30th 
June 2002 (97 
prior to launch 
of the network) 
and 105 after 
launch of the 
network) in 
Dumfries and 
Galloway, 
South West 
Aim 
To investigate the setup and 
operation of a managed care 
network for cardiac services, and 
assess its impact on quality of 
patient care and resource 
implications 
Intervention 
Establishment of a managed 
clinical network for cardiac 
services in a predominantly rural 
area in South West Scotland 
Design  
Quasi-experimental study design 
(interrupted time series) - Single 
case study using process 
evaluation and observational 
 The network brought clinicians, patients and 
managers together to redesign services. 
 There was statistically significant improvement in 
2 out of 16 clinical care indicators: immediate 
aspirin administration (Regression coefficient= -
35.9; p=0.037) & pain to needle times 
(Regression coefficient= -1.207; p=0.051) 
 There was non-significant improvement in 9 
other indicators.  
 Changes were not noticeable until after a 2 year 
start-up period 
 No improvement in 5 indicators. 
 Set-up costs of the MCN were £52,615 during its 
pilot year. A further £50,000 was allocated for 
administrative support and time of the clinical 
lead following the MCN’s launch. These costs are 
underestimates due to the difficulty in obtaining 
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Reference  
 
Country  Type of Network  
 
Sample  Study Aim, Design, Method and 
Indicators 
 
Primary Results  
 
Scotland before and after comparison 
Method 
 Document Reviews  
 Interviews with two patients 
and a random sample of 12 
health service personnel 
 Analysis of routinely 
collected clinical data  
Indicators 
 Process evaluation of 
network setup – how was the 
network set up, how did it 
operate, what did it do? – 
clinical leadership, 
scepticism & lack of support, 
collaboration, 
communication, quality, 
equity 
 Outcome evaluation of 
network impact – impact on 
16 quality of patient care 
indices, including percentage 
of patients receiving: 
immediate aspirin, 
thrombolysis, discharge 
medication, cardiac 
rehabilitation, secondary 
prevention at 6 months post 
MI 
 Economic evaluation of cost 
of setup and operation of 
network – what were the 
resource implications of the 
network? 
data.  
 No significant difference in hospital cost of care 
(£2,055 before and £2,053 after launch of MCN), 
length of stay or resource use. 
 An energetic lead clinician and change in 
structure of the network from a flat internal 
structure to mainly hierarchical was crucial to the 
stability and acceptability of the network, leading 
to its successful implementation. 
 
McCullough et al 
2014 
Scotland Scottish Sarcoma 
Managed Clinical 
158 patients 
identified 
Aim 
To determine whether the 
 Prior to establishment of the network more 
patients were referred directly to the sarcoma 
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Reference  
 
Country  Type of Network  
 
Sample  Study Aim, Design, Method and 
Indicators 
 
Primary Results  
 
Network 
(SSMCN) 
through a 
database of all 
patients with 
histopathology 
reports 
presenting with 
sarcomas of the 
trunk or 
extremity in 
Grampian 
between 1991 
and 2009 (79 
before 
establishment of 
the network, 79 
after; the 
network was 
established in 
2004). An 
additional 144 
records (48% of 
all records) 
were 
unavailable due 
to medical 
record 
destruction; 
most of these 
were from the 
before period.  
establishment of the Scottish 
Sarcoma Network improved the 
quality of diagnosis, treatment 
and care of sarcoma patients 
Intervention 
Establishment of the Sarcoma 
Managed Clinical Network. Key 
interventions included facilitating 
national multidisciplinary 
discussion of all sarcoma cases, 
registering case details and 
provision of care by a 
multidisciplinary team. 
Design 
Retrospective observational 
comparison before and after the 
establishment of the sarcoma 
clinical  network 
Method 
 Cohort analysis of patient 
records pre- and post-
establishment of the network 
using administrative datasets 
and medical records 
Indicators 
 Referral to specialised 
sarcoma services 
 Time to specialist review, 
 Preoperative magnetic 
resonance imaging scanning 
 Proportion of patients 
undergoing investigation with 
MRI scan prior to excision of 
sarcoma 
 Proportion of patients 
undergoing appropriate 
service by GPs, while subsequently greater 
numbers presented from other hospital specialists 
with referral numbers peaking in 2005 and 2006 
following the initiation of the network.  
 More patients were seen by more specialities 
after establishment of the network.  
 Time interval from receipt of a referral to initial 
assessment by the service improved from a 
median of 19.5 days to 10 days after the SSN was 
established (p=0.016). However the interval 
between initial GP consultation and initial 
assessment by service increased from 35 to 41 
days (p=0.57). 
 Patients undergoing investigation with a magnetic 
resonance imaging (MRI) scan prior to excision 
of the sarcoma, increased from 67% to 86% after 
the establishment of the network (p = .0009) 
 There was an increase in the number of patients 
undergoing appropriate biopsy from 57% to 79% 
(p=0.006). 
 Data were available on the adequacy of surgical 
margins in 69 patients in each group. Resection 
margins were grouped into complete and 
incomplete margins. Prior to the network, 33 
(48%) patients had documented complete 
resection and 36 (52%) were documented as 
incomplete. Post network this has increased to 56 
(81%) complete margins and 13 (19%) (p 
<0.001). 
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Reference  
 
Country  Type of Network  
 
Sample  Study Aim, Design, Method and 
Indicators 
 
Primary Results  
 
biopsy 
 Complete margins achieved at 
surgical resection 
Ray-Coquard et al 
2002 
France  Regional cancer 
network of 
hospitals 
Experimental 
group – 
patients at 4 
hospitals 
(private and 
public) 
Control group 
– patients at 3 
hospitals 
(private and 
public) 
 
Breast Cancer 
Women with 
newly referred 
localised breast 
cancer. 
Experimental 
Group: 
1994 N = 282 
1996 N = 346 
 
Control Group: 
1994 N = 194 
1996 N = 172 
 
Colon Cancer 
All new patients 
with colon 
cancer. 
Experimental 
Group -: 
1994 N = 95 
Aim 
To assess the compliance of 
medical practice with clinical 
practice guidelines in hospitals in 
a region with a regional cancer 
network and a matched region 
without a network at two time 
points.  
Intervention 
Implementation of clinical 
practice guidelines (CPGs) 
through a regional clinical 
network 
Design  
Controlled before and after study 
with hospitals in a matched 
control region  
Method 
 Analysis of institutional 
medical records from patients 
pre- and post-implementation 
of clinical practice guidelines    
Indicators 
 The number of overall 
treatment sequences judged to 
conform with clinical practice 
guidelines or to be evidence-
based 
 For breast cancer procedures 
the overall treatment 
sequence included: initial 
examination; surgery; 
chemotherapy; radiotherapy; 
 Compliance with guidelines for the overall 
treatment sequence was significantly higher in 
1996 (36%; 95%CI: 30-42) than in 1994 (12%; 
95%CI: 8-16) in the experimental group for 
breast cancer (p<0.001).  
 Compliance with guidelines for the overall 
treatment sequence was significantly higher in 
1996 (46%; 95%CI: 30-54) than in 1994 (14%; 
95%CI: 7-21) in the experimental group for colon 
cancer (p<0.001).  
 There was no change in the compliance rate in 
the control group for both cancers: 
 The number of medical decisions that conformed 
to clinical practice guidelines or judged to be 
based on scientific evidence was significantly 
higher in the experimental groups after the 
intervention. There was no significant change in 
the control groups. 
 Breast cancer: 62% (95%CI: 54-64) in 1996 
vs 47% (95%CI: 41-53) in 1994 (p<0.001) 
 Colon cancer: 86% (95%CI: 80-92) in 1996 
vs 74% (95%CI: 65-82) in 1994 (p<0.001) 
7 
Reference Country Type of Network Sample Study Aim, Design, Method and 
Indicators 
Primary Results 
1996 N = 94 
Control Group: 
1994 N = 89 
1996 N = 118   
hormonal therapy and follow-
up 
 For colon cancer procedures
the overall treatment
sequence included: initial
examination; surgery;
chemotherapy and follow-up
Ray-Coquard et al 
2005 
France Regional cancer 
network of 
hospitals 
All new patients 
with colon 
cancer and 
breast cancer at 
two audit 
points. 
Experimental 
group – 4 
hospitals 
(private and 
public) 
Control group 
– 3 hospitals
(private and 
public) 
Colon Cancer 
Experimental 
group 
1996 N = 177 
1999 N = 200 
Control group 
1996 N = 118 
1999 N = 100 
Breast cancer 
Experimental 
Aim 
To evaluate the persistence of 
conformity to clinical practice 
guideline (CPG) 
recommendations in a cancer 
network through an audit of 
medical practice records 
Intervention 
Implementation of CPG through a 
clinical network initiated in 1995 
Design  
Quasi-experimental study design - 
Controlled transversal study in 
experimental (cancer network) 
and control (no cancer network) 
groups 
Method 
 Analysis of institutional
medical records at two audit
points
Indicators 
 The number of 825 assessable
overall treatment sequences
judged to conform with
clinical practice guideline
recommendations or to be
evidence based
 The overall treatment
 Amongst breast cancer patients, compliance of
medical decisions with CPG recommendations in
the experimental group was similar for both
periods (40%; 95%CI: 35-45 in 1996 vs 36%;
95%CI: 31-41 in 1999; p=0.25). Compliance was
also the same in the control group (7% in 1996
vs 4% in 1999; p=0.99). Of note, the stratified
analysis showed that only cancer centres
maintained their initial compliance for surgical
procedures (>85% and 75% in the experimental
and control groups, respectively) whereas
compliance rates decreased to less than 70% in
all other institutions.
 For breast cancer patients, the proportion of
medical decisions that were consistent with CPG
or based on scientific evidence remained at the
same level between 1996 (50%; 95%CI: 45-55)
and 1999 (44%; 95%CI: 39-49) (p=0.01). In the
control group, these results were 8% in 1996
(95%CI: 4-12) vs 10% (95%CI: 6-14) (p=0.58).
 Amongst colon cancer patients, compliance of
medical decisions with CPG recommendations in
the experimental group increased between 1996
(56%; 95%CI: 49-63) and 1999 (73%; 95%CI:
67-79) (p=0.003). Compliance was also the same
in the control group (7% in 1996 vs 4% in 1999;
p=0.99). Compliance was also higher in the
control group (38%; 95%CI: 30-48 in 1996 vs
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group 
1996 N = 444 
1999 N = 381 
 
Control group 
1996 N = 172 
1999 N = 204 
sequence included decisions 
for each type of procedure 
individually (surgery, 
radiotherapy, chemotherapy, 
hormone therapy, initial 
examination, and follow-up) 
67%; 95%CI: 58-76 in 1999; p<0.001). Stratified 
analyses showed that the compliance rate of the 
overall treatment sequence was higher in 1999 
than in 1996 for any stage of disease in the 
experimental group, but only for the metastatic 
stage in the control group (and not for the 
localised group, p=0.11). 
 For colon cancer patients, the proportion of 
medical decisions that were consistent with CPG 
or based on scientific evidence remained at the 
same level between 1996 (83%; 95%CI: 76-89) 
and 1999 (75%; 95%CI: 69-81) (p=0.49). In the 
control group, compliance increased from 59% in 
1996 (95%CI: 50-67) to 68% (95%CI: 59-77) 
(p=0.01). 
 The authors concluded that in this network, 
clinical practice guidelines were able to produce 
sustained improvements in adherence to medical 
practice over time compared with a control 
region. 
Spence & Henderson-
Smart 2011 
Australia Australian and 
New Zealand 
Neonatal Network 
All neonatal 
nurses, 
midwives, 
neonatologists, 
junior medical 
staff, allied 
health and 
families 
providing care 
for newborn 
infants in 23 
tertiary 
institutions with 
a neonatal 
intensive care 
Aim 
To establish a process 
incorporating a team approach for 
using evidence to support practice 
change and prove its effectiveness 
in closing the evidence practice 
gap for newborn pain 
Intervention 
The implementation model used a 
clinical network with state 
facilitators, local champions and 
project teams. Interventions 
included:  
 Resource documents 
distributed to each 
 Statistically significant increase in the percentage 
of attending staff aware of an available clinical 
practice guideline for management of newborn 
pain (61% to 86%; p=0.000)  
 21% improvement in the number of infants 
receiving sucrose for procedural pain (p<0.005). 
 Use of pain assessment tool increased from 14% 
to 22%, although was still under-utilised.  
 56% (13/23) of units introduced the use of a pain 
assessment tool into practice. 
 Distribution of information resulted in an 
increase in family awareness that their infant can 
experience pain and strategies to manage the pain 
(19% to 57%, p=0.000). The proportion of 
families that received any form of printed 
9 
Reference Country Type of Network Sample Study Aim, Design, Method and 
Indicators 
Primary Results 
unit, one special 
care unit and 
special care 
nurseries in 9 
district hospitals 
across 8 
Australian 
states 
participated in 
the project. 
Neonates of all 
gestational ages 
and post-natal 
ages who were 
in-patients in 
each unit during 
the audits were 
included as part 
of a quality 
improvement 
project. 
participating unit 
 Educational workshops on
critical appraisal
 Audit and feedback at
baseline and after 18 months
 Point of care reminders
 Posters and parent
information brochures
 Clinical practice guideline
Design  
Observational before-and-after 
study.  
Methods 
 Surveys of clinical practices
 Prospective collection of data
from participating units at
baseline and 18 months after
commencement of the project
 Audit of the use of a pain
assessment tool for ventilated
neonates 3 months prior to
the project and 2 years after
commencement
 Audits with families of
infants
Indicators 
 Use of sucrose or
breastfeeding for procedural
pain
 Use of pain assessment tool
for ventilated neonates
 Parents awareness of their
infant’s pain
information doubled from 8% to 17%. 
 Some targets were not met during the two year
study period but a process for sustainability was
established through the network to allow that to
occur in the future
 Improving patient outcomes
McClellan et al 1999 US End Stage Renal 
Disease  (ESRD) 
Within each 
ESRD network, 
Aim  
To assess the association between 
 At baseline there was substantial variation
between networks in URR, with mean age,
10 
Reference Country Type of Network Sample Study Aim, Design, Method and 
Indicators 
Primary Results 
Networks each year 
between 1994 
and 1997, an 
annual random 
sample was 
selected of 
Medicare 
beneficiaries 
aged 18 and 
over receiving 
haemodialysis 
in the fourth 
quarter of 1993 
– 1996.
Network 
specific 
interventions 
were conducted 
with a 10% 
sample of 
treatment 
centres in each 
of the18 ESRD 
Networks  
quality improvement 
interventions and change in  
haemodialysis adequacy using 
network specific interventions 
Intervention 
Network specific interventions 
included education on quality 
improvement, workshops, on-site 
assistance, distribution of an 
algorithm for assessing dialysis 
adequacy and distribution of 
clinical practice guidelines. 
National intervention reports were 
generated, comparing URRs by 
network, distribution of 
guidelines and patient education. 
Design  
Evaluation of a population-based, 
prospective quality improvement 
intervention.  
Method 
 Completion of a network-
specific activities survey to
ascertain interventions
undertaken by each network,
and an annual patient-level
survey (completed by staff at
each dialysis facility) to
inform calculation of URRs.
 Analysis of haemodialysis
adequacy before and after
national and network-specific
quality improvements
interventions
Indicators 
proportions of patients who were male or black, 
and distribution of causes of ESRD.  
 Mean URR increased from 63% in 1993 to 67%
in 1996 (p<0.001).
 The proportion of under-dialysed patients
decreased from 56.6% in 1993 to 31.7% in 1996
(p<0.0001).
 Prolonged supervision in selected facilities was
associated with an increased rate of improvement
in URR from 62.1% at baseline to 67.7% after the
intervention (p<0.001).
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 Network-specific Urea 
reduction ratios (URRs) 
Tideman et al 2014 Australia Integrated cardiac 
support network 
(Integrated 
Cardiovascular 
Clinical Network 
– ICCNet) 
29,623 
independent 
contiguous 
episodes of MI 
identified 
through hospital  
administrative 
data and 
statewide death 
records from 1 
July 2001 to 30 
June  2010 in 
rural and 
metropolitan 
hospitals in 
South Australia, 
representing all 
independent 
contiguous 
cases of MI in 
South Australia 
during that time 
period. 
 
Aim 
 To evaluate the impact of the 
regionalised Integrated 
Cardiovascular Clinical 
Network (ICCNet) on 30-day 
mortality among patients with 
acute myocardial infarction 
(MI) presenting to hospitals in 
a rural setting.  
Intervention 
Three key design features of the 
network: 
 Standardised risk 
stratification and evidence-
based treatment protocols 
 Point-of-care testing for 
whole-blood troponin T levels 
with central quality control 
 A designated on-call 
consultant cardiologist to 
ensure response within 10 
minutes and facilitation of 
transfer to metropolitan 
hospitals  
Design 
Retrospective state-wide 
observational comparison of 
outcomes before and after the 
establishment of a regionalised 
integrated Cardiovascular clinical 
network 
Method 
 Analysis of routinely 
 The mean predicted 30-day mortality was lower 
among rural patients compared with metropolitan 
patients, while actual mortality rates were higher 
(30-day mortality: rural, 705/5630 [12.52%] v 
metropolitan, 2140/23 993 [8.92%]; adjusted 
odds ratio [OR], 1.46; 95% CI, 1.33–1.60; P< 
0.001). 
 Overall, annual mortality rates declined over the 
9 years (per year, ORrisk-adj 0.97 [95% CI, 0.95–
0.99]; P < 0.001). However, these declines were 
greater in rural areas (interaction between year 
and rural location, P = 0.04). In 2001, the 
adjusted OR for patients presenting in rural areas 
was 1.69 (95% CI, 1.40–2.04; P < 0.001), but by 
2010 this was no longer significant. 
 Among rural hospitals, 30-day mortality was 
lower among patients presenting to hospitals 
integrated into the clinical network compared 
with those not in the network (OR=0.78; 
P=0.007).  
 After adjustment for temporal improvement in 
MI outcome, baseline comorbidities and MI 
characteristics, availability of immediate cardiac 
support (i.e. presentation to an ICCNet hospital) 
was associated with a 22% relative odds 
reduction in 30-day mortality (OR, 0.78; 95% CI, 
0.65–0.93; P= 0.007). 
 A strong association between network support 
and transfer of patients to metropolitan hospitals 
was observed (before ICCNet, 1102/2419 
[45.56%] v after ICCNet, 2100/3211 [65.4%]; P< 
0.001). Increased transfers were associated with a 
lower total length of stay compared with 
12 
Reference Country Type of Network Sample Study Aim, Design, Method and 
Indicators 
Primary Results 
collected data for patients 
with a diagnosis of 
myocardial infarction pre- and 
post-implementation of the 
network, comparing rural 
network hospitals with rural 
non-network hospitals and 
metropolitan hospitals. 
Indicators 
 Risk-adjusted 30-day
mortality
 Rate of transfer of rural
patients to metropolitan
hospitals
 Proportion of patients
receiving angiography
admissions before implementation of the 
network. 
 Rates of angiography increased among rural
patients, but remained lower than metro patients.
The difference between rural and metro patients
diminished over the time period.
 Increasing co-morbidities were associated with a
lower likelihood of transfer among rural patients.
Patients presenting to rural hospitals within the
network were more likely to be transferred to a
metro hospital than patients presenting to rural
hospitals outside the network (OR=2.23;
P<0.001) and were associated with a reduction in
mortality across all degrees of comorbid risk.
13 
Qualitative Articles 
Reference Country Type of Network Sample Study Aim, Design, Method and 
Indicators 
Results 
 Features and outcomes of effective networks
Ahgren & Axelsson. 
2007 
Sweden ‘Chains of care’ 
(managed clinical 
networks) for 
patients having 
the same illness or 
symptom 
6 chains of care 
networks –  
3 selected to be 
successful 
3 selected to be 
unsuccessful in 
developing 
chains of care in 
4 counties. 
Aim 
To identify the factors and their 
relative importance that may be 
important for the development of 
chains of care  
Design 
Cross-sectional embedded 
multiple-case study  
Method 
Semi-structured group and 
individual interviews and studies 
of documents  
Indicators 
Success of network: 
Extent of functional integration 
that included clinical, 
administrative as well as financial 
integration within the chain of 
care. 
Explanatory factors were: 
 Development focus
 Development opportunities
 Organisational structure
 Organisational culture
Each sub-unit of analysis had 
several indicators. 
 Success of networks was based on the extent of
their functional integration
 It was important that the focus of the
development was compatible with the culture of
the organisations
 3 networks were considered to be unsuccessful
based on their lack of functional integration
 The three major determinants of successful
networks were: professional dedication of the
staff within the networks; legitimacy of the
network; confidence of the staff and organisations
involved.
 Networks initiated locally by dedicated
professionals, physicians in particular, are more
likely to have a successful outcome
Baker & Wright 2006 UK Managed clinical 
network for 
paediatric liver 
services 
93 practitioners, 
patients, 
families of 
patients, drug 
company 
representatives 
Aim 
To address the special problems 
arising from tension between need 
for centralisation of skills and 
advantages of decentralisation of 
care 
 The requirements of patients and families
overlapped with the ideals of professionals
 Results of the three sessions agreed broadly on
the elements essential to the creation of a
successful clinical network
 Key elements included patient education, open
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and NHS 
managers  
Design/Method 
Appreciative enquiry sessions 
held in 3 locations: Crieff, 
Birmingham & London 
Indicators 
 Learning 
 Roles and relationships 
 Share-care and liver disease at 
home 
 Access to services/first 
interaction 
 Standards, protocol and safety  
and inclusive communication, customer care, a 
clear care pathway, and national protocols, guides 
and standards 
 The vision for the MCN was partner 
relationships, respect for autonomy, personal 
autonomy, information and service access, least 
possible disruption of normal life with flexibility 
according to personal needs and patient 
centredness 
 Features of a successful network were identified 
as: 
 Care as close to home as possible 
 Open and inclusive communication 
 A clear care pathway 
 Better customer care including interactions 
with a key worker/coordinator 
Cunningham et al 
2012 
Australia Advisory clinical 
networks – two 
networks for 
musculoskeletal 
health in two 
states in Australia 
(New South 
Wales and 
Western 
Australia) 
36 interviews 
with key 
informants 
(network 
managers, 
network 
members and 
stakeholders 
including 
representatives 
from 
Departments of 
Health and 
clinical and 
non-
governmental 
organisations) 
Aim 
To describe the features and roles 
of clinical networks and identify 
factors relating to clinical network 
effectiveness and sustainability, 
and to explore achievements of 
the networks. 
Design 
Longitudinal comparative case 
study 
Methods 
Semi-structured in-depth 
interviews to ascertain perceptions 
of network members and 
stakeholders regarding key factors 
relating to clinical network 
effectiveness and sustainability 
conducted between March-August 
2011 
 19 of 92 core members in 
 Interviewees perceived a network to be 
successful: 
 At the community level if there was greater 
consultation, greater agreement and 
acceptance of network recommendations, 
greater implementation of Models of Care, 
improving practice patient care and 
measureable improvement in patient 
outcomes;  
 At the network level if the network was able 
to get together measured by growth in 
network membership, broad stakeholder 
representation, and contribution of the 
network manager and network leadership;  
 At the member level if there is member 
participation and responsiveness in the 
network, member contribution to the network, 
and success in embedding practice changes in 
the member’s own hospital/clinic. 
 Network manager and leadership were perceived 
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NSW interviewed 
 17 of 34 core members in WA 
interviewed 
Indicators 
 Measures of effectiveness at 
the community, network and 
member level at the short, 
medium and long term 
 Key achievements of each 
network 
as being critical for the success of the networks. 
 Both networks used a distributive leadership 
model, and a structure of establishing key 
working groups led by expert members of the 
network. 
 Stakeholders noted the role of networks in 
identifying gaps between current practice and 
evidence-based practice; directing care into more 
evidence-based practices and improve 
professional/patient interface; collaboration 
across health sites; effective communication with 
and inclusion of a broad range of stakeholders; 
engaging clinicians and enabling them to 
contribute to policy. 
 Challenges included funding and a disconnection 
between network recommendations and 
implementation especially if the network did not 
have the authority for implementation. 
Hogard & Ellis 2010 UK Managed clinical 
network for 
personality 
disorder (PD) 
All members of 
staff involved in 
the MCN 
Aim 
To evaluate how the network had 
performed in its purpose to 
establish a better coordinated 
service for patients with PD and 
what changes or refinements 
might be required 
Design 
Evaluation Trident methodology 
Method 
Evaluation of outcomes, 
processes and multiple 
stakeholder perspectives over a 2 
year period including: interviews, 
focus groups, telephone 
interviews, questionnaires, 
documentation analysis and NHS 
data sets. Processes were further 
 On the basis of the audit, staff in the network 
could be described as in a partnership in that they 
shared values and objectives. However such 
commitments in principle do not guarantee 
clinical effectiveness. 
 Positives of the network reported included being 
able to provide a holistic service to users 
including provision of a nonmedical assessment 
and formulation and ultimately encouraging 
better engagement with clients. The wide range of 
services linking into the network was also 
commended. 
 Negatives of the network reported included a lack 
of funding and resources leading to limited 
capacity to coordinate care for a large number of 
clients, the speed with which the network was 
able to process referrals, and poor 
communication. Tension in relationships between 
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Indicators 
Results 
assessed using the following 
standardised dedicated measures: 
A partnership audit tool (PAT); a 
care programme approach audit 
tool (CPA) and the PD self-
capabilities framework self-audit 
tool (PDCF). 
Indicators: 
 Outcomes- Focus on 2 key
outcomes relating to
effectiveness of treatment
provided: reduction in
frequency of crises;
reduction in inappropriate
service use
 Process – 5 main focuses:
organisational and
functional structure; service
user pathway; partnership;
care planning approach
(CPA); staff development
needs
 Stakeholder interviews –
explored five core themes:
1. Attitude prior to joining
the network; 2. Attitude 
changes as a result of 
joining the network; 3. The 
impact of MCNs; 4. 
Working relationships; and 
5. The value added by the
PD MCN 
network staff and referrers were also reported, 
with participants noting a need to improve 
working relationships and transfer of knowledge. 
 Record keeping for assessment and clinical
assessment was at an early stage and there was a
need for a more systematic use of assessment
instruments and data management instruments
 The service did not keep appropriate information
that could be used to measure outcomes and tools
to measure crisis were being used inconsistently
by network staff. There were challenges in
capturing whether there was an impact for service
users and a lack of evidence regarding clinical
outcomes.
 Much of what was reported in this evaluation
relied on anecdotal data, due to a lack of formal
evidence.
 While the network had achieved its objectives to
establish new operational structures it was
unclear whether it had maintained or improved
clinical services.
 Stakeholder interviews indicated that prior to
joining the MCN a number of staff had
previously viewed PD in a negative light. Many
staff reported that their attitude towards PD had
not changed since joining the network but a
number did explain that their knowledge and
experience had increased significantly.
 Staff highlighted the benefits of working as part
of a MCN which was viewed as a way to provide
an efficient and informed service.
 Working relationships within the MCN were
viewed positively on the whole, despite some
tensions between network staff and the referrers.
 The MCN was considered by staff to have added
value by raising the profile of PD and helping to
17 
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share skills and knowledge across a number of 
agencies and services. 
 However the benefits of the MCN “remain 
theoretical rather than proven”. 
   
McInnes et al 2012 Australia Voluntary 
collegial clinical 
networks in New 
South Wales, 
Australia 
established by the 
NSW Agency for 
Clinical 
Innovation 
27 interviews 
with network 
drivers 
especially 
network 
managers (9), 
network 
participants (6), 
senior health 
service 
managers in a 
clinical 
operations or 
clinical 
governance role 
at a hospital (4), 
and senior 
policy-makers 
(8). 
Aim 
To identify key stakeholders’ 
views on the conditions required 
to establish successful and 
effective clinical networks and 
what they identify as outcomes of 
successful clinical networks. 
Design 
Comparative case study 
Methods 
A purposive maximum variation 
sampling approach was used to 
recruit the four types of 
participants. 27 individual semi-
structured face-to-face interviews 
were conducted. Sample size was 
determined by saturation of 
themes. 
Indicators 
 Factors necessary for 
effective networks 
 Outcomes indicating whether 
clinical networks are effective  
 Factors necessary for networks to be effective 
included: 
 Building relationships within and with 
external networks and a strong commitment 
to the networks 
 A bottom-up approach to integration, 
preferably locally-initiated but with 
formalisation of the networks 
 Supportive policy environments and links 
with state health agencies and local health 
services  
 Strong leadership, including passionate 
clinical leaders, was necessary for effective 
structure, organisation and governance 
 A strategic, feasible evidence-based work 
plan with measureable milestones and that 
was valuable to participants 
 Adequate resources including a dedicated 
network manager and technological resources 
 The ability to implement changes in practice 
or service delivery to address gaps in current 
practice, that are relevant to members, 
feasible and measureable  
 Features of ineffective networks included: 
 Lack of funding and resources 
 Tension between network members 
 Poor communication 
 Poor record keeping making it difficult to 
assess impact 
 Poor teamwork and working relationships 
 Lack of inclusion of certain populations 
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 The following outcomes of successful clinical
networks were identified:
 Better working relationships and greater
interdisciplinary collaboration in patient care
and development of research projects
 Open and transparent partnerships with
external stakeholders such as the health
department and greater mutual understanding
of perspectives
 More effective clinical services reflected by
improving patient journeys, clear care
pathways, provision of holistic services,
standardising care, reducing variation in care,
reducing costs and monitoring quality
 Implementation and wide-scale spread of
network initiatives and impact on practice
 Growth of the network
 Network Implementation
Fleury et al 2002 Canada Mental health 
integrated service 
network 
N = 143 staff 
and 
administrators 
at all levels of 
service 
intervention, 
clients of self-
help groups and 
outpatient 
clinics and 
relatives and 
friends of the 
mentally ill 
selected using 
an intentional 
sampling 
strategy and 
interviewed in 
Aim 
To examine the process of 
implementing regional planning 
and the influence of contextual, 
structural, cultural and dynamic 
factors on forming networks 
Design  
Case study and multi-dimensional 
analytic model 
Method 
 Interviews
 Review of primary sources
(e.g. minutes,
correspondence,
administrative documents and
policies)
 Review of secondary sources
 The study found that regional planning involving
stakeholders was not sufficient for implementing
mental health care networks integration as it did
not create a genuine reconfiguration of services
 Successful implementation was inhibited by
several factors including:
 the large number of professionals involved in
different services,
 ambivalence towards network priorities when
and if opposed to organisational priorities and
rigidity of established practices,
 centrality rather than dispersion of power,
 the lack of recognition of legitimacy and
expertise of planners,
 irreconcilable visions of system structuring,
 the lack of clinical, function and professional
integration,
 hospitals maintained a centralised position in
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six time periods 
from Winter 
1995 to 
Summer 1997 
(e.g. mental health, 
organisational theory, 
network literature)  
Indicators 
The framework focused on three 
lines of analysis:  
 Context for implementing the 
regional planning procedure 
 Determinants of 
implementing and impact of 
regional planning such as 
problem-setting, network 
direction setting and 
structuring 
 The dynamic of developing 
regional planning 
the networks that allowed them to hoard 
resources. 
 The study reinforced that reform can only be 
implemented with the approval and genuine 
participation of the professionals directly 
involved the field 
Tolson et al 20059  Scotland Managed clinical 
network 
(Palliative Care), 
linking primary, 
secondary and 
tertiary care 
1 network 
sample in study 
 
3 older men, 
their families,  
the doctors and 
nurses 
providing care, 
along with 13 
members of the 
network 
management 
group 
Aim 
 To evaluate, refine and inform 
the ongoing development of 
the MCN.  
 To reflect of the merits and 
challenges of a realistic 
evaluation design in 
establishing a new palliative 
care MCN to implement a 
care guideline for pain 
management in a primary care 
setting. 
Design 
A “realistic evaluation design”.  A 
qualitative pilot study evaluating 
guideline implementation at three 
separate points (6, 11, and 15 
months) during the 
implementation of managed 
 Progress in establishing the network was much 
slower than expected and was hindered by: 
inexperience in change management and 
unfamiliarity with leading practice development 
projects and supporting practitioner learning. 
 Co-ordination, leadership and strategic support 
(particularly professional buy-in) in change-
management were critical to success. 
 There was a consistent trend of an increasing 
recognition over time about the pivotal role of 
practitioners in the development of the network. 
 Professional outcomes centred on improved team 
working and enhanced communication, increased 
knowledge, greater satisfaction, reflective 
practice and increased commitment to evidence-
based care.  
 In terms of patient outcomes, there was 
accumulating evidence of better pain 
management and symptom control, and increased 
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clinical network.  
Method 
Findings from qualitative 
interviews and patient-level 
clinical data comprised case 
studies of patient-centred 
experiences of care. These case 
studies, along with semi-
structured interviews with health-
care professionals informed the 
evaluation, reviewed and refined 
by the network executive. 
Indicators 
Relationships between: 
 Context 
 Mechanisms  
 Outcomes  
knowledge through better patient education.  
 The amount of time and input demanded of the 
coordinator role was high and increased with 
wider reach of the network. 
 The length of time and effort required to achieve 
buy-in into the network is high. This often 
involves a “values reconciliation” phase  where 
members examine and compare their own/team 
values and practices to those of the network.  
 Networks can only be effective if the appropriate 
(often numerous) steps are taken and the context 
is favourable (e.g. clinicians are receptive to audit 
and feedback).  
 
 
Touati et al 20068  Canada Managed clinical 
network (cancer) 
5 hospitals 
offering 
oncological 
services in the 
Quebec region 
Aim 
To determine the extent of clinical 
leadership as a means for 
transforming health care in an 
oncological services network 
Design 
Longitudinal qualitative case 
study using process analysis to 
examine how the networks 
influenced change  
Method 
Data collected from 1999-2003 
included: 
 Non-participant observation 
of 50 administrative meetings 
relating to governance of 
change 
 65 semi-structured interviews 
with network promoters 
 Inter-professional and inter-organisational trust 
developed in all hospitals.  However the level of 
commitment by physicians and professionals to 
the implementation of the network varied.  
 All of the hospitals attempted to stabilise 
oncology teams and felt that they benefited from 
administrative support to set up clinical teams. 
 In varying degrees all hospitals implemented 
measures to foster cooperation between 
professionals. Interdisciplinary team meetings 
were being held in 4 out of 5 hospitals but 
oncologists did not participate in all hospitals. 
 In 4 out of 5 hospitals, most respondents shared 
the philosophy and vision promoted by the 
governance of the network with regard to: 
response to all of the individual’s needs; 
coordinated care; standardisation of clinical 
practices; and patient-centered care. 
 Clinical leadership is effective in implementing 
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including clinician leaders, 
professionals from 
multidisciplinary teams, 
hospital managers 
 Document analysis (e.g. 
protocols, budget statements) 
Indicators 
 Origins of change 
 Facets of integration: 
- normative  
- functional 
- clinical 
change but is limited. Contextual variables, the 
nature of the changes emphasized (those 
consistent with the actors’ values and interests) 
fostered change.  
 Positive change is more likely to be achieved by a 
‘constellation of clinical, administrative and 
political leaders’ at different levels of the health 
care system.  
 To enhance the coordination of care, coordination 
committees were set up to jointly formalise 
processes involving nursing care case-
management. Longstanding collaboration 
facilitated the implementation of these 
committees.  
 The study highlights the complexity of health 
services integration processes which demand 
considerable time, resources and initiatives at 
different levels of the health system. 
 Organisational Structure 
Addicott R 2008 UK Managed clinical 
network for 
cancer services 
117 
professionals 
from 5 cancer 
networks in 
London 
Aim 
To explore the changing model of 
governance in the UK, 
particularly the increasing focus 
on networks and the role of the 
network Board 
Design 
Comparative case study 
Method 
 Semi-structured interviews 
with nurses, clinicians, 
managers and policy makers 
 Document analysis 
 Observation at meetings  
Indicators 
 Network structure 
 Purpose of the network 
 Cancer network management teams and Boards 
had limited strategic influence as networks were 
constrained by a continued emphasis on 
centralised performance management and 
structural reconfiguration 
 Success of decision making was dependent on 
seniority of representation on the network Board. 
In only 1 out 5 networks the Board had high 
representation from extremely senior 
representatives and this Board had a noteworthy 
impact on strategic decision making. 
 Both the network management teams and Board 
only had minimal decision-making influence 
within a prevailing centralised bureaucratic 
structure. Although the espoused logic of the 
network was to decentralise decision making to a 
local level, power and budgetary responsibilities 
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Indicators 
Results 
 Network Management Team
approach to networking
 Characteristics of the Board
 Approach to organisational
change
ultimately remained centralised. Network Boards 
have had limited scope for strategic decision 
making. 
 The key finding is that the managed network
model was not powerful enough to
deinstitutionalise the prevailing governance
discourse of performance management and
centralised accountability.
Addicott R & Ferlie 
E 2007 
UK Managed clinical 
network for 
cancer services 
117 
professionals 
from 5 cancer 
networks in 
London 
Aim 
To explore and theorise the nature 
of power relations within a 
network model of governance 
Design 
Comparative case study 
Method 
 Semi-structured interviews
with nurses, clinicians,
managers and policy makers
 Document analysis
 Observation at meetings
Indicators 
3 tracers of power relationships: 
 Centralisation of specialist
services
 Budget/resource allocation
 Education and training
activities
 The 5 networks were structured in similar ways
due to the national policy agenda.
 Network Management Teams had no statutory
influence or performance management
mechanism and had to rely on interpersonal skills
to influence cooperation. A lack of these skills
frequently resulted in inability to generate
meaningful changes or control the delivery of
services.
 Decision making was dominated by medical staff
in all 5 networks.
 During localised decision-making and
implementation of policy less dominant medical
professionals presented barriers in an attempt to
exert influence.
 These cases demonstrated that the internal
divisions in the medical profession, with active
power and influence unevenly distributed in
favour of those in the cancer centre while less
powerful medical professionals were then forced
into defensive mode to resist decisions that had
been made.
Addicott R, 
McGivern G & Ferlie 
E 2007 
UK Managed clinical 
network for 
cancer services 
117 
professionals 
from 5 cancer 
networks in 
London 
Aim 
To explore how stakeholders 
involved in the delivery of cancer 
services in the UK adopted or 
adapted managed clinical 
networks as a novel managerial 
 The knowledge sharing purpose of networks was
distorted by top-down structural reorganisation
demands of central government resulting in
superficial bottom-up adoption of the networks
models and a lack of focus on process or strategic
issues.
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technique for sharing best practice 
and knowledge 
Design 
Comparative case study 
Method 
 Semi-structured interviews 
with nurses, clinicians, 
managers and policy makers 
 Document analysis 
 Observation at meetings  
Indicators 
3 tracers of knowledge 
management: 
 Centralisation of specialist 
services 
 Budget/resource allocation 
 Education and training 
activities (an indicator for 
knowledge management 
activity) 
 The centralisation process was feared by 
clinicians and negatively impacted on alternative 
educational and knowledge sharing activities. 
 In 4 out of 5 networks there was frequent 
resistance to making decisions and implementing 
changes. 
 One network demonstrated greater network-wide 
investment in education and training activities. 
This was largely due to a strong, well-perceived 
Network Management Team which began to 
develop an educational strategy across the 
network. 
 Overall, networks had little impact on 
organisational processes. The majority of 
networks had a limited focus on educational and 
training activities, and broader issues surrounding 
organisational change.  
 One network was an outlier. An open and 
facilitative approach to managing networks was 
more successful. The network was more 
successful in building on pre-existing 
relationships that were evident prior to 
establishment of the networks. Those involved in 
managing and leading the network were 
successful in considering the needs of the local 
context during the process of implementing the 
network.  
 Organisational Learning and Knowledge 
Addicott et al 2006 UK Managed clinical 
network for 
cancer services  
117 
professionals 
from 5 cancer 
networks in 
London 
Aim 
To explore whether the 
knowledge management function 
of managed clinical networks was 
realised in practice 
Design 
Observational, cross-sectional  
organisational process study  
 There was little evidence of change in practice 
within 4 out of 5 networks. This was considered 
to be a result of interorganisational competition 
following from structural reconfiguration, an 
emphasis on achieving targets and conformance 
with protocols and persistent interprofessional 
boundaries.  
 In 1 out of 5 networks there was cohesion within 
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Method 
 Semi-structured interviews 
with nurses, clinicians, 
managers and policy makers 
 Document analysis 
 Observation at meetings  
Indicators 
Network impact on: 
 structural reconfiguration 
 budgetary allocation 
 educational and training 
activity 
the network and the structural reconfiguration 
process resulted in significant changes in 
practice. 
 In this ‘successful’ network, there was more 
evidence of learning, training, knowledge 
sharing, and education. This was thought to be 
due in part to the network being well and 
supportively managed, facilitating engagement, 
having a detailed understanding of cancer 
services, a localised appreciation for the 
dynamics of the organisations involved, and good 
pre-existing relationships between members of 
the network prior to commencement.  
 Lack of success in the other four networks was 
perceived as being due to limited time and 
resources, lack of enthusiasm from network 
members, and increased competition for 
resources within each network. Respondents from 
cancer centres were more positive about the 
learning aspects of the networks than 
representatives from peripheral units. Some 
thought that learning would become a greater 
priority when structural reconfigurations were 
underway or complete.  
Burnett et al 2005 UK Managed clinical 
networks (MCNs) 
9 interviewees 
from Scottish 
MCN priority 
areas: cancer, 
coronary heart 
disease, stroke 
and mental 
health and a 
representative 
from local 
health 
community co-
Aim 
To explore the extent to which the 
information culture and practices 
within MCNs and whether they 
are able to deliver improved care  
Design/Method 
Qualitative information and 
knowledge needs analysis 
comparing responses from MCN 
respondents with those from a 
previous study of staff working in 
a more traditional environment   
 Evidence-based practice was a requirement 
within the Scottish Health Service in general and 
within the MCN in particular, noting the 
importance of being able to access information. 
 Individuals working within the MCN perceived 
that information and knowledge had an impact on 
service delivery and demonstrated a greater 
ability to reflect on the value of knowledge and 
information in their roles 
 Information and communication technologies 
(and in particular the e-Library) was widely 
recognised as an important for access to health 
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Results 
operative; 
respondents 
represented a 
range of roles 
including 
specialist 
nurses, lead 
clinicians, 
planning and 
implementation 
managers.  
Method 
 Semi-structured in-depth
interviews; approximately 1
hour in duration.
Indicators 
 How MCN staff used
knowledge in their roles,
requirements of the
knowledge base and problems
with knowledge provision;
 Role of information in
supporting evidence based
practice
 Perceptions of the e-Library
 Education and training
 IT support
 Barriers to the use of
information
care knowledge and MCN respondents reported a 
greater need for and confidence in information 
literacy. 
 MCN respondents also considered colleagues an
important source of information with emphasis on
the inter-disciplinary and cross-boundary aspects
of MCNs facilitating knowledge transfer.
 Healthcare professionals in MCNs discussed
information facilitating communication with
patients and including patients as a part of the
“knowledge network”.
 The MCN group demonstrated an ability to
reflect on the value of information and
knowledge in their roles. They saw information
and knowledge as having an impact on service
delivery. They also recognised that it is vital to
have easy and timely access to the information
and knowledge they require to operate as
effectively and efficiently as possible.
Appendix III
PRISMA 2009 Checklist
PRISMA 2009 Checklist 
Section/topic  # Checklist item  Reported on page #  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  43 
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, 
participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and 
implications of key findings; systematic review registration number.  
43-44 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  44-46 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, 
outcomes, and study design (PICOS).  
46 
METHODS   
Protocol and registration  5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide 
registration information including registration number.  
N/A 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-­‐up) and report characteristics (e.g., years considered, 
language, publication status) used as criteria for eligibility, giving rationale.  
49 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify 
additional studies) in the search and date last searched.  
49 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that it could be 
repeated.  
Appendix I 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, 
included in the meta-­‐analysis).  
49-52, 
Appendix I 
Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes 
for obtaining and confirming data from investigators.  
52, 
Appendix 
II 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and 
simplifications made.  
Appendix I 
Risk of bias in individual 
studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was 
done at the study or outcome level), and how this information is to be used in any data synthesis.  
51, 
Appendix I 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  N/A 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including measures of consistency 
(e.g., I2) for each meta-­‐analysis.  
N/A 
 
PRISMA 2009 Checklist 
Section/topic  # Checklist item  Reported on page #  
Risk of bias across studies  15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective 
reporting within studies).  
N/A 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating 
which were pre-­‐specified.  
N/A 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at 
each stage, ideally with a flow diagram.  
Fig. 
2.1&2.2, 
Appendix I 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and 
provide the citations.  
52, 
Appendix 
II 
Risk of bias within studies  19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).  Table 2.2, 
2.4 
Results of individual studies  20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each 
intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.  
52-68, 
Table 2.3, 
2.5,  
Appendix 
II 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.  N/A 
Risk of bias across studies  22 Present results of any assessment of risk of bias across studies (see Item 15).  N/A 
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).  N/A 
DISCUSSION   
Summary of evidence  24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to 
key groups (e.g., healthcare providers, users, and policy makers).  
68-74 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of 
identified research, reporting bias).  
72-73 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for future research.  74 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the 
systematic review.  
xvii 
 
From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. 
Appendix IV
Survey of urologist members of the Urological Society of
Australia and New Zealand (USANZ)
1NHMRC Partnership Grant 1011474 
Improving care for men with locally 
advanced prostate cancer 
Survey of Urologists 
2Background
There is currently much debate over the most appropriate treatment for high-­‐risk prostate
cancer. In particular, there are controversies in post-­‐prostatectomy radiotherapy.
This survey aims to assess the current views and practice of urologists relating to adjuvant
radiotherapy for men with locally advanced prostate cancer following radical prostatectomy.
You have been selected to participate in the study as a member of the Urological Society of
Australia and New Zealand (USANZ).
The survey forms part of a wider study funded by the National Health and Medical Research
Council (NHMRC) and the Prostate Cancer Foundation of Australia (PCFA) with the research
being undertaken in partnership with The Sax Institute, University of Sydney, Cancer Council
NSW and the NSW Agency for Clinical Innovation (ACI).
Participation in this survey is entirely voluntary. Submitting a completed survey is an
indication of your consent to participate in the study. All aspects of the study, including the
results, will be strictly confidential. Your responses will be anonymous and aggregated with
those of other respondents in all reports relating to this study.
If you would like further information about the study and how your responses will be used,
please read the Participant Information Sheet.
31.1 For each scenario, we are interested in your current level of certainty about which treatment
option is better. Please rate your certainty by circling the number that best reflects your view. If
you are completely undecided between the two options, please circle ‘0’. If, however, you
consider one treatment option to be superior, for whatever reason, please indicate how strongly
you hold this view by circling the appropriate number on the scale.
Section 1 – Clinical Uncertainty
Case 1
A 64 year old man, previously well, presented with a pre-­‐op PSA of 12.2. Patient had radical
prostatectomy 10 weeks ago. Pathology results show a Gleason 3+4=7 carcinoma with
extracapsular extension and positive margins near apex over a 2mm front. Seminal vesicle
and lymph nodes were clear. Post radical prostatectomy he has good urinary control. Post-­‐
op PSA 0.01. No return of erections.
Watchful waiting
is preferable
Undecided Adjuvant
radiotherapy is
preferable
5 4 3 2 1 0 1 2 3 4 5
Case 2
A 58 year old man had a nerve sparing radical prostatectomy 3 months ago for a low volume
Gleason 3+4=7 carcinoma (20% high grade) with 0.2mm extracapsular extension in left
peripheral zone but clear surgical margins. No perineural or lymphovascular invasion.
Seminal vesicles clear. 0/12 nodes involved. Post-­‐op PSA <0.01. Some dribbling on straining
but pad free. Partial erections but inadequate for intercourse.
Watchful waiting
is preferable
Undecided Adjuvant
radiotherapy is
preferable
5 4 3 2 1 0 1 2 3 4 5
Case 3
A 62 year old man had a non nerve sparing prostatectomy for a clinical T3 prostate cancer
with pre-­‐op PSA of 14. Histopathology demonstrates a widespread Gleason 4+4=8
carcinoma with multifocal sites of extracapsular extension and involvement of base of right
seminal vesicle. Multiple sites of positive surgical margins. Post-­‐op PSA 0.04. No lymph node
involvement. Good urinary function and no erections.
Watchful waiting
is preferable
Undecided Adjuvant
radiotherapy is
preferable
5 4 3 2 1 0 1 2 3 4 5
41.2 Thinking about your understanding of the current literature and evidence for treatment of prostate
cancer, please rate the extent to which you agree or disagree with each statement by ticking ONE
option:
a. Immediate external irradiation after radical prostatectomy improves biochemical
progression-­‐free survival and local control in patients with positive surgical margins or
pT3 prostate cancer who are at high risk of progression.
Strongly Somewhat Somewhat Strongly Don’t
disagree disagree agree agree know
b. Relapse after local therapy is defined by prostate-­‐specific antigen (PSA) values >0.2
ng/ml following radical prostatectomy (RP) and >2 ng/ml above the nadir PSA after
radiation therapy (RT).
Strongly Somewhat Somewhat Strongly Don’t
disagree disagree agree agree know
c. All high risk patients should have multidisciplinary input and be referred by their
urologist to a radiation oncologist before treatment to ensure informed decision
making based on discussion of the relative advantages and disadvantages of adjuvant
radiotherapy or watchful waiting.
Strongly Somewhat Somewhat Strongly Don’t
disagree disagree agree agree know
d. There are no data from randomised controlled trials to define the benefits of salvage
radiation versus adjuvant therapy or salvage radiation versus systemic therapy (either
at time of PSA rise or at time of radiographic progression).
Strongly Somewhat Somewhat Strongly Don’t
disagree disagree agree agree know
5In this section we are interested in your opinions about clinical practice guidelines in
general.
2.2 On the scale provided please rate the extent to which you agree or disagree with each
statement by placing an X in ONE box.
In general, clinical guidelines:
Section 2 – Clinical Practice Guidelines
2.1 Do you use any clinical guidelines in your practice? Yes / No
2.1a How many clinical guidelines do you use in your practice? 1-­‐5 / 6-­‐10 / 11 -­‐15 / >15
strongly
disagree
disagree neither
agree
nor
disagree
agree strongly
agree
Don’t
know
Are good educational tools
Are a convenient source of advice
Are intended to improve quality by
standardising care
Improve patient outcomes
Are intended to cut costs
Interfere with my professional
autonomy
Are oversimplified ‘cookbook’
medicine
Are too rigid to apply and adapt to
individual patients
Limit my ability to apply clinical
judgement
Are based on an unbiased synthesis of
robust scientific evidence
Are not readily accessible when I want
to refer to them
Provide contradictory advice
6In the next section we are interested in your opinions about this specific clinical
guideline recommendation.
In 2010, Australia Cancer Network and Cancer Council Australia in conjunction
with the Prostate Cancer Foundation of Australia and Andrology Australia
published the Clinical Practice Guidelines for the Management of Locally Advanced
and Metastatic Prostate Cancer.
2.3 Are you aware of this guideline? Yes / No
2.3a How did you find out about it?
Direct mail Urology Association Journal
Internet search Patient Colleague
Hospital department/administration Other
A Grade B recommendation in the guideline states “patients with extracapsular
extension, seminal vesicle involvement or positive surgical margins receive post-­‐
operative external beam radiation therapy within four months of surgery”.
2.4 Following radical prostatectomy who do you believe is the person best placed to
decide on the most appropriate post-­‐operative treatment option? Please select ONE
option:
The urological surgeon is best placed to decide
The radiation oncologist is best placed to decide
The medical oncologist is best placed to decide
The MDT is best placed to decide
The patient is best placed to decide
72.5 Considering the recommendation for patients with extracapsular extension, seminal vesicle
involvement or positive surgical margins to receive post-­‐operative external beam
radiotherapy within four months of surgery, please rate the extent to which you agree or
disagree with each statement by placing an X in ONE box:
strongly
disagree
disagree neither
agree
nor
disagree
agree strongly
agree
Don’t
know
The recommendation is based on a
valid interpretation of the
underpinning evidence
The side-­‐effects of adjuvant
radiotherapy for patients with locally
advanced prostate cancer outweigh
the benefits
There are other recommendations for
the appropriate management of this
patient population that conflict with
this one
Following this recommendation will
lead to improved patient outcomes
If I follow this recommendation my
patients may experience unnecessary
discomfort
I support post-­‐operative external
beam radiation therapy for patients
but not within four months of surgery
If I don’t follow this recommendation I
may be liable for malpractice
This recommendation is consistent
with my clinical experience with this
patient group
This recommendation is consistent
with the opinions of my respected
clinical colleagues
This recommendation does not reflect
evidence that is emerging on this topic
This recommendation should only be
followed within fully informed decision
making by the patient
82.6 Considering the recommendation for patients with extracapsular extension, seminal vesicle
involvement or positive surgical margins to receive post-­‐operative external beam radiation
therapy within four months of surgery:
There are 3 randomised controlled trials (ARO, EORTC, SWOG) comparing adjuvant
radiotherapy versus observation post radical prostatectomy in patients with extracapsular
extension, seminal vesicle involvement and/or positive surgical resection margins. Two of
these trials were conducted in Europe and one in the US.
a. How many randomised controlled trials do you think are necessary to provide an
acceptable level of evidence to support this recommendation? 1 / 2-­‐3 / 4-­‐5 / >5
b. How many years follow up of patients would be necessary to convince you of the
benefits of adjuvant radiotherapy? <1 yr / 2-­‐3yrs / 4-­‐5 yrs / 6-­‐8 yrs / 9-­‐10 yrs /
>10yrs
c. When considering evidence from randomised controlled trials to do you think it is
necessary to have local, Australian data? Yes / No
d. Randomised trials have demonstrated a range of survival effects following adjuvant
radiotherapy for this patient group. Thinking about the current evidence, what is the
minimum survival benefit you consider acceptable for you to follow this
recommendation? Please complete ONE OPTION.
Days Months Years
e. What do you consider to be the maximum proportion of men who suffer from rectal
damage or develop faecal incontinence as a result of radiotherapy for this treatment
to be unacceptable? Please place an X on the scale below.
__________________________________________________________________
0% 100%
2.7 Do you have any comments on adjuvant radiotherapy following radical
prostatectomy?
93.2 Thinking about your current clinical practice, on the scale provided please rate the extent to
which you agree or disagree with each statement by placing an X in ONE box:
Section 3 – Innovation
3.1 Which best describes your feelings about trying new procedures in your practice?
(Circle ONE)
1. I experiment with new procedures
2. I prefer to wait until others have tried new procedures
3. I prefer to wait until new procedures have been established for a while
4. I only try new procedures when regulations require them
strongly
disagree
disagree neither
agree
nor
disagree
agree strongly
agree
Don’t
know
Clinical experience is the only form of
valid knowledge in decision-­‐making
I am comfortable recommending
contentious treatments or procedures
if I am confident of the evidence
behind them
I discuss all treatment options with my
patients to allow them to make an
informed decision
I sometimes forget to discuss guideline
recommendations with patients
I would like guidance as to how to
apply recommendations to specific
patients
I am confident in applying
recommendations for individual
patients in my practice
I would like guidance about how to
provide information on the pros/cons
of radiotherapy without overburdening
patients
10
4. Considering the recommendation for patients with extracapsular extension, seminal vesicle
involvement or positive surgical margins to receive post-­‐operative external beam radiation therapy
within four months of surgery, please rate the extent to which you agree or disagree with each
statement by placing an X in ONE box:
5. Thinking about your clinical practice, on the scale provided please rate the extent to which you agree
or disagree with each statement by placing an X in ONE box.
Urology leaders in my organisation:
Section 4 – Other Factors
strongly
disagree
disagree neither
agree
nor
disagree
agree strongly
agree
Don’t
know
This recommendation takes into
consideration the needs and preferences
of patients
Routinely referring patients to radiation
oncology will increase costs
Other urologists will be critical of me if I
routinely refer these patients to radiation
oncology
This guideline is likely to be followed by
most of my colleagues
It would be easy to incorporate this new
process into practice in my clinical setting
if I wanted to
Section 5 – Readiness for change
strongly
disagree
disagree neither
agree
nor
disagree
agree strongly
agree
Don’t
know
Believe that current practice patterns can
be improved
Encourage and support changes in
practice patterns to improve patient care
Are willing to try new protocols
Work cooperatively with senior
leadership/clinical management to make
appropriate changes
11
Section 6 – About You
6.1 Gender: Male / Female
6.2 Age group: 20-­‐30 / 31-­‐40 / 41-­‐50 / 51-­‐60 / >60
6.3 Which type of practice do you have? (Circle ONE option for your major
appointment):
VMO/Consultant
Salaried University Academic
Staff Specialist
Registrar/Junior Medical Officer
Other (please specify) __________________________________________________
6.4 How many years have you been a practicing Urologist?
0-­‐5 / 6-­‐10 / 11-­‐15 / 16–20 / 21–25 / 26-­‐30 / >30
6.5 Do you perform Radical Prostatectomy? Yes / No
6.5a Approximately how many new patients diagnosed with prostate cancer do you care
for in a TYPICAL MONTH? _________________________________________patients
6.5b Approximately what percentage of your practice is comprised of prostate cancer
patients? ___________________________________________________________ %
6.5c What percentage of your patients are in ACTIVE TREATMENT for prostate cancer (as
opposed to routine surveillance or follow up)? _____________________________ %
6.6 Which of the following best describes the location in which you practice? (Circle
ONE option only):
Capital city
Other major urban area
Rural
Remote
Other
6.7 In which setting do you treat the MAJORITY of prostate cancer patients: (Circle ONE
option only):
Teaching hospital
Public, non-­‐teaching hospital
Private hospital
THANK YOU FOR YOUR TIME
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Urologist name: ___________________________ Hospital: _________________ Date consented: __________________ 
Opinion Leaders 
 Date 
received 
Method of 
delivery 
(e.g. MDT 
meeting, 
V/C,  
email, 
phone) 
Data source 
(e.g. MDT attendance record, Post-intervention 
follow up checklist, interviews) 
Minimum 
requirement 
met? (Y/N) 
CLICC Video 
 
    
Discussion with 
Clinical Leader 
    
Discussion with 
Urology Network Co-
Chair 
    
Printed Materials 
 Date 
received 
Method of 
delivery 
(e.g. MDT 
meeting, 
email, post) 
Data source 
(e.g.  MDT attendance record / Post-
intervention follow up checklist / survey 
Minimum 
requirement 
met? (Y/N) 
Urologist Resource  
 
   
Full Clinical 
Practice Guideline 
 
 
   
Supporting papers     
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Audit & Feedback 
 Date 
Sent 
Attended 
MDT meeting 
(Y/N – date) 
Individual 
report 
viewed 
(Y/N) 
Data source  
(e.g. MDT agenda, 
minutes, EzyMsg report, 
interviews) 
Minimum 
requireme
nt met? 
(Y/N) 
Feedback report 1 – Baseline 
individual  
    
 
 
Feedback report 2 – Baseline 
aggregate 
    
 
 
Feedback report 3 – 6 months 
individual 
    
 
 
Feedback report 4 – End of 
study 
    
 
 
Systems & Processes 
 Date 
first 
implement
ed 
Number of 
MDT 
meetings 
with 
flagged 
cases 
Date 
ceased 
(if 
applicable
) 
Additional 
information 
Data source  
(e.g.  Pathology, MDT 
agendas & minutes, MDT 
flagging data 
collection forms) 
Minimum 
requireme
nt met? 
(Y/N) 
MDT flagging 
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Evaluation 
Date sent Completed 
survey/interview? (Y/N) 
Date 
completed/received 
First survey 
Second survey 
Third (last) survey 
End-of-study interview 
Minimum requirement for intervention element to be considered “received”? 
Minimum requirement 
Opinion leader One option required: Watched CLICC video, OR  Had discussion with Clinical 
Leader, OR Had discussion with Urology Network Co-Chair 
Printed Materials Received CLICC printed resource (required) 
Optional (but not sufficient): Received Full Clinical Practice Guideline AND/OR 
Received Supporting papers 
Audit & Feedback Required: Sent all feedback reports since agreement to participate 
MDT flagging Required: MDT flagging implemented since agreement to participate 
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Improving care for men with locally advanced prostate 
cancer 
UROLOGIST INFORMATION STATEMENT 
Introduction 
You are invited to participate in this study as a Urologist who performs Radical 
Prostatectomy in one of the hospitals participating in this research that is part of the NSW 
Agency for Clinical Innovation Urology Network in NSW hospitals. This study aims to 
develop and trial an intervention, to implement the Australian Cancer Network’s Clinical 
Practice Guidelines for the Management of Locally Advanced and Metastatic Prostate 
Cancer. Specifically, the study aims to increase fully informed decision making in 
patients with high risk prostate cancer following radical prostatectomy.  
This study is being conducted by the Sax Institute, led by A/Prof Mary Haines, in 
partnership with the University of Sydney, Cancer Council NSW and the NSW Agency for 
Clinical Innovation (ACI).  A full list of investigators is provided below.  This study has been 
funded by the National Health and Medical Research Council (NHMRC) and the 
Prostate Cancer Foundation of Australia (PCFA). The study is registered with the Australia 
New Zealand Clinical Trials Registry: ACTRN12611001251910. 
Study Procedures 
Consent 
If you agree to participate in this study, you will be asked to sign the Urologist Consent 
Form.  
Questionnaire 
You will then be asked to complete a short questionnaire (5-10mins) relating to your 
current knowledge and attitudes towards adjuvant radiotherapy for patients with high-
risk prostate cancer after radical prostatectomy. This survey will be repeated 6 months 
after the intervention session and at the end of the study.  
Interactive Education Session 
You will participate in a short (10-15 minute) interactive education session. At this session 
you will be provided with printed materials and a summary of the evidence underlying 
the guideline recommendation including a video presentation. You will have the 
opportunity to discuss any concerns.   
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Medical Audit 
You will be asked to allow a research assistant to attend your practice at a convenient 
time to perform an audit of medical records of some of your prostate cancer cases.  The 
research assistant will collect re-identifiable (ie coded) data from medical records of 
prostate cancer cases who have undergone a radical prostatectomy during the study 
period and meet the criteria of ‘high-risk’ following surgery. 
Feedback 
After the interactive education session you will be provided with a quarterly 
performance report describing the number of prostate cancer cases referred to 
radiation oncology at the individual, hospital, regional and state level, obtained through 
the post-intervention medical audit, via email or SMS depending on your preferred 
method of communication.  This report will also include information on the number of 
prostate cancer cases at high-risk discussed at MDT meetings.  An aggregated quarterly 
feedback report will additionally be provided by the Clinical Leader at an MDT meeting. 
Automatic Case Flagging at MDT Meetings 
You will be asked to provide consent for the names of all patients who are subject to a 
histopathological examination of a radical prostatectomy specimen for prostate cancer 
and who have extracapusular extension, positive surgical margins or seminal vesicle 
invasion to be submitted to the urology MDT for discussion. 
Interview 
At the end of the study you will be invited to participate in an audiotaped telephone 
interview (10-15 minutes) where you will receive feedback on results and have the 
opportunity to discuss reasons why changes occurred and why the intervention did or 
did not result in greater referral.  
Risks 
It is not expected that you will be exposed to any risks by taking part in this study. 
Benefits 
While we intend that this research study furthers medical knowledge and may improve 
treatment of men with locally advanced prostate cancer in the future, it may not be of 
direct benefit to you. 
Costs 
Participation in this study will not cost you anything, nor will you be paid. 
Voluntary Participation 
Participation in this study is entirely voluntary.  You do not have to take part in it.  If you 
do take part, you can withdraw at any time without having to give a reason.  Whatever 
your decision, please be assured that it will not affect your relationship with the 
researcher(s) or the Sax Institute, Prostate Cancer Foundation of Australia, University of 
Sydney, Cancer Council NSW or the NSW Agency for Clinical Innovation now or in the 
future. 
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Confidentiality 
All the information collected from you for the study will be treated confidentially, and 
only the researchers named below will have access to it.  The study results may be 
presented at a conference or in a scientific publication, but individual participants and 
individual medical records will not be identifiable in such a presentation or publication. 
Further Information 
If you would like to know more at any stage, please feel free to contact Bea Brown, 
study Research Fellow, on (02) 9188 9540 or bea.brown@saxinstitute.org.au. 
Ethics Approval and Complaints 
This study has been approved by the Ethics Review Committee (RPAH Zone) of the Sydney 
Local Health District.  Any person with concerns or complaints about the conduct of this 
study should contact the Executive Officer on 02 9515 6766 and quote protocol number 
[X12-0388]. 
The conduct of this study at Royal North Shore Hospital has been authorised by the 
Northern Sydney Local Health District. Any person with concerns or complaints about the 
conduct of this study may also contact the Research Governance Officer on telephone 
number 02 9926 4560 and quote SSA/13/HAWKE/234 or protocol number 1307-229M. 
Investigators and Affiliations 
 Mrs Jane Bois, Sax Institute
 Dr Andrew Brooks, NSW Agency for Clinical Innovation and Westmead Hospital
 Mrs Bea Brown, Sax Institute and University of Sydney
 A/Prof Mary Haines, Sax institute and University of Sydney
 A/Prof Andrew Kneebone, Northern Clinical School, University of Sydney
 Prof Dianne O’Connell, Cancer Council NSW
 Dr David Smith, Cancer Council NSW
 Prof Jane Young, The University of Sydney
This information sheet is for you to keep. 
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06-03 
Improving care for men with locally advanced prostate cancer 
UROLOGIST CONSENT FORM
I, .................................................................................................................................................. [name] 
of ..............................................................................................................................………… [hospital] 
have read and understood the Information for Urologists on the above-named research 
study and have discussed the study with............................................................................................ 
I have been made aware of the procedures involved in the study, including any known or 
expected inconvenience, risk, discomfort or potential side effect and of their implications as 
far as they are currently known by the researchers. 
I understand that a research assistant will attend my office to collect specific re-identifiable 
(ie coded) information from the medical records of some of my prostate cancer cases 
(public and private), and I agree to this. 
I provide consent for the names of all my patients (public and private) who are subject to a 
histopathological examination of a radical prostatectomy specimen for prostate cancer and 
who have extracapusular extension, positive surgical margins or seminal vesicle invasion to 
be submitted to the urology MDT for discussion.  
I understand that the end of study interview will be audio taped and I agree to this. 
I freely choose to participate in this study and understand that I can withdraw at any time. 
I understand that the research study is strictly confidential. 
I hereby agree to participate in this research study. 
NAME: .............................................................................................................. 
SIGNATURE: .............................................................................................................. 
DATE: ........................... 
MOBILE PHONE NO.: ………………………............... FAX NO.: ...................................................... 
EMAIL ADDRESS: …………………………………………………………….. 
CONTACT DETAILS FOR ACCESS TO PATIENT RECORDS:  
…………………………………………………………………………………………………… 
…………………………………………………………………………………………………… 
I PREFER TO BE CONTACTED VIA THE FOLLOWING METHOD FOR THE PURPOSES OF AUDIT AND 
FEEDBACK: 
 Email     Mobile phone     Mail/letter     Other (please specify): ......................................... 
PUBLIC PATHOLOGIST TO CONTACT FOR MDT CASE FLAGGING:...................................................... 
PRIVATE PATHOLOGIST TO CONTACT FOR MDT CASE FLAGGING:.................................................... 
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Scope of this document 
This is a protocol for the post-intervention interview with Urologist Clinical Leaders involved in 
the CLICC study. The interview forms part of a mixed methods study to identify the 
mechanisms of provider and organisational change. The interview will additionally explore 
factors that hindered or facilitated the implementation of the CLICC study. 
Procedure for data collection 
Interview invitations and arrangements 
The research team will contact Urologist Clinical Leaders either by telephone or email to 
request a convenient time to conduct the post intervention interview. This interview is 
included in the Clinical Leaders Terms of Reference. The interview will be conducted face-to-
face in consulting rooms or by teleconference. 
Outline of the Interview Guide; verbal instructions and prompts for 
interviewer 
Introduction  
(outline of verbal instructions for the meeting) 
• Introduce all of the people attending the meeting, with reference to their role in the
study.
• Thank the Urologist Clinical Leaders for their involvement in the CLICC study.
• Outline the “agenda” for the meeting, in which they will be given some feedback on
on their hospital and asked to think about why changes may/may not have
happened.
• Talk them through the hospital specific report which will provide feedback obtained
through the medical audit of patient records and document review.
• Explain that we are going to be asking the same questions of all of Urologist Clinical
Leaders involved in the study to identify common themes and determine which
intervention components were successful in overcoming which barriers and facilitated
provider and organisation change. We will also explore any reasons why the
intervention may not have worked or had limited success and areas for improvement.
• This interview will be recorded and transcribed after the meeting.
Sax Institute 
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Interview Guide 
Role and work in the CLICC study 
• What did you understand to be your role as a Clinical Leader in the CLICC study?
• Could you describe the work you undertook as a Clinical Leader for the CLICC study?
• Did you feel sufficiently informed about what you were expected to do?
• Could you describe any factors that hindered or facilitated your role in the project?
• As a Clinical Leader do you feel that you were able to interact with Urologists in your
hospital and offer guidance and support?
Factors facilitating or hindering the work or the project in general 
• Do you think the CLICC study was successful in your hospital?
• Were there factors that hindered or facilitated the implementation of the project?
• What conditions do you see as critical to the project’s success/lack of success?
• What specific features of the CLICC study led to the desired effects?
o Printed materials,
o MDT video,
o Feedback reports [presented at MDT meetings, individual reports]
o MDT flagging of high-risk cases
• How important were the MDT coordinator and pathologist in facilitating the study?
• Did discussion of cases at the MDT meeting change your referral patterns or those of
your colleagues? [In what way?]
• Has the study affected relationships with your colleagues? [urologists and others]
Relevance/benefits for the participants 
• What are the main issues the project can contribute to in the care of high-risk men
following radical prostatectomy?
• Have there been any wider changes in the pattern of care for these men for you
personally, within your hospital or more generally?
• Why were these changes made?
Expectations concerning the project and its effects 
• What do you think are the main benefits of this project?
• Do you have any concerns regarding the implementation of the project?
• Do you think that urologists at your site or elsewhere were gaming numbers?
• Will you continue any CLICC elements at your hospital?
• Is there anything else that you would like to elaborate on or share regarding the
CLICC study?
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Scope of this document 
This is a protocol for the post-intervention interview with the Urologists involved in the CLICC 
study. The interview forms part of a mixed methods study to identify the mechanisms of 
provider and organisational change. The interview will additionally explore factors that 
hindered or facilitated the implementation of the CLICC study. 
Procedure for data collection 
Interview invitations and arrangements 
The research team will liaise with the Urologist to arrange a convenient time to conduct the 
post intervention interview by telephone. Participation in the interview is included in the 
Participant Information Statement for Urologists. 
Outline of the Interview; verbal instructions and prompts for interviewer 
• Welcome: “Thank you for participating in this interview. As a Urologist participant in this
study, your point of view is important to us. We know that you are very busy and we
greatly appreciate your contribution to this project. Participation in this interview is
entirely voluntary and you are free to end the interview at any time.”
• Purpose: “The purpose of this interview is determine your views about the Clinician-Led
Improvement in Cancer Care (CLICC) study that was roled out in your hospital during
the period [date] to [date].  We are going to be asking the same questions of all of
Urologists  involved in the study to identify common themes and determine which
intervention components were successful in overcoming which barriers and facilitated
provider and organisation change. We will also explore any reasons why the
intervention may not have worked or had limited success and areas for
improvement”.
• Recording: This interview will be recorded and transcribed after the meeting.
• Do you have any questions?”
• Outline the “agenda” for the meeting, in which they will be given some feedback on
on their hospital and asked to think about why changes may/may not have
happened.
• Feedback: Talk them through the hospital specific report which will provide feedback
obtained through the medical audit of patient records and document review.
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Question Guide 
Role and work in the CLICC study 
[PROMPT] The CLICC study at your hospital comprised the following elements: [printed 
materials, MDT video, support from Clinical Leaders, feedback reports presented at MDT 
meetings, individual feedback reports, MDT flagging of high-risk cases] 
• Could you tell me which components of CLICC you experienced?
Information, facilitation 
• Did you feel sufficiently informed about what the study was hoping to achieve?
• The Clinical Leader at your hospital was [name]. Do you think he was supportive of
CLICC? Did you have sufficient interaction with him about the study?
Factors facilitating or hindering the work or the project in general 
• Do you think the CLICC study was successful in your hospital?
• What conditions do you see as critical to the project’s success/lack of success?
• What specific features of the project do you think were most helpful?
o Printed materials
o MDT video
o Support from Clinical Leaders
o Feedback reports [presented at MDT meetings, individual feedback reports]
o MDT flagging of high-risk cases
• Has the study affected MDT decision-making?
• Has the study affected relationships with your colleagues? [urologists and others]
• Do you have any concerns regarding the implementation of the project?
Relevance/benefits for the participants 
• To what extent did CLICC lead to changes to your care for men at high-risk following
prostatectomy? [What are the major differences in the care of these patients? Why
did you make these changes?]
• Have there been any wider changes in the pattern of care for these men for you
personally, within your hospital or more generally? [Why were these changes made?]
• What are the main issues CLICC can contribute to in the care of high-risk men
following radical prostatectomy?
Expectations concerning the project and its effects 
• What do you think are the main benefits of this project?
• Is there anything else that you would like to elaborate on or share regarding the
CLICC study?
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CLICC printed resource
CURRENT RADIOTHERAPY TECHNIQUES
Morbidity after radiation treatment is intimately linked to the volume of normal tissue treated. Decisions 
regarding dose should be made by the treating physician who has full knowledge of the patient’s functional 
status, history and toxicity tolerance.1
ADJUVANT RADIOTHERAPY 
FOLLOWING PROSTATECTOMY IN 
HIGH-RISK PATIENTS: SUPPORTING 
INFORMED DECISION-MAKING
Informed decision-making about the use of adjuvant/
salvage radiotherapy can be supported by:
• Discussion	with	patients	before	surgery about
the possibility of adverse features being detected
through pathological examination of the prostate
specimen - these features do not reflect the quality
of surgery.
• Referral	 to	 a	 radiation	 oncologist	 to discuss
what radiation treatment would involve at the
patient’s local radiotherapy unit.
Referral should not mean the patient will receive 
radiotherapy but will allow thoughtful discussion 
of possible short- and long-term side effects of 
radiotherapy as well as the potential benefits of 
preventing recurrence. The decision to administer 
radiotherapy should be made by the patient and the 
multidisciplinary team with full consideration of the 
patient’s history, values, preferences, quality of life 
and functional status.1
PATIENT PERSPECTIVES 
Studies from the US, UK, Canada and Europe consistently show 
that patients with advanced cancer are generally willing to undergo 
aggressive treatment and endure significant toxicity for a smaller 
benefit than their health providers indicated they would if in the 
same situation. 2-5
Focus groups with NSW consumer representatives revealed that 
patients want the following information to make a decision about 
their treatment:
• Who will be involved in the treatment process to optimise
long-term outcomes.
• The risk of short or long-term recurrence after initial
treatment and management options if this occurs.
• The benefits and potential side effects of secondary
treatment options.
1. Thompson et al. Adjuvant and salvage radiotherapy after prostatectomy: AUA/ASTRO Guideline. J Urol 190: 441-449, 2013. 	 	2.	Kuchuk et al. Patient
perceptions about potential side effects and benefits from chemotherapy agents (abstract 6595). J Clin Oncol 31(15S), 2013.   3. Matsuyama et al. Why do
patients choose chemotherapy near the end of life? A review of the perspectives of those facing death from cancer. J Clin Oncol 24(21): 3490-3496, 2006.   4.
Silverstri et al. Preferences for chemotherapy in patients with advanced non-small cell lung cancer: Descriptive study based on scripted reviews. BMJ 317:771-
775, 1998.   5. Elkin et al. Treatment decision-making preferences in older patients with metastatic colorectal cancer (abstract 8519). J Clin Oncol 24(18S):472s,
2006. 
In Conventional “2D” External Beam Radiotherapy (EBRT), radiation borders 
are determined by bone anatomy seen on a plain  X-Ray. This uncertainty results 
in large volumes of radiation and unnecessary irradation of surrounding organs 
such as the hips, rectum, bladder and small bowel.  2D EBRT was the technique 
of radiotherapy used in the EORTC and SWOG trials.
The current minimum standard is 3-Dimensional Conformal Radiotherapy 
(3D-CRT),  which allows more precise delivery to the target organ as the contours 
of the treated area are based on CT anatomy rather than a plain X-Ray.  The full 
dose (green line) covers the CT determined volume but cannot be precisely 
shaped, consequently causing additional normal tissue to be unnecessarily 
irradiated. 
Many centres now have capacity to deliver Intensity Modulated Radiation 
Therapy (IMRT) or Volumetric Modulated Arc Therapy (VMAT) which can achieve 
tightly conformal dose distributions with the use of non-uniform radiation beams 
delivered by multileaf collimators, which are constantly reshaped many times 
during treatment. 
Data from three large randomised controlled trials (RCTs) involving over 1,800 men with locally advanced 
prostate cancer (EORTC8, SWOG9 and ARO10) and a number of retrospective studies demonstrate that 
adjuvant	radiotherapy	significantly	reduces	the	risk	of	biochemical	recurrence.
ADJUVANT RADIOTHERAPY 
FOLLOWING PROSTATECTOMY 
IN HIGH-RISK PATIENTS:  
THE EVIDENCE
TOXICITIES
EORTC8 and SWOG9 used Conventional External  Beam 
Radiotherapy (EBRT) which has been replaced with more 
sophisticated radiotherapy techniques. In SWOG9, at 10-year 
follow-up, urethral stricture (17.8% vs 9.5%) and proctitis (3.3% vs 
0%) were more common in the RP+ART arm. EORTC8 reported 
no significant difference (p=0.05) in severe (Grade 3 or more) late 
toxicity (RP+ART 4.2% vs RP 2.6%). 
The current minimum standard is 3-Dimensional Conformal 
Radiotherapy (3D-CRT). Toxicity data for ARO10, the only RCT to 
use 3D-CRT, are reported below.
RP + ART RP only
AC
UT
E
Gastrointestinal
Rectal Grade 2 12% NR
Rectal Grade 3 0% NR
Genitourinary Bladder Grade 3 3% NR
LA
TE
Gastrointestinal Rectal Grade 2 1.4% 0%
Genitourinary
All Grade 2 2.0% 0%
All Grade 3 0.7% 0%
Urethral Stricture 1.4% 0.6%
BENEFITS OF ADJUVANT RADIOTHERAPY (ART)
RCT
Biochemical	
Progression	Free	
Survival
Local	Recurrence
Clinical	Progression	
Free	Survival
Overall	Survival
RP	+	ART RP	only RP	+	ART RP	only RP	+	ART RP	only RP	+	ART RP	only
EORTC8 61% 38% 8.4% 17.3%* 70.3%* 64.8% 76.9%^ 80.7%^
SWOG9 65% 36% 8% 22% 70% 49% 74% 66%
ARO10 61% 40% NR NR NR NR NR NR
Follow-up	time	periods:	10-years for all EORTC data; 10 years for all SWOG data except overall survival which was at 12-years;
5-years for all ARO data.
NR = Not reported    RP = Radical Prostatectomy    *Result was borderline significant    ^Not statistically significant, p=0.05
ADJUVANT VS SALVAGE RADIOTHERAPY
The use of ART may involve irradiation of some patients 
who never would have had recurrent cancer. Observational 
studies report outcomes from 48 ART arms (n=4,043) and 
137 salvage radiotherapy (SRT) arms (n=13,549). ART arms 
generally report lower rates of biochemical and metastatic 
recurrence than SRT arms.7 There are currently no RCT data 
comparing ART with SRT. This is the focus of ongoing trials 
(RAVES, RADICALS). 
RCT data presented above compare ART with observation only post-prostatectomy.
6. Australian Cancer Network 2010 Clinical Guidelines for the Management of Men with Locally Advanced and Metastatic Prostate Cancer   7. American
Urological Association 2013 Adjuvant and salvage radiotherapy after prostatectomy guidelines   8. EORTC Trial 22911 (Van der Kwast TH, et al. J Clin Oncol
25(7): 4178-4186, 2007 and Bolla M, et al. Lancet 380: 2018-2027, 2012)    9. SWOG S8794 (Thompson IM Jr et al. JAMA 296(19): 2329-2335, 2006 and
Thompson IM Jr et al. J Urol 181: 956-962, 2009)   10. ARO Trial 96–02/AUP AP 09/95 (Wiegel T et al. J Clin Oncol 27(18): 2924-2930, 2009)
The Australian Cancer Network Clinical Practice Guidelines6 recommend: ‘Patients with extracapsular extension, seminal 
vesicle involvement or positive surgical margins should receive post-operative external beam radiation therapy within four 
months of surgery... The role of active surveillance and early salvage radiotherapy has not been defined.’
American Urological Association guidelines7 similarly recommend that ‘physicians should offer adjuvant radiotherapy to 
patients with adverse pathologic findings at prostatectomy’.
QUALITY OF LIFE
In the SWOG9 
randomised trial, 
quality of life 
by 5 years after 
treatment was 
significantly better 
in the RP+ART arm. 
Appendix IX
Feedback report templates
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[DATE]
Dear [NAME]
Thank you for your ongoing support and input into the CLICC study.
Please find below your initial feedback report, which provides individual, site and study level baseline data. This
report complements the data presented at the [SITE} Hospital Urology MDT meeting on [DATE].
NOTES:
1. Data collection is ongoing. Figures are based on data available at the time this report was produced and
are subject to change following further review of medical records.
* Data collected at time of report – excluding [SITE] Hospital
** Abbreviations: PSM – positive surgical margin, EPE – extracapsular extension, SVI – seminal vesicle invasion
Abbreviations: PSM – positive surgical margin, EPE -­‐ extracapsular extension, SVI – seminal vesicle invasion
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PSM + SVI EPE + SVI PSM +
EPE + SVI
ProporBon of men with one or more high risk features by adverse
feature
Urologist (N=27)
Site (N=104)
All other sites (N=424)
Urologist Site (N=) Study aggregate* 
Prostatectomies performed 1 January 2013 – [DATE] 50 216 873 
Men with one or more high risk features (PSM/EPE/SVI) 
post prostatectomy** 
27 
(54%) 
104 
(48%) 
424 
(49%) 
Referrals to Radiotherapy - men with one or more high risk 
features 
7/27 
(26%) 
28/104 
(27%) 
117/424 
(28%) 
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Abbreviations: PSM – positive surgical margin, EPE -­‐ extracapsular extension, SVI – seminal vesicle invasion
If you have any queries or would like further information please contact implementation@saxinstitute.org.au.
Kind regards,
The CLICC Team 
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[DATE]
Dear [NAME],
Thank you for your ongoing support and input into the CLICC study.
This report complements the data presented at the [SITE] Hospital Urology MDT meeting on [DATE].
Note: Data collection is ongoing. Figures are based on data available at the time this report was produced
and are subject to change following further review of medical records.
Table 1: MDT Flagging: Cases flagged and discussed at an MDT meeting – Post-­‐CLICC
Data on MDT discussion reflects information from MDT agendas and letters of recommendation collected after
the commencement of the CLICC project. Data is collected in real-­‐time and reflects cases flagged at [SITE]
Hospital from [DATE] – [DATE].
Urologist Site 
Number of cases flagged for MDT discussion 8 20 
Number of flagged cases discussed at a MDT meeting 4 (50%) 
10* 
(50%) 
MDT recommendation 
for cases discussed at 
a MDT meeting 
Referral to radiation oncologist and/or discussion of 
radiotherapy 
1 
(25%) 
5 
(50%) 
Observation (“watch and wait”) 2 (50%) 
2 
(20%) 
Other or unknown 1 (25%) 
3 
(30%) 
*Discussion data missing for 10 cases; recommendation information only missing for 3 cases
Abbreviations: MDT – multidisciplinary team
Figure 1: Proportion of men with high risk features following radical prostatectomy – Pre-­‐CLICC
This graph shows the proportion of men who were found to have high risk features following radical
prostatectomy at each site during the baseline period of the study (i.e. before the commencement of the
CLICC project). Statistics are inclusive of all pre-­‐CLICC cases from 1 January 2013 until the CLICC study began at
the site (dates vary).
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One or more high risk
features (PSM/EPE/SVI)
Abbreviations: PSM – positive surgical margin, EPE – extracapsular extension, SVI – seminal vesicle invasion,
RP – radical prostatectomy
[SITE]: N=216 (high
risk=48%)
All other sites: N=1022
(high risk=49%)
N = Number of RPs
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Figure 2: Proportion of men with one or more high risk features by adverse feature – Pre-­‐CLICC
The figure shows the proportion of men who were found to have one or more high risk features upon radical prostatectomy in the baseline period (i.e. before the
commencement of the CLICC project) categorised by high risk feature of the study at each site. Categories are mutually exclusive. Statistics are inclusive of all pre-­‐CLICC
cases from 1 January 2013 until the CLICC study began at the site (dates vary).
Abbreviations: PSM – positive surgical margin, EPE -­‐ extracapsular extension, SVI – seminal vesicle invasion
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Figure 3: Proportion of men with high risk feature(s) referred to radiotherapy – Pre-­‐CLICC
The figure shows the proportion of men with one or more high risk features post-­‐radical prostatectomy in the baseline period (i.e. before the commencement of the CLICC
project) who were referred to radiotherapy for consultation at each site. Statistics are inclusive of all pre-­‐CLICC cases from 1 January 2013 until the CLICC study began at
the site (dates vary).
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Figure 4: Proportion of men referred to radiotherapy with a specific adverse feature – Pre-­‐CLICC
The figure shows the proportion of men referred to radiotherapy with a specific high risk feature(s) in the baseline period at each site (i.e. before the commencement of
the CLICC project). E.g. at [SITE], 7% of all men referred to radiotherapy had PSM, 36% had EPE, 21% had both PSM and EPE, etc. Categories are mutually exclusive.
Proportions for each site total 100%. Statistics are inclusive of all pre-­‐CLICC cases from 1 January 2013 until the CLICC study began at the site (dates vary).
Abbreviations: PSM – positive surgical margin, EPE -­‐ extracapsular extension, SVI – seminal vesicle invasion
If you have any queries or would like further information please contact implementation@saxinstitute.org.au.
Kind regards,
The CLICC Team
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[DATE]
Dear [NAME],
Thank you for your ongoing support and input into the CLICC study.
Please find below your third feedback report, which compares individual, site level, and aggregate study data on your practice before and after commencement of the CLICC study. This
report complements the data scheduled to be presented at the [SITE] Hospital Urology MDT meeting on [DATE].
NOTES:
1. Referral information may not be available for patients where medical records were reviewed less than 6 months post-­‐prostatectomy. Referral data will be verified through
further record review.
2. Data collection is ongoing. Figures are based on data collected from patient medical records at the time this report was produced and are subject to change following further
record review.
3. Time periods for [SITE]:
• Pre-­‐CLICC: 1 January 2013 – [DATE]
• Post-­‐CLICC: [DATE] onwards
(RPs for the month of [Month, Year] are excluded as this was when CLICC commenced at [SITE] and is considered to be a period of transition)
Urologist Site* Study Aggregate** 
Pre-CLICC Post-CLICC Pre-CLICC Post-CLICC Pre-CLICC Post-CLICC 
Number of radical prostatectomies performed 165 94 226 153 1061 N/A 
Men with one or more high risk features (PSM/EPE/SVI) post prostatectomy*** 73 (44%) 
34 
(36%) 
101 
(45%) 
68 
(44%) 
508 
(48%) N/A 
Referrals to Radiotherapy - men with one or more high risk features 1 (1%) 
3 
(9%) 
14 
(14%) 
11 
(16%) 
158 
(31%) N/A 
* Participating [SITE] urologists (N=X) ** Data collected at time of report – excluding [SITE]. Statistics are inclusive of all pre-­‐CLICC cases (dates vary for each site). Data for the post-­‐CLICC
period were not available for all other participating sites at the time of this report. These data will be provided in your final feedback report.
*** Abbreviations: PSM – positive surgical margin, EPE – extracapsular extension, SVI – seminal vesicle invasion
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MDT case flagging: Numbers of high risk cases flagged and discussed at an
MDT meeting and MDT recommendations
Urologist Site 
Number of cases flagged for MDT discussion 22 46 
Number of flagged cases discussed at an MDT meeting 18 (82%) 
33 
(72%) 
MDT 
recommendation 
for cases 
discussed at an 
MDT meeting 
Referral to radiation oncologist and/or 
discussion of radiotherapy 
15 
(83%) 
25 
(76%) 
Observation (“watch and wait”) 3 
(17%) 
7 
(21%) 
Other or unknown 0 
(0%) 
1 
(3%) 
Note: Data on MDT discussion reflects information provided by MDT Coordinators and is
collected on an ongoing basis. Figures include all patients flagged from [DATE] to [DATE].
Data have not been provided for some flagged cases. Figures are subject to change
following further record review.
Abbreviations: MDT – multidisciplinary team
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Abbreviations: PSM – positive surgical margin, EPE -­‐ extracapsular extension, SVI – seminal vesicle invasion 
The first figure shows the proportion of high risk cases by adverse feature(s) (e.g. in the pre-­‐CLICC period, 15% of patients identified as high risk at [SITE] (red bar) had PSM only; 26% had
PSM and EPE, etc.). The second figure shows the proportion of men within each specific adverse feature category referred to radiotherapy (e.g. in the pre-­‐CLICC period, 0% of patients
with PSM only at [SITE] (red bar absent) were referred; 4% of patients with PSM and EPE were referred, etc.).
If you have any queries or would like further information please contact implementation@saxinstitute.org.au.
Kind regards,
The CLICC Team 
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[DATE]
Dear [NAME],
Thank you for your ongoing support and input into the CLICC study.
This report complements the data presented at the [SITE] Hospital Urology MDT meeting on [DATE].
Note: Data collection is ongoing. Figures are based on data available at the time this report was produced
and are subject to change following further review of medical records.
Table 1: MDT Flagging: Cases flagged and discussed at an MDT meeting – Post-­‐CLICC
Data on MDT discussion reflects information collected after the commencement of the CLICC project from
pathology, MDT notes in medical records and information provided by the MDT coordinator. Data is collected
in real-­‐time and reflects cases flagged at [SITE] Hospital from [DATE] – [DATE].
Urologist Site All Other Sites 
Number of cases flagged for MDT discussion 48 85 225 
Number of flagged cases discussed at a MDT meeting 17 (35%) 
36 
(42%) 
193 
(86%) 
Number of flagged cases to be represented when PSA available* 14 
(29%) 
16 
(19%) N/A 
Number of flagged cases with no information on whether they 
were discussed** 
17 
(35%) 
32 
(38%) 
21 
(9%) 
MDT recommendation 
for cases discussed at 
a MDT meeting 
Referral to radiation oncologist and/or 
discussion of radiotherapy 
16 
(94%) 
30 
(83.3%) 
109 
(56.5%) 
Observation (“watch and wait”) 1 (6%) 
3 
(8.3%) 
37 
(19.2%) 
Other or unknown*** 0 (0%) 
3 
(8.3%) 
47 
(24.3%) 
*No evidence of further MDT discussion
**No evidence of MDT discussion in MDT records
***No recommendation recorded in MDT records
Abbreviations: MDT – multidisciplinary team
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Figure 1: Proportion of men with high risk features following radical prostatectomy – Pre-­‐CLICC
This graph shows the proportion of men who were found to have high risk features following radical
prostatectomy at each site during the baseline period of the study (i.e. before the commencement of the
CLICC project). Statistics are inclusive of all pre-­‐CLICC cases from 1 January 2013 until the CLICC study began at
the site (dates vary).
Figure 2: Proportion of men with high risk feature(s) referred to radiotherapy – Pre-­‐CLICC
The figure shows the proportion of men with one or more high risk features post-­‐radical prostatectomy in the
baseline period (i.e. before the commencement of the CLICC project) who were referred to radiotherapy for
consultation at each site. Statistics are inclusive of all pre-­‐CLICC cases from 1 January 2013 until the CLICC study
began at the site (dates vary).
If you have any queries or would like further information please contact implementation@saxinstitute.org.au.
Kind regards,
The CLICC Team
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RP – radical prostatectomy
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Appendix X
Clinical data collection forms
Improving Evidence Based Care for Men with 
Locally Advanced Prostate Cancer
Prostate Cancer Case Data Collection Form 
To be completed separately from clinical data collection form.
Patient Details
Date of Birth  ______/______/_______ (DD/MM/YYYY)        Medical Records No. __________________
First Name _____________________________   Middle Name _____________________________ 
Last Name ________________________________________________________________________ 
Address ______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
Postcode: _________________________ State: ____________________
Doctor Details
Name of Doctor who performed RP  _________________________________________________
Hospital at which RP was performed  ________________________________________________
Name of Registrar (if present) _______________________________________________________
Name of Doctor managing post-surgical care (if different from above)________________________
Report completed by: ____________________________________________________________________________
Date report completed: _______/________/________ (DD/MM/YYYY)
Location: _______________________________________________________________________________________
Study ID Number: _______________________________________________________________________________
Prostate Cancer Case Data Collection Form , Version 3, May 2014 Page 1 of 1
Date Report Completed: ______________________(DD/MM/YYYY)                    Study ID Number: _________________________
Hospital: __________________________________________               Urologist: _________________________________
Patient Details
9.  Date of Birth:   _____ /_______ (MM/YYYY)
10.  Postcode: __________________
11. Private health insurance?
	  Private health insurance 
	  Dept of Veterans’ Affairs white or gold card
	  Health care concession card
	  None of these
12. Country of birth:
   Australia
   Another country (specify): _____________________
13. Existing co-morbidities:
  None
  Diabetes
  Renal disease
  Cardiovascular disease
  Liver disease
  COPD/Respiratory disease
   Other (specify) ______________________________
Clinical Data Collection Form, Version 3, May 2014           Page 1 of 3
Clinical Data Collection Form
Improving evidence based care for men with locally advanced prostate cancer
Surgery Details
Extracapsular extension? Positive surgical margins? Seminal vesicle invasion? Regional lymph node involvement at diagnosis or after surgery?
Yes   /   No   /   Unsure Yes   /   No   /   Unsure Yes   /   No   /   Unsure Yes   /   No   /   Unsure
2. What was the patient’s disease stage at post surgery 
pathology?
 Stage: ___________________________
 Nodes: ___________________________
 Metastasis: _______________________
3. Date of  surgery: ____ / ____ / _______ (DD/MM/YYYY)
4. What was the surgical procedure? 
 (Tick all that apply)
 	Laparoscopic RP  
 	Retropubic RP
 	Robotic RP
5. Identified as high risk by the pathologist?
	   Yes 
	   No
	   Unsure
6. What was the patient’s Gleason score at post surgery 
pathology?
 Primary _______   Secondary _______
 Tertiary _______    Total  ____________
	   Gleason not assessed 
7. Were there any surgical complications?
	   No 
	   Yes. If yes, please specify: ______________________
 ________________________________________________
 ________________________________________________
8. Length of stay for surgery
 
Date admitted    ____ / ____ / ___  (DD/MM/YYYY) 
 
Date separated    ____ / ____ / ___ (DD/MM/YYYY)
Diagnosis Details
14. Date of diagnosis: 
   
____ / ____ / ___ (DD/MM/YYYY)
15. What was the patient’s Gleason Score at diagnosis?
 Primary _______   Secondary _______
 Tertiary _______    Total  ____________
	   Gleason not assessed
16. Date and result of the last PSA test done before diag-
nosis (prior to hormonal therapy if received)
 
 Date____ / ____ / ____       PSA_________ng/mL
	   Unknown
	   Not done before diagnosis
20. Date of post surgery consults with urologist:
 ____  / ____  / ________ (DD/MM/YYYY)
 ____  / ____  / ________ (DD/MM/YYYY) 
 ____  / ____  / ________ (DD/MM/YYYY)
21. Date and result of PSA tests done since surgery
 ____  / ____  / ________ (DD/MM/YYYY)  PSA _____ ng/ml
 ____  / ____  / ________ (DD/MM/YYYY)  PSA _____ ng/ml
 ____  / ____  / ________ (DD/MM/YYYY)  PSA _____ ng/ml
  Unknown
22. Urologist referred patient  to radiation oncologist for
consideration of adjuvant radiotherapy?
  Yes
Date Referred: ___ /___ /_____  (DD/MM/YYYY)
Radiation Oncologist  
 __________________________________________
Radiation Oncology Unit
 __________________________________________
	   No
	   Unsure
23. Urologist referred to radiotherapy as
  Adjuvant
  Salvage
  Other (specify): _____________________________
 ___________________________________________
24. Urologists’ reasons given for not referring to
radiation oncologist for adjuvant therapy?
  No
  Yes (specify)  _______________________________
______________________________________________
______________________________________________
25. Did the patient have Hormone Therapy?
  Yes 	   No
26. What was the course of Hormone Therapy?
 Continuous
 Intermittent
Date Started ____ /____ /_______  (DD/MM/YYYY)
Date Finished ____ /____ /________  (DD/MM/YYYY)
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Pre Prostatectomy Consult Post Prostatectomy Consult
17. Patient referred to radiation oncologist prior to
prostatectomy?
  Yes i) Referred by urologist
ii) Referred by GP
iii) Other
Please specify: ____________________
  No
  Unsure
18. Consultation with radiation oncologist prior to
prostatectomy?
  Yes
Date of consult: ___ /___ /_____  (DD/MM/YYYY)
Radiation Oncologist  
 __________________________________________
Radiation Oncology Unit
 __________________________________________
	   No
19. Decided to have radiotherapy?
  Yes
  No - no reason given
  No - reason given (specify):__________________
_____________________________________________
_____________________________________________
Improving evidence based care for men with locally advanced prostate cancer
Study ID Number: ____________
27. Consultation with radiation oncologist, post prosta-
tectomy?
  Yes 	   No
28. Date of  initial consult with radiation oncologist:
____  / ____  / ________ (DD/MM/YYYY)
29. Radiation oncologist referred to radiotherapy as
  Adjuvant
  Salvage
  Other (specify): _____________________________
 ___________________________________________
30. Received radiotherapy post prostatectomy?
  Yes
  No – no reason given
  No – reason given (specify) ________________
 _________________________________________
31. Hospital location of radiotherapy?
___________________________________________
32. Radiotherapy
Date Started: ____ /____ /________ (DD/MM/YYYY)
Finished: ____ /____  /_________ (DD/MM/YYYY)
Total dose:_________________________________GY
No. of fractions: _____________________________
33. Is there evidence that the patient was referred to a
MDT?
  No
  Yes i) Noted by Clinician	 
ii) Letter from MDT	 
iii) Other 
    Please specify:  ___________________
34. Which MDT was the patient referred to?
______________________
Date of MDT  ____  / ____  / ________ (DD/MM/YYYY)
MDT Recommendation _______________________
____________________________________________
____________________________________________
____________________________________________
____________________________________________
MDT
Radiotherapy
Improving evidence based care for men with locally advanced prostate cancer
35. Patient was referred for enrolment in RAVES trial?
  Yes 	   No 	   Unsure
36. Date of enrolment in RAVES:
____ /____ /________ (DD/MM/YYYY)
37. Clinician’s reasons given for not referring to RAVES
trial?
  No
  Yes (specify)  _______________________________
______________________________________________
______________________________________________
38. Radiation oncologist’s reasons given for not refer-
ring to RAVES trial?
  No
  Yes (specify)  _______________________________
______________________________________________
______________________________________________
Raves
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 Study ID Number: ____________
Version 3, May 2014
Im
p
ro
vi
ng
 e
vi
d
en
ce
 b
as
ed
 c
ar
e 
fo
r 
m
en
 w
ith
 lo
ca
lly
 a
d
va
nc
ed
 p
ro
st
at
e 
ca
nc
er
P
ro
st
at
e 
C
an
ce
r 
C
as
e 
E
lig
ib
ili
ty
 F
o
rm
H
os
pi
ta
l: 
__
__
__
__
__
__
__
__
__
__
__
__
__
__
__
__
__
__
__
_ 
   
U
ro
lo
gi
st
: _
__
__
__
__
__
__
__
__
__
__
__
__
__
__
__
__
__
__
__
__
__
A
ll 
m
en
 re
ce
iv
in
g 
ra
di
ca
l p
ro
st
at
ec
to
m
y 
du
rin
g 
pe
rio
d 
__
__
  /
 _
__
_ 
 /
 _
__
__
__
_ 
  t
o 
 _
__
_ 
 /
 _
__
_ 
 /
 _
__
__
__
_ 
(D
D
/M
M
/Y
Y
Y
Y
)
M
ed
ic
al
 
R
ec
o
rd
 
N
um
b
er
D
at
e 
o
f 
R
P
T
3a
 e
xt
ra
 
ca
p
su
la
r 
ex
te
ns
io
n
Y
/N
/U
P
o
si
ti
ve
 
su
rg
ic
al
 
m
ar
g
in
s 
Y
/N
/U
T
3b
 
se
m
in
al
 
ve
si
cl
e 
in
va
si
o
n
Y
/N
/U
P
o
st
 R
P
 
P
S
A
 le
ve
l 
(n
g
/m
l)
Id
en
ti
fi
ed
 a
s 
hi
g
h 
ri
sk
 b
y 
p
at
ho
lo
g
is
t?
Y
/N
/U
E
lig
ib
le
 
Y
/N
/U
N
o
te
s
Y
=
Ye
s 
  N
=
 N
o 
  U
=
 U
ns
ur
e
Appendix XI
CLICC Clinical Leader and urologist participant surveys
NHMRC Parternship Project 1011474 
Clinician Led Improvements in 
Cancer Care (CLICC) 
Australia New Zealand Clinical Trials Registry: ACTRN12611001251910 
Survey of Urologist Participants
Baseline 
Survey of Urologist Participants, Version 1, 28 November 2012 Page 2 of 7 
Background 
There is currently much debate over the most appropriate treatment for high-risk prostate 
cancer.  In particular, there are controversies in post-prostatectomy radiotherapy. 
This survey aims to assess the current views and practice of urologists relating to adjuvant 
radiotherapy for men with locally advanced prostate cancer following radical prostatectomy.  
The survey forms part of a wider study funded by the National Health and Medical Research 
Council (NHMRC) and the Prostate Cancer Foundation of Australia (PCFA) with the research 
being undertaken in partnership with The Sax Institute, University of Sydney, Cancer Council 
NSW and the NSW Agency for Clinical Innovation (ACI). Australia New Zealand Clinical Trials 
Registry: ACTRN12611001251910. 
You have been selected to participate as a urologist who performs radical prostatectomy in 
one of the 9 NSW hospitals taking part in the study. 
Participation in this survey is entirely voluntary. Submitting a completed survey is an 
indication of your consent to participate in the study. All aspects of the study, including the 
results, will be strictly confidential. Your responses will be anonymous and aggregated with 
those of other respondents in all reports relating to this study.  
If you would like further information about the study and how your responses will be used, 
please read the participant information sheet provided. 
Survey of Urologist Participants, Version 1, 28 November 2012 Page 3 of 7 
1. For each scenario, we are interested in your current level of certainty about which treatment
option is better. Please rate your certainty by circling the number that best reflects your view.  If
you are completely undecided between the two options, please circle ‘0’. If, however, you
consider one treatment option to be superior, for whatever reason, please indicate how strongly
you hold this view by circling the appropriate number on the scale.
Case 1 
A 64 year old man, previously well, presented with a pre-op PSA of 12.2. Patient had radical 
prostatectomy 10 weeks ago. Pathology results show a Gleason 3+4=7 carcinoma with 
extracapsular extension and positive margins near apex over a 2mm front. Seminal vesicle 
and lymph nodes were clear.  Post radical prostatectomy he has good urinary control. Post-
op PSA 0.01. No return of erections. 
Watchful waiting 
is preferable 
   Undecided Adjuvant 
radiotherapy is 
preferable 
5 4 3 2 1 0 1 2 3 4 5 
Case 2 
A 58 year old man had a nerve sparing radical prostatectomy 3 months ago for a low volume 
Gleason 3+4=7 carcinoma (20% high grade) with 0.2mm extracapsular extension in left 
peripheral zone but clear surgical margins. No perineural or lymphovascular invasion. 
Seminal vesicles clear. 0/12 nodes involved. Post-op PSA <0.01. Some dribbling on straining 
but pad free. Partial erections but inadequate for intercourse. 
Watchful waiting 
is preferable 
   Undecided Adjuvant 
radiotherapy is 
preferable 
5 4 3 2 1 0 1 2 3 4 5 
Case 3 
A 62 year old man had a non nerve sparing prostatectomy for a clinical T3 prostate cancer 
with pre-op PSA of 14. Histopathology demonstrates a widespread Gleason 4+4=8 
carcinoma with multifocal sites of extracapsular extension and involvement of base of right 
seminal vesicle. Multiple sites of positive surgical margins. Post-op PSA 0.04. No lymph node 
involvement. Good urinary function and no erections. 
Watchful waiting 
is preferable 
   Undecided Adjuvant 
radiotherapy is 
preferable 
5 4 3 2 1 0 1 2 3 4 5 
 Survey of Urologist Participants, Version 1, 28 November 2012 Page 4 of 7 
2. Thinking about your understanding of the current literature and evidence for treatment of prostate 
cancer, please rate the extent to which you agree or disagree with each statement by ticking ONE 
option: 
 
 
 
 
 
 
a. Immediate external irradiation after radical prostatectomy improves biochemical 
progression-free survival and local control in patients with positive surgical margins or 
pT3 prostate cancer who are at high risk of progression.   
Strongly   Somewhat  Somewhat Strongly Don’t  
disagree  disagree agree  agree  know 
 
 
 
 
 
b. Relapse after local therapy is defined by prostate-specific antigen (PSA) values >0.2 
ng/ml following radical prostatectomy (RP) and >2 ng/ml above the nadir PSA after 
radiation therapy (RT). 
Strongly   Somewhat  Somewhat Strongly Don’t  
disagree  disagree agree  agree  know 
 
 
 
 
 
c. All high risk patients should have multidisciplinary input and be referred by their 
urologist to a radiation oncologist before treatment to ensure informed decision 
making based on discussion of the relative advantages and disadvantages of adjuvant 
radiotherapy or watchful waiting. 
Strongly   Somewhat  Somewhat Strongly Don’t  
disagree  disagree agree  agree  know 
 
 
 
 
 
d. There are no data from randomised controlled trials to define the benefits of salvage 
radiation versus adjuvant therapy or salvage radiation versus systemic therapy (either 
at time of PSA rise or at time of radiographic progression). 
Strongly   Somewhat  Somewhat Strongly Don’t  
disagree  disagree agree  agree  know 
Survey of Urologist Participants, Version 1, 28 November 2012 Page 5 of 7 
3. Considering the recommendation for patients with extracapsular extension, seminal vesicle
involvement or positive surgical margins to receive post-operative external beam
radiotherapy within four months of surgery, please rate the extent to which you agree or
disagree with each statement by placing an X in ONE box:
strongly 
disagree 
disagree neither 
agree 
nor 
disagree 
agree strongly 
agree 
Don’t 
know 
The recommendation is based on a 
valid interpretation of the 
underpinning evidence 
The side-effects of adjuvant 
radiotherapy for patients with locally 
advanced prostate cancer outweigh 
the benefits 
There are other recommendations for 
the appropriate management of this 
patient population that conflict with 
this one 
Following this recommendation will 
lead to improved patient outcomes 
If I follow this recommendation my 
patients may experience unnecessary 
discomfort 
 I support post-operative external 
beam radiation therapy for patients 
but not within four months of surgery 
If I don’t follow this recommendation I 
may be liable for malpractice 
This recommendation is consistent 
with my clinical experience with this 
patient group 
This recommendation is consistent 
with the opinions of my respected 
clinical colleagues  
This recommendation does not reflect 
evidence that is emerging on this topic 
This recommendation should only be 
followed within fully informed decision 
making by the patient 
Survey of Urologist Participants, Version 1, 28 November 2012 Page 6 of 7 
5. Considering the recommendation for patients with extracapsular extension, seminal vesicle
involvement or positive surgical margins to receive post-operative external beam radiation
therapy within four months of surgery:
4. Following radical prostatectomy who do you believe is the person best placed to
decide on the most appropriate post-operative treatment option? Please select ONE
option:
The urological surgeon is best placed to decide 
The radiation oncologist is best placed to decide 
The medical oncologist is best placed to decide 
The MDT is best placed to decide 
The patient is best placed to decide 
a. Randomised trials have demonstrated a range of survival effects following adjuvant
radiotherapy for this patient group. Thinking about the current evidence, what is the
minimum survival benefit you consider acceptable for you to follow this
recommendation? Please complete ONE OPTION.
 Days  Months  Years 
b. What do you consider to be the maximum proportion of men who suffer from rectal
damage or develop faecal incontinence as a result of radiotherapy for this treatment
to be unacceptable? Please place an X on the scale below.
__________________________________________________________________ 
0%  100%
c. Do you have any comments on adjuvant radiotherapy following radical
prostatectomy?
Survey of Urologist Participants, Version 1, 28 November 2012 Page 7 of 7 
6.1  Gender:  Male / Female 
6.2 Age group: 20-30 / 31-40 / 41-50 / 51-60 / >60 
6.3 Which type of practice do you have? (Circle ONE option for your major 
appointment): 
VMO/Consultant 
Salaried University Academic 
Staff Specialist 
Registrar/Junior Medical Officer 
Other (please specify) __________________________________________________ 
6.4 How many years have you been a practicing Urologist? 
0-5  /  6-10  /  11-15  /  16–20  /  21–25  /  26-30  /   >30 
6.5 Do you perform Radical Prostatectomy? Yes / No 
6.5a Approximately how many new patients diagnosed with prostate cancer do you care 
for in a TYPICAL MONTH? _________________________________________patients 
6.5b Approximately what percentage of your practice is comprised of prostate cancer 
patients? ___________________________________________________________ % 
6.5c What percentage of your patients are in ACTIVE TREATMENT for prostate cancer (as 
opposed to routine surveillance or follow up)? _____________________________ % 
6.6 Which of the following best describes the location in which you practice? (Circle 
ONE option only): 
Capital city 
Other major urban area 
Rural 
Remote 
Other 
6.7 In which setting do you treat the MAJORITY of prostate cancer patients: (Circle ONE 
option only):   
Teaching hospital 
Public, non-teaching hospital 
Private hospital 
THANK YOU FOR YOUR TIME 
NHMRC Parternship Project 1011474 
Clinician Led Improvements in 
Cancer Care (CLICC) 
Australia New Zealand Clinical Trials Registry: ACTRN12611001251910 
Survey of Urologist Participants
End of Study 
Survey of Urologist Participants, Version 1, 28 November 2012 Page 2 of 6 
Background 
There is currently much debate over the most appropriate treatment for high-risk prostate 
cancer.  In particular, there are controversies in post-prostatectomy radiotherapy. 
This survey aims to assess the current views and practice of urologists relating to adjuvant 
radiotherapy for men with locally advanced prostate cancer following radical prostatectomy.  
The survey forms part of a wider study funded by the National Health and Medical Research 
Council (NHMRC) and the Prostate Cancer Foundation of Australia (PCFA) with the research 
being undertaken in partnership with The Sax Institute, University of Sydney, Cancer Council 
NSW and the NSW Agency for Clinical Innovation (ACI). Australia New Zealand Clinical Trials 
Registry: ACTRN12611001251910. 
You have been selected to participate as a urologist who performs radical prostatectomy in 
one of the 9 NSW hospitals taking part in the study. 
Participation in this survey is entirely voluntary. Submitting a completed survey is an 
indication of your consent to participate in the study. All aspects of the study, including the 
results, will be strictly confidential. Your responses will be anonymous and aggregated with 
those of other respondents in all reports relating to this study.  
If you would like further information about the study and how your responses will be used, 
please read the participant information sheet provided. 
Survey of Urologist Participants, Version 1, 28 November 2012 Page 3 of 6 
1. For each scenario, we are interested in your current level of certainty about which treatment
option is better. Please rate your certainty by circling the number that best reflects your view.  If
you are completely undecided between the two options, please circle ‘0’. If, however, you
consider one treatment option to be superior, for whatever reason, please indicate how strongly
you hold this view by circling the appropriate number on the scale.
Case 1 
A 64 year old man, previously well, presented with a pre-op PSA of 12.2. Patient had radical 
prostatectomy 10 weeks ago. Pathology results show a Gleason 3+4=7 carcinoma with 
extracapsular extension and positive margins near apex over a 2mm front. Seminal vesicle 
and lymph nodes were clear.  Post radical prostatectomy he has good urinary control. Post-
op PSA 0.01. No return of erections. 
Watchful waiting 
is preferable 
   Undecided Adjuvant 
radiotherapy is 
preferable 
5 4 3 2 1 0 1 2 3 4 5 
Case 2 
A 58 year old man had a nerve sparing radical prostatectomy 3 months ago for a low volume 
Gleason 3+4=7 carcinoma (20% high grade) with 0.2mm extracapsular extension in left 
peripheral zone but clear surgical margins. No perineural or lymphovascular invasion. 
Seminal vesicles clear. 0/12 nodes involved. Post-op PSA <0.01. Some dribbling on straining 
but pad free. Partial erections but inadequate for intercourse. 
Watchful waiting 
is preferable 
   Undecided Adjuvant 
radiotherapy is 
preferable 
5 4 3 2 1 0 1 2 3 4 5 
Case 3 
A 62 year old man had a non nerve sparing prostatectomy for a clinical T3 prostate cancer 
with pre-op PSA of 14. Histopathology demonstrates a widespread Gleason 4+4=8 
carcinoma with multifocal sites of extracapsular extension and involvement of base of right 
seminal vesicle. Multiple sites of positive surgical margins. Post-op PSA 0.04. No lymph node 
involvement. Good urinary function and no erections. 
Watchful waiting 
is preferable 
   Undecided Adjuvant 
radiotherapy is 
preferable 
5 4 3 2 1 0 1 2 3 4 5 
 Survey of Urologist Participants, Version 1, 28 November 2012 Page 4 of 6 
2. Thinking about your understanding of the current literature and evidence for treatment of prostate 
cancer, please rate the extent to which you agree or disagree with each statement by ticking ONE 
option: 
 
 
 
 
 
 
a. Immediate external irradiation after radical prostatectomy improves biochemical 
progression-free survival and local control in patients with positive surgical margins or 
pT3 prostate cancer who are at high risk of progression.   
Strongly   Somewhat  Somewhat Strongly Don’t  
disagree  disagree agree  agree  know 
 
 
 
 
 
b. Relapse after local therapy is defined by prostate-specific antigen (PSA) values >0.2 
ng/ml following radical prostatectomy (RP) and >2 ng/ml above the nadir PSA after 
radiation therapy (RT). 
Strongly   Somewhat  Somewhat Strongly Don’t  
disagree  disagree agree  agree  know 
 
 
 
 
 
c. All high risk patients should have multidisciplinary input and be referred by their 
urologist to a radiation oncologist before treatment to ensure informed decision 
making based on discussion of the relative advantages and disadvantages of adjuvant 
radiotherapy or watchful waiting. 
Strongly   Somewhat  Somewhat Strongly Don’t  
disagree  disagree agree  agree  know 
 
 
 
 
 
d. There are no data from randomised controlled trials to define the benefits of salvage 
radiation versus adjuvant therapy or salvage radiation versus systemic therapy (either 
at time of PSA rise or at time of radiographic progression). 
Strongly   Somewhat  Somewhat Strongly Don’t  
disagree  disagree agree  agree  know 
Survey of Urologist Participants, Version 1, 28 November 2012 Page 5 of 6 
3. Considering the recommendation for patients with extracapsular extension, seminal vesicle
involvement or positive surgical margins to receive post-operative external beam
radiotherapy within four months of surgery, please rate the extent to which you agree or
disagree with each statement by placing an X in ONE box:
strongly 
disagree 
disagree neither 
agree 
nor 
disagree 
agree strongly 
agree 
Don’t 
know 
The recommendation is based on a 
valid interpretation of the 
underpinning evidence 
The side-effects of adjuvant 
radiotherapy for patients with locally 
advanced prostate cancer outweigh 
the benefits 
There are other recommendations for 
the appropriate management of this 
patient population that conflict with 
this one 
Following this recommendation will 
lead to improved patient outcomes 
If I follow this recommendation my 
patients may experience unnecessary 
discomfort 
 I support post-operative external 
beam radiation therapy for patients 
but not within four months of surgery 
If I don’t follow this recommendation I 
may be liable for malpractice 
This recommendation is consistent 
with my clinical experience with this 
patient group 
This recommendation is consistent 
with the opinions of my respected 
clinical colleagues  
This recommendation does not reflect 
evidence that is emerging on this topic 
This recommendation should only be 
followed within fully informed decision 
making by the patient 
Survey of Urologist Participants, Version 1, 28 November 2012 Page 6 of 6 
5. Considering the recommendation for patients with extracapsular extension, seminal vesicle
involvement or positive surgical margins to receive post-operative external beam radiation
therapy within four months of surgery:
4. Following radical prostatectomy who do you believe is the person best placed to
decide on the most appropriate post-operative treatment option? Please select ONE
option:
The urological surgeon is best placed to decide 
The radiation oncologist is best placed to decide 
The medical oncologist is best placed to decide 
The MDT is best placed to decide 
The patient is best placed to decide 
a. Randomised trials have demonstrated a range of survival effects following adjuvant
radiotherapy for this patient group. Thinking about the current evidence, what is the
minimum survival benefit you consider acceptable for you to follow this
recommendation? Please complete ONE OPTION.
 Days  Months  Years 
b. What do you consider to be the maximum proportion of men who suffer from rectal
damage or develop faecal incontinence as a result of radiotherapy for this treatment
to be unacceptable? Please place an X on the scale below.
__________________________________________________________________ 
0%  100%
c. Do you have any comments on adjuvant radiotherapy following radical
prostatectomy?
THANK YOU FOR YOUR TIME 
	  SURVEY SCORING KEY AND 	  SUMMARY	  SCORE	  CALCULATION	  METHOD	  
Survey	  domains:	  1. Attitudes	  towards	  clinical	  practice	  guidelines	  in	  general	  (USANZ	  hardcopy	  survey	  Q2.2,	  CLICC	  participant	  survey	  Q3)2. Attitudes	  towards	  the	  recommendation	  for	  patients	  with	  extracapsularextension,	  seminal	  vesicle	  involvement	  or	  positive	  surgical	  margins	  toreceive	  post-­‐operative	  external	  beam	  radiotherapy	  within	  four	  months	  ofsurgery	  (USANZ	  hard	  copy	  survey	  Q2.5,	  CLICC	  participant	  survey	  Q3)Responses	  for	  questions	  in	  the	  above	  domains	  were	  scored	  as	  follows:	  1	  =	  strongly	  disagree	  2	  =	  disagree	  3	  =	  neither	  agree	  nor	  disagree	  4	  =	  agree	  5	  =	  strongly	  agree	  Don’t	  know	  coded	  as	  missing	  A	  summary	  score	  was	  calculated	  from	  respondents’	  total	  scores	  on	  questions	  within	  each	  domain	  by	  summing	  the	  values	  for	  all	  non-­‐missing	  items	  and	  dividing	  by	  the	  total	  number	  of	  items	  completed	  to	  assess	  overall	  attitudes	  and	  beliefs	  relating	  to	  clinical	  practice	  guidelines	  in	  general	  and	  towards	  the	  recommendation	  for	  adjuvant	  radiotherapy.	  
General	  Summary	  Score	  A	  summary	  score	  for	  attitudes	  towards	  guidelines	  in	  general	  was	  calculated	  as	  the	  sum	  of	  scores	  on	  questions	  10	  –	  21	  inclusive.	  Negatively	  worded	  items	  (Qs	  14,	  15,	  16,	  17,	  18,	  20,	  21)	  were	  reverse	  coded	  around	  the	  midpoint	  into	  new	  variables	  (Q14r,	  Q15r,	  Q16r,	  Q17r,	  Q18r,	  Q20r,	  Q21r)	  such	  that:	  	  1	  =	  strongly	  agree	  2	  =	  agree	  3	  =	  neither	  agree	  nor	  disagree	  4	  =	  disagree	  5	  =	  strongly	  disagree	  Don’t	  know	  coded	  as	  missing	  
General	  summary	  score	  =	  (Q10	  +	  Q11	  +	  Q13	  +	  Q14r	  +Q15r	  +	  Q16r	  +	  Q17r	  +	  
Q18r	  +	  Q19	  +	  Q20r	  +	  Q21r)	  /	  number	  of	  items	  completed.	  	  
ART	  Summary	  Score	  	  A	  summary	  score	  for	  attitudes	  towards	  the	  recommendation	  for	  adjuvant	  radiotherapy	  (ART)	  was	  calculated	  as	  the	  sum	  of	  scores	  on	  questions	  25	  –	  35	  inclusive.	  	  Negatively	  worded	  items	  (Qs	  26,	  27,	  29,	  30,	  34)	  were	  reverse	  coded	  around	  the	  midpoint	  into	  new	  variables	  (Q26r,	  Q27r,	  Q29r,	  Q30r,	  Q34r)	  such	  that:	  	  	  1	  =	  strongly	  agree	  2	  =	  agree	  3	  =	  neither	  agree	  nor	  disagree	  4	  =	  disagree	  5	  =	  strongly	  disagree	  Don’t	  know	  coded	  as	  missing	  	  
ART	  summary	  score	  =	  (Q25	  +	  Q26r	  +	  Q27r	  +	  Q28	  +	  Q29r	  +	  Q30r	  +	  Q31	  +	  
Q32	  +	  Q32	  +	  Q34r	  +	  Q35)	  /	  number	  of	  items	  completed.	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Email: Mary.Haines@saxinstitute.org.au  
Dear A/Prof Haines 
RE: NHMRC partnership grant APP1011474 – Improving evidence based case for locally 
advance prostate cancer (CIA: Haines) – request to confirm that ethics approval is not 
required for year 1 development phase (2011) 
Thank you for your letter dated 5 January 2012 where you outline a revised start date of your 
research project due to protracted contractual negotiations and we note that you have been 
granted a deferred start date by the NHMRC of 1 November 2011. We note you will be required to 
seek ethics approval prior to commencing phases 1 and 2 of your study, and understand this will 
take place in July 2012.  
We re-confirm that you do not require ethics approval for the development phase, as the activities 
undertaken are deemed to be of negligible risk according to National Statement of Ethical Conduct 
in Human Research (2007). 
We understand that the development phase of the study will involve the following activities: 
 Recruitment of staff
 Recruitment of clinicians to be involved in the study
 Designing the intervention
 Developing the data collection tools
 Preparation of an ethics submission
Please do not hesitate to contact Research Integrity (Human Ethics) should you require further 
information or clarification. 
Yours sincerely 
Dr Margaret Faedo 
Manager, Human Ethics 
On behalf of the HREC 
cc: Yamini Sindoba Sandiran 
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A/Prof Mary Haines 
The Sax Institute 
School of Public Health 
The University of Sydney 
Email: mary.haines@saxinstitute.org.au 
Dear A/Prof Haines 
Thank you for your correspondence dated 12 September 2012 addressing comments made to you by 
the Human Research Ethics Committee (HREC). 
I am pleased to inform you that with the matters now addressed your protocol entitled “Improving 
evidence based care for men with locally advanced prostate cancer - Survey of Australian 
Urologists” has been approved. 
Details of the approval are as follows: 
Protocol No.: 15222 
Approval Date: 17 September 2012 
First Annual Report Due: 30 September 2013 
Authorised Personnel: A/Prof Mary Haines 
Prof Jane Young 
Mrs Bernadette Brown 
Mrs Jane Bois 
Documents Approved: 
Document Version Number Date 
Information for Participants Version 2 10 September 2012 
Implied Consent Wording Version 2 10 September 2012 
Competition Entry Form Version 1 20 August 2012 
Survey of Urologists n/a n/a 
Invitation letter from CI Version 1 9 August 2012 
Email invite to websurvey participants Version 1 16 August 2012 
Email reminder to websurvey participants Version 1 9 August 2012 
HREC approval is valid for four (4) years from the approval date stated in this letter and is granted 
pending the following conditions being met: 
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Condition/s of Approval 
 Continuing compliance with the National Statement on Ethical Conduct in Research Involving
Humans.
 Provision of an annual report on this research to the Human Research Ethics Committee from
the approval date and at the completion of the study. Failure to submit reports will result in
withdrawal of ethics approval for the project.
 All serious and unexpected adverse events should be reported to the HREC within 72 hours.
 All unforeseen events that might affect continued ethical acceptability of the project should be
reported to the HREC as soon as possible.
 Any changes to the protocol including changes to research personnel must be approved by
the HREC by submitting a Modification Form before the research project can proceed.
Chief Investigator / Supervisor’s responsibilities: 
1. You must retain copies of all signed Consent Forms (if applicable) and provide these to the HREC
on request.
2. It is your responsibility to provide a copy of this letter to any internal/external granting agencies if
requested.
Please do not hesitate to contact Research Integrity (Human Ethics) should you require further 
information or clarification. 
Yours sincerely 
Dr Margaret Faedo 
Manager, Human Ethics 
On behalf of the HREC 
cc: Bea Brown 
bea.brown@saxinstitute.org.au 
This HREC is constituted and operates in accordance with the National Health and Medical 
Research Council’s (NHMRC) National Statement on Ethical Conduct in Human Research 
(2007), NHMRC and Universities Australia Australian Code for the Responsible Conduct of 
Research (2007) and the CPMP/ICH Note for Guidance on Good Clinical Practice. 
Research Integrity 
Human Research Ethics Committee 
Friday, 27 March 2015 
Assoc Prof Mary Haines 
School of Public Health: Public Health; Sydney Medical School 
Email: mary.haines@saxinstitute.org.au 
Dear Mary 
Your request to modify the below project submitted on 17 February 2015 was considered by the 
Executive of the Human Research Ethics Committee at its meeting on 17 March 2015 
The Committee had no ethical objections to the modification/s and has approved the project to 
proceed. 
Details of the approval are as follows: 
Project No.: 2012/2403 
Project Title: Improving evidence based care for men with locally advanced 
prostate cancer - Survey of Australian Urologists 
Revised Completion Date: 30 September 2016  
Please do not hesitate to contact Research Integrity (Human Ethics) should you require further 
information or clarification. 
Yours sincerely 
Dr Fiona Gill 
Chair 
Executive, Human Research Ethics Committee 
This HREC is constituted and operates in accordance with the National Health and Medical 
Research Council’s (NHMRC) National Statement on Ethical Conduct in Human Research 
(2007), NHMRC and Universities Australia Australian Code for the Responsible Conduct of 
Research (2007) and the CPMP/ICH Note for Guidance on Good Clinical Practice. 

























Appendix XIII
Evidence of copyright approvals
8/03/16 11:45 AMRE: American Joint Committee on Cancer Prostate Cancer Staging ... - Bea Brown
Page 1 of 3https://outlook.office.com/owa/#viewmodel=ReadMessageItem&Ite…BWTamU8wP9RemoAAJQUeOxAAA%3D&IsPrintView=1&wid=55&ispopout=1
RE: American Joint Committee on Cancer Prostate Cancer Staging 7th
Edition
Dear Bea:   Apologies for the delay.  This permission request is approved without fee for one-time use only in
your dissertation in print and electronic format.   The thesis can be viewed worldwide electronically.  Please use
the following attribution line:  Used with permission of the American Joint Committee on Cancer (AJCC),
Chicago, Illinois. The original and primary source for this information is the AJCC Cancer Staging Manual,
Seventh Edition (2010) published by Springer Science+Business Media.
Thanks and best wishes. Richard
Richard Lansing
Springer | Editorial Director, Clinical Medicine
233 Spring Street | New York, New York 10013-1578 USA
tel: 212 460 1532
mobile: 973 262 0316
fax: 212 460 1575
Richard.Lansing@Springer.com
From: Bea Brown [mailto:Bea.Brown@saxinstitute.org.au] 
Sent: Tuesday, March 01, 2016 3:20 AM
To: Lansing, Richard, Springer US
Subject: Fw: American Joint Committee on Cancer Prostate Cancer Staging 7th Edition
Dear Richard,
I am writing to follow up on my earleir email to request permission to reproduce an image (as detailed below)
in my PhD thesis.
I look forward to your response.
Kind regards,
Bea
Bea Brown
Research Fellow, Implementation Research Group
Sax Institute 
ACN 095 542886
Lansing, Richard, Springer US <Richard.Lansing@springer.com>
Wed 2/03/2016 9:18 AM
To:Bea Brown <Bea.Brown@saxinstitute.org.au>;
8/03/16 11:45 AMRE: American Joint Committee on Cancer Prostate Cancer Staging ... - Bea Brown
Page 2 of 3https://outlook.office.com/owa/#viewmodel=ReadMessageItem&Ite…BWTamU8wP9RemoAAJQUeOxAAA%3D&IsPrintView=1&wid=55&ispopout=1
Level 13, Building 10, 235 Jones Street Ultimo NSW 2007
Phone: 02 9188 9500 
Direct: 02 9188 9540
Mobile: 0425 400 694
Fax: 02 9188 9501
PO Box K617 Haymarket NSW 1240
From: Bea Brown
Sent:Wednesday, 10 February 2016 2:52 PM
To: richard.lansing@springer.com
Subject: American Joint Committee on Cancer Prostate Cancer Staging 7th Edition
Dear Richard,
I am completing a PhD degree at the University of Sydney and would like to request permission to reproduce the
above quick reference in my thesis (https://cancerstaging.org/referencesU
tools/quickreferences/Documents/ProstateSmall.pdf). I understand you own the copyright of the work as the
publisher.
Prostate Cancer Staging. 7th Edition - AJCC
cancerstaging.org
7th EDITION Primary Tumor (T) CLINICAL TX Primary tumor cannot be assessed T0 No evidence of primary
tumor T1 Clinically inapparent tumor neither
I wish to make my research thesis available for public access on the Internet via Sydney Digital Theses,
(http://echolarship.usyd.edu.au), the University’s digital archive of research theses.
I wish to seek from you a limited, nonUexclusive licence to include the work listed above for an indefinite period in the
electronic version of my thesis to be made available on open access via Sydney Digital Theses. I would welcome the
opportunity to use this resource in my research thesis and look forward to your granting permission on the attached
form by return email. Should you wish not to grant permission, or if you are not the copyright holder of this resource,
I would appreciate it if you would notify me in writing.
Yours sincerely,
Bea Brown.
Bea Brown
Research Fellow, Implementation Research
Sax Institute 
ACN 095 542886
Copyright Transfer Agreement: Example of CTA 
This is an example of the Copyright Transfer Agreement (CTA) that you will be asked to complete 
if your paper is accepted for publication. This document is for your information only – please do 
NOT complete this version of the form. If your paper is accepted you will receive further 
instructions about how to complete the form.  
[JOURNAL NAME] 
Published by Wiley on behalf of     (the “Owner”) 
or 
Published by Wiley (the “Owner”) 
or 
Published by Wiley and  (together the “Owner”) 
COPYRIGHT TRANSFER AGREEMENT 
Date:    
Contributor name:  
Contributor address: 
Manuscript number:  
Re: Manuscript entitled  (the “Contribution”) 
for publication in        (the “Journal”) 
published by  (“Wiley”)  
Dear Contributor(s): 
Thank you for submitting your Contribution for publication. In order to expedite the editing and 
publishing process and enable the Owner to disseminate your Contribution to the fullest extent, we 
need to have this Copyright Transfer Agreement executed. If the Contribution is not accepted for 
publication, or if the Contribution is subsequently rejected, this Agreement shall be null and void. 
Publication cannot proceed without a signed copy of this Agreement. 
A. COPYRIGHT 
1. The Contributor assigns to the Owner, during the full term of copyright and any extensions or
renewals, all copyright in and to the Contribution, and all rights therein, including but not limited 
to the right to publish, republish, transmit, sell, distribute and otherwise use the Contribution in 
whole or in part in electronic and print editions of the Journal and in derivative works throughout 
the world, in all languages and in all media of expression now known or later developed, and to 
license or permit others to do so. For the avoidance of doubt, “Contribution” is defined to only 
include the article submitted by the Contributor for publication in the Journal and does not extend 
to any supporting information submitted with or referred to in the Contribution (“Supporting 
Information”). To the extent that any Supporting Information is submitted to the Journal for online 
hosting by the Journal alongside the Contribution, the Owner is granted a perpetual, non-exclusive 
license to host and disseminate this Supporting Information for this purpose. 
2. Reproduction, posting, transmission or other distribution or use of the final Contribution in
whole or in part in any medium by the Contributor as permitted by this Agreement requires a 
citation to the Journal suitable in form and content as follows: (Title of Article, Contributor, Journal 
Title and Volume/Issue, Copyright © [year], copyright owner as specified in the Journal, 
Publisher). Links to the final article on the publisher website are encouraged where appropriate. 
B. RETAINED RIGHTS 
Notwithstanding the above, the Contributor or, if applicable, the Contributor’s employer, retains all 
proprietary rights other than copyright, such as patent rights, in any process, procedure or article 
of manufacture described in the Contribution.  
C. PERMITTED USES BY CONTRIBUTOR 
1. Submitted Version. The Owner licenses back the following rights to the Contributor in the
version of the Contribution as originally submitted for publication (the “Submitted Version”): 
a. The right to self-archive the Submitted Version on the Contributor’s personal website,
place in a not for profit subject-based preprint server or repository or in a Scholarly 
Collaboration Network (SCN) which has signed up to the STM article sharing principles 
[http://www.stm-assoc.org/stm-consultations/scn-consultation-2015/](“Compliant SCNs”), 
or in the Contributor’s company/ institutional repository or archive. This right extends to 
both intranets and the Internet. The Contributor may replace the Submitted Version with 
the Accepted Version, after any relevant embargo period as set out in paragraph C.2(a) 
below has elapsed. The Contributor may wish to add a note about acceptance by the 
Journal and upon publication it is recommended that Contributors add a Digital Object 
Identifier (DOI) link back to the Final Published Version. 
b. The right to transmit, print and share copies of the Submitted Version with colleagues,
including via Compliant SCNs, provided that there is no systematic distribution of the 
Submitted Version, e.g. posting on a listserve, network (including SCNs which have not 
signed up to the STM sharing principles) or automated delivery. 
2. Accepted Version. The Owner licenses back the following rights to the Contributor in the
version of the Contribution that has been peer-reviewed and accepted for publication, but not final 
(the “Accepted Version”): 
a. The right to self-archive the Accepted Version on the Contributor’s personal website, in
the Contributor’s company/institutional repository or archive, in Compliant SCNs, and in 
not for profit subject-based repositories such as PubMed Central, subject to an embargo 
period of 12 months for scientific, technical and medical (STM) journals and 24 months for 
social science and humanities (SSH) journals following publication of the Final Published 
Version. There are separate arrangements with certain funding agencies governing reuse 
of the Accepted Version as set forth at the following website: 
http://www.wiley.com/go/funderstatement. The Contributor may not update the Accepted 
Version or replace it with the Final Published Version. The Accepted Version posted must 
contain a legend as follows: This is the accepted version of the following article: FULL 
CITE, which has been published in final form at [Link to final article]. This article may be 
used for non-commercial purposes in accordance with the Wiley Self-Archiving Policy 
[http://olabout.wiley.com/WileyCDA/Section/id-820227.html]. 
b. The right to transmit, print and share copies of the Accepted Version with colleagues,
including via Compliant SCNs (in private research groups only before the embargo and 
publicly after), provided that there is no systematic distribution of the Accepted Version, 
e.g. posting on a listserve, network (including SCNs which have not signed up to the STM 
sharing principles) or automated delivery. 
3. Final Published Version. The Owner hereby licenses back to the Contributor the following
rights with respect to the final published version of the Contribution (the “Final Published 
Version”): 
a. Copies for colleagues. The personal right of the Contributor only to send or transmit
individual copies of the Final Published Version in any format to colleagues upon their 
specific request, and to share copies in private sharing groups in Compliant SCNs, provided 
no fee is charged, and further provided that there is no systematic external or public 
distribution of the Final Published Version, e.g. posting on a listserve, network or 
automated delivery. 
b. Re-use in other publications. The right to re-use the Final Published Version or parts
thereof for any publication authored or edited by the Contributor (excluding journal 
articles) where such re-used material constitutes less than half of the total material in such 
publication. In such case, any modifications must be accurately noted. 
c. Teaching duties. The right to include the Final Published Version in teaching or training
duties at the Contributor’s institution/place of employment including in course packs, e-
reserves, presentation at professional conferences, in-house training, or distance learning. 
The Final Published Version may not be used in seminars outside of normal teaching 
obligations (e.g. commercial seminars). Electronic posting of the Final Published Version in 
connection with teaching/training at the Contributor’s company/institution is permitted 
subject to the implementation of reasonable access control mechanisms, such as user 
name and password. Posting the Final Published Version on the open Internet is not 
permitted. 
d. Oral presentations. The right to make oral presentations based on the Final Published
Version. 
4. Article Abstracts, Figures, Tables, Artwork and Selected Text (up to 250 words).
a. Contributors may re-use unmodified abstracts for any non-commercial purpose. For
online uses of the abstracts, the Owner encourages but does not require linking back to 
the Final Published Version.  
b. Contributors may re-use figures, tables, artwork, and selected text up to 250 words
from their Contributions, provided the following conditions are met: 
(i) Full and accurate credit must be given to the Final Published Version. 
(ii) Modifications to the figures and tables must be noted. Otherwise, no changes 
may be made.  
(iii) The re-use may not be made for direct commercial purposes, or for financial 
consideration to the Contributor.  
(iv) Nothing herein will permit dual publication in violation of journal ethical 
practices.  
D. CONTRIBUTIONS OWNED BY EMPLOYER 
1. If the Contribution was written by the Contributor in the course of the Contributor’s employment
(as a “work-made-for-hire” in the course of employment), the Contribution is owned by the 
company/institution which must execute this Agreement (in addition to the Contributor’s 
signature). In such case, the company/institution hereby assigns to the Owner, during the full 
term of copyright, all copyright in and to the Contribution for the full term of copyright throughout 
the world as specified in paragraph A above. 
For company/institution-owned work, signatures cannot be collected electronically and so instead 
please print off this Agreement, ask the appropriate person in your company/institution to sign the 
Agreement as well as yourself in the space provided below, and email a scanned copy of the 
signed Agreement to the Journal production editor. For production editor contact details, please 
visit the Journal’s online author guidelines.  
2. In addition to the rights specified as retained in paragraph B above and the rights granted back
to the Contributor pursuant to paragraph C above, the Owner hereby grants back, without charge, 
to such company/institution, its subsidiaries and divisions, the right to make copies of and 
distribute the Final Published Version internally in print format or electronically on the Company’s 
internal network. Copies so used may not be resold or distributed externally. However, the 
company/institution may include information and text from the Final Published Version as part of 
an information package included with software or other products offered for sale or license or 
included in patent applications. Posting of the Final Published Version by the company/institution 
on a public access website may only be done with written permission, and payment of any 
applicable fee(s). Also, upon payment of the applicable reprint fee, the company/institution may 
distribute print copies of the Final Published Version externally. 
E. GOVERNMENT CONTRACTS 
In the case of a Contribution prepared under U.S. Government contract or grant, the U.S. 
Government may reproduce, without charge, all or portions of the Contribution and may authorize 
others to do so, for official U.S. Government purposes only, if the U.S. Government contract or 
grant so requires. (U.S. Government, U.K. Government, and other government employees: see 
notes at end.)  
F. COPYRIGHT NOTICE 
The Contributor and the company/institution agree that any and all copies of the Final Published 
Version or any part thereof distributed or posted by them in print or electronic format as permitted 
herein will include the notice of copyright as stipulated in the Journal and a full citation to the 
Journal.  
G. CONTRIBUTOR’S REPRESENTATIONS 
The Contributor represents that the Contribution is the Contributor’s original work, all individuals 
identified as Contributors actually contributed to the Contribution, and all individuals who 
contributed are included. If the Contribution was prepared jointly, the Contributor has informed 
the co-Contributors of the terms of this Agreement and has obtained their written permission to 
execute this Agreement on their behalf. The Contribution is submitted only to this Journal and has 
not been published before, has not been included in another manuscript, and is not currently 
under consideration or accepted for publication elsewhere. If excerpts from copyrighted works 
owned by third parties are included, the Contributor shall obtain written permission from the 
copyright owners for all uses as set forth in the standard permissions form or the Journal’s Author 
Guidelines, and show credit to the sources in the Contribution. The Contributor also warrants that 
the Contribution and any submitted Supporting Information contains no libelous or unlawful 
statements, does not infringe upon the rights (including without limitation the copyright, patent or 
trademark rights) or the privacy of others, or contain material or instructions that might cause 
harm or injury. The Contributor further warrants that there are no conflicts of interest relating to 
the Contribution, except as disclosed. Accordingly, the Contributor represents that the following 
information shall be clearly identified on the title page of the Contribution: (1) all financial and 
material support for the research and work; (2) any financial interests the Contributor or any co-
Contributors may have in companies or other entities that have an interest in the information in 
the Contribution or any submitted Supporting Information (e.g., grants, advisory boards, 
employment, consultancies, contracts, honoraria, royalties, expert testimony, partnerships, or 
stock ownership); and (3) indication of no such financial interests if appropriate.  
H. USE OF INFORMATION 
The Contributor acknowledges that, during the term of this Agreement and thereafter, the Owner 
(and Wiley where Wiley is not the Owner) may process the Contributor’s personal data, including 
storing or transferring data outside of the country of the Contributor’s residence, in order to 
process transactions related to this Agreement and to communicate with the Contributor. By 
entering into this Agreement, the Contributor agrees to the processing of the Contributor’s 
personal data (and, where applicable, confirms that the Contributor has obtained the permission 
from all other contributors to process their personal data). Wiley shall comply with all applicable 
laws, statutes and regulations relating to data protection and privacy and shall process such 
personal data in accordance with Wiley’s Privacy Policy located at: www.wiley.com/go/privacy.  
[ ] I agree to the COPYRIGHT TRANSFER AGREEMENT as shown above, consent to execution and 
delivery of the Copyright Transfer Agreement electronically and agree that an electronic signature 
shall be given the same legal force as a handwritten signature, and have obtained written
permission from all other contributors to execute this Agreement on their behalf. 
Contributor's signature (type name here):     
Date:  
SELECT FROM OPTIONS BELOW: 
[ ] Contributor-owned work 
[ ] U.S. Government work  
Note to U.S. Government Employees 
A contribution prepared by a U.S. federal government employee as part of the employee's official 
duties, or which is an official U.S. Government publication, is called a "U.S. Government work", 
and is in the public domain in the United States. In such case, Paragraph A.1 will not apply but the 
Contributor must type his/her name (in the Contributor's signature line) above. Contributor 
acknowledges that the Contribution will be published in the United States and other countries. If 
the Contribution was not prepared as part of the employee's duties or is not an official U.S. 
Government publication, it is not a U.S. Government work. 
[ ]U.K. Government work (Crown Copyright)  
Note to U.K. Government Employees 
For Crown Copyright this form cannot be completed electronically and should be printed 
off, signed in the Contributor’s signatures section above by the appropriately authorised 
individual and returned to the Journal production editor by email.  For production editor 
contact details please visit the Journal’s online author guidelines.  The rights in a contribution 
prepared by an employee of a UK government department, agency or other Crown body as part of 
his/her official duties, or which is an official government publication, belong to the Crown. 
Contributors must ensure they comply with departmental regulations and submit the appropriate 
authorisation to publish. If your status as a government employee legally prevents you from 
signing this Agreement, please contact the Journal production editor. 
[ ]Other  
Including Other Government work or Non-Governmental Organisation work 
Note to Non-U.S., Non-U.K. Government Employees or Non-Governmental Organisation Employees 
For Other Government or Non-Governmental Organisation work this form cannot be 
completed electronically and should be printed off, signed in the Contributor’s 
signatures section above by the appropriately authorised individual and returned to the 
Journal production editor by email.  For production editor contact details please visit the 
Journal’s online author guidelines.  If you are employed by the Department of Veterans Affairs in 
Australia, the World Bank, the World Health Organization, the International Monetary Fund, the 
European Atomic Energy Community, the Jet Propulsion Laboratory at California Institute of 
Technology, the Asian Development Bank, or are a Canadian Government civil servant, please 
download a copy of the license agreement from http://exchanges.wiley.com/authors/copyright-
and-permissions 333.html and return it to the Journal Production Editor. If your status as a 
government or non-governmental organisation employee legally prevents you from signing this 
Agreement, please contact the Journal production editor. 
Name of Government/Non-Governmental Organisation: 
[ ] Company/institution owned work (made for hire in the course of employment) For "work 
made for hire" this form cannot be completed electronically and should be printed off, signed and 
returned to the Journal production editor by email.  For production editor contact details please visit 
the Journal’s online author guidelines. If you are an employee of Amgen, please download a copy of the 
company addendum from http://exchanges.wiley.com/authors/copyright-and-permissions 333.html and 
return your signed license agreement along with the addendum. 
Name of Company/Institution: 
Authorized Signature of Employer: 
Date:  
Signature of Employee:  
Date:  
Licensing
In submitting an article to any of the journals published by BioMed Central, I certify that:
2. I warrant, on behalf of myself and my co-authors, that:
the article is original, has not been formally published in any other peer-reviewed journal, is not under consideration by
any other journal and does not infringe any existing copyright or any other third party rights;
I am/we are the sole author(s) of the article and have full authority to enter into this agreement and in granting rights to
BioMed Central are not in breach of any other obligation;
the article contains nothing that is unlawful, libellous, or which would, if published, constitute a breach of contract or of
confidence or of commitment given to secrecy;
I/we have taken due care to ensure the integrity of the article. To my/our - and currently accepted scientific - knowledge
all statements contained in it purporting to be facts are true and any formula or instruction contained in the article will
not, if followed accurately, cause any injury, illness or damage to the user.
3. I, and all co-authors, agree that the article, if editorially accepted for publication, shall be licensed under the Creative
Commons Attribution License 4.0. In line with BioMed Central's Open Data Policy, data included in the article shall be made
available under the Creative Commons 1.0 Public Domain Dedication waiver, unless otherwise stated. If the law requires that
the article be published in the public domain, I/we will notify BioMed Central at the time of submission, and in such cases not
only the data but also the article shall be released under the Creative Commons 1.0 Public Domain Dedication waiver. For the
avoidance of doubt it is stated that sections 1 and 2 of this license agreement shall apply and prevail regardless of whether the
article is published under Creative Commons Attribution License 4.0 or the Creative Commons 1.0 Public Domain Dedication
waiver.
1. [End of BioMed Central’s license agreement]
2. ____________________________________________________________________________________
Explanatory notes regarding BioMed Central’s license agreement
As an aid to our authors, the following paragraphs provide some brief explanations concerning the Creative Commons licenses
that apply to the articles published in BioMed Central-published journals and the rationale for why we have chosen these
licenses.
The Creative Commons Attribution License (CC BY), of which CC BY 4.0 is the most recent version, was developed to facilitate
open access as defined in the founding documents of the movement, such as the 2003 Berlin Declaration. Open access content
has to be freely available online, and through licensing their work under CC BY authors grant users the right to unrestricted
dissemination and re-use of the work, with only the one proviso that proper attribution is given to authors. This liberal
licensing is best suited to facilitate the transfer and growth of scientific knowledge. The Open Access Scholarly Publishers
Association (OASPA) therefore strongly recommends the use of CC BY for the open access publication of research literature,
and many research funders worldwide either recommend or mandate that research they have supported be published under CC
BY. Examples for such policies include funders as diverse as the Wellcome Trust, the Australian Governments, the European
Commission’s Horizon 2020 framework programme, or the Bill & Melinda Gates Foundation.
The default use of the Creative Commons 1.0 Public Domain Dedication waiver (CC0 or CC zero) for data published within
articles follows the same logic: facilitating maximum benefit and the widest possible re-use of knowledge. It is also the case that
in some jurisdictions copyright does not apply to data. CC0 waives all potential copyrights, to the extent legally possible, as well
as the attribution requirement. The waiver applies to data, not to the presentation of data. If, for instance, a table or figure
displaying research data is reproduced, CC BY and the requirement to attribute applies. Increasingly, however, new insights are
possible through the use of big data techniques, such as data mining, that harness the entire corpus of digital data. In such
cases attribution is often technically infeasible due to the sheer mass of the data mined, making CC0 the most suitable licensing
tool for research outputs generated from such innovative techniques.
It is important to differentiate between legal requirements and community norms. It is first and foremost a community norm,
not a law, that within the scientific community attribution mostly takes the form of citation. It is also a community norm that
researchers are expected to refer to their sources, which usually takes the form of citation. Across all cases of research reuse
(including data, code, etc), community norms will apply as is appropriate for the situation: researchers will cite their sources
where it is feasible, regardless of the applicable license. CC0 therefore covers those instances that lie beyond long-established
community norms. The overall effect, then, of CC0 for data is to enable further use, without any loss of citations. For further
explanation, we recommend you refer to our Open Data FAQ.
In the following, we provide the licenses’ summaries as they can be found on the Creative Commons website:
The Creative Commons Attribution License 4.0 provides the following summary (where ‘you’ equals ‘the
user’):
You are free to:
Share:— copy and redistribute the material in any medium or format
Adapt:— remix, transform, and build upon the material
for any purpose, even commercially. The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
Attribution— You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do
so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
No additional restrictions—You may not apply legal terms or technological measures that legally restrict others from doing
anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by
an applicable exception or limitation.
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example,
other rights such as publicity, privacy, or moral rights may limit how you use the material.
Please note: For the terms set in italics in the summary above further details are provided on the Creative Commons web
page from which the summary is taken (http://creativecommons.org/licenses/by/4.0/).
The Creative Commons 1.0 Public Domain Dedication waiver provides the following summary:
No Copyright
The person who associated a work with this deed has dedicated the work to the public domain by waiving all of his or her rights
to the work worldwide under copyright law, including all related and neighbouring rights, to the extent allowed by law.
You can copy, modify, distribute and perform the work, even for commercial purposes, all without asking permission.
See Other Information below.
Other Information
In no way are the patent or trademark rights of any person affected by CC0, nor are the rights that other persons may
have in the work or in how the work is used, such as publicity or privacy rights.
Unless expressly stated otherwise, the person who associated a work with this deed makes no warranties about the work,
and disclaims liability for all uses of the work, to the fullest extent permitted by applicable law.
When using or citing the work, you should not imply endorsement by the author or the affirmer.
Please note: For the terms set in italics in the summary above further details are provided on the Creative Commons web
page from which the summary is taken (http://creativecommons.org/publicdomain/zero/1.0/).
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